# 2026年1月9日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 通过线粒体依赖性STING激活的免疫重塑增强卡博替尼在肝细胞癌中的疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508119)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41508119
**DOI：** 10.1186/s13046-025-03632-z

### 第一部分 原文与翻译

**英文原标题：** Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探索通过线粒体依赖性STING通路激活进行免疫重塑，以增强卡博替尼治疗肝细胞癌的疗效。其核心方法可能涉及利用线粒体功能失调激活cGAS-STING通路，从而重塑肿瘤免疫微环境。主要发现是这种免疫重塑策略能够增强卡博替尼的治疗反应。研究的创新性在于将靶向治疗（卡博替尼）与特定的先天免疫激活机制（线粒体-STING轴）相结合，为克服肝癌治疗耐药性提供了新思路。局限性在于摘要信息缺失，具体实验设计、模型、临床前或临床数据细节尚不明确，其转化潜力和普适性有待进一步验证。

---

## 2. 急性髓系白血病治疗前骨髓驻留白血病细胞表现出独特的钙信号失调特征和干细胞样特征，反映微小残留病前体细胞。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508052)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41508052
**DOI：** 10.1186/s13046-025-03634-x

### 第一部分 原文与翻译

**英文原标题：** Pre-therapeutic bone marrow-resident leukemic cells in acute myeloid leukemia exhibit a distinct dysregulated calcium signature and stem-like profile reflecting minimal residual disease precursors.

> **英文摘要：**
> BACKGROUND: Acute myeloid leukemia (AML) remains a high-risk hematologic malignancy due to frequent relapse and therapeutic resistance. Although induction therapy can achieve cytological remission, a fraction of leukemic cells (minimal residual disease, MRD) persists within the protective bone marrow (BM) microenvironment. MRD is heterogeneous and may include subclones with intrinsic survival features present before therapy. Among these, rare BM-resident leukemic cells (BMresLC) may represent pre-adapted precursors of MRD, maintained in a low-proliferative (Ki67) or quiescent state. We previously showed that calcium signaling through ORAI1-dependent store-operated calcium entry (SOCE) contributes not only to AML stemness and drug resistance but also to the regulation of the G0-G1 cell-cycle transition and the emergence of slow-cycling leukemic cells. With this study, we have characterized the stemness and calcium signature of BMresLC before any therapeutic intervention. Our results, beyond further characterizing a population of cells rarely studied, could thus pave the way to new therapeutic opportunities combining current treatments with the targeting of relevant pathways highlighted by our work.
> 
> METHODS: A patient-derived xenograft (PDX) model in NSG (NOD/SCID/IL2Rγ) mice was used to localize, isolate, and characterize human BMresLC. Whole-bone clearing and 3D-Imaris imaging enabled spatial localization of rare leukemic cells. Flow cytometry and qPCR assessed cell-cycle status, immunophenotype (CD34, CD38, TIM-3, PD-L1, Ki67), stemness, and calcium-signaling components (ORAI1-3, STIM1-2, NFATc1-4). SOCE was measured using Indo-1 assays. Comparative analyses were performed against diagnostic AML cells, public MRD RNA-seq datasets, and prognosis-stratified patient cohorts.
> 
> RESULTS: BMresLC displayed an immune-evasive immunophenotype and contained a small fraction of Ki67 quiescent cells, but were not enriched in fully quiescent cells. Instead, they predominantly exhibited a Ki67 slow-cycling profile, consistent with a low-proliferative persistent state. Transcriptional analysis revealed overexpression of stemness-associated genes and selective downregulation of calcium-signaling components ORAI1, ORAI2, STIM2, and NFATc1/c4, consistent with a SOCE-suppressed calcium signature. Functional assays confirmed reduced calcium influx. Compared with post-therapy MRD datasets, BMresLC showed some stemness and immune-evasion traits but displayed a distinct pre-therapeutic calcium signature, suggesting that it represents an early, persistent state preceding full MRD remodeling. Prognostic subgroup analysis further showed that BMresLC calcium and stemness profiles partially recapitulate features of adverse-risk AML, including differences in CD34, CD38, PD-L1, MMRN1, LAPTM4B, NFATc2, and STIM2 expression.
> 
> CONCLUSIONS: Our findings identify a distinctive calcium- and stemness-based signature in BMresLC, representing a pre-MRD survival state characterized by slow cycling rather than enrichment in strict quiescence. This pre-therapeutic signature may contribute to MRD establishment and relapse risk in AML.

> **中文摘要：**
> 背景：急性髓系白血病（AML）由于频繁复发和治疗耐药，仍然是一种高风险血液恶性肿瘤。尽管诱导治疗可以实现细胞学缓解，但一部分白血病细胞（微小残留病，MRD）持续存在于具有保护作用的骨髓（BM）微环境中。MRD具有异质性，可能包含治疗前就已存在的具有内在生存特征的亚克隆。其中，罕见的骨髓驻留白血病细胞（BMresLC）可能代表了MRD的预适应前体细胞，它们维持在低增殖（Ki67）或静止状态。我们先前的研究表明，通过ORAI1依赖性钙库操纵性钙内流（SOCE）的钙信号传导不仅有助于AML的干细胞特性和耐药性，还参与调控G0-G1细胞周期转换和慢周期白血病细胞的出现。通过本研究，我们表征了在任何治疗干预之前BMresLC的干细胞特性和钙信号特征。我们的结果，除了进一步表征了很少被研究的细胞群体外，还可能为结合当前治疗与靶向我们工作中强调的相关通路的新治疗机会铺平道路。
> 
> 方法：使用NSG（NOD/SCID/IL2Rγ）小鼠中的人源异种移植（PDX）模型来定位、分离和表征人BMresLC。全骨透明化和3D-Imaris成像实现了罕见白血病细胞的空间定位。流式细胞术和qPCR评估了细胞周期状态、免疫表型（CD34、CD38、TIM-3、PD-L1、Ki67）、干细胞特性以及钙信号传导组分（ORAI1-3、STIM1-2、NFATc1-4）。使用Indo-1检测法测量SOCE。与诊断时的AML细胞、公共MRD RNA-seq数据集以及预后分层患者队列进行了比较分析。
> 
> 结果：BMresLC表现出免疫逃逸的免疫表型，并包含一小部分Ki67静止细胞，但并未富集完全静止的细胞。相反，它们主要表现出Ki67慢周期特征，与低增殖的持续状态一致。转录分析显示干细胞相关基因过表达，以及钙信号传导组分ORAI1、ORAI2、STIM2和NFATc1/c4选择性下调，这与SOCE受抑制的钙信号特征一致。功能实验证实了钙内流减少。与治疗后MRD数据集相比，BMresLC显示出一些干细胞特性和免疫逃逸特征，但表现出独特的治疗前钙信号特征，表明它代表了在MRD完全重塑之前的早期、持续状态。预后亚组分析进一步显示，BMresLC的钙信号和干细胞特征部分重现了不良风险AML的特征，包括CD34、CD38、PD-L1、MMRN1、LAPTM4B、NFATc2和STIM2表达的差异。
> 
> 结论：我们的研究结果在BMresLC中鉴定出一个独特的基于钙信号和干细胞特征的分子标签，它代表了一种以慢周期而非严格静止富集为特征的MRD前生存状态。这种治疗前的特征可能有助于AML中MRD的形成和复发风险。

### 第二部分 AI 大师评价

本研究旨在揭示急性髓系白血病（AML）治疗前骨髓驻留白血病细胞（BMresLC）的生物学特征，以阐明其作为微小残留病（MRD）前体细胞的作用。研究创新性地结合了PDX模型、全骨3D成像和多组学分析，系统地表征了BMresLC的细胞周期、免疫表型、干细胞特性及钙信号通路。核心发现是BMresLC具有独特的“慢周期”表型、免疫逃逸特征以及以SOCE通路关键组分下调为标志的钙信号失调特征，这将其与治疗后MRD及不良预后AML联系起来。研究局限性在于主要基于PDX模型，需在更多患者原代样本中验证，且钙信号失调与慢周期表型之间的因果机制有待深入探索。

---

## 3. 亚细胞空间图谱揭示远端胆管癌神经周围侵袭的微环境重塑。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508044)
**期刊：** Journal of hematology & oncology
**PMID：** 41508044
**DOI：** 10.1186/s13045-025-01773-4

### 第一部分 原文与翻译

**英文原标题：** A subcellular spatial atlas illuminates the microenvironmental remodeling of perineural invasion in distal cholangiocarcinoma.

> **英文摘要：**
> Distal cholangiocarcinoma (dCCA) arises from the distal bile duct and is anatomically embedded within the pancreatic head, adjacent to abundant autonomic nerve plexuses. This unique location renders dCCA particularly prone to perineural invasion (PNI), a pathological hallmark that contributes to its dismal prognosis. However, the spatial architecture and molecular drivers that orchestrate PNI remain poorly defined. Here, we applied Xenium subcellular resolution spatial转录组学平台 to profile resected tumor tissues from dCCA patients stratified by PNI status pathologically. A spatially resolved atlas comprising a total of 20 cell types was generated, uncovering enrichment of Schwann cells, type 2 conventional dendritic cells (cDC2), M2-like macrophages, cancer associated fibroblasts (CAFs) and B/plasma cells in PNI-high tumors, along with depletion of exhausted CD8 T cells. Heterogeneous malignant cells in PNI-high tumors demonstrated activation of extracellular matrix remodeling and axonogenesis pathways, in line with the initial pathological classification. Spatial mapping further revealed distinct PNI-associated niches, notably matrix-producing CAFs (mCAFs)-macrophage clusters exhibiting coordinated enrichment of inflammatory and fibrotic programs. We further identified the LAMB3-DAG1 axis as a potential mediator of dCCA cells-Schwann cell interaction, while the preferential proximity of arteries to Schwann cells suggested additional microenvironmental support for nerve invasion. Collectively, our study provides a comprehensive subcellular atlas of PNI in dCCA, uncovering coordinated epithelial, stromal, and immune remodeling that drives perineural invasion. The identified biomarkers not only hold promise for patient stratification but may also guide intraoperative navigation and surgical margin determination, offering new avenues for precision therapy.

> **中文摘要：**
> 远端胆管癌（dCCA）起源于远端胆管，解剖上位于胰头内，毗邻丰富的自主神经丛。这种独特的位置使得dCCA特别容易发生神经周围侵袭（PNI），这是导致其预后不良的病理学标志。然而，协调PNI的空间结构和分子驱动因素仍不明确。本研究应用Xenium亚细胞分辨率空间转录组学平台，对根据PNI状态进行病理分层的dCCA患者的切除肿瘤组织进行了分析。我们生成了一个包含总共20种细胞类型的空间解析图谱，揭示了PNI高表达肿瘤中雪旺细胞、2型经典树突状细胞（cDC2）、M2样巨噬细胞、癌症相关成纤维细胞（CAFs）以及B/浆细胞的富集，同时伴随耗竭CD8 T细胞的减少。PNI高表达肿瘤中的异质性恶性细胞显示出细胞外基质重塑和轴突生成通路的激活，这与最初的病理分类相符。空间定位进一步揭示了独特的PNI相关生态位，特别是产基质CAFs（mCAFs）-巨噬细胞簇，它们表现出炎症和纤维化程序的协同富集。我们进一步确定了LAMB3-DAG1轴是dCCA细胞与雪旺细胞相互作用的潜在介质，而动脉对雪旺细胞的优先邻近性提示了神经侵袭的额外微环境支持。总之，我们的研究为dCCA中的PNI提供了一个全面的亚细胞空间图谱，揭示了驱动神经周围侵袭的协调性上皮、基质和免疫重塑。所鉴定的生物标志物不仅有望用于患者分层，还可能指导术中导航和手术切缘确定，为精准治疗提供新途径。

### 第二部分 AI 大师评价

本研究旨在利用高分辨率空间转录组学技术，系统解析远端胆管癌（dCCA）神经周围侵袭（PNI）的细胞与分子空间特征。研究通过构建亚细胞水平的空间图谱，成功鉴定了与PNI密切相关的多种细胞类型（如雪旺细胞、M2样巨噬细胞、mCAFs）及其形成的特定生态位，并揭示了LAMB3-DAG1轴等潜在的分子互作机制。其创新性在于首次在亚细胞空间维度上描绘了dCCA中PNI的复杂微环境重塑网络，为理解其发生机制提供了前所未有的视角，发现的生物标志物具有转化为临床应用的潜力。然而，研究主要基于组织样本的静态分析，对PNI的动态过程及所发现分子通路的因果功能验证尚需后续实验深入探索。

---

## 4. 用于上尿路尿路上皮癌检测的UroCAD测试的临床验证：一项前瞻性多中心研究结果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41508041)
**期刊：** Journal of hematology & oncology
**PMID：** 41508041
**DOI：** 10.1186/s13045-025-01772-5

### 第一部分 原文与翻译

**英文原标题：** Clinical validation of UroCAD test for upper tract urothelial carcinoma detection: results from a prospective multi-center study.

> **英文摘要：**
> BACKGROUND: Upper tract urothelial carcinoma (UTUC) poses diagnostic challenges due to its anatomical complexity and limited accessibility.
> 
> METHODS: This prospective multicenter study (NCT05043662) evaluated the diagnostic性能 of UroCAD, a novel non-invasive assay based on chromosomal copy number variation (CNV) analysis, in 244 patients with suspected UTUC or benign upper urinary tract conditions.
> 
> RESULTS: Urine samples were analyzed for arm-level chromosomal aberrations (|Z-score|≥ 3.21), with histopathology as the reference standard. UroCAD demonstrated excellent diagnostic accuracy: sensitivity 91.0%, specificity 97.0%, and overall accuracy 93.4%. Performance was consistent across tumor locations (renal pelvis: 96.8%, ureter: 86.4%) and grades (high-grade: 93.5%, low-grade: 76.2%). Compared to urine cytology, UroCAD showed significantly higher sensitivity (91.2% vs. 52.9%, P < 0.001). CNV profiling revealed grade-associated patterns, with high-grade tumors frequently exhibiting amplifications on 1q and 8q. The extent (MaxZ) and number (CountZ) of chromosomal alterations correlated positively with tumor grade, supporting UroCAD's potential utility in molecular grading.
> 
> CONCLUSIONS AND CLINICAL IMPLICATIONS: The UroCAD test demonstrates robust diagnostic performance for UTUC detection with high specificity and high sensitivity. The consistent performance across various clinical scenarios and the identification of specific chromosomal alteration patterns support its potential as a valuable clinical tool for both initial diagnosis and treatment monitoring. These findings warrant larger-scale validation studies to confirm its utility in routine clinical practice.

> **中文摘要：**
> 背景：上尿路尿路上皮癌（UTUC）由于其解剖结构复杂和可及性有限，给诊断带来了挑战。
> 
> 方法：这项前瞻性多中心研究（NCT05043662）评估了UroCAD（一种基于染色体拷贝数变异分析的新型无创检测方法）在244例疑似UTUC或良性上尿路疾病患者中的诊断性能。
> 
> 结果：以组织病理学为金标准，对尿液样本进行了臂水平染色体畸变分析（|Z分数|≥ 3.21）。UroCAD显示出优异的诊断准确性：灵敏度91.0%，特异性97.0%，总体准确率93.4%。其性能在不同肿瘤部位（肾盂：96.8%，输尿管：86.4%）和分级（高级别：93.5%，低级别：76.2%）中表现一致。与尿液细胞学检查相比，UroCAD显示出显著更高的灵敏度（91.2% 对 52.9%，P < 0.001）。CNV谱分析揭示了与肿瘤分级相关的模式，高级别肿瘤常在1q和8q上表现出扩增。染色体改变的程度（MaxZ）和数量（CountZ）与肿瘤分级呈正相关，支持了UroCAD在分子分级方面的潜在用途。
> 
> 结论与临床意义：UroCAD测试在UTUC检测中表现出稳健的诊断性能，具有高特异性和高灵敏度。其在各种临床场景下的一致性能以及对特定染色体改变模式的识别，支持其作为初始诊断和治疗监测的宝贵临床工具的潜力。这些发现需要进行更大规模的验证研究，以确认其在常规临床实践中的效用。

### 第二部分 AI 大师评价

本研究旨在通过前瞻性多中心设计，临床验证基于尿液染色体拷贝数变异（CNV）分析的新型无创检测UroCAD对上尿路尿路上皮癌（UTUC）的诊断价值。研究发现，UroCAD相比传统尿液细胞学具有显著更高的灵敏度（91.2% vs. 52.9%），且总体准确率高（93.4%），在不同肿瘤部位和分级中性能稳定。其创新性在于不仅提供了高精度的诊断，还通过CNV谱（如1q、8q扩增）揭示了与肿瘤分级相关的分子模式，展现了辅助分子分级的潜力，有望成为UTUC诊断和监测的重要工具。局限性在于仍需更大规模的研究来验证其在常规临床实践中的普适性。

---

## 5. 高危型HPV E6/E7驱动NSD2上调并破坏HPV相关头颈癌中的上皮分化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507992)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41507992
**DOI：** 10.1186/s13046-025-03631-0

### 第一部分 原文与翻译

**英文原标题：** NSD2 upregulation is driven by high-risk HPV E6/E7 and disrupts epithelial differentiation in HPV-associated head and neck cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探讨高危型HPV在头颈癌中致癌的新机制，聚焦于表观遗传调节因子NSD2。研究通过分子生物学方法，揭示了HPV癌蛋白E6/E7通过驱动NSD2表达上调，进而破坏上皮细胞分化程序，这可能是HPV相关头颈癌发生发展的关键环节。其创新性在于将HPV感染与特定的表观遗传失调直接联系起来，为靶向治疗提供了新思路。局限性在于摘要信息缺失，无法评估具体的研究模型、实验方法及更详细的发现。

---

## 6. BACE2通过剪切脂质转运蛋白调控脂质摄取以支持癌细胞增殖。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507981)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41507981
**DOI：** 10.1186/s13046-025-03626-x

### 第一部分 原文与翻译

**英文原标题：** BACE2 tunes lipid uptake through lipid transporters shedding supporting cancer cell proliferation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在揭示BACE2在调控癌细胞脂质代谢中的新机制。研究提出，BACE2通过剪切细胞膜上的脂质转运蛋白，影响脂质摄取，从而满足癌细胞快速增殖的能量和生物合成需求。这一发现将BACE2的功能从传统的神经退行性疾病领域拓展至肿瘤代谢领域，揭示了肿瘤代谢调控的一个潜在新靶点。然而，由于摘要不可用，具体的实验方法、关键数据以及该机制在不同癌症类型中的普适性等细节尚不明确，有待全文验证。

---

## 7. 对一名活体基因编辑猪肾脏移植受者进行免疫特征分析。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507576)
**期刊：** Nature medicine
**PMID：** 41507576
**DOI：** 10.1038/s41591-025-04053-3

### 第一部分 原文与翻译

**英文原标题：** Immune profiling in a living human recipient of a gene-edited pig kidney.

> **英文摘要：**
> Xenotransplantation of gene-edited pig kidneys offers a promising solution to the shortage of kidneys for organ transplantation. We recently performed a gene-edited pig kidney transplantation into a living human recipient with end-stage kidney disease. Here, using transcriptomics, proteomics, metabolomics and multiplexed imaging, we conducted high-dimensional immune profiling in this individual. Despite profound depletion of circulating T cells, early T cell-mediated rejection occurred within 1 week after transplantation, likely driven by subtherapeutic immunosuppression and the presence of residual CD8 T cells in lymph nodes. This T cell-mediated rejection event was reversed by intensified immunosuppression. After treatment, adaptive immunity remained suppressed, whereas innate immune activation, characterized by sustained monocyte and macrophage activity along with elevated levels of interleukin-1 beta and granulocyte-macrophage colony-stimulating factor, persisted. Comparative transcriptomic analysis showed that xenograft rejection profiles resembled those typically observed in human allograft rejection, while also revealing unique innate immune signatures. We did not detect antibody-mediated rejection. The levels of circulating pig donor-derived cell-free DNA rose during the initial rejection episode and declined with treatment, supporting the potential of cell-free DNA measurements as a noninvasive biomarker of xenograft rejection. These findings define the distinct immune landscape of kidney xenotransplantation and highlight the need for regimens targeting both innate and adaptive immunity to improve outcomes.

> **中文摘要：**
> 基因编辑猪肾脏的异种移植为解决器官移植中的肾脏短缺问题提供了一个有前景的方案。我们最近为一名患有终末期肾病的活体受者进行了基因编辑猪肾脏移植。在此，我们利用转录组学、蛋白质组学、代谢组学和多重成像技术，对该个体进行了高维度的免疫特征分析。尽管循环T细胞被大量耗竭，但在移植后1周内仍发生了早期T细胞介导的排斥反应，这可能是由亚治疗水平的免疫抑制和淋巴结中残留的CD8 T细胞所驱动。通过加强免疫抑制，这一T细胞介导的排斥事件得以逆转。治疗后，适应性免疫仍处于抑制状态，而先天性免疫激活则持续存在，其特征是持续的单核细胞和巨噬细胞活性以及白细胞介素-1β和粒细胞-巨噬细胞集落刺激因子水平升高。比较转录组分析显示，异种移植排斥的特征谱与通常在人类同种异体移植排斥中观察到的相似，同时也揭示了独特的先天性免疫特征。我们未检测到抗体介导的排斥反应。循环中猪供体来源的游离DNA水平在初始排斥事件期间升高，并随着治疗而下降，这支持了游离DNA测量作为异种移植排斥无创生物标志物的潜力。这些发现定义了肾脏异种移植独特的免疫格局，并强调了需要同时针对先天性和适应性免疫的治疗方案以改善预后。

### 第二部分 AI 大师评价

本研究旨在通过多组学技术，首次在活体基因编辑猪肾脏移植受者中进行高维免疫特征分析，以揭示异种移植的免疫应答机制。研究发现，尽管进行了T细胞耗竭，仍发生了早期T细胞介导的排斥，并揭示了以单核/巨噬细胞持续活化为特征的先天性免疫激活在排斥中的重要作用。创新性地发现异种排斥与同种排斥的转录谱相似但具有独特的先天性免疫特征，并验证了供体来源游离DNA作为无创生物标志物的潜力。然而，研究仅基于单一个案，其普适性有待验证，且未能检测到抗体介导排斥，可能受限于观察时间或方法敏感性。

---

## 8. 纳武利尤单抗围手术期治疗在可切除III期非小细胞肺癌患者中的临床结局：按淋巴结状态进行的3期CheckMate 77T研究探索性分析。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507539)
**期刊：** Nature cancer
**PMID：** 41507539
**DOI：** 10.1038/s43018-025-01104-z

### 第一部分 原文与翻译

**英文原标题：** Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.

> **英文摘要：**
> Individuals with non-small-cell lung cancer (NSCLC) with metastases to the ipsilateral mediastinum or subcarinal lymph nodes (N2 disease) have poor long-term survival. This exploratory analysis from the randomized phase 3 CheckMate 77T study assessed clinical outcomes by nodal status in individuals with stage III NSCLC who received neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab (nivolumab) versus neoadjuvant chemotherapy followed by surgery and adjuvant placebo (placebo). Here we show that among patients with N2 disease, nivolumab versus placebo improved event-free survival (1-year rate, 70% versus 45%; hazard ratio, 0.46 (95% confidence interval, 0.30-0.70)) and pathological complete response rate (22.0% versus 5.6%); 77% versus 73% had definitive surgery, of whom 84% versus 74% received a simple lobectomy. Furthermore, nivolumab improved outcomes versus placebo in patients with multistation N2 NSCLC (1-year event-free survival rate: 71% versus 46%; hazard ratio, 0.43 (0.21-0.88); pathological complete response rate, 29.0% versus 2.7%). In the N2 subgroup with definitive surgery, 67% and 59% of patients had nodal downstaging after surgery (57% versus 44% downstaged to node-negative disease). Median EFS in randomized patients with stage III non-N2 NSCLC was not reached with nivolumab and 17.0 months with placebo (1-year EFS rate, 74% versus 62%; hazard ratio, 0.60 (0.33-1.08)). No new safety signals were identified. These findings support perioperative nivolumab plus neoadjuvant chemotherapy as an efficacious treatment for stage III N2 disease and suggest that N2 status may not predict poor prognosis in resectable NSCLC treated with perioperative immunotherapy. ClinicalTrials.gov identifier: NCT04025879 .

> **中文摘要：**
> 伴有同侧纵隔或隆突下淋巴结转移（N2疾病）的非小细胞肺癌（NSCLC）患者长期生存率较差。这项来自随机3期CheckMate 77T研究的探索性分析，评估了III期NSCLC患者按淋巴结状态划分的临床结局，这些患者分别接受了新辅助纳武利尤单抗联合化疗后手术及辅助纳武利尤单抗（纳武利尤单抗组）与新辅助化疗后手术及辅助安慰剂（安慰剂组）的治疗。我们在此表明，在N2疾病患者中，与安慰剂相比，纳武利尤单抗改善了无事件生存率（1年率：70% 对比 45%；风险比，0.46（95%置信区间，0.30-0.70））和病理完全缓解率（22.0% 对比 5.6%）；77% 对比 73%的患者接受了根治性手术，其中84% 对比 74%接受了单纯肺叶切除术。此外，对于多站N2 NSCLC患者，纳武利尤单抗相较于安慰剂也改善了结局（1年无事件生存率：71% 对比 46%；风险比，0.43（0.21-0.88）；病理完全缓解率，29.0% 对比 2.7%）。在接受根治性手术的N2亚组中，分别有67%和59%的患者在术后出现淋巴结降期（57% 对比 44%降期为淋巴结阴性）。在随机分组的III期非N2 NSCLC患者中，纳武利尤单抗组的中位EFS尚未达到，安慰剂组为17.0个月（1年EFS率，74% 对比 62%；风险比，0.60（0.33-1.08））。未发现新的安全性信号。这些发现支持纳武利尤单抗联合新辅助化疗的围手术期方案是治疗III期N2疾病的有效方法，并提示在接受围手术期免疫治疗的可切除NSCLC中，N2状态可能不再预示不良预后。ClinicalTrials.gov标识符：NCT04025879。

### 第二部分 AI 大师评价

本研究旨在通过CheckMate 77T试验的探索性分析，评估围手术期纳武利尤单抗方案在可切除III期NSCLC患者中的疗效，并特别关注淋巴结状态（尤其是N2疾病）对预后的影响。研究采用随机对照设计，比较了纳武利尤单抗联合新辅助化疗后手术及辅助治疗与单纯化疗后手术及安慰剂的疗效差异。核心发现表明，对于预后通常较差的N2疾病患者，纳武利尤单抗方案显著改善了无事件生存率和病理完全缓解率，甚至在多站N2患者中也显示出明确获益，并实现了较高的淋巴结降期率，这挑战了传统上N2状态作为不良预后指标的观念。该研究的创新性在于为III期N2 NSCLC这一高危亚组提供了强有力的围手术期免疫治疗证据，但其局限性在于这是一项探索性分析，结果需在更大规模的前瞻性研究中进一步验证，且非N2亚组的EFS获益未达到统计学显著性，提示仍需更长时间的随访。

---

## 9. 利用GSK3β抑制剂靶向β-catenin降解可诱导急性淋巴细胞白血病细胞死亡。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507538)
**期刊：** Nature cancer
**PMID：** 41507538
**DOI：** 10.1038/s43018-025-01093-z

### 第一部分 原文与翻译

**英文原标题：** Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia.

> **英文摘要：**
> As part of canonical Wnt signaling, T cell factor (TCF)-β-catenin complexes promote MYC-dependent proliferation. Lesions of the β-catenin protein degradation machinery are common oncogenic drivers. Here, we show that B cell acute lymphoblastic leukemia (B-ALL) lacks these mutations and critically depends on unencumbered β-catenin protein degradation. Compared to solid tumors, we found that mouse and human B-ALL express β-catenin protein at much lower levels; β-catenin protein was constitutively phosphorylated by glycogen synthase kinase 3B (GSK3β) and poised for proteasomal degradation. Instead of TCF-β-catenin complexes to activate MYC, β-catenin paired with B lymphoid Ikaros and NuRD complex factors, resulting in MYC repression and acute cell death. To leverage β-catenin protein degradation as a previously unrecognized vulnerability in B-ALL, we validated GSK3β inhibition in patient-derived xenograft models in vivo. CRISPR screens confirmed β-catenin protein degradation as a central mechanistic target of established GSK3β inhibitors. As several GSK3β inhibitors achieved favorable safety profiles in clinical trials, our results provide a rationale for repurposing these compounds for persons with refractory B cell malignancies.

> **中文摘要：**
> 作为经典Wnt信号通路的一部分，T细胞因子（TCF）-β-catenin复合物促进MYC依赖性增殖。β-catenin蛋白降解机制的损伤是常见的致癌驱动因素。在此，我们发现B细胞急性淋巴细胞白血病（B-ALL）缺乏这些突变，并且关键依赖于不受阻碍的β-catenin蛋白降解。与实体瘤相比，我们发现小鼠和人类B-ALL表达的β-catenin蛋白水平要低得多；β-catenin蛋白被糖原合成酶激酶3B（GSK3β）持续磷酸化，并准备进行蛋白酶体降解。β-catenin并非与TCF形成复合物来激活MYC，而是与B淋巴Ikaros和NuRD复合物因子配对，导致MYC抑制和急性细胞死亡。为了利用β-catenin蛋白降解这一先前未被认识的B-ALL弱点，我们在体内患者来源的异种移植模型中验证了GSK3β抑制的效果。CRISPR筛选证实β-catenin蛋白降解是现有GSK3β抑制剂的核心机制靶点。由于几种GSK3β抑制剂在临床试验中已显示出良好的安全性，我们的研究结果为将这些化合物重新用于难治性B细胞恶性肿瘤患者提供了理论依据。

### 第二部分 AI 大师评价

本研究旨在探索B细胞急性淋巴细胞白血病（B-ALL）中β-catenin蛋白降解通路作为治疗靶点的潜力。研究团队通过比较B-ALL与实体瘤的β-catenin表达与磷酸化状态，结合CRISPR筛选和体内PDX模型验证，揭示了B-ALL细胞依赖GSK3β介导的β-catenin持续降解以维持生存，而抑制GSK3β会破坏这一平衡，导致β-catenin与Ikaros/NuRD复合物结合并引发细胞死亡。其核心创新性在于发现了B-ALL中一个不同于经典Wnt/β-catenin促癌通路的、依赖β-catenin降解的独特生存机制，并提出了将已有临床安全性数据的GSK3β抑制剂进行药物重用的新策略。局限性在于研究主要基于临床前模型，其向人体转化的有效性和安全性仍需进一步临床试验证实，且未详细探讨可能存在的耐药机制。

---

## 10. CDK10通过抑制天然免疫感知来限制抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507537)
**期刊：** Nature cancer
**PMID：** 41507537
**DOI：** 10.1038/s43018-025-01101-2

### 第一部分 原文与翻译

**英文原标题：** CDK10 inhibits innate sensing to constrain antitumor immunity.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探索CDK10在肿瘤免疫微环境中的新功能。研究揭示了CDK10通过抑制细胞内的天然免疫感知通路，从而削弱了机体的抗肿瘤免疫反应。这一发现将细胞周期激酶CDK10与先天免疫调控联系起来，为理解肿瘤免疫逃逸提供了新视角，并可能提示CDK10是一个潜在的免疫治疗靶点。然而，由于摘要不可用，其具体的研究方法、实验模型以及结论的详细证据链尚不明确，这是当前信息的主要局限性。

---

## 11. CDK10抑制核酸传感器介导的抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507536)
**期刊：** Nature cancer
**PMID：** 41507536
**DOI：** 10.1038/s43018-025-01100-3

### 第一部分 原文与翻译

**英文原标题：** CDK10 suppresses nucleic acid sensors-mediated antitumor immunity.

> **英文摘要：**
> Cancer immunotherapies have revolutionized cancer treatment, yet many patients fail to respond. Activating innate immunity offers a promising approach to enhance therapeutic efficacy, but the signaling kinases directly regulating this process to boost antitumor responses remain elusive. Here we conduct an in vivo kinome CRISPR screen and identify CDK10 as a key suppressor of tumor immune surveillance. Mechanistically, CDK10 phosphorylates DNMT1 and RAP80 to reduce the accumulation of double-stranded RNA and R-loops, which alleviates the activation of innate immune pathways mediated by MDA5 and cGAS. Kinase inhibitor screens identify NVP-AST487 and ponatinib as selective CDK10 inhibitors. Both genetic and pharmacological inhibition of CDK10 activates MDA5 and cGAS pathways, fostering an immunoactive tumor microenvironment that enhances cancer immunotherapy in multiple mouse tumor models. Clinically, low CDK10 expression in tumors correlates with better immunotherapy responses. These findings establish CDK10 as a pivotal modulator of tumor immunity and a potential therapeutic target.

> **中文摘要：**
> 癌症免疫疗法已经彻底改变了癌症治疗，但许多患者未能产生应答。激活先天免疫为提升治疗效果提供了一种有前景的策略，然而直接调控此过程以增强抗肿瘤反应的信号激酶仍不明确。本研究通过体内激酶组CRISPR筛选，鉴定出CDK10是肿瘤免疫监视的一个关键抑制因子。机制上，CDK10通过磷酸化DNMT1和RAP80来减少双链RNA和R-loop的积累，从而减轻由MDA5和cGAS介导的先天免疫通路激活。激酶抑制剂筛选鉴定出NVP-AST487和普纳替尼是选择性的CDK10抑制剂。无论是遗传学还是药理学抑制CDK10，均能激活MDA5和cGAS通路，营造一个免疫活跃的肿瘤微环境，进而在多种小鼠肿瘤模型中增强癌症免疫疗法的效果。临床上，肿瘤中CDK10的低表达与更好的免疫治疗反应相关。这些发现确立了CDK10作为肿瘤免疫的关键调节因子和一个潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在探索调控先天免疫以增强抗肿瘤免疫应答的关键激酶。研究者通过体内激酶组CRISPR筛选，结合机制研究与抑制剂筛选，系统性地揭示了CDK10通过磷酸化DNMT1和RAP80抑制核酸传感器MDA5/cGAS通路的新机制，并验证了其作为药物靶点的潜力。其创新性在于首次将CDK10确立为连接表观遗传调控、基因组不稳定性与肿瘤免疫监视的核心负向节点，为联合免疫治疗提供了新靶点。局限性在于临床相关性仅为观察性关联，且CDK10抑制剂的体内特异性与潜在脱靶效应需进一步验证。

---

## 12. 塑造胶质母细胞瘤免疫的免疫抑制机制与治疗干预

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507535)
**期刊：** Nature cancer
**PMID：** 41507535
**DOI：** 10.1038/s43018-025-01097-9

### 第一部分 原文与翻译

**英文原标题：** Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity.

> **英文摘要：**
> Plasticity is a hallmark of aggressive tumors, including glioblastoma (GBM), enabling tumor cells and the tumor microenvironment (TME) to adapt to diverse niches and evade treatment. Here, we discuss how innate and adaptive immune players cooperate in time and space to create an immunosuppressive TME that supports GBM growth and confers resistance to conventional treatments and immunotherapies. We highlight how therapeutic interventions reshape the TME, underscoring the need for targeted approaches to overcome resistance. We introduce the concepts of local TME priming and TME rewiring as necessary foundations for achieving more effective and durable clinical responses in the future.

> **中文摘要：**
> 可塑性是包括胶质母细胞瘤（GBM）在内的侵袭性肿瘤的标志，它使肿瘤细胞和肿瘤微环境（TME）能够适应不同的生态位并逃避治疗。在此，我们讨论了先天性和适应性免疫参与者如何在时间和空间上协同作用，创造一个支持GBM生长并赋予其对常规治疗和免疫疗法抵抗性的免疫抑制性TME。我们强调了治疗干预如何重塑TME，并强调了需要有针对性的方法来克服这种抵抗性。我们引入了局部TME启动和TME重塑的概念，作为未来实现更有效、更持久的临床反应的必要基础。

### 第二部分 AI 大师评价

本文是一篇综述，核心目的是系统阐述胶质母细胞瘤（GBM）免疫抑制微环境（TME）的形成机制与重塑策略。其方法侧重于从时空维度解析固有及适应性免疫细胞在TME中的协同作用。文章的主要发现/观点是，GBM的免疫抑制TME是其治疗抵抗的关键，而治疗干预可以重塑TME。其创新性在于提出了“局部TME启动”和“TME重塑”这两个概念框架，为开发更有效的联合疗法指明了方向。局限性在于作为一篇观点/综述，其结论主要基于现有文献的综合分析，缺乏新的实验数据支持，具体转化路径仍需进一步探索。

---

## 13. 瞬时机械激活Piezo1通道促进造血干细胞的体外扩增。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507440)
**期刊：** Cell research
**PMID：** 41507440
**DOI：** 10.1038/s41422-025-01209-1

### 第一部分 原文与翻译

**英文原标题：** Transient mechanical activation of the Piezo1 channel facilitates ex vivo expansion of hematopoietic stem cells.

> **英文摘要：**
> Achieving long-term ex vivo expansion of functional hematopoietic stem cells (HSCs) is essential for advancing HSC-based clinical therapies. Although mechanosensitive ion channels are known to play key roles in the hematopoietic system, their involvement in HSC expansion remains unclear. Here, we show that Piezo1 is highly expressed in HSCs. Both genetic deletion and prolonged chemical activation of Piezo1 impair cultured HSC function, indicating that transient mechanical activation of Piezo1 is required for maintenance of HSCs in culture. To achieve this, we screened various microspheres and found that PS500 (500-nm polystyrene microspheres) significantly enhanced ex vivo expansion of mouse bone marrow HSCs with long-term repopulating capacity. PS500 also expanded human umbilical cord blood HSCs capable of engraftment in immunodeficient mice. Mechanistically, PS500 activates Piezo1, triggering Ca-dependent expression of proliferative cytokines and subsequent STAT3 activation, which support HSC self-renewal and proliferation. Together, these findings show that PS500 enables transient Piezo1 activation and efficient, non-toxic expansion of functional HSCs, offering a promising approach for the generation of transplantable HSCs for clinical use.

> **中文摘要：**
> 实现功能性造血干细胞（HSCs）的长期体外扩增对于推进基于HSC的临床治疗至关重要。尽管已知机械敏感离子通道在造血系统中发挥关键作用，但它们在HSC扩增中的参与仍不清楚。在此，我们发现Piezo1在HSCs中高表达。Piezo1的基因敲除和长时间的化学激活均会损害培养的HSC功能，这表明Piezo1的瞬时机械激活是维持培养中HSCs所必需的。为实现这一点，我们筛选了多种微球，发现PS500（500纳米聚苯乙烯微球）能显著增强具有长期重建能力的小鼠骨髓HSCs的体外扩增。PS500也能扩增能够在免疫缺陷小鼠中植入的人脐带血HSCs。从机制上讲，PS500激活Piezo1，触发钙依赖性增殖细胞因子的表达和随后的STAT3激活，从而支持HSC的自我更新和增殖。总之，这些发现表明，PS500能够实现Piezo1的瞬时激活以及功能性HSCs的高效、无毒扩增，为生成可用于临床的移植性HSCs提供了一种有前景的方法。

### 第二部分 AI 大师评价

本研究旨在解决功能性造血干细胞体外扩增的难题，核心创新在于利用PS500微球对Piezo1通道进行瞬时机械激活。研究者通过筛选微球材料，并结合遗传学和药理学手段，明确了Piezo1的瞬时而非持续激活是维持HSC功能的关键，并揭示了其下游通过钙离子、细胞因子和STAT3信号通路促进HSC自我更新的分子机制。该研究为临床级HSC的规模化制备提供了新颖且具转化潜力的物理-生物学策略，但研究结果主要基于小鼠模型和体外实验，其长期安全性和在大型动物或人体内的有效性仍需进一步验证。

---

## 14. 为CBFA2T3::GLIS2急性髓系白血病寻找靶向疗法。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507381)
**期刊：** Leukemia
**PMID：** 41507381
**DOI：** 10.1038/s41375-025-02845-7

### 第一部分 原文与翻译

**英文原标题：** Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.

> **英文摘要：**
> CBFA2T3::GLIS2-positive pediatric acute myeloid leukemia (AML) remains one of the worst prognostic AML subgroups. To uncover innovative targeted therapy approaches in this disease subtype we performed genome-scale CRISPR-Cas9 screening that highlighted a strong, selective dependency on JAK2 compared to other types of cancer. Using a doxycycline-inducible JAK2 knockout (KO) system, we validated JAK2 dependency in CBFA2T3::GLIS2 cell lines, observing impaired proliferation in vitro and in vivo and apoptosis induction in vitro. Both type I (ruxolitinib) and type II (CHZ868) JAK2 inhibitors showed selective in vitro activity in CBFA2T3::GLIS2-positive AML models. To identify resistance and sensitizer mechanisms to JAK2 inhibitors, we used CRISPR-Cas9 ruxolitinib anchor screening in CBFA2T3::GLIS2 AML. sgRNAs targeting negative regulators of the MAPK pathway were enriched in the ruxolitinib-treated cells. Similarly, CBFA2T3::GLIS2 AML sublines grown to resistance under chronic ruxolitinib treatment expressed pathogenic NRAS mutations. Both approaches converged on MAPK pathway activation as a resistance mechanism to ruxolitinib treatment. Combining ruxolitinib with MEK inhibitors showed a synergistic effect in cell lines and patient-derived xenograft (PDX) cells expressing the fusion and in vivo activity in a CBFA2T3::GLIS2 AML PDX, suggesting a potential approach to target this signaling circuitry in this poor outcome AML subtype.

> **中文摘要：**
> CBFA2T3::GLIS2阳性儿童急性髓系白血病（AML）仍然是预后最差的AML亚组之一。为了揭示该疾病亚型中创新的靶向治疗方法，我们进行了基因组规模的CRISPR-Cas9筛选，结果显示与其他癌症类型相比，该亚型对JAK2存在强烈且选择性的依赖性。利用多西环素诱导的JAK2敲除（KO）系统，我们在CBFA2T3::GLIS2细胞系中验证了JAK2依赖性，观察到体外和体内增殖受损以及体外凋亡诱导。I型（鲁索替尼）和II型（CHZ868）JAK2抑制剂均在CBFA2T3::GLIS2阳性AML模型中显示出选择性的体外活性。为了确定对JAK2抑制剂的耐药和增敏机制，我们在CBFA2T3::GLIS2 AML中使用了CRISPR-Cas9鲁索替尼锚定筛选。靶向MAPK通路负调控因子的sgRNA在鲁索替尼处理的细胞中富集。类似地，在长期鲁索替尼处理下生长出耐药性的CBFA2T3::GLIS2 AML亚系表达了致病性NRAS突变。两种方法均指向MAPK通路激活是鲁索替尼治疗的耐药机制。将鲁索替尼与MEK抑制剂联用，在表达该融合基因的细胞系和患者来源异种移植（PDX）细胞中显示出协同效应，并在一个CBFA2T3::GLIS2 AML PDX模型中显示出体内活性，这提示了一种靶向这一信号通路以治疗该不良预后AML亚型的潜在方法。

### 第二部分 AI 大师评价

本研究旨在为预后极差的CBFA2T3::GLIS2融合基因阳性儿童AML寻找靶向治疗策略。核心方法是利用CRISPR-Cas9全基因组筛选发现该亚型对JAK2的特异性依赖，并通过功能实验和抑制剂测试加以验证。主要发现是JAK2抑制剂（如鲁索替尼）具有选择性活性，但MAPK通路激活（如NRAS突变）会导致耐药，而联合MEK抑制剂可克服耐药并产生协同效应。创新性在于系统性地从依赖基因发现、耐药机制解析到联合治疗策略验证，为临床转化提供了明确路径；局限性在于研究主要基于临床前模型，其结论需在临床试验中进一步验证，且未探讨其他可能的耐药或协同机制。

---

## 15. 作者更正：关于BCDX2复合物在同源重组中功能的结构性见解。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507367)
**期刊：** Nature
**PMID：** 41507367
**DOI：** 10.1038/s41586-025-10081-3

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Structural insights into BCDX2 complex function in homologous recombination.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文为《自然》期刊上关于BCDX2复合物研究的作者更正。其核心目的在于修正先前发表论文中的错误，以确保关于该复合物在同源重组中功能的结构生物学发现（可能涉及晶体学或冷冻电镜方法）的准确性得以维持。这体现了顶级期刊对研究数据严谨性和可重复性的高度重视。然而，由于缺乏摘要，无法直接评估其具体科学内容、创新点或潜在局限性。

---

## 16. 体积压缩调控AXIN的相分离，并作为运算放大器双向调节类器官中的Wnt信号通路。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507229)
**期刊：** Nature communications
**PMID：** 41507229
**DOI：** 10.1038/s41467-025-68209-y

### 第一部分 原文与翻译

**英文原标题：** Volumetric compression regulates the phase separation of AXIN and acts as an operational amplifier to bidirectionally modulate Wnt signaling in organoids.

> **英文摘要：**
> Protein phase separation has emerged as a crucial mechanism for spatiotemporal regulation of intracellular processes, yet its potential to integrate and compute diverse extracellular signals is not fully understood. Here, we show a mechano-biochemical circuit that harnesses phase separation to process mechanical and biochemical inputs, modulating cell fate decisions. We demonstrate that volumetric compression bidirectionally regulates canonical Wnt/β-catenin signaling, where the presence of Wnt ligands determines the locations of AXIN phase separation to form either LRP6 signalosomes on the cell membrane or β-catenin destruction complexes in the cytosol, while the mechanical stimulus promotes degree of phase separation to amplify either the positive or negative signal. This circuit enhances healthy intestinal organoid proliferation while suppressing patient-derived colorectal cancer organoid growth, revealing its potential for precise mechanotherapy. Our findings establish phase separation as a critical component in mechanical signal transduction and provide a framework for integrating mechanical and biochemical cues in cellular decision-making. This approach opens avenues for targeted therapies and deepens our understanding of how cells process complex environmental information.

> **中文摘要：**
> 蛋白质相分离已成为细胞内过程时空调控的关键机制，但其整合与计算多种细胞外信号的潜力尚未被完全理解。在此，我们展示了一种利用相分离来处理机械与生化输入，从而调控细胞命运决定的力学生物化学回路。我们证明，体积压缩可双向调控经典的Wnt/β-catenin信号通路：其中Wnt配体的存在决定了AXIN相分离的位置，从而在细胞膜上形成LRP6信号体或在细胞质中形成β-catenin破坏复合体，而机械刺激则促进相分离的程度，以放大正向或负向信号。该回路能促进健康肠道类器官的增殖，同时抑制患者来源的结直肠癌类器官的生长，揭示了其在精准机械疗法方面的潜力。我们的研究确立了相分离在机械信号转导中的关键作用，并为整合机械与生化线索以参与细胞决策提供了一个框架。这一方法为靶向治疗开辟了新途径，并加深了我们对细胞如何处理复杂环境信息的理解。

### 第二部分 AI 大师评价

本研究旨在揭示蛋白质相分离如何整合机械与生化信号以调控细胞命运。作者在类器官模型中构建了一个“力学生物化学回路”，发现体积压缩作为机械输入，通过调控AXIN蛋白的相分离程度，双向放大Wnt/β-catenin信号，其方向由Wnt配体（生化输入）决定。其核心创新在于将相分离概念化为一个可双向运算的“放大器”，并直接连接了机械力感知与经典发育信号通路，为“精准机械疗法”提供了新范式。然而，研究主要基于类器官模型，其在体（in vivo）的有效性、具体力学感受器以及该回路在其他组织或疾病中的普适性，仍有待进一步探索。

---

## 17. 通过增强TCR信号强度，敲除TIGIT可挽救低亲和力TCR工程化T细胞的抗肿瘤活性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507193)
**期刊：** Nature communications
**PMID：** 41507193
**DOI：** 10.1038/s41467-025-67263-w

### 第一部分 原文与翻译

**英文原标题：** TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

> **英文摘要：**
> T-cell avidity is a major determinant of Adoptive T cell therapy (ACT) efficacy for cancer treatment. However, high-avidity tumor-specific T cells can rarely be isolated from cancer patients, highlighting the need for strategies to enhance the cytotoxic capacity of low-avidity cells. Here, we rescue the anti-tumor functions of low-avidity T cells against pancreatic ductal adenocarcinoma (PDAC) by knocking-out TIGIT, a key inhibitory molecule expressed on exhausted CD8 T cells infiltrating gastrointestinal tumors. We uncover that TIGIT disruption by base editing boosts the intracellular signal transduction derived from a weak T cell receptor (TCR) engagement enforcing cytoskeletal rearrangements, thus increasing T cell avidity and stabilizing the immunological synapse. Accordingly, TIGIT disruption enables low-avidity T cells to exert robust degranulation, comparable to that of high-avidity T cells, and potent and durable anti-tumor capacity in vivo in male mice. These results highlight TIGIT knockout as a potential strategy to enhance low-avidity T cell function and broaden the repertoire of TCR engineered T cells in the treatment of pancreatic cancer and other solid malignancies.

> **中文摘要：**
> T细胞亲和力是决定过继性T细胞疗法（ACT）治疗癌症效果的主要因素。然而，从癌症患者体内很难分离出高亲和力的肿瘤特异性T细胞，这凸显了需要制定策略来增强低亲和力细胞的细胞毒性能力。在本研究中，我们通过敲除TIGIT（一种在浸润胃肠道肿瘤的耗竭性CD8 T细胞上表达的关键抑制性分子），挽救了低亲和力T细胞对胰腺导管腺癌（PDAC）的抗肿瘤功能。我们发现，通过碱基编辑破坏TIGIT，可以增强由弱T细胞受体（TCR）结合所引发的细胞内信号转导，从而强制细胞骨架重排，进而提高T细胞亲和力并稳定免疫突触。因此，TIGIT的破坏使低亲和力T细胞能够发挥强大的脱颗粒作用（与高亲和力T细胞相当），并在雄性小鼠体内表现出强效且持久的抗肿瘤能力。这些结果强调了TIGIT敲除作为一种潜在策略，可增强低亲和力T细胞的功能，并拓宽TCR工程化T细胞在胰腺癌和其他实体恶性肿瘤治疗中的应用范围。

### 第二部分 AI 大师评价

本研究旨在解决过继性T细胞疗法中高亲和力T细胞来源稀缺的瓶颈问题。研究者通过碱基编辑技术敲除抑制性受体TIGIT，成功增强了低亲和力TCR工程化T细胞的抗肿瘤功能。核心发现是TIGIT敲除通过增强弱TCR信号下游的细胞骨架重排，提升了T细胞亲和力与免疫突触稳定性，从而在胰腺癌模型中恢复了低亲和力T细胞的脱颗粒与体内抗肿瘤效力。该策略的创新性在于从信号强度层面改造低亲和力T细胞，为拓宽TCR-T细胞疗法在实体瘤中的应用提供了新思路，但研究目前仅限于雄性小鼠模型，其临床转化潜力及在雌性个体中的效果仍需进一步验证。

---

## 18. 基于小球藻来源细胞外囊泡的纳米凝胶通过抑制cGAS-STING通路治疗放射性肺损伤。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507189)
**期刊：** Nature communications
**PMID：** 41507189
**DOI：** 10.1038/s41467-025-68140-2

### 第一部分 原文与翻译

**英文原标题：** Chlorella-derived extracellular vesicle-based nanogels suppress cGAS-STING for treatment of radiation-induced lung injury.

> **英文摘要：**
> Radiation-induced lung injury (RILI) represents a critical complication associated with radiation exposure, requiring targeted treatment strategies in clinical practice. Here, we pioneered the extraction of extracellular vesicles (EVs) from Chlorella and innovatively developed a multifunctional nanogel platform (RU.521-EVs NPs) by combining them with the cGAS inhibitor RU.521. The Chlorella-derived EVs possess a naturally high abundance of antioxidant enzymes (e.g., SOD2, CAT) and anti-inflammatory lipids (e.g., linolenic acid). RU.521-EVs NPs could synergistically inhibit excessive activation of the cGAS-STING pathway, and significantly reduce the secretion of pro-inflammatory factors. In the RILI mouse model, the nanogel demonstrated significant anti-inflammatory and anti-fibrosis activity, with no observed systemic toxicity. Their biological safety, cost-effectiveness, and multifaceted anti-radiation mechanisms of nanogels make them particularly beneficial in contexts such as medical radiation exposure, providing a strategy for the clinical translation of RILI that emphasizes both safety and long-term efficacy.

> **中文摘要：**
> 放射性肺损伤（RILI）是与辐射暴露相关的一种严重并发症，在临床实践中需要靶向治疗策略。本研究开创性地从小球藻中提取了细胞外囊泡（EVs），并通过将其与cGAS抑制剂RU.521结合，创新性地开发了一种多功能纳米凝胶平台（RU.521-EVs NPs）。小球藻来源的EVs天然富含抗氧化酶（如SOD2、CAT）和抗炎脂质（如亚麻酸）。RU.521-EVs NPs能够协同抑制cGAS-STING通路的过度激活，并显著减少促炎因子的分泌。在RILI小鼠模型中，该纳米凝胶表现出显著的抗炎和抗纤维化活性，且未观察到全身毒性。该纳米凝胶的生物安全性、成本效益以及多方面的抗辐射机制，使其在医疗辐射暴露等场景中尤为有益，为RILI的临床转化提供了一种兼顾安全性和长期疗效的策略。

### 第二部分 AI 大师评价

本研究旨在开发一种新型纳米凝胶平台，用于治疗放射性肺损伤。其核心创新在于首次利用小球藻来源的细胞外囊泡作为天然抗氧化/抗炎成分载体，并与cGAS抑制剂RU.521结合，构建了协同抑制cGAS-STING通路的纳米药物。研究结果表明，该纳米凝胶在小鼠模型中有效减轻了炎症和纤维化，且安全性良好。其优势在于整合了生物源材料的天然活性与合成药物的靶向性，为RILI治疗提供了新策略；但摘要未提及其在大型动物模型中的验证数据，其长期生物分布与代谢途径也有待进一步阐明。

---

## 19. 用于评估用药依从性的生物可吸收RFID胶囊。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507185)
**期刊：** Nature communications
**PMID：** 41507185
**DOI：** 10.1038/s41467-025-67551-5

### 第一部分 原文与翻译

**英文原标题：** Bioresorbable RFID capsule for assessing medication adherence.

> **英文摘要：**
> Medication non-adherence remains a critical healthcare challenge, contributing to approximately 125,000 preventable deaths each year and incurring over $100 billion in annual costs in the United States. Current adherence assessment strategies are constrained by limited scalability, suboptimal patient acceptability, and environmental sustainability concerns. To address these limitations, we developed SAFARI (Smart Adherence via FARaday cage And Resorbable Ingestible), a bioresorbable, passive RFID system that enables precise monitoring of medication ingestion events. The platform incorporates a novel cellulose-metal particle-based radiofrequency (RF) shielding layer, effectively creating a Faraday cage that facilitates reliable signal detection. By employing fully biodegradable materials, SAFARI obviates the need for device retrieval or battery replacement, thereby mitigating electronic waste. Moreover, the tags are compatible with standard gelatin or hydroxypropyl methylcellulose (HPMC) capsules, further enhancing clinical translational potential. In vivo evaluation in swine models corroborated SAFARI's ability to accurately detect ingestion events while demonstrating complete biodegradation following administration. These findings highlight the system's potential to improve patient adherence tracking without introducing significant logistical burdens or ecological impact. As such, SAFARI establishes a foundational framework for the development of next-generation, eco-conscious adherence monitoring solutions and associated interventions-ultimately aiming to bolster therapeutic outcomes and reduce healthcare expenditures.

> **中文摘要：**
> 用药不依从性仍然是一个关键的医疗保健挑战，每年导致约125,000例可预防的死亡，并在美国造成超过1000亿美元的年均成本。当前的依从性评估策略受限于可扩展性有限、患者接受度欠佳以及环境可持续性问题。为了解决这些局限性，我们开发了SAFARI（通过法拉第笼和可吸收可摄入物实现的智能依从性监测），这是一种生物可吸收的被动RFID系统，能够精确监测药物摄入事件。该平台采用了一种新型的基于纤维素-金属颗粒的射频屏蔽层，有效形成了一个法拉第笼，从而促进了可靠的信号检测。通过使用完全可生物降解的材料，SAFARI无需设备回收或电池更换，从而减少了电子废物。此外，该标签与标准的明胶或羟丙甲纤维素胶囊兼容，进一步增强了临床转化潜力。在猪模型中的体内评估证实了SAFARI能够准确检测摄入事件，同时证明其在给药后能够完全生物降解。这些发现凸显了该系统在不引入显著物流负担或生态影响的情况下改善患者依从性跟踪的潜力。因此，SAFARI为开发下一代具有生态意识的依从性监测解决方案及相关干预措施奠定了基础框架，最终旨在改善治疗效果并降低医疗支出。

### 第二部分 AI 大师评价

本研究旨在解决用药依从性监测中存在的可扩展性、患者接受度和环境可持续性等关键挑战。其核心创新在于开发了一种名为SAFARI的生物可吸收、无源RFID胶囊系统，该系统利用新型纤维素-金属颗粒射频屏蔽层形成法拉第笼，实现了对药物摄入事件的可靠检测。在猪模型中的验证表明，该系统既能准确监测摄入，又能完全生物降解，避免了电子废物问题，并与标准胶囊兼容，显示出良好的临床转化前景。其局限性在于目前仅在动物模型中得到验证，未来需要进一步的人体临床试验来评估其安全性、有效性和长期性能。

---

## 20. 用于高通量检测转移性细菌感染循环肿瘤细胞的机械表型分析芯片

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507183)
**期刊：** Nature communications
**PMID：** 41507183
**DOI：** 10.1038/s41467-025-68152-y

### 第一部分 原文与翻译

**英文原标题：** A Mechanophenotyping chip for high-throughput detection of metastatic bacteria-infected circulating tumor cells.

> **英文摘要：**
> Emerging evidence underscores biophysical characteristics of cancer cells as key modulators of cancer progression and metastasis. Herein, we reported a cell-mechanophenotyping screening microfluidic chip (termed LesM) for the high-efficient capture of circulating tumor cells (CTCs) and evaluation of single-cell deformation to reveal the hematogenous metastatic potential of bacteria-infected breast cancer. LesM employs L-shaped traps to capture single cells, leveraging bacteria-infected CTCs with cytoskeletal reorganization traverse narrowed channels while rigid native cells are retained. The platform demonstrates an average single-cell capture efficiency of 95.42% and specificity of 85.34% in discriminating infected versus non-infected breast cancer cells, validated through parallel in vivo metastatic assays. LesM enables high-throughput sensing up to 10,240 cells of mechanical signatures and microbial cargo, correlating with metastatic risk and antibiotic response. By bridging biomechanics and intratumoral microbiota detection, LesM offers a transformative liquid biopsy tool for predicting distant metastasis and guiding antimicrobial therapies in bacteria-infected breast cancers.

> **中文摘要：**
> 新出现的证据强调，癌细胞的生物物理特性是癌症进展和转移的关键调节因素。在此，我们报道了一种细胞机械表型筛选微流控芯片（命名为LesM），用于高效捕获循环肿瘤细胞（CTCs）并评估单细胞变形，以揭示细菌感染乳腺癌的血行转移潜力。LesM采用L形陷阱捕获单细胞，利用细胞骨架重组的细菌感染CTCs能够穿过狭窄通道，而僵硬的原始细胞则被截留。该平台在区分感染与非感染乳腺癌细胞方面，平均单细胞捕获效率为95.42%，特异性为85.34%，并通过平行的体内转移实验得到验证。LesM能够对多达10,240个细胞的机械特征和微生物负荷进行高通量传感，这些特征与转移风险和抗生素反应相关。通过桥接生物力学和瘤内微生物群检测，LesM为预测细菌感染乳腺癌的远处转移和指导抗菌治疗提供了一种变革性的液体活检工具。

### 第二部分 AI 大师评价

本研究旨在开发一种新型微流控芯片（LesM），通过检测单细胞机械特性来评估细菌感染乳腺癌细胞的转移潜力。其核心创新在于将细胞力学表型分析与瘤内微生物检测相结合，利用细胞骨架重组导致的变形能力差异来高效分选感染细胞。该平台展现出高捕获效率和特异性，并能实现高通量分析，为液体活检和精准抗菌治疗提供了新工具。然而，其应用目前聚焦于乳腺癌，且结论主要基于体外和动物模型验证，未来需在更广泛的癌症类型和临床队列中进一步评估其预测价值。

---

## 21. METTL3缺失通过调控巨噬细胞中ISG15-FASN轴介导的脂质代谢促进胶质瘤进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507178)
**期刊：** Nature communications
**PMID：** 41507178
**DOI：** 10.1038/s41467-025-68079-4

### 第一部分 原文与翻译

**英文原标题：** METTL3 abrogation promotes glioma progression through regulating the ISG15-FASN axis-mediated lipid metabolism in macrophages.

> **英文摘要：**
> Tumor-associated macrophages (TAMs) constitute a pivotal cellular component within the intricate tumor microenvironment (TME). However, the relationship between the N6-methyladenosine (m6A) and metabolic pattern of TAMs remains poorly understood. Here we show that the m6A methyltransferase METTL3 is conspicuously downregulated in monocyte-derived macrophages from glioblastoma (GBM) patients. Conditional knockout of Mettl3 in myeloid cells augments lipid metabolism and accelerates glioma progression. Furthermore, we found that METTL3 deficiency facilitates fatty acid synthase (FASN) expression, while compromising CD8 T cell response. Mechanistically, ISG15 is highly expressed in METTL3-deficient macrophages. ISG15 interacts with FASN and regulates FASN ISGylation and its stability through impeding FASN ubiquitination. Notably, the suppression of ISG15 in METTL3-deficient macrophages reverses the enhanced FASN expression and restores CD8 T cell functionality. Furthermore, we demonstrate that FASN knockout or FASN inhibitor treatment in myeloid cells abrogates the exaggerated tumor progression triggered by METTL3 knockout. Collectively, this study highlights the pivotal role of m6A in regulating macrophage metabolism and identifies potential targets in controlling GBM progression.

> **中文摘要：**
> 肿瘤相关巨噬细胞（TAMs）是复杂肿瘤微环境（TME）中的关键细胞组分。然而，N6-甲基腺苷（m6A）与TAMs代谢模式之间的关系仍知之甚少。本研究发现，在胶质母细胞瘤（GBM）患者的单核细胞来源巨噬细胞中，m6A甲基转移酶METTL3显著下调。在髓系细胞中条件性敲除Mettl3会增强脂质代谢并加速胶质瘤进展。此外，我们发现METTL3缺陷促进了脂肪酸合酶（FASN）的表达，同时损害了CD8 T细胞反应。机制上，ISG15在METTL3缺陷的巨噬细胞中高表达。ISG15与FASN相互作用，并通过阻碍FASN泛素化来调控FASN的ISGylation修饰及其稳定性。值得注意的是，在METTL3缺陷的巨噬细胞中抑制ISG15可逆转增强的FASN表达并恢复CD8 T细胞功能。此外，我们证明在髓系细胞中敲除FASN或使用FASN抑制剂处理，能够消除由METTL3敲除引发的过度肿瘤进展。总之，本研究强调了m6A在调控巨噬细胞代谢中的关键作用，并确定了控制GBM进展的潜在靶点。

### 第二部分 AI 大师评价

本研究旨在探索m6A修饰在肿瘤相关巨噬细胞代谢重编程中的作用及其对胶质瘤进展的影响。研究采用临床样本分析、条件性基因敲除小鼠模型、分子互作与修饰检测等方法。核心发现是METTL3缺失通过上调ISG15，促进FASN的ISGylation修饰以稳定其蛋白水平，从而驱动巨噬细胞脂质代谢重编程，最终抑制抗肿瘤CD8 T细胞功能并加速胶质瘤生长。其创新性在于首次将m6A修饰、ISGylation翻译后修饰与巨噬细胞脂代谢轴联系起来，为GBM免疫代谢治疗提供了新靶点（ISG15-FASN轴）。局限性在于研究主要基于小鼠模型，其在人体肿瘤微环境中的普适性及靶向该轴的治疗策略有待进一步临床验证。

---

## 22. USP10通过拮抗DTX3L介导的SATB2泛素化促进胶质瘤干细胞维持与胶质母细胞瘤生长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507172)
**期刊：** Nature communications
**PMID：** 41507172
**DOI：** 10.1038/s41467-025-67418-9

### 第一部分 原文与翻译

**英文原标题：** USP10 promotes glioma stem cell maintenance and glioblastoma growth by antagonizing DTX3L-mediated SATB2 ubiquitination.

> **英文摘要：**
> Special AT-rich sequence-binding protein 2 (SATB2) is a nuclear matrix-associated protein with a pivotal role in glioblastoma (GBM) progression. However, the mechanisms underpinning aberrant SATB2 expression remain elusive. Here, we identify the ubiquitin specific peptidase 10 (USP10) as a deubiquitinase and the deltex E3 ubiquitin ligase 3 L (DTX3L) as a ubiquitin ligase of SATB2 in glioma stem cells (GSCs). USP10 and DTX3L regulate SATB2 ubiquitination at the K266 residue through mutually exclusive interactions and opposing activities. USP10, enriched in GSCs, is induced by transcription factor YY2. Knockdown of USP10 or overexpression of DTX3L markedly downregulates SATB2, resulting in the inhibition of GSC self-renewal and GBM growth, which can be rescued by the overexpression of SATB2. Importantly, pharmacological inhibition of USP10 by Wu-5 effectively suppresses tumor growth. These findings highlight the antagonistic roles of USP10 and DTX3L in the regulation of GBM malignancy and propose USP10 as a potential therapeutic target.

> **中文摘要：**
> 特殊AT富集序列结合蛋白2（SATB2）是一种核基质相关蛋白，在胶质母细胞瘤（GBM）进展中起关键作用。然而，支持SATB2异常表达的机制仍不清楚。在此，我们鉴定出泛素特异性肽酶10（USP10）是SATB2的去泛素化酶，而Deltex E3泛素连接酶3L（DTX3L）是SATB2在胶质瘤干细胞（GSCs）中的泛素连接酶。USP10和DTX3L通过相互排斥的相互作用和相反的功能，在K266位点调控SATB2的泛素化。在GSCs中富集的USP10由转录因子YY2诱导。敲低USP10或过表达DTX3L会显著下调SATB2，从而抑制GSC的自我更新和GBM的生长，而这种抑制可被SATB2的过表达所挽救。重要的是，使用Wu-5药物抑制USP10能有效抑制肿瘤生长。这些发现揭示了USP10和DTX3L在调控GBM恶性进展中的拮抗作用，并提出USP10是一个潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明胶质母细胞瘤中关键蛋白SATB2表达异常的上游调控机制。通过分子生物学方法，研究者鉴定出USP10和DTX3L分别是SATB2的去泛素化酶和泛素连接酶，并揭示了它们通过竞争性结合和拮抗活性在K266位点精细调控SATB2稳定性的新机制。其核心创新在于构建了“YY2-USP10-DTX3L-SATB2”这一全新的调控轴，并提供了靶向USP10的小分子抑制剂Wu-5的临床前疗效证据，为GBM治疗提供了新靶点。局限性在于研究主要基于细胞和动物模型，其临床转化潜力及在GBM不同分子亚型中的普适性有待进一步验证。

---

## 23. 酵母属间染色体转移可改善表型并引发广泛的转录响应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507170)
**期刊：** Nature communications
**PMID：** 41507170
**DOI：** 10.1038/s41467-025-68164-8

### 第一部分 原文与翻译

**英文原标题：** Intergeneric chromosomal transfer in yeast results in improved phenotypes and widespread transcriptional responses.

> **英文摘要：**
> Interspecific genetic exchanges caused by natural hybridization or horizontal gene transfer can lead to enhanced phenotypes, which are often of interest for industrial applications and evolutionary research. However, transferring genetic materials between distantly related species, such as intergeneric yeasts, presents technical challenges. In this study, we establish a method to transfer individual chromosomes from Saccharomyces cerevisiae (Sc) into Kluyveromyces marxianus (Km), an emerging model for bioproduction. The Sc chromosome of interest is circularized, genetically modified to carry Km centromeres and replication origins, and transformed into Km via protoplast transformation. Using this method, we generate two synthetic strains, each containing a full set of Km chromosomes and either Sc chromosome I or III. The Sc chromosomes exhibit normal replication, segregation, and active transcription after the transfer. The synthetic strains display enhanced phenotypes in flocculation and salt tolerance, which is found to be caused by transgressive expression of FLO9 and SPS22 on the transferred Sc chromosomes, respectively. Transcriptomic analysis reveal that transgressive expression is prevalent among the transferred Sc genes, suggesting evolution of lineage-specific cis- and trans-regulatory interactions across a long evolutionary timescale. Our strategy has potential applications in optimizing cell factories, constructing synthetic genomes, and advancing evolutionary research.

> **中文摘要：**
> 由自然杂交或水平基因转移引起的种间遗传交换可导致表型增强，这在工业应用和进化研究中常受关注。然而，在亲缘关系较远的物种（如属间酵母）之间转移遗传物质存在技术挑战。在本研究中，我们建立了一种将单个染色体从酿酒酵母（Sc）转移到马克斯克鲁维酵母（Km，一种新兴的生物生产模型）中的方法。目标Sc染色体被环化，经基因改造携带Km着丝粒和复制起点，并通过原生质体转化法转入Km。利用此方法，我们构建了两株合成菌株，每株均含有一套完整的Km染色体以及Sc的I号或III号染色体。转移后，Sc染色体表现出正常的复制、分离和活跃转录。合成菌株在絮凝和耐盐性方面显示出增强的表型，这分别被发现是由转移的Sc染色体上FLO9和SPS22基因的越亲表达所致。转录组分析揭示，越亲表达在转移的Sc基因中普遍存在，这表明在漫长的进化时间尺度上，谱系特异性的顺式和反式调控相互作用发生了进化。我们的策略在优化细胞工厂、构建合成基因组以及推进进化研究方面具有潜在应用价值。

### 第二部分 AI 大师评价

本研究旨在开发一种克服属间遗传障碍的技术，实现酵母染色体跨属转移。其核心创新在于建立了一套方法学：通过染色体环化、替换调控元件（着丝粒和复制起点）及原生质体转化，成功将酿酒酵母的完整染色体稳定导入马克斯克鲁维酵母中。研究发现，转移的染色体不仅功能正常，还通过其基因的普遍性“越亲表达”赋予了宿主新的有益表型，这揭示了长进化时间尺度下调控网络的重塑。该策略为合成生物学和进化研究提供了强大工具，但其局限性在于目前仅验证了单个染色体的转移，且对大规模、多染色体转移的兼容性及潜在细胞负担尚未可知。

---

## 24. 时间分辨多组学分析揭示染色质O-GlcNAc修饰促进衰老相关转录程序

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507163)
**期刊：** Nature communications
**PMID：** 41507163
**DOI：** 10.1038/s41467-025-68143-z

### 第一部分 原文与翻译

**英文原标题：** Time-resolved multiomics profiling reveals chromatin O-GlcNAc modification promotes senescence-associated transcriptional program.

> **英文摘要：**
> O-GlcNAc modification is a key cellular signal, but its role in regulating senescence-associated transcription remains poorly understood. Here, we apply a time-resolved chemical genomics strategy to map dynamic O-GlcNAc chromatin-associated proteins (OCPs) during oncogene-induced senescence (OIS) in primary human fibroblasts. Chromatin O-GlcNAc modification continues to accumulate, while 1,987 senescence-associated OCPs undergo dynamic shifts in genomic occupancy across diverse epigenetic chromatin states and display bimodal regulatory activities within the 3,466-gene senescence transcriptome. O-GlcNAc facilitates the formation of dual-function complexes: TF-SWI/SNF activates senescence-associated secretory phenotype (SASP) genes at promoters, whereas NuRD enforces the repression of cell-cycle regulators at enhancers. Furthermore, we identify O-GlcNAc modified JUN and GATAD2A as key regulators of OIS phenotypes in both in vitro and in vivo models of senescence-driven tumorigenesis. These findings reveal dynamic regulation and chromatin organization principles of O-GlcNAc-related epigenetic factors, providing insights into cellular senescence and potential therapeutic strategies.

> **中文摘要：**
> O-GlcNAc修饰是一种关键的细胞信号，但其在调控衰老相关转录中的作用仍知之甚少。本研究应用时间分辨化学基因组学策略，在原代人成纤维细胞的癌基因诱导衰老（OIS）过程中，绘制了动态的O-GlcNAc染色质相关蛋白（OCPs）图谱。染色质O-GlcNAc修饰持续积累，而1,987个衰老相关OCPs在不同表观遗传染色质状态下的基因组占据发生动态变化，并在包含3,466个基因的衰老转录组中表现出双峰调控活性。O-GlcNAc促进了双功能复合物的形成：TF-SWI/SNF在启动子处激活衰老相关分泌表型（SASP）基因，而NuRD则在增强子处强化细胞周期调控因子的抑制。此外，我们在衰老驱动的肿瘤发生的体外和体内模型中，鉴定出O-GlcNAc修饰的JUN和GATAD2A是OIS表型的关键调控因子。这些发现揭示了O-GlcNAc相关表观遗传因子的动态调控和染色质组织原则，为理解细胞衰老和潜在治疗策略提供了见解。

### 第二部分 AI 大师评价

本研究核心目的是阐明O-GlcNAc修饰在衰老相关转录调控中的动态作用。方法上，创新性地结合了时间分辨化学基因组学与多组学分析，系统描绘了OIS过程中OCPs的动态图谱。主要发现包括：揭示了OCPs在染色质上的动态重分布及其双峰调控功能，并鉴定出O-GlcNAc修饰的JUN和GATAD2A为关键调控因子，连接了表观修饰与衰老表型。其创新性在于首次从时间维度系统解析了O-GlcNAc在衰老中的染色质调控网络，并提出了“双功能复合物”模型。局限性在于研究主要基于成纤维细胞的OIS模型，其在其他衰老类型或组织中的普适性有待验证，且具体的分子调控细节仍需深入探索。

---

## 25. 动力蛋白维持核被膜稳态与基因组稳定性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507158)
**期刊：** Nature communications
**PMID：** 41507158
**DOI：** 10.1038/s41467-025-68130-4

### 第一部分 原文与翻译

**英文原标题：** Dynamins maintain nuclear envelope homeostasis and genome stability.

> **英文摘要：**
> The nuclear envelope is a protective barrier for the genome and a mechanotransduction interface between cytoplasm and nucleus, whose malfunction disrupts nucleocytoplasmic transport, compromises DNA repair, accelerates telomere shortening, and promotes genomic instability. Mechanisms governing nuclear envelope remodeling and maintenance in interphase and post-mitotic cells remain poorly understood. Here, we report a role for dynamins, a family of essential brain-enriched membrane- and microtubule-binding GTPases, in preserving nuclear envelope and genomic homeostasis. Cells lacking dynamins exhibit nuclear envelope dysmorphisms, including buds with long narrow necks where damaged DNA frequently accumulates. These cells also show impaired autophagic clearance, reduced levels of key DNA repair proteins, and aberrant microtubules. Nocodazole treatment restores nuclear morphology and reduces DNA damage. Collectively, the data reveal that dynamins promote nuclear envelope homeostasis and removal of damaged DNA via their GTPase activity and interaction with microtubules, providing insights into mechanisms that uphold genome stability and counteract aging-related pathologies.

> **中文摘要：**
> 核被膜是基因组的保护性屏障，也是细胞质与细胞核之间的机械转导界面，其功能障碍会破坏核质运输、损害DNA修复、加速端粒缩短并促进基因组不稳定性。调控间期和分裂后细胞中核被膜重塑与维持的机制仍知之甚少。本文中，我们报道了动力蛋白——一个关键的、富含于脑组织、能与膜和微管结合的GTP酶家族——在维持核被膜和基因组稳态中的作用。缺乏动力蛋白的细胞表现出核被膜形态异常，包括带有长窄颈的芽状突起，受损DNA常在此处积累。这些细胞还表现出自噬清除功能受损、关键DNA修复蛋白水平降低以及微管异常。诺考达唑处理可恢复核形态并减少DNA损伤。总之，这些数据揭示，动力蛋白通过其GTP酶活性和与微管的相互作用，促进核被膜稳态和受损DNA的清除，为理解维持基因组稳定性和对抗衰老相关病理的机制提供了见解。

### 第二部分 AI 大师评价

本研究旨在探究动力蛋白在维持核被膜稳态与基因组稳定性中的作用。通过构建动力蛋白缺失的细胞模型，结合形态学观察、DNA损伤检测、蛋白质水平分析及微管解聚药物干预等方法，揭示了动力蛋白通过其GTP酶活性及与微管的相互作用，调控核被膜形态、促进受损DNA清除的新机制。其创新性在于将传统上研究集中于胞质膜动力学的动力蛋白家族功能拓展至核被膜稳态与基因组完整性维护领域，为理解衰老及基因组不稳定相关疾病提供了新视角。局限性在于研究主要基于细胞模型，其在体生理病理意义及具体下游效应分子通路有待进一步阐明。

---

## 26. 靶向治疗时代慢性淋巴细胞白血病的一线治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507154)
**期刊：** Blood cancer journal
**PMID：** 41507154
**DOI：** 10.1038/s41408-025-01434-2

### 第一部分 原文与翻译

**英文原标题：** First-line treatment for CLL in the era of targeted therapy.

> **英文摘要：**
> In the decade since FDA approval of the first-generation Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted agents, as monotherapy or in combination regimens, have decisively replaced chemoimmunotherapy as the standard of care. In national CLL guidelines updated from 2023 through 2025 - including those from France, Germany, and the US - chemoimmunotherapy is considered a treatment option in only exceptional cases, reflecting broad consensus among experts that targeted therapies should be used universally in the management of previously untreated CLL. The primary first-line treatment options for CLL comprise continuous therapies based on the BTK inhibitors ibrutinib, zanubrutinib, or acalabrutinib, or fixed-duration regimens combining the BCL2 inhibitor venetoclax with obinutuzumab or the BTK inhibitors ibrutinib or acalabrutinib (with or without obinutuzumab). Selecting the appropriate targeted therapy requires careful evaluation of a multitude of factors, including molecular disease features (especially del[17p]/TP53 and IGHV mutational status), comorbidities, comedications, and the patient's preferences. Focusing on primary treatment options, we review data from the key controlled trials that support the first-line use of targeted therapies for patients with CLL, consider ongoing trials that may support clinical decision-making in the future, and assess the potential to personalize treatment regimens in CLL based on minimal residual disease status.

> **中文摘要：**
> 自美国食品药品监督管理局批准第一代布鲁顿酪氨酸激酶抑制剂伊布替尼以来的十年间，慢性淋巴细胞白血病的治疗格局已发生转变。靶向药物，无论是作为单药还是联合方案，已明确取代化学免疫疗法成为标准治疗。在2023年至2025年更新的各国CLL指南中——包括法国、德国和美国的指南——化学免疫疗法仅在特殊情况下被视为一种治疗选择，这反映了专家们达成的广泛共识，即靶向治疗应普遍用于既往未经治疗的CLL的管理。CLL的主要一线治疗方案包括基于BTK抑制剂（伊布替尼、泽布替尼或阿卡替尼）的持续疗法，或BCL2抑制剂维奈克拉联合奥妥珠单抗或联合BTK抑制剂（伊布替尼或阿卡替尼，联合或不联合奥妥珠单抗）的固定疗程方案。选择合适的靶向治疗需要仔细评估多种因素，包括分子疾病特征（尤其是del[17p]/TP53和IGHV突变状态）、合并症、合并用药以及患者的偏好。本文聚焦于主要治疗方案，回顾了支持靶向疗法一线用于CLL患者的关键对照试验数据，探讨了可能为未来临床决策提供支持的正在进行中的试验，并评估了基于微小残留病状态实现CLL治疗方案个体化的潜力。

### 第二部分 AI 大师评价

本文旨在综述靶向治疗时代CLL一线治疗的现状与进展。其核心方法是系统回顾关键对照试验数据，并分析当前指南共识与未来研究方向。主要发现是靶向药物（BTK抑制剂和BCL2抑制剂）已全面取代化学免疫疗法成为标准一线治疗，且治疗方案选择需基于分子特征、共病等多因素进行个体化决策。文章的创新性在于系统梳理了从持续治疗到固定疗程的多种靶向方案，并前瞻性地探讨了基于微小残留病的个体化治疗潜力；其局限性在于作为一篇综述，未提供新的原始临床数据，且对未来方向的评估基于现有试验的推断。

---

## 27. SOX2赋予特定皮肤祖细胞群肿瘤易感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507151)
**期刊：** Nature communications
**PMID：** 41507151
**DOI：** 10.1038/s41467-025-66251-4

### 第一部分 原文与翻译

**英文原标题：** SOX2 confers tumour permissiveness in a specific skin progenitor population.

> **英文摘要：**
> The continuous renewal of the skin relies on stem and progenitor cells, yet their differential susceptibility to oncogenic mutations in cutaneous squamous cell carcinoma (cSCC) remains unclear. Rapid cSCC develops in melanoma patients on BRAF inhibitors due to paradoxical MAPK activation. To model this in mice, we use two complementary approaches: HRAS with a BRAF inhibitor to mimic paradoxical MAPK activation, and BRAF, which drives MAPK hyperactivation without further treatment. We target these mutations to the interfollicular stem and differentiation-committed progenitors of the basal epidermis. While stem cells rapidly form tumours, progenitors exhibit long-latency resistance despite retaining mutations and repopulating the basal layer. Ultimately, both populations produce similar tumours, showing a shared transformation process. However, SOX2 is uniquely upregulated in progenitor-derived tumours and is expressed in 20% of human cSCC, indicating it might mark tumours arising from committed progenitors. Here, we show that SOX2 overexpression, along with MAPK activation, in progenitors induces a stem-like state and renders this otherwise resistant population permissive to rapid transformation.

> **中文摘要：**
> 皮肤的持续更新依赖于干细胞和祖细胞，然而它们在皮肤鳞状细胞癌（cSCC）中对致癌突变的不同易感性尚不清楚。由于矛盾的MAPK激活，黑色素瘤患者在使用BRAF抑制剂后会快速发生cSCC。为了在小鼠中模拟这一过程，我们使用了两种互补的方法：HRAS联合BRAF抑制剂以模拟矛盾的MAPK激活，以及单独使用BRAF（无需额外处理即可驱动MAPK过度激活）。我们将这些突变靶向基底表皮的毛囊间干细胞和分化定向祖细胞。虽然干细胞能快速形成肿瘤，但祖细胞尽管保留了突变并重新填充了基底层，却表现出长潜伏期的抵抗性。最终，两种细胞群产生了相似的肿瘤，显示了一个共同的转化过程。然而，SOX2在祖细胞来源的肿瘤中特异性上调，并且在20%的人类cSCC中表达，表明它可能标志着起源于定向祖细胞的肿瘤。在此，我们证明，在祖细胞中过表达SOX2，连同MAPK激活，会诱导出一种干细胞样状态，并使这个原本具有抵抗性的细胞群变得易于发生快速转化。

### 第二部分 AI 大师评价

本研究旨在阐明皮肤不同基底细胞亚群（干细胞与定向祖细胞）对致癌转化的易感性差异。研究者巧妙地利用HRAS/BRAF抑制剂组合与BRAF单独激活两种小鼠模型，模拟了临床中BRAF抑制剂引发的矛盾性MAPK激活，并将突变精准靶向特定细胞群。核心发现是，SOX2在原本抵抗的定向祖细胞中特异性上调，并与MAPK协同作用，诱导其重编程为干细胞样状态，从而获得快速肿瘤形成能力。这一发现创新性地揭示了SOX2作为细胞起源标志物和转化“许可因子”的双重作用，为理解cSCC异质性提供了新视角；局限性在于主要基于小鼠模型，其在人类cSCC中的普遍性及具体下游机制仍需深入探索。

---

## 28. 在MRD时代，“更少”是否“足够”且“安全”？——基于美法仑剂量评估多发性骨髓瘤患者自体干细胞移植的结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507137)
**期刊：** Blood cancer journal
**PMID：** 41507137
**DOI：** 10.1038/s41408-025-01437-z

### 第一部分 原文与翻译

**英文原标题：** Is Less "Sufficient" and "Safe" in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探讨在微小残留病（MRD）监测时代，降低自体干细胞移植（ASCT）预处理方案中美法仑剂量的可行性。研究通过比较不同美法仑剂量组患者的结局，评估“减量”策略在维持疗效（是否“足够”）与降低毒性（是否“安全”）方面的表现。其核心创新性在于挑战了传统高剂量美法仑作为ASCT标准预处理方案的范式，试图在MRD指导下实现治疗的个体化与降级。然而，由于摘要不可用，无法获知其具体研究方法、样本量及关键发现，这构成了评价本研究价值的主要局限性。

---

## 29. YBX1通过协调LDHA介导的代谢重编程与NF-κB激活来驱动透明细胞肾细胞癌进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507134)
**期刊：** Cell death & disease
**PMID：** 41507134
**DOI：** 10.1038/s41419-025-08261-0

### 第一部分 原文与翻译

**英文原标题：** YBX1 orchestrates LDHA-mediated metabolic reprogramming and NF-κB activation to drive clear cell renal cell carcinoma progression.

> **英文摘要：**
> Renal cell carcinoma (RCC) is sometimes referred to as a "metabolic disease", as nearly all types of RCC are associated with the reprogramming of glucose and lipid metabolism. Y-box binding protein 1 (YBX1) plays a crucial regulatory role in the development and progression of various cancers. In the early stages of our study, we analyzed the YBX1 binding proteins in 786-O cells using IP-MS and found that YBX1 is involved in the glycolysis process of RCC. Subsequent experiments showed that YBX1 is an oncogene that is significantly upregulated in RCC. Functionally, YBX1 promotes glycolysis in RCC, and both in vitro and in vivo experiments demonstrate that YBX1 contributes to the malignant progression of RCC. The correlation between YBX1 and Lactate Dehydrogenase A (LDHA) expression was predicted by bioinformatics and further explored in clinical RCC tissues. Mechanistically, YBX1 interacts with LDHA and co-localizes in the cytoplasm. CUT&Tag and functional experiments further revealed that YBX1 regulates LDHA through transcription. Additionally, YBX1 and LDHA activate the nuclear factor kappa-B (NF-κB) signaling pathway. Silencing the LDHA gene or using an LDHA inhibitor rescued the YBX1-mediated activation of the NF-κB signaling pathway and inhibited lactic acid production and RCC cell proliferation. In conclusion, these findings provide new insights into the oncogenic role of YBX1 in glycolysis and suggest that the YBX1-LDHA-NF-κB axis may represent a promising therapeutic target of RCC.

> **中文摘要：**
> 肾细胞癌（RCC）有时被称为一种“代谢性疾病”，因为几乎所有类型的RCC都与葡萄糖和脂质代谢的重编程有关。Y-box结合蛋白1（YBX1）在多种癌症的发生发展中起着关键的调控作用。在我们研究的早期阶段，我们利用IP-MS分析了786-O细胞中的YBX1结合蛋白，发现YBX1参与了RCC的糖酵解过程。后续实验表明，YBX1是一个在RCC中显著上调的癌基因。在功能上，YBX1促进了RCC的糖酵解，体外和体内实验均证明YBX1促进了RCC的恶性进展。通过生物信息学预测了YBX1与乳酸脱氢酶A（LDHA）表达之间的相关性，并在临床RCC组织中进一步探索。在机制上，YBX1与LDHA相互作用并在细胞质中共定位。CUT&Tag和功能实验进一步揭示，YBX1通过转录调控LDHA。此外，YBX1和LDHA激活了核因子κB（NF-κB）信号通路。沉默LDHA基因或使用LDHA抑制剂，挽救了YBX1介导的NF-κB信号通路激活，并抑制了乳酸产生和RCC细胞增殖。总之，这些发现为YBX1在糖酵解中的致癌作用提供了新的见解，并表明YBX1-LDHA-NF-κB轴可能代表了一个有前景的RCC治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明转录因子YBX1在透明细胞肾细胞癌（ccRCC）代谢重编程和恶性进展中的具体作用机制。研究综合运用了IP-MS、生物信息学分析、CUT&Tag、体外及体内功能实验等多种技术手段，系统性地揭示了YBX1通过转录调控LDHA，进而激活NF-κB信号通路，最终驱动肿瘤糖酵解和增殖的分子轴。其创新性在于将YBX1这一多能调控因子与RCC核心的代谢表型（瓦博格效应）及关键的促炎/促生存通路（NF-κB）直接联系起来，提出了一个整合性的致癌轴，为靶向RCC代谢提供了新的潜在靶点。局限性在于，摘要中未提及该轴在RCC不同亚型或临床分期中的特异性，且主要基于细胞系和临床组织相关性，其体内治疗潜能的直接验证有待进一步报道。

---

## 30. NAT10介导的ac4C修饰调控胶质母细胞瘤进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507133)
**期刊：** Cell death & disease
**PMID：** 41507133
**DOI：** 10.1038/s41419-025-08315-3

### 第一部分 原文与翻译

**英文原标题：** NAT10-mediated ac4C modifications regulate glioblastoma progression.

> **英文摘要：**
> N4-acetylcytidine (ac4C) is a recently identified mRNA modification, with N-acetyltransferase 10 (NAT10) being the sole known enzyme responsible for its catalysis. However, the biological functions and regulatory mechanisms of NAT10-mediated ac4C modification in glioblastoma (GBM) remain largely unclear. In this study, we aimed to elucidate the regulatory pathways and functional implications of NAT10 and ac4C modification in GBM. We found that NAT10 is significantly upregulated in GBM, and its elevated expression is associated with disease progression and poor patient prognosis. Functionally, NAT10 promotes glioblastoma cell proliferation and migration in vitro and accelerates tumor growth in vivo. Mechanistically, we identified BOC mRNA, a member of the immunoglobulin superfamily of cell adhesion molecules, as a direct target of NAT10-catalyzed ac4C modification. This modification enhances both the stability and translational efficiency of BOC mRNA, thereby contributing to GBM progression. Furthermore, we demonstrate that HIF1α, a key transcription factor in the hypoxic response, directly activates NAT10 transcription by binding to hypoxia response elements HRE1 and HRE2, leading to increased ac4C modification of BOC mRNA under hypoxic conditions. Notably, pharmacological inhibition of NAT10 effectively suppresses its enzymatic activity, particularly under hypoxia, underscoring its potential as a therapeutic target in GBM. In summary, our findings reveal a critical role for NAT10-mediated mRNA ac4C modification in GBM oncogenesis and highlight NAT10 as a promising target for therapeutic intervention.NAT10 was upregulated in GBM, and NAT10 facilitated GBM progression in vitro and in vivo. Mechanistically, NAT10 catalyzed ac4C modification of BOC mRNA and maintained its stability and promoted translation. Besides, HIF1α influenced NAT10 and its ac4C writer function through transcriptional activation.

> **中文摘要：**
> N4-乙酰胞苷（ac4C）是近期发现的一种mRNA修饰，N-乙酰转移酶10（NAT10）是已知唯一负责其催化的酶。然而，NAT10介导的ac4C修饰在胶质母细胞瘤（GBM）中的生物学功能和调控机制在很大程度上仍不清楚。本研究旨在阐明NAT10和ac4C修饰在GBM中的调控通路和功能影响。我们发现NAT10在GBM中显著上调，其高表达与疾病进展和患者不良预后相关。在功能上，NAT10在体外促进胶质母细胞瘤细胞增殖和迁移，在体内加速肿瘤生长。在机制上，我们鉴定出细胞粘附分子免疫球蛋白超家族成员BOC mRNA是NAT10催化的ac4C修饰的直接靶标。该修饰增强了BOC mRNA的稳定性和翻译效率，从而促进GBM进展。此外，我们证明缺氧反应的关键转录因子HIF1α通过结合缺氧反应元件HRE1和HRE2直接激活NAT10转录，导致缺氧条件下BOC mRNA的ac4C修饰增加。值得注意的是，NAT10的药理学抑制能有效抑制其酶活性，尤其是在缺氧条件下，这突显了其作为GBM治疗靶点的潜力。总之，我们的研究结果揭示了NAT10介导的mRNA ac4C修饰在GBM肿瘤发生中的关键作用，并强调NAT10是一个有前景的治疗干预靶点。NAT10在GBM中上调，并在体外和体内促进GBM进展。机制上，NAT10催化BOC mRNA的ac4C修饰并维持其稳定性、促进翻译。此外，HIF1α通过转录激活影响NAT10及其ac4C写入功能。

### 第二部分 AI 大师评价

本研究旨在阐明NAT10介导的ac4C修饰在胶质母细胞瘤（GBM）中的功能与调控机制。通过结合临床样本分析、体内外功能实验及分子机制探索，研究发现NAT10在GBM中高表达并促进肿瘤进展，其通过催化BOC mRNA的ac4C修饰增强其稳定性和翻译效率。创新性地揭示了缺氧信号关键因子HIF1α通过转录激活NAT10，将缺氧微环境与表观转录调控联系起来，并验证了NAT10抑制剂的治疗潜力。研究局限性在于，对ac4C修饰在GBM中更广泛的靶标谱及其下游通路网络仍需进一步探索，且体内药效学数据有待补充。

---

## 31. 研究性抗B7-H3抗体偶联药物vobramitamab duocarmazine在儿童肉瘤临床前模型中展现出体外和体内抗肿瘤活性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507126)
**期刊：** Cell death & disease
**PMID：** 41507126
**DOI：** 10.1038/s41419-025-08397-z

### 第一部分 原文与翻译

**英文原标题：** The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models.

> **英文摘要：**
> Prognosis for pediatric sarcoma (pSC)-affected patients, especially those with relapsed/refractory disease, is dismal. The available treatment options are unsatisfactory, challenging researchers to address this unmet need. The investigational B7-H3 targeted ADC vobramitamab duocarmazine (vobra duo) showed clinical effectiveness towards several B7-H3-positive adult tumors and pre-clinical efficacy in pediatric neuroblastoma models. Cytotoxicity of vobra duo was evaluated in 2D and 3D models toward pSC cell lines expressing B7-H3, showing a dose-dependent cell viability reduction. Proliferation was assessed by time-lapse single-cell segmentation. Compared to controls, vobra duo resulted in a significant increase in the cell doubling time. AKT/mTOR master effectors of cell proliferation were investigated by phospho-specific western blot assays. A down-modulation of phospho-AKT/ -P70 S6K and -4E-BP1 protein expression was detected in both A204 (rhabdomyosarcoma) and U-2-OS (osteosarcoma) cells, the most treatment-sensitive and resistant cell lines, respectively, suggesting their involvement in vobra duo-mediated anti-proliferative effect. In response to treatment, all cell lines underwent apoptotic cell death. A significant increase in the executioner cleaved caspase-3 was detected, and a partial but significant reversion of apoptotic cell death was noted following pre-treatment with the pan-caspase inhibitor, Q-VD-OP-h. Vobra duo also triggered caspase-independent apoptotic events: i) increased AIF nuclear translocation, ii) increased mitochondrial superoxide production, and iii) the depolarization of mitochondrial membrane potential. In vivo, the effectiveness of vobra duo was assayed by single and repeated intravenous administration in the mouse rhabdomyosarcoma model. The single injection of 3 mg/Kg of vobra duo induced a significant tumor growth delay. Repeated vobra duo doses ameliorated this outcome, reverting rhabdomyosarcorma to rhabdomyoma tumor, by increasing Desmin and Myogenin/Myf-4 differentiation markers expression, and reducing both Ki-67 and CD133. In conclusion, the in vitro and in vivo anti-tumor effects towards pSC highlight the need to extend the investigation to patient-derived preclinical models, to pave the way for clinical translation.

> **中文摘要：**
> 儿童肉瘤（pSC）患者，特别是复发/难治性患者的预后极差。现有的治疗方案不尽人意，这促使研究人员致力于解决这一未满足的临床需求。研究性B7-H3靶向抗体偶联药物vobramitamab duocarmazine（vobra duo）已在多种B7-H3阳性成人肿瘤中显示出临床有效性，并在儿童神经母细胞瘤模型中显示出临床前疗效。在表达B7-H3的pSC细胞系中，通过2D和3D模型评估了vobra duo的细胞毒性，结果显示其能剂量依赖性地降低细胞活力。通过延时单细胞分割技术评估了细胞增殖情况。与对照组相比，vobra duo导致细胞倍增时间显著增加。通过磷酸化特异性蛋白质印迹法研究了细胞增殖的关键效应因子AKT/mTOR通路。在分别对治疗最敏感和最耐药的细胞系A204（横纹肌肉瘤）和U-2-OS（骨肉瘤）中，均检测到磷酸化AKT、-P70 S6K和-4E-BP1蛋白表达的下调，表明它们参与了vobra duo介导的抗增殖效应。所有细胞系在治疗后均发生凋亡性细胞死亡。检测到执行者cleaved caspase-3显著增加，并且在用泛caspase抑制剂Q-VD-OP-h预处理后，观察到凋亡性细胞死亡出现部分但显著的逆转。Vobra duo也触发了不依赖caspase的凋亡事件：i) AIF核转位增加，ii) 线粒体超氧化物产生增加，以及iii) 线粒体膜电位去极化。在体内，通过在小鼠横纹肌肉瘤模型中单次和重复静脉给药评估了vobra duo的有效性。单次注射3 mg/Kg的vobra duo可显著延迟肿瘤生长。重复给药改善了这一结果，通过增加分化标志物Desmin和Myogenin/Myf-4的表达，并降低Ki-67和CD133的表达，使横纹肌肉瘤逆转为横纹肌瘤。总之，针对pSC的体外和体内抗肿瘤效应凸显了将研究扩展到患者来源的临床前模型的必要性，从而为临床转化铺平道路。

### 第二部分 AI 大师评价

本研究旨在评估研究性ADC药物vobra duo在儿童肉瘤临床前模型中的抗肿瘤活性。研究综合运用了体外2D/3D细胞模型、延时成像、信号通路蛋白检测以及小鼠体内模型等多种方法。核心发现表明，vobra duo通过剂量依赖性地抑制细胞增殖（涉及AKT/mTOR通路下调）并诱导caspase依赖与非依赖的凋亡通路，在体外有效杀伤肉瘤细胞；在体内，该药物不仅能延缓肿瘤生长，还能诱导肿瘤向更良性的表型分化，显示出超越单纯细胞毒性的治疗潜力。研究的创新性在于首次系统揭示了vobra duo在儿童肉瘤中的多机制抗肿瘤效应，特别是其诱导肿瘤分化的能力，为这类难治性肿瘤提供了新的治疗思路。局限性在于所有实验均基于细胞系和异种移植模型，未来需在患者来源的模型中进行验证以增强临床相关性。

---

## 32. 牛磺酸转运蛋白SLC6A6表达促进间充质基质细胞功能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507125)
**期刊：** Cell death & disease
**PMID：** 41507125
**DOI：** 10.1038/s41419-025-08233-4

### 第一部分 原文与翻译

**英文原标题：** Taurine transporter SLC6A6 expression promotes mesenchymal stromal cell function.

> **英文摘要：**
> Mesenchymal stromal cell (MSC) differentiation is critical for the development, maintenance, and repair of bone tissue. MSCs also play a key role in regulating self-renewal and differentiation of normal hematopoietic and leukemic stem cells. Our prior work has identified a key role of taurine produced by bone marrow osteolineage cells in supporting the growth of taurine transporter (TauT or Slc6a6) expressing leukemia cells. Here, we analyze multiple murine non-hematopoietic bone marrow single-cell RNA-sequencing datasets and discover that TauT expression is enriched in MSCs in vivo. Although taurine supplements have been shown to mitigate bone defects in aged mice, its role in regulating MSC populations that give rise to bone cells is poorly understood. Using TauT genetic loss-of-function murine models, we find that TauT loss impacts murine MSC populations in vivo and impairs MSC osteogenic differentiation in vitro. This is associated with decreased bone mineral density and bone strength in young and aged TauT knockout mice. Importantly, shRNA-based knockdown of TAUT expression in primary human donor MSCs reduces osteogenic differentiation. TauT null MSCs are unable to support self-renewal and expansion of co-cultured hematopoietic stem and progenitor populations, indicating broad functional defects. Mechanistically, TauT loss results in downregulation of inositol metabolism, increased oxidative stress, and reduced Wnt/β-catenin signaling, which induce MSC senescence. Collectively, our data identifies taurine as a key regulator of MSC maintenance and osteogenic fate determination.

> **中文摘要：**
> 间充质基质细胞（MSC）的分化对于骨组织的发育、维持和修复至关重要。MSCs还在调节正常造血干细胞和白血病干细胞的自更新与分化中发挥关键作用。我们先前的研究已发现，由骨髓成骨谱系细胞产生的牛磺酸在支持表达牛磺酸转运蛋白（TauT或Slc6a6）的白血病细胞生长中起关键作用。本研究通过分析多个小鼠非造血骨髓单细胞RNA测序数据集，发现TauT表达在体内MSCs中富集。尽管补充牛磺酸已被证明可以减轻老年小鼠的骨缺陷，但其在调控产生骨细胞的MSC群体中的作用尚不清楚。利用TauT基因功能缺失小鼠模型，我们发现TauT缺失会影响体内小鼠MSC群体，并在体外损害MSC的成骨分化。这与年轻和年老TauT敲除小鼠骨密度和骨强度下降相关。重要的是，在原代人供体MSCs中基于shRNA敲低TAUT表达会降低成骨分化。TauT缺失的MSCs无法支持共培养的造血干细胞和祖细胞群体的自我更新与扩增，表明其存在广泛的功能缺陷。从机制上讲，TauT缺失导致肌醇代谢下调、氧化应激增加以及Wnt/β-catenin信号通路减弱，从而诱导MSC衰老。总之，我们的数据将牛磺酸确定为MSC维持和成骨命运决定的关键调节因子。

### 第二部分 AI 大师评价

本研究旨在探究牛磺酸转运蛋白SLC6A6/TauT在间充质基质细胞（MSC）功能中的作用。研究团队整合了单细胞测序数据分析与TauT基因敲除小鼠模型，并结合体外功能实验，系统性地揭示了TauT表达对MSC维持、成骨分化及支持造血功能的重要性。其创新性在于首次将牛磺酸代谢与MSC的衰老及功能缺陷联系起来，并阐明了涉及肌醇代谢、氧化应激和Wnt/β-catenin信号通路的分子机制。然而，研究主要基于小鼠模型和体外实验，TauT调控的精确下游效应分子网络及其在人类生理与病理条件下的直接转化意义，仍有待进一步验证。

---

## 33. 血小板衰老与去唾液酸化增强凋亡启动并增加对BCL-X的依赖性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41507122)
**期刊：** Cell death & disease
**PMID：** 41507122
**DOI：** 10.1038/s41419-025-08205-8

### 第一部分 原文与翻译

**英文原标题：** Platelet aging and desialylation increase apoptotic priming and BCL-X dependence.

> **英文摘要：**
> Platelets are short-lived anucleate cells essential for primary hemostasis and recognized for their functions in thrombosis, immunity, antimicrobial defense, neurodegeneration, as well as cancer growth and metastasis. Their brief lifespan in circulation is controlled by the removal of sialic acid residues from the platelet surface (desialylation) and also the mitochondrial apoptosis pathway, with high expression of the anti-apoptotic protein BCL-X being required for platelet survival. This dependence on BCL-X has prevented the clinical deployment of recently developed small molecule inhibitors of BCL-X, which have promising activity in solid as well as liquid cancers but cause on-target thrombocytopenia. Here, we investigate the functional relationship between platelet desialylation and apoptosis to determine how cross-talk between these mechanisms may impact platelet lifespan. We find that platelets progressively lose sialic acid residues and become more primed for apoptosis while in circulation, resulting in aged platelets that are desialylated and highly prone to undergoing apoptosis. In addition, platelet desialylation via endogenous or exogenous factors directly increases their BCL-X dependence and accelerates apoptosis, which can be reversed by treatment with the sialidase inhibitor DANA (2,3-dehydro-2-deoxy-N-acetylneuraminic acid). Notably, young platelets recently released into circulation are less primed for apoptosis and less dependent on BCL-X for survival. Consistent with these changes in priming, platelets aged in vitro exhibit increasing expression of multiple pro-apoptotic proteins including BIM, BAK and PUMA along with increasing cleaved caspase 3. Leveraging the lower BCL-X dependence of young platelets, stimulation of de novo platelet production with the thrombopoietin receptor agonist romiplostim prevents BH3 mimetic-induced thrombocytopenia in vivo and may prevent severe platelet loss in patients treated with BCL-X inhibitors.

> **中文摘要：**
> 血小板是寿命短暂的无核细胞，对初级止血至关重要，并因其在血栓形成、免疫、抗菌防御、神经退行性变以及癌症生长和转移中的作用而被认识。它们在循环中的短暂寿命受血小板表面唾液酸残基的去除（去唾液酸化）以及线粒体凋亡途径的调控，其中抗凋亡蛋白BCL-X的高表达是血小板存活所必需的。这种对BCL-X的依赖性阻碍了近期开发的BCL-X小分子抑制剂的临床应用，这些抑制剂在实体瘤和液体瘤中具有良好的活性，但会引起靶向性血小板减少症。在此，我们研究了血小板去唾液酸化与凋亡之间的功能关系，以确定这些机制之间的相互作用如何影响血小板寿命。我们发现，血小板在循环过程中逐渐失去唾液酸残基，并变得更容易启动凋亡，从而形成去唾液酸化且极易发生凋亡的衰老血小板。此外，通过内源性或外源性因素引起的血小板去唾液酸化直接增加了它们对BCL-X的依赖性并加速了凋亡，而使用唾液酸酶抑制剂DANA（2,3-脱氢-2-脱氧-N-乙酰神经氨酸）处理可以逆转这一过程。值得注意的是，新近释放到循环中的年轻血小板凋亡启动程度较低，且生存对BCL-X的依赖性较小。与这些启动状态的变化一致，体外衰老的血小板表现出多种促凋亡蛋白（包括BIM、BAK和PUMA）的表达增加，同时cleaved caspase 3也增加。利用年轻血小板对BCL-X依赖性较低的特点，使用血小板生成素受体激动剂罗米司亭刺激新生血小板的产生，可在体内防止BH3模拟物诱导的血小板减少症，并可能预防接受BCL-X抑制剂治疗患者的严重血小板丢失。

### 第二部分 AI 大师评价

本研究旨在阐明血小板衰老过程中去唾液酸化与线粒体凋亡途径之间的功能联系，以解释血小板寿命调控机制。研究通过体内外实验发现，衰老导致血小板去唾液酸化，并上调促凋亡蛋白表达，从而增强凋亡启动和对BCL-X的依赖性，而年轻血小板则依赖性较低。其创新性在于揭示了血小板衰老与凋亡启动的分子关联，并提出了通过使用促血小板生成药物（如罗米司亭）提升年轻血小板比例，来缓解BCL-X抑制剂所致血小板减少症的潜在治疗策略，为克服此类抗癌药物的关键毒性提供了新思路。然而，研究主要基于实验模型，该策略在临床患者中的有效性和安全性仍需进一步验证。

---

## 34. 勘误：关于‘德曲妥珠单抗在1级间质性肺病/肺炎恢复后再次治疗的汇总分析’：[《肿瘤学年鉴》第36卷第11期，2025年11月，第1389-1399页]。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41506947)
**期刊：** Annals of oncology : official journal of the European Society for Medical Oncology
**PMID：** 41506947
**DOI：** 10.1016/j.annonc.2025.12.001

### 第一部分 原文与翻译

**英文原标题：** Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399].

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇针对已发表研究的勘误声明。其核心目的是对先前发表的关于德曲妥珠单抗在1级间质性肺病/肺炎恢复后再次治疗的汇总分析进行更正。作为勘误，其主要方法是对原文中的错误进行识别和修正，而非提出新的研究数据或结论。其核心发现或价值在于确保已发表文献的准确性和完整性，这对于后续的临床决策和学术引用至关重要。然而，作为勘误，其本身不包含新的研究发现或创新性数据，其局限性在于无法提供关于该药物再治疗安全性与有效性的具体信息，读者需结合原文阅读。

---

## 35. CD73阻断通过增加巨噬细胞介导的抗原呈递，增强溶瘤单纯疱疹病毒在实体瘤中的抗肿瘤疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41506791)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41506791
**DOI：** 10.1136/jitc-2025-013640

### 第一部分 原文与翻译

**英文原标题：** CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation.

> **英文摘要：**
> BACKGROUND: Oncolytic herpes simplex virus (oHSV) therapy is a live virus-based immunotherapy that lyses tumor cells which release antigens and activate antitumor immunity. oHSV therapy has been shown to increase ATP production and release of extracellular ATP (eATP). In the extracellular tumor microenvironment, eATP functions as an immune-activating damage-associated molecular pattern but is hydrolyzed to extracellular adenosine (eADO), which can be immune-suppressive. eADO is generated by the sequential action of ectoenzymes CD39 and CD73 (). Here, we examined the role of immunosuppressive eADO signaling in regulating antitumor immune efficacy of oHSV. METHODS: We evaluated changes in eADO signaling in vitro and in patient specimens after virotherapy. A genetic CD73 knock-out mouse model and blocking antibodies were used to assess the impact of CD73 on virotherapy in two different solid tumor models. Single-cell RNA sequencing was employed to assess changes in immune cell infiltration and communication. Flow cytometric immunophenotyping and immunofluorescent imaging were utilized to confirm single-cell sequencing predicted changes in tumor microenvironment. RESULTS: Transcriptomic analysis of patient tumors pre-virotherapy and post-virotherapy with CAN-3110 revealed increased expression of the adenosine receptor gene  after treatment. High  gene expression, as well as gene signatures suggestive of adenosine signaling, correlated with a significantly worse prognosis for patients with solid tumors. Single-cell sequencing of immune cells recruited to tumor-bearing brain hemispheres in CD73 knockout mice revealed an increase in macrophage-mediated antigen presentation and CD4 T cell cross-communication. Intracranial tumor-bearing CD73 knock-out mice treated with oHSV showed significant therapeutic improvement as the result of oHSV compared with wild-type mice. Combination of virotherapy with CD73 antibody blockade also resulted in enhanced antitumor efficacy. CONCLUSIONS: Here, we identify that immunosuppressive eADO signaling in the TME is a major barrier to oHSV therapy and CD73 blockade prevents tumor immune escape. The combination of oHSV with CD73 blockade supports the development of an antitumor immune memory response in solid tumors. This study supports clinical development of this combination strategy.

> **中文摘要：**
> 背景：溶瘤单纯疱疹病毒（oHSV）疗法是一种基于活病毒的免疫疗法，通过裂解肿瘤细胞释放抗原并激活抗肿瘤免疫。研究表明，oHSV疗法会增加ATP的产生和细胞外ATP（eATP）的释放。在细胞外肿瘤微环境中，eATP作为一种免疫激活性的损伤相关分子模式发挥作用，但会被水解为细胞外腺苷（eADO），后者具有免疫抑制作用。eADO由外切酶CD39和CD73的连续作用生成。本研究探讨了免疫抑制性eADO信号在调节oHSV抗肿瘤免疫疗效中的作用。方法：我们在体外和患者标本中评估了病毒疗法后eADO信号的变化。使用遗传性CD73敲除小鼠模型和阻断抗体，在两种不同的实体瘤模型中评估CD73对病毒疗法的影响。采用单细胞RNA测序评估免疫细胞浸润和通讯的变化。利用流式细胞术免疫表型分析和免疫荧光成像，确认单细胞测序预测的肿瘤微环境变化。结果：对患者接受CAN-3110病毒治疗前后的肿瘤进行转录组分析显示，治疗后腺苷受体基因表达增加。高基因表达以及提示腺苷信号传导的基因特征，与实体瘤患者显著更差的预后相关。对CD73敲除小鼠荷瘤大脑半球募集的免疫细胞进行单细胞测序发现，巨噬细胞介导的抗原呈递和CD4 T细胞交叉通讯增加。与野生型小鼠相比，经oHSV治疗的颅内荷瘤CD73敲除小鼠显示出显著的治疗改善。病毒疗法联合CD73抗体阻断也增强了抗肿瘤疗效。结论：本研究发现，肿瘤微环境中的免疫抑制性eADO信号是oHSV疗法的主要障碍，而CD73阻断可防止肿瘤免疫逃逸。oHSV联合CD73阻断有助于在实体瘤中形成抗肿瘤免疫记忆反应。本研究支持该联合策略的临床开发。

### 第二部分 AI 大师评价

本研究旨在阐明溶瘤病毒（oHSV）疗法中免疫抑制性腺苷信号通路的阻碍作用，并探索联合CD73阻断的增效策略。研究综合运用了患者样本转录组学、CD73敲除小鼠模型、单细胞测序及抗体阻断等多种手段，方法学上较为系统。核心发现是，CD73缺失或阻断能重塑肿瘤免疫微环境，特别是增强巨噬细胞的抗原呈递功能，从而协同oHSV提升抗实体瘤疗效并诱导免疫记忆。其创新性在于从代谢免疫角度揭示了oHSV疗效的关键限制因素，并提出了具有转化潜力的联合治疗新方案。局限性在于研究主要基于临床前模型，其结论在人体中的普适性及联合治疗的安全性、最佳时机等仍需后续临床研究验证。

---

## 36. 新表位预测的系统性评估对临床观察到的T细胞反应及其对免疫逃逸的影响提出挑战。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41506790)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41506790
**DOI：** 10.1136/jitc-2025-013271

### 第一部分 原文与翻译

**英文原标题：** Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.

> **英文摘要：**
> Peptide presentation on human leukocyte antigens (HLAs) is essential for initiating T-cell responses and all consequences of this presentation including anticancer immunity or immune escape. Many studies have relied on in silico prediction tools rather than biological measurement of HLA presentation to study these effects. To better assess the frequency and consequences of neoantigen presentation, we overexpressed 125 combinations of full-length neoantigens and one HLA class I allele to experimentally validate presentation of mutated and non-mutated HLA ligands through HLA ligand isolation followed by tandem mass spectrometry. A successful presentation was observed only in 22% of predicted cases with strong implications on previously described downstream effects. For example, the association of HLA loss of heterozygosity with predicted neoepitopes was challenged for 58% (73/125) of combinations. Furthermore, when testing 51 sequences used for personalized messenger RNA neoepitope vaccines, we observed that clinical responses were independent of the presentation status of the neoepitopes. Even a presumably neoepitope-specific and strongly expanded T cell receptor clone from a neoantigen vaccination study could not be linked to a successfully presented neoepitope. Overall, these data highlight the importance of validating the presentation of neoepitopes to fully understand our interpretation of clinical mutation-specific responses and their related effects, including immune evasion.

> **中文摘要：**
> 人类白细胞抗原（HLA）上的肽段呈递对于启动T细胞反应以及由此产生的所有后果（包括抗癌免疫或免疫逃逸）至关重要。许多研究依赖于计算机预测工具，而非HLA呈递的生物学测量来研究这些效应。为了更好地评估新抗原呈递的频率和后果，我们过表达了125种全长新抗原与一种HLA I类等位基因的组合，通过HLA配体分离和串联质谱法，实验验证了突变和非突变HLA配体的呈递。仅在22%的预测案例中观察到了成功的呈递，这对先前描述的下游效应具有强烈影响。例如，对于58%（73/125）的组合，HLA杂合性缺失与预测新表位之间的关联性受到了挑战。此外，在测试用于个性化信使RNA新表位疫苗的51条序列时，我们观察到临床反应与新表位的呈递状态无关。即使是来自一项新抗原疫苗接种研究的、推测为新表位特异性且强烈扩增的T细胞受体克隆，也无法与一个成功呈递的新表位相关联。总之，这些数据凸显了验证新表位呈递的重要性，以充分理解我们对临床突变特异性反应及其相关效应（包括免疫逃逸）的解读。

### 第二部分 AI 大师评价

本研究通过实验方法系统评估了新表位预测工具的准确性，揭示了其与真实生物学呈递之间存在显著差距。核心发现包括预测呈递成功率低（22%），且临床反应与预测呈递状态无关，这直接挑战了基于预测新表位构建的免疫逃逸和疫苗疗效模型。该研究的创新性在于提供了大规模的实验验证数据，强调了实验验证在肿瘤免疫研究中的必要性。局限性在于研究主要基于过表达系统，且样本量有限，未来需要在更多样化的临床样本和体内环境中进行验证。

---

## 37. 机遇敲门：针对全球癌症大流行的共享肿瘤相关抗原疫苗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41506789)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41506789
**DOI：** 10.1136/jitc-2025-013130

### 第一部分 原文与翻译

**英文原标题：** Opportunity knocking: shared tumor-associated antigen vaccines against global cancer pandemic.

> **英文摘要：**
> Shared tumor-associated antigen (TAA) vaccines are the legacy of several generations of cancer immunologists who have labored to bring them to patients with cancer to improve their disease outcome and eventually use them to prevent cancer. TAA vaccines failed as monotherapy but the development of checkpoint inhibitors and other reagents that can modify immunosuppressive tumor microenvironment, warrants their reassessment in combination immunotherapy trials. They now sit on shelves and in freezers of academic labs and pharmaceutical companies, but if shown effective in the new setting, could be quickly turned into broadly applicable, inexpensive, off-the-shelf vaccines. Shared TAA vaccines also provide a unique opportunity to address the global cancer pandemic by repurposing them for cancer prevention. The opportunity that shared TAA vaccines provide to help patients now and to protect millions globally from the agony of cancer diagnosis in the future, is either not fully recognized, recognized but ignored, or at best, being put on hold.

> **中文摘要：**
> 共享肿瘤相关抗原（TAA）疫苗是几代癌症免疫学家努力的成果，他们致力于将其带给癌症患者以改善疾病结局，并最终用于预防癌症。TAA疫苗作为单一疗法失败了，但检查点抑制剂及其他能够改变免疫抑制性肿瘤微环境的试剂的发展，为在联合免疫治疗试验中重新评估它们提供了依据。它们目前被搁置在学术实验室和制药公司的货架和冰柜中，但若能在新背景下被证明有效，则可迅速转化为广泛适用、价格低廉、即取即用的疫苗。共享TAA疫苗还提供了一个独特的机会，通过将其重新用于癌症预防来应对全球癌症大流行。共享TAA疫苗所提供的、既能帮助当前患者又能保护全球数百万人免于未来癌症诊断痛苦的机遇，要么未被充分认识，要么被认识但忽视，或者充其量被搁置。

### 第二部分 AI 大师评价

本文旨在重新审视共享肿瘤相关抗原（TAA）疫苗的价值，提出其在联合免疫治疗时代的新机遇。核心方法是利用现有已开发的TAA疫苗，与检查点抑制剂等免疫调节剂联合使用，并探索其从治疗转向预防的潜力。文章的核心发现是，这些“现成”疫苗若在联合疗法中被证实有效，有望快速转化为低成本、广谱的癌症防治工具。其创新性在于提出了对现有失败疗法进行“老药新用”和“治疗转预防”的战略性思路，但局限性在于该观点主要基于理论推演，尚缺乏新临床试验数据的直接支持，且对疫苗重新评估和转化所面临的具体科学、监管和商业障碍分析不足。

---

## 38. 记忆B细胞亚群在错配修复缺陷型结直肠癌中塑造抗肿瘤免疫及对PD-1阻断治疗的反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41506788)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41506788
**DOI：** 10.1136/jitc-2025-012121

### 第一部分 原文与翻译

**英文原标题：** Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers.

> **英文摘要：**
> BACKGROUND: Mismatch repair deficiency (dMMR) colorectal cancer (CRC) is characterized by abundant tumor-infiltrating lymphocytes and tertiary lymphoid structures (TLSs). However, while B cells are pivotal for TLS formation, their function and the signaling pathways driving their activation in dMMR CRCs remain undefined. METHODS: Data from The Cancer Genome Atlas (TCGA) database analyzed by XCELL method and multiplex immunofluorescence (MIF) staining tissue slides were used to compare the abundance and distribution of TLSs and B cell populations between dMMR and proficient MMR cohorts. Then MLH1 knockdown models both in vitro and in vivo were used to mimic dMMR/high microsatellite instability (MSI-H) tumors and explore the influence of tumor cells on B cell behavior. RESULTS: TCGA analysis and MIF staining revealed a significant association between memory B cell abundance, TLS formation, and improved prognosis in dMMR CRCs. In vivo MLH1 knockdown models showed that B cell depletion enhanced tumor growth and reduced the efficacy of anti-PD-1 treatment in dMMR CRCs. Furthermore, in vitro experiments demonstrated a dsDNA/STING/type I interferon (IFN)/STAT1/ signaling pathway mediating the dMMR-induced increase in memory B cells. CONCLUSIONS: In conclusion, these findings show that CCL19 generated by STING/type I IFN/STAT1 pathway in dMMR/MSI-H CRC cells can promote the expansion of memory B cells, which suppresses tumor growth and enhances the efficacy of PD-1 blockade.

> **中文摘要：**
> 背景：错配修复缺陷（dMMR）结直肠癌（CRC）的特征是存在丰富的肿瘤浸润淋巴细胞和三级淋巴结构（TLSs）。然而，尽管B细胞对TLS形成至关重要，但它们在dMMR CRC中的功能以及驱动其活化的信号通路仍不明确。方法：使用XCELL方法分析癌症基因组图谱（TCGA）数据库的数据，并结合多重免疫荧光（MIF）染色组织切片，比较dMMR与错配修复正常（pMMR）队列中TLSs和B细胞群体的丰度与分布。随后，利用体外和体内的MLH1敲低模型模拟dMMR/高微卫星不稳定性（MSI-H）肿瘤，并探索肿瘤细胞对B细胞行为的影响。结果：TCGA分析和MIF染色显示，在dMMR CRC中，记忆B细胞的丰度、TLS形成与改善的预后之间存在显著关联。体内MLH1敲低模型表明，B细胞耗竭会促进dMMR CRC的肿瘤生长并降低抗PD-1治疗的疗效。此外，体外实验证明，一条dsDNA/STING/I型干扰素（IFN）/STAT1信号通路介导了dMMR诱导的记忆B细胞增加。结论：总之，这些发现表明，dMMR/MSI-H CRC细胞中由STING/I型IFN/STAT1通路产生的CCL19能够促进记忆B细胞的扩增，从而抑制肿瘤生长并增强PD-1阻断的疗效。

### 第二部分 AI 大师评价

本研究旨在阐明dMMR结直肠癌中B细胞，特别是记忆B细胞的功能与作用机制。研究通过整合TCGA数据分析、多重免疫荧光染色以及体外/体内基因敲低模型，方法学上较为系统。核心发现是揭示了dMMR通过激活dsDNA/STING/I型IFN/STAT1通路，诱导肿瘤细胞产生CCL19，进而驱动记忆B细胞扩增，促进三级淋巴结构形成，最终增强抗肿瘤免疫并提升PD-1抑制剂疗效。其创新性在于将dMMR的分子特征与B细胞介导的适应性免疫直接联系起来，并明确了上游信号通路，为联合免疫治疗提供了新靶点。局限性在于，研究主要基于模型和回顾性数据，其结论在临床患者中的普适性及具体转化应用策略仍需进一步验证。

---

## 39. 染色体外DNA携带的结构变异驱动致癌融合转录本的扩增。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41506267)
**期刊：** Cell
**PMID：** 41506267
**DOI：** 10.1016/j.cell.2025.12.009

### 第一部分 原文与翻译

**英文原标题：** EcDNA-borne structural variants drive oncogenic fusion transcript amplification.

> **英文摘要：**
> Extrachromosomal DNA (ecDNA) amplifications are key drivers of human cancers. Here, we show that ecDNAs are major platforms for generating and amplifying oncogene fusion transcripts across diverse cancer types. By integrating analysis of whole-genome and transcriptome sequences from tumor samples and cancer cell lines of a wide variety of tissue types, we reveal that ecDNAs have the highest rate of oncogene fusion events of any copy-number alteration. Focusing on the most common ecDNA fusion hotspot, we find that fusion of the 5' end of the long noncoding RNA gene, PVT1-with exon 1 joined to diverse 3' partners-confers increased RNA stability, potentially via an SRSF1-dependent mechanism, and enhances MYC-dependent transcription and cancer细胞 survival. These results demonstrate that ecDNA fosters genome instability and frequent oncogene fusion formation in cancer.

> **中文摘要：**
> 染色体外DNA（ecDNA）扩增是人类癌症的关键驱动因素。本研究显示，ecDNA是跨多种癌症类型生成和扩增致癌基因融合转录本的主要平台。通过整合分析来自多种组织类型的肿瘤样本和癌细胞系的全基因组及转录组序列，我们揭示了ecDNA在所有拷贝数变异中具有最高的致癌基因融合事件发生率。聚焦于最常见的ecDNA融合热点，我们发现长链非编码RNA基因PVT1的5'端（其外显子1与多种3'端伙伴基因连接）的融合，可能通过一种SRSF1依赖的机制赋予RNA更高的稳定性，并增强MYC依赖性转录和癌细胞的存活。这些结果表明，ecDNA促进了癌症中的基因组不稳定性和频繁的致癌基因融合形成。

### 第二部分 AI 大师评价

本研究旨在揭示染色体外DNA（ecDNA）在致癌基因融合形成与扩增中的核心作用。研究团队采用整合基因组学与转录组学分析的方法，系统比较了多种癌症样本和细胞系。其核心发现是，ecDNA是所有拷贝数变异中致癌基因融合事件发生率最高的平台，并首次阐明PVT1-MYC融合通过SRSF1依赖机制增强RNA稳定性的具体分子机制，从而驱动肿瘤发生。该研究的创新性在于将ecDNA的物理结构与致癌融合转录本的生成及功能直接关联，深化了对癌症基因组进化的理解；局限性在于主要基于测序数据的关联分析，所提出的SRSF1机制等具体通路有待后续实验验证。

---

## 40. 通过细胞因子活性标记在体检测免疫反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41506266)
**期刊：** Cell
**PMID：** 41506266
**DOI：** 10.1016/j.cell.2025.12.011

### 第一部分 原文与翻译

**英文原标题：** In vivo detection of immune responses via cytokine activity labeling.

> **英文摘要：**
> While much is known about the identity and regulation of cytokine-producing cells, the cell types that respond to cytokines remain largely uncharacterized. To address this knowledge gap, we developed "cytokine cellular locating platforms" (CyCLoPs), a reporter system that translates cytokine receptor engagement into a genetically traceable signal. In vitro, CyCLoPs demonstrated high specificity, robust signal-to-background ratios, and broad applicability for probing diverse cytokine receptor interactions. In vivo, interleukin (IL)-17A-CyCLoPs reporter mice enabled the identification of IL-17A-responsive intestinal epithelial cells predominantly localized in the ileal villi following commensal bacterial colonization. Interferon-gamma (IFN-γ)-CyCLoPs reporter mice allowed for the detection of IFN-γ-exposed CD8 T cells within tumors, which expressed CD36, CD38, and leptin receptor and displayed gene signatures associated with reduced effector function. Collectively, CyCLoPs offers a platform for the direct visualization and characterization of cytokine-induced cellular responses and provides a tool for investigating how cytokines orchestrate distinct immunological outcomes in health and disease.

> **中文摘要：**
> 尽管我们对细胞因子产生细胞的身份和调控已有较多了解，但对响应细胞因子的细胞类型仍知之甚少。为了弥补这一知识空白，我们开发了“细胞因子细胞定位平台”（CyCLoPs），这是一种将细胞因子受体结合转化为可遗传追踪信号的报告系统。在体外，CyCLoPs显示出高特异性、强大的信噪比以及用于探测多种细胞因子受体相互作用的广泛适用性。在体内，白细胞介素（IL）-17A-CyCLoPs报告小鼠能够识别在共生菌定植后主要位于回肠绒毛的IL-17A应答性肠上皮细胞。干扰素-γ（IFN-γ）-CyCLoPs报告小鼠则可用于检测肿瘤内暴露于IFN-γ的CD8 T细胞，这些细胞表达CD36、CD38和瘦素受体，并显示出与效应功能降低相关的基因特征。总之，CyCLoPs为直接可视化和表征细胞因子诱导的细胞反应提供了一个平台，并为研究细胞因子如何在健康和疾病状态下协调不同的免疫学结果提供了工具。

### 第二部分 AI 大师评价

本研究旨在解决细胞因子应答细胞在体识别这一关键难题。其核心创新在于开发了CyCLoPs报告系统，将受体信号转化为可遗传追踪的标记，实现了对细胞因子活性的直接、高特异性可视化。研究通过IL-17A和IFN-γ两个模型，成功在肠道和肿瘤微环境中定位了特定的应答细胞群，并揭示了其新的表型和功能特征，为理解细胞因子的时空作用提供了强大工具。然而，该方法目前依赖于转基因报告小鼠，限制了其在人体或非模式生物中的直接应用，且主要反映的是受体被激活的“历史”事件，而非实时的动态信号。

---

## 41. 改良FOLFOXIRI联合帕尼单抗一线治疗RAS野生型转移性结直肠癌：III期TRIPLETE研究的最终结果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505697)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41505697
**DOI：** 10.1200/JCO-25-01337

### 第一部分 原文与翻译

**英文原标题：** Upfront Modified FOLFOXIRI Plus Panitumumab for  Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

> **英文摘要：**
> We report 5-year results of the phase III randomized TRIPLETE study. Eligible patients with  wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovorin, oxaliplatin (mFOLFOX)/panitumumab (control group, n = 217) versus modified fluorouracil, leucovorin, oxaliplatin, irinotecan (mFOLFOXIRI)/panitumumab (experimental group, n = 218). We present overall survival (OS) and updated outcomes in the intention-to-treat population. The median follow-up was 60.2 months (IQR, 49.3-70.0). The median OS was 41.1 and 33.3 months for experimental and control groups, respectively (hazard ratio [HR], 0.79 [95% CI, 0.63 to 0.99];  = .049). OS outcomes favored the experimental group regardless of clinical features. No differences in objective response rate (primary end point; 75%/78%, odds ratio, 0.84 [95% CI, 0.54 to 1.31];  = .442), early tumor shrinkage rate ( = .954), depth of response ( = .573), no residual tumor resection rate ( = .329), and progression-free survival (HR, 0.95 [95% CI, 0.78 to 1.16];  = .606) were confirmed. Among patients alive at the time of disease progression, the median postprogression survival was 24.6 and 17.7 months for experimental and control groups, respectively (HR, 0.79 [95% CI, 0.62 to 1.01];  = .062). Similar proportions of patients in both groups received subsequent lines of therapy (control/experimental: second line 73%/71%, third line 51%/49%, fourth line 31%/32%), as well as nonpalliative locoregional treatments (control/experimental: 16%/16%). Upfront mFOLFOXIRI/panitumumab significantly improves OS compared with mFOLFOX/panitumumab in patients with  wild-type mCRC.

> **中文摘要：**
> 我们报告了III期随机TRIPLETE研究的5年结果。符合条件的RAS野生型转移性结直肠癌（mCRC）患者接受一线改良氟尿嘧啶、亚叶酸、奥沙利铂（mFOLFOX）/帕尼单抗（对照组，n = 217）对比改良氟尿嘧啶、亚叶酸、奥沙利铂、伊立替康（mFOLFOXIRI）/帕尼单抗（试验组，n = 218）治疗。我们报告意向治疗人群的总生存期（OS）和更新的结局。中位随访时间为60.2个月（IQR，49.3-70.0）。试验组和对照组的中位OS分别为41.1个月和33.3个月（风险比[HR]，0.79 [95% CI，0.63至0.99]；P = .049）。无论临床特征如何，OS结果均支持试验组。在客观缓解率（主要终点；75%/78%，比值比，0.84 [95% CI，0.54至1.31]；P = .442）、早期肿瘤退缩率（P = .954）、缓解深度（P = .573）、无残留肿瘤切除率（P = .329）和无进展生存期（HR，0.95 [95% CI，0.78至1.16]；P = .606）方面均未确认存在差异。在疾病进展时存活的患者中，试验组和对照组的中位进展后生存期分别为24.6个月和17.7个月（HR，0.79 [95% CI，0.62至1.01]；P = .062）。两组中接受后续治疗线数的患者比例相似（对照组/试验组：二线治疗73%/71%，三线治疗51%/49%，四线治疗31%/32%），接受非姑息性局部区域治疗的比例也相似（对照组/试验组：16%/16%）。对于RAS野生型mCRC患者，一线使用mFOLFOXIRI/帕尼单抗相比mFOLFOX/帕尼单抗显著改善了OS。

### 第二部分 AI 大师评价

本研究旨在评估在RAS野生型转移性结直肠癌（mCRC）一线治疗中，强化化疗方案（mFOLFOXIRI）联合帕尼单抗是否优于标准双药方案（mFOLFOX）联合帕尼单抗。其核心创新点在于探索了在靶向治疗基础上增加化疗强度的价值。最终结果显示，强化方案显著延长了总生存期（OS），这是该研究最重要的发现。然而，研究也存在局限性：无进展生存期（PFS）和客观缓解率等关键次要终点均未显示差异，提示OS获益可能主要源于后续治疗或进展后生存的延长，而非初始肿瘤控制能力的根本性提升。

---

## 42. 加强癌症随机临床试验中体重指数的代表性与报告。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505673)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41505673
**DOI：** 10.1200/JCO-25-02077

### 第一部分 原文与翻译

**英文原标题：** Enhancing Representation and Reporting of Body Mass Index in Cancer Randomized Clinical Trials.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文旨在探讨如何改进癌症随机临床试验中体重指数的数据收集与报告规范。其核心目的可能是提升BMI作为关键协变量或预后/预测因素在试验数据分析中的代表性和报告质量，以增强研究结果的普适性和可解释性。鉴于摘要不可用，其具体方法（如提出新的报告标准或数据收集框架）和发现尚不明确。其创新性可能在于系统性地关注了临床试验中一个常被忽视但至关重要的患者特征维度，但缺乏摘要也限制了对其完整贡献和潜在局限性的评估。

---

## 43. 勘误：诱导治疗后放化疗对比化疗在不可切除胰腺癌转化为可切除中的获益：随机CONKO-007试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505667)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41505667
**DOI：** 10.1200/JCO-25-03004

### 第一部分 原文与翻译

**英文原标题：** Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

该文献为CONKO-007试验的勘误，该试验旨在评估诱导治疗后，放化疗对比单纯化疗在将初始不可切除的胰腺癌转化为可切除状态方面的疗效。作为一项随机对照试验，其核心目的是为局部晚期胰腺癌的转化治疗策略提供高级别循证医学证据。鉴于摘要信息缺失，无法直接评价其具体发现与结论，但该研究设计本身针对临床关键问题，其结果对优化多模式治疗序列具有重要价值。然而，勘误的性质提示原始发表可能存在数据或表述错误，读者在引用时需结合勘误内容审慎评估。

---

## 44. 个体化癌症治疗相关证据研究（I-PREDICT）N-of-1精准肿瘤学研究：通过分子谱分析匹配个体化剂量、个性化药物组合。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505666)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41505666
**DOI：** 10.1200/JCO-25-01453

### 第一部分 原文与翻译

**英文原标题：** Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.

> **英文摘要：**
> PURPOSE: Malignancies have complex and distinct molecular profiles that may not segregate by tumor type. However, most precision oncology treatments are matched to a single biomarker. We aimed to optimize therapy for advanced cancers using individually dosed drug regimens customized to cotarget multiple molecular alterations. METHODS: Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT; NCT02534675) is a prospective, investigator-initiated, multidepartment/pan-cancer trial for aggressive advanced/metastatic malignancies. Patients had tissue and/or blood next-generation sequencing (NGS; Foundation Medicine). A molecular tumor board made suggestions. Degree of biomarker matching to drugs given was calculated by a matching score (MS; broadly, number of pathogenic alterations targeted divided by total pathogenic alterations). RESULTS: Overall, 210 evaluable patients (n = 456 consented) received ≥1 US Food and Drug Administration-approved drug (mostly off label) after NGS. Median number of pathogenic alterations/tumor was five (range, 0-20); approximately 95% of patients had unique molecular landscapes. Consistent with I-PREDICT's objective to optimize/tailor treatment for each patient, we administered 157 different regimens (including 103 personalized combinations without established safety/dosing data). For previously unstudied combinations, starting doses were reduced and titrated to tolerance (intrapatient dose-finding); only 6.5% experienced Grade 3/4 drug-related toxicities ( 15.5% of those receiving established regimens). Higher disease control rate (stable disease ≥6 months/objective response), and longer progression-free survival and overall survival correlated significantly/independently/linearly with greater degrees of drug matching to alterations (higher MS), but did not vary by drug number or dosages. CONCLUSION: The I-PREDICT strategy of maximizing personalized biomarker matching with individually dosed customized drug combinations enabled safe and active N-of-1 matched treatment, including regimens previously unstudied in Phase I trials. I-PREDICT represents a blueprint for a new personalized precision oncology paradigm, which merits validation via additional prospective trials.

> **中文摘要：**
> 目的：恶性肿瘤具有复杂且独特的分子谱，可能无法按肿瘤类型进行区分。然而，大多数精准肿瘤治疗仅匹配单一生物标志物。我们的目标是使用定制的、针对多个分子改变的个体化剂量给药方案来优化晚期癌症的治疗。方法：个体化癌症治疗相关证据研究（I-PREDICT；NCT02534675）是一项针对侵袭性晚期/转移性恶性肿瘤的前瞻性、研究者发起的、多科室/泛癌种试验。患者接受了组织和/或血液的下一代测序（NGS；Foundation Medicine）。一个分子肿瘤委员会提供建议。生物标志物与所给药物的匹配程度通过匹配评分（MS；大致为靶向的致病性改变数量除以总致病性改变数量）计算。结果：总体而言，210名可评估患者（共入组456名）在NGS后接受了≥1种美国食品药品监督管理局批准的药物（大部分为超适应症使用）。每个肿瘤的致病性改变中位数为5个（范围0-20）；约95%的患者具有独特的分子图谱。与I-PREDICT为每位患者优化/定制治疗的目标一致，我们实施了157种不同的方案（包括103种无既定安全性/剂量数据的个性化组合）。对于先前未研究过的组合，起始剂量被降低并根据耐受性进行滴定（患者内剂量探索）；仅有6.5%的患者经历了3/4级药物相关毒性（接受既定方案的患者中为15.5%）。更高的疾病控制率（疾病稳定≥6个月/客观缓解）、更长的无进展生存期和总生存期与药物对改变的匹配程度（更高的MS）呈显著/独立/线性相关，但与药物数量或剂量无关。结论：I-PREDICT通过最大化个性化生物标志物匹配与个体化剂量定制药物组合的策略，实现了安全且有效的N-of-1匹配治疗，包括先前在I期试验中未研究过的方案。I-PREDICT代表了一种新的个性化精准肿瘤学范式的蓝图，值得通过更多前瞻性试验进行验证。

### 第二部分 AI 大师评价

本研究（I-PREDICT）旨在突破传统精准肿瘤学中单一生物标志物匹配的局限，通过为每位晚期癌症患者定制靶向多个分子改变的个体化剂量药物组合，实现“N-of-1”式治疗。其核心创新在于采用前瞻性、泛癌种设计，通过匹配评分量化治疗方案的个性化程度，并采用患者内剂量探索策略以管理未知组合的风险。研究发现，更高的匹配评分（而非药物数量或剂量）与显著改善的临床结局线性相关，这为基于多靶点匹配的精准治疗范式提供了有力证据。然而，该研究作为单臂试验，其结论仍需在前瞻性随机对照试验中得到验证，且复杂的方案制定对多学科团队和药物可及性提出了极高要求。

---

## 45. Blinatumomab在KMT2A重排急性淋巴细胞白血病婴儿中的持续获益：长期结局、毒性及药代动力学研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505662)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41505662
**DOI：** 10.1200/JCO-25-01806

### 第一部分 原文与翻译

**英文原标题：** Sustained Benefit of Blinatumomab in Infants With -Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.

> **英文摘要：**
> -rearranged infant ALL (-r ALL) has a poor prognosis. Adding blinatumomab, a bispecific T-cell engager targeting CD19, to standard chemotherapy for infants with -r ALL improved short-term outcomes. Here, we present long-term results, toxicity, and pharmacokinetics of blinatumomab from this study. Thirty infants received Interfant-06 protocol chemotherapy with one additional postinduction blinatumomab course. Disease-free survival (DFS) and overall survival (OS) were compared with a historical Interfant-06-selected cohort without blinatumomab. Infection and administration of intravenous immunoglobulin (IVIg) and granulocyte-colony stimulating factor (G-CSF) were documented. Blinatumomab's steady-state浓度 (Css) and clearance (CL) were analyzed. The median follow-up was 4.2 years (range, 3.2-6.0). Blinatumomab significantly improved outcomes compared with controls, with a 4-year DFS of 83.3% versus 44.0% and a 4-year OS of 93.3% versus 60.2%. No infection-related fatality occurred postinduction, in contrast to 4% in Interfant-06. IVIg was administered in 19 (63%) patients, and G-CSF in five (17%). The mean Css of blinatumomab was 706 ± 194 pg/mL/d, and the median CL was 0.89 L/h/m (range, 0.57-2.66). Adding blinatumomab to standard treatment for infants with -r ALL resulted in sustained improvement in outcome. Pharmacokinetics were comparable across pediatric age groups. The benefit of blinatumomab in frontline therapy remains promising and awaits further confirmation in ongoing trials.

> **中文摘要：**
> KMT2A重排婴儿急性淋巴细胞白血病（KMT2A-r ALL）预后不良。在KMT2A-r ALL婴儿的标准化疗基础上添加靶向CD19的双特异性T细胞衔接器Blinatumomab，改善了短期结局。本文报告了该研究中Blinatumomab的长期结果、毒性及药代动力学数据。30名婴儿接受了Interfant-06方案化疗，并在诱导后增加了一个疗程的Blinatumomab。将无病生存期（DFS）和总生存期（OS）与历史性的、未使用Blinatumomab的Interfant-06筛选队列进行比较。记录了感染以及静脉注射免疫球蛋白（IVIg）和粒细胞集落刺激因子（G-CSF）的使用情况。分析了Blinatumomab的稳态浓度（Css）和清除率（CL）。中位随访时间为4.2年（范围：3.2-6.0）。与对照组相比，Blinatumomab显著改善了结局，4年DFS为83.3%对比44.0%，4年OS为93.3%对比60.2%。诱导后未发生感染相关死亡，而Interfant-06方案中为4%。19名（63%）患者使用了IVIg，5名（17%）使用了G-CSF。Blinatumomab的平均Css为706 ± 194 pg/mL/d，中位CL为0.89 L/h/m（范围：0.57-2.66）。在KMT2A-r ALL婴儿的标准治疗中添加Blinatumomab带来了结局的持续改善。其药代动力学特征在儿科各年龄组间具有可比性。Blinatumomab在一线治疗中的获益前景广阔，有待正在进行的试验进一步证实。

### 第二部分 AI 大师评价

本研究旨在评估Blinatumomab联合标准化疗治疗高危KMT2A重排婴儿ALL的长期疗效与安全性。核心方法是在Interfant-06化疗方案基础上，于诱导后增加一个疗程的Blinatumomab，并与历史队列进行比较。研究发现，该方案显著提升了4年DFS和OS，且未发生诱导后感染相关死亡，药代动力学数据稳定。其创新性在于首次提供了该靶向药物在此特殊高危人群中的长期随访证据，证实了其持续获益。局限性在于样本量较小且为历史对照设计，其在一线治疗中的确切地位仍需更大规模的前瞻性研究验证。

---

## 46. 回复：关于在癌症随机临床试验中加强体重指数的代表性与报告。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505660)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41505660
**DOI：** 10.1200/JCO-25-02689

### 第一部分 原文与翻译

**英文原标题：** Reply to: Enhancing Representation and Reporting of Body Mass Index in Cancer Randomized Clinical Trials.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是对一篇关于在癌症随机临床试验中改进体重指数（BMI）数据收集与报告方法的评论文章的回应。其核心目的是就如何更全面、标准地纳入和报告BMI这一重要协变量/预后因素进行学术讨论与交流。作为一篇回复性文章，其主要方法是通过文献评述和观点阐述来参与对话。由于摘要不可用，其具体发现与论证细节无法直接获知。这类文章的创新性在于促进对临床试验设计关键细节的关注，但其局限性在于本身可能不包含原始数据或新的分析，论证深度依赖于原文及作者的观点。

---

## 47. IDH突变型胶质瘤的细胞起源

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505560)
**期刊：** Science (New York, N.Y.)
**PMID：** 41505560
**DOI：** 10.1126/science.aed6843

### 第一部分 原文与翻译

**英文原标题：** The source of IDH-mutant gliomas.

> **英文摘要：**
> Deep sequencing of human brain tissue identifies the probable cell of origin of IDH-mutant gliomas.

> **中文摘要：**
> 通过对人脑组织进行深度测序，确定了IDH突变型胶质瘤可能的起源细胞。

### 第二部分 AI 大师评价

本研究旨在探索IDH突变型胶质瘤的细胞起源。研究团队采用深度测序技术对人脑组织进行分析，成功识别出该类型胶质瘤最可能的起源细胞。这一发现具有重要的创新性，为理解该肿瘤的发病机制提供了关键线索，并可能为靶向治疗策略的开发指明方向。然而，摘要信息有限，未提及具体的细胞类型或验证方法，其结论的普适性和临床转化潜力尚需后续研究进一步证实。

---

## 48. IDH突变型胶质瘤起源于携带初始驱动突变的胶质祖细胞。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505555)
**期刊：** Science (New York, N.Y.)
**PMID：** 41505555
**DOI：** 10.1126/science.adt0559

### 第一部分 原文与翻译

**英文原标题：** IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation.

> **英文摘要：**
> Identifying the cell of origin that harbors an initial driver mutation is key to understanding tumor evolution and for the development of new treatments. For isocitrate dehydrogenase (IDH)-mutant gliomas, the most common malignant primary brain tumor in young adults, the cell of origin is currently poorly understood. We conducted deep sequencing on 142 tissues from 70 individuals comprising tumors, peritumoral cortex or subventricular zones, and blood. Low-level  mutations were found in the peritumoral cortex in 37.9% (11 of 29) of patients. Integrating cell-type-specific mutation analysis, the direction of clonal evolution, spatial transcriptomics from patient brains, and a cancer mouse model arising from mutant oligodendrocyte progenitor cell, we determined that glial progenitor cells harboring an initial  mutation were responsible for the development of IDH-mutant gliomas.

> **中文摘要：**
> 识别携带初始驱动突变的起源细胞，是理解肿瘤演变和开发新疗法的关键。对于异柠檬酸脱氢酶（IDH）突变型胶质瘤这一在年轻成人中最常见的恶性原发性脑肿瘤，其起源细胞目前尚不清楚。我们对来自70个个体的142份组织进行了深度测序，这些组织包括肿瘤、瘤周皮质或脑室下区以及血液。在37.9%（29例中的11例）患者的瘤周皮质中发现了低水平的突变。通过整合细胞类型特异性突变分析、克隆演化方向、患者脑组织的空间转录组学以及源自突变少突胶质细胞祖细胞的癌症小鼠模型，我们确定携带初始突变的胶质祖细胞是IDH突变型胶质瘤发生的原因。

### 第二部分 AI 大师评价

本研究旨在阐明IDH突变型胶质瘤的细胞起源，这是理解其发生机制的关键。研究团队采用了多组学整合策略，结合了患者样本的深度测序、空间转录组学分析和动物模型验证，方法学上具有系统性。核心发现是，携带初始IDH突变的胶质祖细胞是这类肿瘤的起源，这为理解肿瘤早期演化提供了直接证据。研究的创新性在于通过多维度证据链锁定了起源细胞，但局限性在于样本量相对有限，且主要聚焦于起源，对后续的肿瘤微环境演变和异质性探讨较少。

---

## 49. 脊髓背角的个体发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505538)
**期刊：** Science (New York, N.Y.)
**PMID：** 41505538
**DOI：** 10.1126/science.adx5781

### 第一部分 原文与翻译

**英文原标题：** Ontogeny of the spinal cord dorsal horn.

> **英文摘要：**
> The dorsal horn of the mammalian spinal cord is organized into laminae where each layer is populated by different neuron types, has distinctive circuit connections, and plays specialized roles in behavior. An outstanding question is how this organization emerges during development from an apparently homogeneous pool of neural progenitors. Here, we show that mouse dorsal neurons are diversified by time, with families of related cell types born as temporal cohorts, and by a spatial-molecular gradient that specifies individual cell types. Excitatory neurons settle into a chronotopic arrangement that transforms their progressive birthdates into anatomical order and is required to establish proper laminae. We identified essential ontogenetic principles that shape dorsal progenitors into the diverse cell types and structure that subserve sensorimotor function.

> **中文摘要：**
> 哺乳动物脊髓背角被组织成板层结构，每一层由不同的神经元类型构成，具有独特的环路连接，并在行为中发挥专门作用。一个悬而未决的问题是，这种组织结构是如何在发育过程中从看似均一的神经前体细胞池中产生的。本研究显示，小鼠背角神经元的多样化受时间和空间-分子梯度的调控：相关的细胞类型家族以时间性群组的方式产生，而空间-分子梯度则指定了单个细胞类型。兴奋性神经元形成一种时间拓扑排列，将其渐进的出生日期转化为解剖学上的有序结构，这对于建立正确的板层是必需的。我们揭示了将背角前体细胞塑造成服务于感觉运动功能的多样化细胞类型和结构的基本个体发生原则。

### 第二部分 AI 大师评价

本研究旨在解析脊髓背角板层结构在发育过程中的形成机制。作者结合时间序列和空间分子梯度分析，揭示了小鼠背角神经元多样化的两个关键维度：时间性群组产生和梯度特异性分化。核心发现是兴奋性神经元遵循“时间拓扑”原则排列，将出生顺序转化为解剖结构，这是板层形成的基础。该研究创新性地整合了时间和空间因素，提出了背角发育的普适性原理，但结论主要基于小鼠模型，其在其他物种（尤其是人类）中的普适性及具体分子机制细节仍有待进一步探索。

---

## 50. 中国人群免疫多组学图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505528)
**期刊：** Science (New York, N.Y.)
**PMID：** 41505528
**DOI：** 10.1126/science.adt3130

### 第一部分 原文与翻译

**英文原标题：** Chinese Immune Multi-Omics Atlas.

> **英文摘要：**
> Human peripheral blood exhibits molecular and cellular heterogeneity across populations, yet the underlying mechanisms remain unclear. We present the Chinese Immune Multi-Omics Atlas (CIMA), characterizing molecular variations linked to sex, age, and genetic variants through multi-omics analysis of more than 10 million circulating immune cells from 428 Chinese adults. CIMA established an enhancer-driven gene regulatory network comprising 237 robust regulons; identified 9600 eGenes and 52,361 caPeaks at cell type resolution; and revealed pleiotropic associations among immune-related disease risk loci, cis-expression quantitative trait loci (QTLs), and chromatin accessibility QTLs. Furthermore, the cell language model CIMA-CLM predicted chromatin accessibility and evaluated the effects of noncoding variants from chromatin sequences and gene expression. CIMA provides a comprehensive reference for immune-related disease research.

> **中文摘要：**
> 人类外周血在不同人群中表现出分子和细胞异质性，但其潜在机制尚不清楚。我们发布了中国人群免疫多组学图谱（CIMA），通过对428名中国成年人的超过1000万个循环免疫细胞进行多组学分析，描绘了与性别、年龄和遗传变异相关的分子变异特征。CIMA建立了一个包含237个稳健调节子的增强子驱动基因调控网络；在细胞类型分辨率下鉴定了9600个eGenes和52,361个caPeaks；并揭示了免疫相关疾病风险位点、顺式表达数量性状位点（QTLs）和染色质可及性QTLs之间的多效性关联。此外，细胞语言模型CIMA-CLM能够预测染色质可及性，并从染色质序列和基因表达层面评估非编码变异的影响。CIMA为免疫相关疾病研究提供了一个全面的参考。

### 第二部分 AI 大师评价

本研究旨在构建首个大规模中国人群免疫多组学参考图谱（CIMA），以解析人群异质性的分子机制。其核心方法是整合单细胞多组学数据，对超过千万个免疫细胞进行分析，系统性地描绘了基因调控网络、数量性状位点及多效性关联。主要创新点在于建立了增强子驱动的调控网络，并开发了可预测染色质可及性的细胞语言模型（CIMA-CLM），为功能变异解读提供了新工具。然而，研究主要聚焦于中国汉族人群，其发现向其他人群的普适性有待进一步验证，且图谱的功能性验证仍需后续实验研究深入展开。

---

## 51. 一种用于胶质母细胞瘤研究的人源肿瘤-免疫类器官模型。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505256)
**期刊：** Cell reports
**PMID：** 41505256
**DOI：** 10.1016/j.celrep.2025.116790

### 第一部分 原文与翻译

**英文原标题：** A human tumor-immune organoid model of glioblastoma.

> **英文摘要：**
> A major obstacle to identifying effective therapies for the aggressive brain tumor glioblastoma is the lack of human-specific, immunocompetent models that reflect the human tumor microenvironment. To address this, we developed the immune-human organoid tumor transplantation (iHOTT) model, an autologous co-culture platform that integrates patient-derived tumor cells and matched peripheral blood mononuclear cells within human cortical organoids to enable the study of patient-specific immune responses and tumor-immune interactions. This platform preserves tumor and immune populations, immune signaling, and cell-cell interactions observed in patient tumors. Treatment of iHOTT with pembrolizumab, a checkpoint inhibitor, mirrors cell-type shifts and cell-cell interactions observed in patients. T cell receptor (TCR) sequencing further reveals pembrolizumab-driven expansion of stem-like CD4 T cell clonotypes exhibiting patient-specific repertoires. These findings establish iHOTT as a physiologically relevant platform for exploring autologous tumor-immune interactions and underscore the need for antigen-targeted strategies to enhance immunotherapy in glioblastoma.

> **中文摘要：**
> 寻找针对侵袭性脑肿瘤胶质母细胞瘤有效疗法的一个主要障碍，是缺乏能够反映人类肿瘤微环境的、具有免疫活性的人源特异性模型。为解决这一问题，我们开发了免疫-人源类器官肿瘤移植（iHOTT）模型，这是一个自体共培养平台，它将患者来源的肿瘤细胞和匹配的外周血单个核细胞整合到人皮层类器官中，从而能够研究患者特异性的免疫反应和肿瘤-免疫相互作用。该平台保留了在患者肿瘤中观察到的肿瘤和免疫细胞群、免疫信号传导以及细胞-细胞相互作用。使用检查点抑制剂帕博利珠单抗处理iHOTT模型，再现了在患者中观察到的细胞类型变化和细胞-细胞相互作用。T细胞受体（TCR）测序进一步揭示了帕博利珠单抗驱动的、具有患者特异性库的干细胞样CD4 T细胞克隆型的扩增。这些发现确立了iHOTT作为一个具有生理相关性的平台，可用于探索自体肿瘤-免疫相互作用，并强调了需要抗原靶向策略来增强胶质母细胞瘤的免疫治疗。

### 第二部分 AI 大师评价

本研究旨在解决胶质母细胞瘤研究中缺乏人源化、免疫活性模型的关键瓶颈。其核心创新在于构建了名为iHOTT的自体共培养平台，该平台将患者来源的肿瘤细胞、匹配的免疫细胞与皮层类器官整合，高度模拟了人体内的肿瘤微环境。研究发现，该平台不仅能重现临床观察到的细胞互作，还揭示了帕博利珠单抗驱动特定干细胞样CD4 T细胞克隆扩增的新机制，为个体化免疫治疗研究提供了有力工具。然而，该模型作为体外系统，在模拟血脑屏障、全身性免疫反应及长期动态过程方面仍存在固有局限性。

---

## 52. 何者存留。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505152)
**期刊：** JAMA
**PMID：** 41505152
**DOI：** 10.1001/jama.2025.23936

### 第一部分 原文与翻译

**英文原标题：** What Remains.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题“What Remains.”（何者存留）具有哲学思辨色彩，暗示了在某种干预、事件或进程之后，对遗留问题、持续影响或根本性要素的探讨。由于摘要缺失，无法获知其具体的研究目的、方法及发现。这限制了对其科学严谨性和创新性的评估。该文献可能旨在引发对医学实践中核心、持久价值的深度思考，或总结某一领域经时间检验后仍具重要意义的内容，但其具体贡献需阅读全文方能确定。

---

## 53. TP53突变髓系肿瘤中的端粒谜题。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505147)
**期刊：** Blood
**PMID：** 41505147
**DOI：** 10.1182/blood.2025031124

### 第一部分 原文与翻译

**英文原标题：** The telomeric puzzle in TP53-mutant myeloid neoplasms.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文聚焦于TP53突变髓系肿瘤中端粒生物学异常这一前沿领域，旨在解析端粒长度、结构或功能改变与疾病发生发展的关联。其核心目的可能是阐明端粒失调在TP53突变背景下驱动基因组不稳定性和疾病进展的具体机制。鉴于摘要暂缺，推测研究可能采用分子生物学、基因组学或细胞模型等方法进行探索。其创新性在于将端粒这一经典衰老标志物与TP53突变这一高危遗传事件相结合，为理解髓系肿瘤的发病机制提供了新视角。然而，具体的研究方法、关键发现以及结论的临床转化潜力，仍需等待全文公布后才能进行深入评估。

---

## 54. 实体肿瘤患者癌症治疗后克隆性造血与心血管疾病风险研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505144)
**期刊：** JAMA oncology
**PMID：** 41505144
**DOI：** 10.1001/jamaoncol.2025.5785

### 第一部分 原文与翻译

**英文原标题：** Clonal Hematopoiesis and Cardiovascular Disease Risk After Cancer Therapy in Patients With Solid Tumors.

> **英文摘要：**
> IMPORTANCE: Cancer survivors have increased cardiovascular disease (CVD) risk partly due to the toxic effects of cancer therapy. Clonal hematopoiesis of indeterminate potential (CHIP), an age-associated blood disorder caused by somatic variants in blood stem cells, is more prevalent among individuals receiving cancer therapy and increases CVD risk independent of traditional risk factors. It is unknown whether CHIP amplifies therapy-related cardiovascular toxic effects in patients with cancer.
> 
> OBJECTIVE: To assess the association between CHIP and CVD risk, accounting for competing risks, among patients with primary solid tumors who received chemotherapy, radiotherapy, or immunotherapy.
> 
> DESIGN, SETTING, AND PARTICIPANTS: A cohort study was conducted using BioVU, Vanderbilt University Medical Center's biorepository linking electronic health records to whole-genome sequencing data from 250 038 participants from 2006 to 2025. In this cohort, participants had a primary solid tumor diagnosis, received chemotherapy, radiotherapy, and/or immunotherapy, and did not have hematologic malignant disease before treatment. Data were analyzed from June 2025 to November 2025.
> 
> EXPOSURES: CHIP variants detected via whole-genome sequencing, chemotherapy, radiotherapy, and immunotherapy.
> 
> MAIN OUTCOMES AND MEASURES: Time to first cardiovascular event, defined as heart failure, ischemic CVD, or arrhythmia following cancer treatment.
> 
> RESULTS: Among 8004 eligible participants (median [IQR] age, 61.9 [52.2-69.9] years; 4385 female individuals [54.8%]) with a primary solid tumor diagnosis, 7438 had no heart failure, 7392 no ischemic CVD, and 6002 no arrhythmia before cancer therapy. Overall, 549 (6.9%) had CHIP. In the propensity score-matched cohort, participants with CHIP had a significantly higher 10-year cumulative incidence of heart failure (20.3%; 95% CI, 16.0%-24.4% vs 14.5%; 95% CI, 13.5%-15.6%; P = .001) and ischemic CVD (25.3%; 95% CI, 20.5%-30.0% vs 18.5%; 95% CI, 17.3%-20.0%; P < .001) compared with those without CHIP. In adjusted Fine-Gray models, CHIP was associated with increased risk of heart failure (subdistribution hazard ratio [sHR], 1.26; 95% CI, 1.02-1.56; P = .03). In an exploratory 24-month landmark analysis, there was a statistically significant interaction between CHIP and intensive chemotherapy (≥7 cycles) on heart failure risk (sHR, 1.02; 95% CI, 1.00-1.04; P = .03).
> 
> CONCLUSIONS AND RELEVANCE: In this cohort study, CHIP was associated with increased CVD risk in patients with solid tumors receiving cancer therapy. This finding suggests incorporating CHIP status may improve cardio-oncology treatment of cancer survivors.

> **中文摘要：**
> 重要性：癌症幸存者心血管疾病风险增加，部分归因于癌症治疗的毒性作用。意义未明的克隆性造血（CHIP）是一种与年龄相关的血液疾病，由造血干细胞体细胞变异引起，在接受癌症治疗的个体中更为普遍，且独立于传统风险因素增加心血管疾病风险。目前尚不清楚CHIP是否会放大癌症患者中治疗相关的心血管毒性作用。
> 
> 目的：评估在接受化疗、放疗或免疫治疗的初发实体肿瘤患者中，CHIP与心血管疾病风险之间的关联，并考虑竞争风险。
> 
> 设计、设置与参与者：这是一项队列研究，使用了范德堡大学医学中心的BioVU生物样本库，该库将电子健康记录与2006年至2025年间250,038名参与者的全基因组测序数据相关联。在该队列中，参与者被诊断为初发实体肿瘤，接受了化疗、放疗和/或免疫治疗，且在治疗前无血液系统恶性肿瘤。数据分析时间为2025年6月至2025年11月。
> 
> 暴露因素：通过全基因组测序检测到的CHIP变异、化疗、放疗和免疫治疗。
> 
> 主要结局与测量指标：首次发生心血管事件的时间，定义为癌症治疗后发生心力衰竭、缺血性心血管疾病或心律失常。
> 
> 结果：在8004名符合条件的初发实体肿瘤参与者（中位[IQR]年龄61.9 [52.2-69.9]岁；4385名女性[54.8%]）中，7438人在癌症治疗前无心力衰竭，7392人无缺血性心血管疾病，6002人无心律失常。总体而言，549人（6.9%）存在CHIP。在倾向评分匹配队列中，与无CHIP的参与者相比，有CHIP的参与者10年心力衰竭累积发生率（20.3%；95% CI，16.0%-24.4% vs 14.5%；95% CI，13.5%-15.6%；P= .001）和缺血性心血管疾病累积发生率（25.3%；95% CI，20.5%-30.0% vs 18.5%；95% CI，17.3%-20.0%；P< .001）均显著更高。在调整后的Fine-Gray模型中，CHIP与心力衰竭风险增加相关（亚分布风险比[sHR]，1.26；95% CI，1.02-1.56；P= .03）。在一项探索性的24个月界标分析中，CHIP与强化化疗（≥7个周期）对心力衰竭风险存在统计学上显著的交互作用（sHR，1.02；95% CI，1.00-1.04；P= .03）。
> 
> 结论与相关性：在这项队列研究中，CHIP与接受癌症治疗的实体肿瘤患者心血管疾病风险增加相关。这一发现提示，将CHIP状态纳入考量可能改善癌症幸存者的心脏肿瘤学治疗。

### 第二部分 AI 大师评价

本研究旨在探究克隆性造血（CHIP）是否会放大实体肿瘤患者癌症治疗后心血管疾病风险。研究采用大规模回顾性队列设计，整合电子健康记录与全基因组测序数据，并运用倾向评分匹配和竞争风险模型进行严谨分析。核心发现是CHIP与心力衰竭及缺血性心血管疾病风险显著增加相关，且与强化化疗存在交互作用，这为心脏肿瘤学风险分层提供了新的生物标志物。其创新性在于首次在大型实体肿瘤患者队列中量化了CHIP对治疗相关心血管毒性的影响，但作为观察性研究，其结论需前瞻性研究验证，且对CHIP变异类型和具体治疗方案的异质性分析有限。

---

## 55. 肿瘤学中尝试权使用研究性药物的伦理考量——在希望与证据间寻求平衡

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505141)
**期刊：** JAMA oncology
**PMID：** 41505141
**DOI：** 10.1001/jamaoncol.2025.5771

### 第一部分 原文与翻译

**英文原标题：** The Ethics of Right to Try Investigational Agents in Oncology-Balancing Hope With Evidence.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文聚焦于肿瘤学领域极具争议的“尝试权”伦理议题，旨在探讨如何平衡晚期癌症患者获取未获批研究性药物的迫切希望与基于循证医学的审慎原则。文章的核心目的并非报告具体临床研究数据，而是对相关伦理框架、政策法规及临床实践困境进行深度剖析。其创新性在于直面医学进步与患者自主权之间的根本张力，为临床医生、政策制定者及伦理委员会提供了关键的决策参考。然而，由于缺乏摘要，无法获知其具体的论证方法、核心发现或结论，这在一定程度上限制了对其内容深度和具体贡献的预先评估。

---

## 56. 2025年联邦医疗补助资格限制下癌症筛查与结果的预测研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505125)
**期刊：** JAMA oncology
**PMID：** 41505125
**DOI：** 10.1001/jamaoncol.2025.5774

### 第一部分 原文与翻译

**英文原标题：** Projected Cancer Screening and Outcomes Under the 2025 Federal Medicaid Eligibility Restrictions.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在评估2025年联邦医疗补助资格限制政策对癌症筛查及后续健康结局的潜在影响。研究很可能采用建模或预测分析方法，量化政策变化对筛查率、癌症分期分布及生存率等关键指标的影响。其创新性在于前瞻性地评估了特定医疗政策在肿瘤防控领域的公共卫生后果，为政策制定提供了循证依据。然而，由于摘要不可得，其具体研究方法、模型假设及潜在局限性（如数据来源、模型不确定性）尚不明确。

---

## 57. 钠-葡萄糖协同转运蛋白2抑制剂用于接受激素治疗的前列腺癌患者。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41505116)
**期刊：** JAMA oncology
**PMID：** 41505116
**DOI：** 10.1001/jamaoncol.2025.5869

### 第一部分 原文与翻译

**英文原标题：** Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy.

> **英文摘要：**
> IMPORTANCE: While preliminary evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors for diabetes may have antitumorigenic effects, their potential benefits in prostate cancer remain unexplored. Understanding their association with outcomes among patients undergoing hormone therapy could inform future adjunct treatment strategies. OBJECTIVE: To evaluate whether the use of SGLT2 inhibitors is associated with clinical outcomes in patients with prostate cancer receiving hormone therapy. DESIGN, SETTING, AND PARTICIPANTS: This population-based, sequential target trial emulation of monthly cohorts used territory-wide electronic health records (January 1, 1993, to April 30, 2025) from the Hong Kong Hospital Authority, covering a population of approximately 7.5 million. Adult men diagnosed with prostate cancer who initiated androgen deprivation therapy (ADT) were included. Follow-up extended through April 2025, and data were analyzed from June to October 2025. EXPOSURES: Use of SGLT2 inhibitors (primarily dapagliflozin and empagliflozin) initiated during hormone therapy and maintained for at least 1 month. Comparator groups included nonusers of SGLT2 inhibitors. MAIN OUTCOMES AND MEASURES: The primary outcome was time to ADT failure. Secondary outcomes include time to next-generation hormonal agent failure, disease-specific survival, and overall survival. Both intention-to-treat and per-protocol analyses were conducted using complementary log-log model regression to provide the hazard ratio (HR) estimate. RESULTS: Among 14 223 eligible patients (median [IQR] age at enrollment, 74 [68-80] years) with a median follow-up of 66 months (95% CI, 65-67 months), intention-to-treat SGLT2 inhibitor use was associated with reduced risk of ADT failure (HR, 0.63; 95% CI, 0.41-0.95; P = .03) and next-generation hormonal agent failure (HR, 0.44; 95% CI, 0.20-0.97; P = .04). Sensitivity analyses confirmed robustness of these findings across different comparator subgroups. Metformin monotherapy was not associated with disease progression but was associated with improved overall survival (HR, 0.59; 95% CI, 0.42-0.83; P = .002). No statistically significant outcome differences were observed between dapagliflozin and empagliflozin. CONCLUSIONS AND RELEVANCE: In this cohort study with a target trial emulation design, SGLT2 inhibitor use was associated with delayed hormone therapy failure in patients with prostate cancer, suggesting a potential oncologic benefit beyond glucose lowering. These findings support the potential of SGLT2 inhibitors in treatment for prostate cancer.

> **中文摘要：**
> 重要性：尽管初步证据表明用于糖尿病的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂可能具有抗肿瘤发生效应，但其在前列腺癌中的潜在益处尚未被探索。了解它们与接受激素治疗患者结局的关联，可为未来的辅助治疗策略提供信息。目的：评估SGLT2抑制剂的使用是否与接受激素治疗的前列腺癌患者的临床结局相关。设计、设置与参与者：这项基于人群、采用序贯目标试验模拟方法的月度队列研究，使用了香港医院管理局覆盖约750万人口的全港电子健康记录（1993年1月1日至2025年4月30日）。研究纳入了诊断为前列腺癌并开始雄激素剥夺疗法（ADT）的成年男性。随访持续至2025年4月，数据分析时间为2025年6月至10月。暴露因素：在激素治疗期间开始使用并至少维持1个月的SGLT2抑制剂（主要为达格列净和恩格列净）。对照组包括未使用SGLT2抑制剂的患者。主要结局与测量指标：主要结局是至ADT失败的时间。次要结局包括至下一代激素药物失败的时间、疾病特异性生存期和总生存期。采用意向性治疗和符合方案分析，并使用互补双对数模型回归来提供风险比（HR）估计值。结果：在14,223名符合条件的患者（入组中位[IQR]年龄为74[68-80]岁，中位随访时间为66个月[95% CI，65-67个月]）中，意向性治疗分析显示，使用SGLT2抑制剂与ADT失败风险降低相关（HR，0.63；95% CI，0.41-0.95；P = .03），也与下一代激素药物失败风险降低相关（HR，0.44；95% CI，0.20-0.97；P = .04）。敏感性分析证实了这些发现在不同对照亚组中的稳健性。二甲双胍单药治疗与疾病进展无关，但与总生存期改善相关（HR，0.59；95% CI，0.42-0.83；P = .002）。达格列净与恩格列净之间未观察到具有统计学意义的结局差异。结论与相关性：在这项采用目标试验模拟设计的队列研究中，使用SGLT2抑制剂与前列腺癌患者激素治疗失败延迟相关，提示其可能具有超越降糖的肿瘤学益处。这些发现支持了SGLT2抑制剂在前列腺癌治疗中的潜力。

### 第二部分 AI 大师评价

本研究旨在探索SGLT2抑制剂对接受激素治疗的前列腺癌患者的潜在抗肿瘤作用。研究创新性地采用了基于大规模真实世界电子健康记录的序贯目标试验模拟设计，有效平衡了观察性研究的因果推断局限性。核心发现是SGLT2抑制剂的使用与ADT及下一代激素治疗失败风险显著降低相关，提示了其作为辅助治疗的潜力。然而，作为观察性研究，尽管采用了先进的分析方法，仍存在未测量混杂因素影响结论的可能性，且研究人群局限于特定地区，其普遍性有待验证。

---

## 58. 从生物学到临床：早期临床试验中开发癌症联合疗法的挑战与策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504671)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41504671
**DOI：** 10.1158/1078-0432.CCR-25-1356

### 第一部分 原文与翻译

**英文原标题：** From Biology to Bedside: Challenges and Strategies in Developing Combination Cancer Therapies in Early-Phase Trials.

> **英文摘要：**
> Recent advances in next-generation sequencing and molecular profiling have significantly expanded our understanding of the tumor mutational landscape, leading to a substantial increase in the number of novel targeted agents. Small molecules have transformed the standard of care for many patients with oncogene-driven cancers. However, single-agent therapies have several limitations, including the development of primary (intrinsic) or secondary (acquired) resistance, which often results in non-durable antitumor responses. Additionally, targeting a single alteration can lead to the upregulation of additional alterations, thereby minimizing activity. The development of novel rational combination strategies is essential to overcome compensatory escape mechanisms, intrinsic and acquired resistance, and other challenges, such as intratumoral heterogeneity and clonal evolution. In this article, we summarize key aspects of early-phase clinical trials of combination therapy, including regulatory, biological, and logistical considerations-such as biomarker integration, real-time molecular profiling, and adaptive trial infrastructure-that shape the future of combination strategies in early-phase oncology trials. We discuss recent successes with combination therapy in the clinic and discuss some current challenges in developing combination trials. Finally, we expand upon previously published guidance and, in the context of Project Optimus, propose recommendations for designing and conducting early-phase clinical trials of combination therapies.

> **中文摘要：**
> 新一代测序和分子谱分析技术的近期进展显著拓展了我们对肿瘤突变谱的理解，导致新型靶向药物的数量大幅增加。小分子药物已经改变了许多致癌基因驱动癌症患者的治疗标准。然而，单药疗法存在若干局限性，包括原发性（内在）或继发性（获得性）耐药的出现，这通常导致抗肿瘤反应不持久。此外，靶向单一改变可能导致其他改变的上调，从而削弱疗效。开发新型合理的联合策略对于克服代偿性逃逸机制、内在和获得性耐药以及其他挑战（如肿瘤内异质性和克隆进化）至关重要。在本文中，我们总结了联合疗法早期临床试验的关键方面，包括监管、生物学和后勤方面的考量——例如生物标志物整合、实时分子谱分析和适应性试验基础设施——这些因素塑造了早期肿瘤学试验中联合策略的未来。我们讨论了联合疗法在临床中的近期成功，并探讨了当前开发联合试验面临的一些挑战。最后，我们在先前发表的指南基础上，结合“Optimus项目”的背景，提出了设计和开展联合疗法早期临床试验的建议。

### 第二部分 AI 大师评价

本文旨在系统阐述早期临床试验中开发癌症联合疗法的核心挑战与应对策略。文章首先基于测序技术进展，指出单药靶向治疗的局限性（如耐药、反应不持久），从而论证了开发合理联合疗法的必要性。其方法聚焦于总结早期试验的关键考量，包括监管、生物学和后勤层面，并整合生物标志物、实时分子谱分析等前沿技术。文章的创新性在于结合“Optimus项目”背景，提出了针对性的试验设计与实施建议，为未来联合策略的优化提供了框架。然而，作为一篇综述性文章，其局限性在于未提供具体的原始临床数据来量化所讨论策略的实际效果。

---

## 59. SARC031：一项评估司美替尼联合西罗莫司治疗不可切除或转移性恶性外周神经鞘瘤（MPNST）患者的2期临床试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504652)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41504652
**DOI：** 10.1158/1078-0432.CCR-25-2887

### 第一部分 原文与翻译

**英文原标题：** SARC031: A Phase 2 Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).

> **英文摘要：**
> PURPOSE: Combined mTOR and MEK inhibition, critical components of the RAS effector pathway underlying the pathogenesis of NF1 related tumors caused regression in a malignant peripheral nerve sheath tumor (MPNST) transgenic mouse model. The primary objective was to determine the clinical获益率 in patients with unresectable/metastatic MPNST.
> 
> EXPERIMENTAL DESIGN: The study design was a multi-institutional open label Simon 2 stage phase 2 study of the MEK inhibitor selumetinib and mTOR inhibitor sirolimus. Patients ≥12 years with histologically confirmed MPNST received selumetinib 50mg twice daily and sirolimus 4mg once daily, in continuous 28-day cycles. Correlative studies evaluated patient-reported pain, immune signature in peripheral blood, and cell-free DNA (cfDNA).
> 
> RESULTS: 21 heavily pretreated patients (7F; median age 41 y (range 16-72), 14 with NF1) with advanced disease enrolled at 5 participating sites. Clinical benefit was observed in only 1/7 in stage 1 and 1/14 in stage 2. The median number of cycles was 2 (range 1-6). Most common adverse events (AEs) were grade ≤2 gastrointestinal toxicity, acneiform rash, hypertriglyceridemia, mucositis, and transaminase elevation. Unlike the preclinical model, early 18FDG-PET scan performed during cycle 1 demonstrated partial metabolic responses in 5 patients (24%) but did not correlate with objective responses post cycle 2. cfDNA was able to detect MPNST with the potential to be a biomarker of response.
> 
> CONCLUSION: The combination was safe with manageable and expected AEs, but did not meet study parameters for further evaluation in MPNST. Correlative studies were informative and may guide future therapeutic trials of MPNST.

> **中文摘要：**
> 目的：联合抑制mTOR和MEK（RAS效应通路的关键组成部分，该通路是NF1相关肿瘤发病机制的基础）在恶性外周神经鞘瘤（MPNST）转基因小鼠模型中引起了肿瘤消退。本研究的主要目的是确定不可切除/转移性MPNST患者的临床获益率。
> 
> 实验设计：本研究设计为一项多中心、开放标签、采用Simon两阶段设计的2期研究，评估MEK抑制剂司美替尼和mTOR抑制剂西罗莫司的联合疗法。年龄≥12岁、经组织学确诊的MPNST患者接受司美替尼（50mg，每日两次）和西罗莫司（4mg，每日一次）治疗，以连续28天为一个周期。相关研究评估了患者报告的疼痛、外周血免疫特征和循环游离DNA（cfDNA）。
> 
> 结果：在5个参与中心入组了21例经过大量预治疗的晚期患者（7例女性；中位年龄41岁（范围16-72岁），其中14例伴有NF1）。仅在阶段1的7例患者中观察到1例临床获益，在阶段2的14例患者中观察到1例。中位治疗周期数为2（范围1-6）。最常见的不良事件（AEs）为≤2级的胃肠道毒性、痤疮样皮疹、高甘油三酯血症、黏膜炎和转氨酶升高。与临床前模型不同，在周期1期间进行的早期18FDG-PET扫描显示5名患者（24%）出现了部分代谢缓解，但这与周期2后的客观缓解无关。cfDNA能够检测到MPNST，并有可能成为疗效的生物标志物。
> 
> 结论：该联合方案安全性良好，不良事件可管理且符合预期，但未达到研究预设的继续评估参数。相关研究提供了有价值的信息，可能指导未来的MPNST治疗试验。

### 第二部分 AI 大师评价

本研究旨在验证基于临床前模型的联合靶向策略（mTOR+MEK抑制）在晚期MPNST患者中的疗效。研究采用经典的Simon两阶段设计，并整合了疼痛评估、免疫特征和cfDNA等转化研究。核心发现是，尽管联合治疗安全性可控，但其临床获益率极低（2/21），未能达到预设的疗效终点，表明该策略在临床转化中未获成功。研究的创新性在于，其转化研究部分揭示了早期代谢反应与后期客观反应的不一致性，并提示cfDNA作为潜在生物标志物的价值，为未来试验设计提供了重要参考。

---

## 60. 未接受过内分泌治疗的子宫内膜癌中的ESR1突变：患病率、特征及预后意义——来自UTOLA II期GINECO试验的结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504649)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41504649
**DOI：** 10.1158/1078-0432.CCR-25-2758

### 第一部分 原文与翻译

**英文原标题：** ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial.

> **英文摘要：**
> RATIONALE: Aromatase inhibitors (AIs) are used to treat estrogen receptor (ER)-positive low-grade endometrioid EC (LGEC). In breast cancer (BC), ESR1 mutations are rare at diagnosis (<5%) but are frequently acquired in of AI-resistant cases and are considered as one of the major resistance mechanisms to endocrine therapy. This study aimed to assess the prevalence of ESR1 mutations (ESR1m) in homonotherapy-naïve EC samples and correlate with molecular profiles, ER expression and clinical outcomes.
> 
> METHODS: 147 patients with advanced EC who had responded to first-line chemotherapy were recruited into the UTOLA trial. Archival EC tumor tissues underwent sequencing of 127 genes including ESR1. Only hotspot mutations in the ligand-binding domain were evaluated. ESR1m prevalence was validated in the Genomics England dataset. In UTOLA, tumors were classified as POLE, dMMR, TP53abn or NSMP based on the PROMISE classification.
> 
> RESULTS: 137/147 patients had sufficient tumor material for sequencing. ESR1m were identified in eight tumors (6%), including Y537S/C/N (N=4), L536H/P (N=2) and E380Q (N=2). A similar prevalence (3.5%) was found among 1311 tumors in the Genomics England dataset. All ESR1m cases were LGEC, ER- and PR-positive and classified as NSMP. Among metastatic NSMP LGEC patients, 22% (8/37) harbored ESR1m. Survival outcomes post-platinum chemotherapy were similar between patients with ESR1m EC and ESR1-wild type (median not reached versus 25.3 months, p=0.114).
> 
> CONCLUSION: ESR1 mutations, while rare overall in treatment-naïve EC, are more prevalent in NSMP LGEC, potentially affecting AI efficacy. ESR1 status should be considered in selecting hormonotherapy and as a stratification factor in AI trials.

> **中文摘要：**
> 研究背景：芳香化酶抑制剂（AIs）用于治疗雌激素受体（ER）阳性的低级别子宫内膜样癌（LGEC）。在乳腺癌（BC）中，ESR1突变在诊断时罕见（<5%），但在AI耐药病例中常为获得性突变，被认为是内分泌治疗的主要耐药机制之一。本研究旨在评估未接受过激素治疗的EC样本中ESR1突变（ESR1m）的患病率，并将其与分子特征、ER表达及临床结局相关联。
> 
> 方法：147名对一线化疗有反应的晚期EC患者被招募入UTOLA试验。对存档的EC肿瘤组织进行了包括ESR1在内的127个基因测序。仅评估配体结合域的热点突变。ESR1m的患病率在Genomics England数据集中得到验证。在UTOLA试验中，根据PROMISE分类将肿瘤分为POLE、dMMR、TP53abn或NSMP型。
> 
> 结果：147名患者中有137名有足够的肿瘤组织进行测序。在8个肿瘤（6%）中鉴定出ESR1m，包括Y537S/C/N（N=4）、L536H/P（N=2）和E380Q（N=2）。在Genomics England数据集的1311个肿瘤中也发现了相似的患病率（3.5%）。所有ESR1m病例均为LGEC、ER和PR阳性，且分类为NSMP。在转移性NSMP LGEC患者中，22%（8/37）携带ESR1m。ESR1m EC患者与ESR1野生型患者在铂类化疗后的生存结局相似（中位生存期未达到 vs 25.3个月，p=0.114）。
> 
> 结论：ESR1突变虽然在未接受过治疗的EC中总体罕见，但在NSMP LGEC中更为普遍，可能影响AI疗效。在选择激素治疗时以及作为AI试验的分层因素时，应考虑ESR1状态。

### 第二部分 AI 大师评价

本研究首次在未接受过内分泌治疗的子宫内膜癌（EC）患者中系统评估了ESR1突变（ESR1m）的患病率及其临床意义。其核心目的是探索ESR1m在EC中的基线特征，以期为芳香化酶抑制剂（AI）治疗提供预测性生物标志物。研究通过前瞻性临床试验（UTOLA）队列和大型公共数据集（Genomics England）进行验证，方法严谨。主要发现是ESR1m在未治疗EC中总体罕见（6%），但在特定分子亚型（NSMP LGEC）中患病率显著升高（22%），且与ER/PR阳性相关，这提示ESR1m可能是EC内分泌治疗的原发性耐药机制，而非仅像乳腺癌那样是获得性耐药。创新性在于将乳腺癌中成熟的耐药机制研究范式成功应用于EC，并明确了其在特定分子亚群中的重要性。局限性在于样本量相对有限，且结论主要基于回顾性样本分析，需要在前瞻性AI治疗试验中进一步验证其预测价值。

---

## 61. 聚乙二醇化脂质体多柔比星治疗晚期难治性硬纤维瘤患者的3期临床试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504634)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41504634
**DOI：** 10.1158/1078-0432.CCR-25-3128

### 第一部分 原文与翻译

**英文原标题：** Phase 3 Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.

> **英文摘要：**
> PURPOSE: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DTs). PATIENTS AND METHODS: In this investigator-initiated, double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m² intravenously) or placebo every 4 weeks for 6 cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety. RESULTS: From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with a hazard ratio (HR) of 0.05 (95% CI, 0.01-0.17; P<0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and 1 (4.3%) in the placebo group (P=0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white-cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P<0.05). CONCLUSIONS: PLD significantly prolonged PFS and induced durable responses than placebo, with a favorable safety profile, for patients with progressive or symptomatic desmoid tumors.

> **中文摘要：**
> 目的：评估聚乙二醇化脂质体多柔比星（PLD）治疗硬纤维瘤（DTs）的疗效和安全性。患者与方法：在这项研究者发起的、双盲、3期试验中，我们将晚期或难治性DTs患者按2:1的比例随机分配，分别接受PLD（50 mg/m²，静脉注射）或安慰剂治疗，每4周一次，共6个周期。疾病进展时允许从安慰剂组交叉至PLD组。主要终点是无进展生存期（PFS）。次要终点是客观缓解和安全性。结果：从2020年11月到2023年3月，共有73名患者被分配接受PLD（49名患者）或安慰剂（24名患者）治疗。中位随访16.1个月后，PLD组的PFS显著长于安慰剂组（未达到 vs. 4.3个月），风险比（HR）为0.05（95% CI，0.01-0.17；P<0.001）。PLD组的2年PFS率为90.4%，安慰剂组为19.6%。在大多数预设亚组中，PFS获益均倾向于PLD组。PLD组中有19名（40.4%）患者观察到确认的客观缓解，安慰剂组为1名（4.3%）（P=0.002）。PLD常见的3级或以上不良事件包括中性粒细胞计数下降（10.6%）、口腔黏膜炎（6.4%）和白细胞减少（4.3%）。在某些患者报告的毒性方面观察到显著的组间差异（P<0.05）。结论：对于进展性或症状性硬纤维瘤患者，与安慰剂相比，PLD能显著延长PFS并诱导持久缓解，且安全性良好。

### 第二部分 AI 大师评价

本研究是一项针对晚期难治性硬纤维瘤的3期随机双盲临床试验，旨在评估聚乙二醇化脂质体多柔比星（PLD）的疗效与安全性。其核心发现是PLD相比安慰剂能显著延长无进展生存期（HR=0.05），并带来更高的客观缓解率，且安全性可接受。创新性在于为这种罕见且治疗选择有限的肿瘤提供了首个高级别循证医学证据，并采用了允许交叉的设计。局限性包括样本量相对较小、随访时间尚不足以评估总生存期，且结果主要适用于进展期患者。

---

## 62. DESTINY-Breast08：一项在HER2低表达转移性乳腺癌患者中评估曲妥珠单抗德鲁替康联合其他抗癌疗法的1b期研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504632)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41504632
**DOI：** 10.1158/1078-0432.CCR-25-0874

### 第一部分 原文与翻译

**英文原标题：** DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancer.

> **英文摘要：**
> PURPOSE: Establish the safety, tolerability, and preliminary activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer therapies in human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). EXPERIMENTAL DESIGN: DESTINY-Breast08 was a two-part, open-label, multicenter, phase 1b study. Patients with locally confirmed HER2-low mBC received T-DXd plus capecitabine, durvalumab+paclitaxel, capivasertib, anastrozole, or fulvestrant. Eligibility criteria for hormone receptor status varied across modules and between study parts. Primary objectives were safety/tolerability and determining recommended phase 2 doses (RP2Ds); secondary endpoints included objective response rate (ORR, per investigator). Results; In the dose-finding phase, 37 patients were assigned to a module. RP2Ds were determined for T-DXd plus capecitabine, capivasertib, anastrozole, or fulvestrant. For strategic reasons, T-DXd+durvalumab+paclitaxel was not pursued beyond the dose-finding phase (n=3). In the dose-expansion phase, 101 patients were assigned to a module. For T-DXd+capecitabine, grade (G)≥3 adverse events (AEs) occurred in 55.0% (11/20) of patients; ORR: 60.0%. For T-DXd+capivasertib, G≥3 AEs occurred in 67.5% (27/40) of patients; ORR: 60.0%. For T-DXd+anastrozole, G≥3 AEs occurred in 47.6% (10/21) of patients; ORR: 71.4%. For T-DXd+fulvestrant, G≥3 AEs occurred in 55.0% (11/20) of patients; ORR: 40.0%. Adjudicated drug-related interstitial lung disease/pneumonitis events were reported for T-DXd+capecitabine (3/20; G2, n=2; G5, n=1), T-DXd+capivasertib (8/40; all G≤2), and T-DXd+fulvestrant (5/20; all G2). CONCLUSIONS: Safety results were generally consistent with known individual profiles for T-DXd and combination drugs. T-DXd plus capecitabine, capivasertib, anastrozole, or fulvestrant demonstrated preliminary clinical activity in patients with HER2-low mBC.

> **中文摘要：**
> 目的：评估曲妥珠单抗德鲁替康（T-DXd）联合其他抗癌疗法在人表皮生长因子受体2（HER2）低表达转移性乳腺癌（mBC）中的安全性、耐受性和初步活性。实验设计：DESTINY-Breast08是一项分为两部分、开放标签、多中心的1b期研究。经当地确认的HER2低表达mBC患者接受了T-DXd联合卡培他滨、度伐利尤单抗+紫杉醇、capivasertib、阿那曲唑或氟维司群治疗。激素受体状态的入组标准在各模块和研究部分之间有所不同。主要目标是安全性/耐受性和确定推荐的2期剂量（RP2D）；次要终点包括客观缓解率（ORR，由研究者评估）。结果：在剂量探索阶段，37名患者被分配至一个模块。确定了T-DXd联合卡培他滨、capivasertib、阿那曲唑或氟维司群的RP2D。出于战略原因，T-DXd+度伐利尤单抗+紫杉醇未在剂量探索阶段（n=3）后继续研究。在剂量扩展阶段，101名患者被分配至一个模块。对于T-DXd+卡培他滨，55.0%（11/20）的患者发生≥3级不良事件（AE）；ORR：60.0%。对于T-DXd+capivasertib，67.5%（27/40）的患者发生≥3级AE；ORR：60.0%。对于T-DXd+阿那曲唑，47.6%（10/21）的患者发生≥3级AE；ORR：71.4%。对于T-DXd+氟维司群，55.0%（11/20）的患者发生≥3级AE；ORR：40.0%。经裁定的药物相关间质性肺病/肺炎事件报告于T-DXd+卡培他滨（3/20；2级，n=2；5级，n=1）、T-DXd+capivasertib（8/40；均为≤2级）和T-DXd+氟维司群（5/20；均为2级）。结论：安全性结果总体上与T-DXd和联合药物各自的已知特征一致。T-DXd联合卡培他滨、capivasertib、阿那曲唑或氟维司群在HER2低表达mBC患者中显示出初步的临床活性。

### 第二部分 AI 大师评价

本研究是一项探索性1b期临床试验，核心目的是评估抗体偶联药物T-DXd与多种不同作用机制药物（化疗、免疫、靶向、内分泌）联合治疗HER2低表达转移性乳腺癌的安全性、耐受性和初步疗效。研究采用模块化设计，高效探索了多种联合方案的推荐2期剂量，并观察到各联合方案均显示出有前景的客观缓解率，尤其是与阿那曲唑联合时ORR达71.4%。其创新性在于系统性地为HER2低表达这一重要亚群探索了多种联合治疗策略，为后续研究奠定了基础。局限性在于作为早期研究，样本量相对较小，且不同模块的激素受体状态入组标准不一，可能影响结果间的直接比较；此外，T-DXd联合度伐利尤单抗和紫杉醇的方案因战略原因早期终止，未能获得扩展期数据。

---

## 63. HIV感染者黑色素瘤的群体分析与免疫学特征图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504629)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41504629
**DOI：** 10.1158/1078-0432.CCR-25-3148

### 第一部分 原文与翻译

**英文原标题：** Population analysis and immunologic landscape of melanoma in people living with HIV.

> **英文摘要：**
> PURPOSE: To dissect the clinical and immunological features of people living with HIV (PLWH) diagnosed with melanoma, who have consistently shown worse outcomes than HIV-negative individuals (PLw/oH) with the same cancer. EXPERIMENTAL DESIGN: We analyzed electronic health records from 1,087 PLWH and 394,437 PLw/oH with melanoma. Demographic and clinical characteristics were compared. Spatial immune transcriptomics (72 immune-related genes) was performed on melanoma tumor samples (n=11), with downstream validation using multiplex immunofluorescence (n=15 PLWH, n=14 PLw/oH). RESULTS: PLWH were diagnosed at a younger age, had greater representation of Hispanic and Black individuals, and showed reduced survival. They also had a markedly increased risk of brain metastases. PLWH experienced significant delays in initiating immune checkpoint inhibitor (ICI) therapy and had worse post-ICI survival, even after balancing covariates. Spatial transcriptomics revealed a more immunosuppressive tumor microenvironment in PLWH, with increased transcription of immune checkpoints (PD1, LAG3) and reduced antigen-presentation markers (HLA-DRB, B2M), with distinct spatial distributions in tumors and surrounding microenvironments. Multiplex immunofluorescence demonstrated features of an exhausted CD8⁺ T cell compartment, including enrichment of PD1intLAG3⁻ and PD1intLAG3⁺ subpopulations, and a significant accumulation of myeloid-derived suppressor cells (CD11b⁺ HLA-DR⁻ CD33⁺). CONCLUSIONS: Melanoma in PLWH is associated with distinct clinical and immunological features, including delayed ICI treatment, reduced survival, and an immunosuppressive microenvironment with exhausted CD8⁺ T cells and expanded myeloid-derived suppressor cells. These findings suggest that chronic HIV infection may impair antitumor immunity in melanoma. Targeting the pathways identified here may improve therapeutic responses and outcomes in this population.

> **中文摘要：**
> 目的：旨在剖析HIV感染者中诊断为黑色素瘤患者的临床与免疫学特征，该人群的预后持续差于患有相同癌症的HIV阴性个体。实验设计：我们分析了1，087名HIV感染者和394，437名HIV阴性黑色素瘤患者的电子健康记录。比较了人口统计学和临床特征。对黑色素瘤肿瘤样本（n=11）进行了空间免疫转录组学分析（72个免疫相关基因），并使用多重免疫荧光进行下游验证（n=15名HIV感染者，n=14名HIV阴性者）。结果：HIV感染者确诊时更年轻，西班牙裔和黑人个体比例更高，且生存期缩短。他们发生脑转移的风险也显著增加。HIV感染者在启动免疫检查点抑制剂治疗方面经历了显著延迟，且治疗后生存更差，即使在平衡协变量后也是如此。空间转录组学揭示，HIV感染者肿瘤微环境更具免疫抑制性，表现为免疫检查点基因转录增加，抗原呈递标志物转录减少，且在肿瘤及其周围微环境中具有独特的空间分布。多重免疫荧光显示CD8⁺ T细胞区室耗竭的特征，包括PD1intLAG3⁻和PD1intLAG3⁺亚群的富集，以及髓源性抑制细胞的显著积聚。结论：HIV感染者的黑色素瘤具有独特的临床和免疫学特征，包括ICI治疗延迟、生存期缩短，以及存在耗竭CD8⁺ T细胞和扩增的髓源性抑制细胞的免疫抑制微环境。这些发现表明，慢性HIV感染可能损害黑色素瘤的抗肿瘤免疫。靶向本文所识别的通路可能改善该人群的治疗反应和预后。

### 第二部分 AI 大师评价

本研究通过大规模队列分析与高维空间组学技术，系统揭示了HIV感染者黑色素瘤预后更差的临床与免疫学机制。其创新性在于整合了真实世界数据与空间多组学验证，首次在组织原位层面描绘了该人群独特的免疫抑制微环境图谱，明确了耗竭T细胞与髓源性抑制细胞的关键作用。然而，研究样本量（尤其是空间组学部分）相对有限，且为观察性设计，因果关系尚需进一步实验验证。这些发现为开发针对HIV感染者黑色素瘤的精准免疫治疗策略提供了重要依据。

---

## 64. 获得性靶点内改变驱动对p53-Y220C再激活剂的临床耐药。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504628)
**期刊：** Cancer discovery
**PMID：** 41504628
**DOI：** 10.1158/2159-8290.CD-25-1761

### 第一部分 原文与翻译

**英文原标题：** Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators.

> **英文摘要：**
> The tumor suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including: (1) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity, and (2) mutations within the Y220C binding surface predicted to hinder drug binding. Functional modeling confirmed these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.

> **中文摘要：**
> 肿瘤抑制基因TP53是癌症中最常发生改变的基因，而存在于1.8%的TP53突变肿瘤中的Y220C热点突变，创造了一个可成药的空腔，使p53失稳。Rezatapopt是一种首创的、口服生物可利用的Y220C突变p53再激活剂，在1/2期PYNNACLE试验中已显示出有前景的初步疗效。我们报告了针对此类疗法的首个临床耐药机制。对rezatapopt进展后的循环肿瘤DNA、肿瘤活检和快速尸检样本进行分析，揭示了与Y220C顺式存在的多种异质性继发性TP53改变，包括：(1) 消除转录活性的DNA结合域突变或移码/无义突变，以及 (2) 预计会阻碍药物结合的Y220C结合表面内的突变。功能建模证实这些双重突变体消除了rezatapopt对p53的再激活和靶基因诱导作用。这些发现为p53 Y220C再激活剂的耐药性建立了一个分子框架，并为利用下一代药物克服耐药性的策略提供了信息。

### 第二部分 AI 大师评价

本研究首次揭示了针对p53-Y220C再激活剂rezatapopt的临床耐药机制，具有重要的开创性意义。研究通过整合循环肿瘤DNA、活检及尸检样本的多组学分析，系统性地发现耐药主要由与Y220C顺式发生的继发性TP53突变驱动，包括破坏p53转录功能或直接阻碍药物结合的突变类型。功能实验验证了这些双重突变体可完全消除药物反应，从而建立了清晰的耐药分子框架。其局限性在于主要基于机制描述，尚未提出并验证成熟的克服耐药策略，但为开发下一代药物指明了明确方向。

---

## 65. 时空蛋白质组学图谱揭示食管鳞状细胞癌进展的早期预警信号。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504491)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41504491
**DOI：** 10.1002/advs.202514343

### 第一部分 原文与翻译

**英文原标题：** Spatio-Temporal Proteomic Landscape Reveals Early Warning Signals of Esophageal Squamous Cell Carcinoma Progression.

> **英文摘要：**
> Esophageal squamous cell carcinoma (ESCC) remains a lethal malignancy lacking reliable biomarkers for precancerous lesion monitoring and intervention. In this study, formalin-fixed, paraffin-embedded archived tissue biopsies from 134 individuals across two cohorts are collected, spanning five stages of ESCC progression. Laser capture microdissection is employed to isolate the epithelial lesion (L) and the adjacent non-lesion (N) tissues. Proteomic profiling reveals a comprehensive spatio-temporal landscape of ESCC progression, encompassing 4461 proteins. Dynamic network biomarker analysis indicates moderate dysplasia (MOD) as the critical turning stage, warranting clinical attention. A seven-protein diagnostic panel (CCDC86, GBP6, PDCD6IP, C19orf53, SF3A3, GMPPB, ARPC5) with an area under the curve (AUC) of 0.956 achieves superior early detection, and the key signatures are validated by immunohistochemistry in an independent cohort. Functional validation using malignantly transformed HET-1A cells, ESCC cells, and mouse xenograft models identifies GBP6 as a novel target: DNA damage-induced progressive loss of GBP6 promotes ESCC progression by accelerating cell cycle and inducing epithelial-mesenchymal transition. Critically, PARP1 inhibition rescues GBP6 loss by suppressing TP63 and prevents ESCC progression. Overall, this study provides a systematic proteomic atlas of ESCC progression, identifies MOD as a pivotal clinical decision point, and proposes PARP1-TP63-GBP6 axis targeting as a novel intervention strategy.

> **中文摘要：**
> 食管鳞状细胞癌（ESCC）仍是一种致命的恶性肿瘤，缺乏用于癌前病变监测和干预的可靠生物标志物。本研究收集了来自两个队列共134名个体的福尔马林固定、石蜡包埋存档组织活检样本，涵盖ESCC进展的五个阶段。采用激光捕获显微切割技术分离上皮病变（L）和邻近非病变（N）组织。蛋白质组学分析揭示了ESCC进展的全面时空图谱，涵盖4461种蛋白质。动态网络生物标志物分析表明，中度异型增生（MOD）是关键转折阶段，值得临床关注。一个由七种蛋白质（CCDC86, GBP6, PDCD6IP, C19orf53, SF3A3, GMPPB, ARPC5）组成的诊断组合，其曲线下面积（AUC）为0.956，实现了优异的早期检测，并且关键标志物在独立队列中通过免疫组织化学得到了验证。使用恶性转化的HET-1A细胞、ESCC细胞和小鼠异种移植模型进行的功能验证，确定GBP6为一个新靶点：DNA损伤诱导的GBP6渐进性缺失通过加速细胞周期和诱导上皮-间质转化来促进ESCC进展。至关重要的是，抑制PARP1可通过抑制TP63来挽救GBP6的缺失，并阻止ESCC进展。总之，本研究提供了ESCC进展的系统性蛋白质组学图谱，确定了MOD作为关键的临床决策点，并提出靶向PARP1-TP63-GBP6轴作为一种新的干预策略。

### 第二部分 AI 大师评价

本研究旨在通过时空蛋白质组学解析ESCC进展，以发现早期预警标志物。其核心方法是通过激光显微切割获取精准组织样本，结合蛋白质组学与动态网络分析，将中度异型增生（MOD）确定为关键的临床干预转折点。主要创新在于：1）构建了涵盖4461种蛋白的ESCC进展全景图谱；2）鉴定出具有高诊断效能（AUC=0.956）的七蛋白标志物组合；3）深入揭示了PARP1-TP63-GBP6这一全新的促癌分子轴，并提出了靶向干预策略。局限性在于，研究主要基于回顾性存档样本，其前瞻性临床验证和靶向策略的转化应用效果仍需进一步评估。

---

## 66. 基于内皮细胞的血管“绷带”用于血脑屏障修复与靶向siRNA递送。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504311)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41504311
**DOI：** 10.1002/advs.202517780

### 第一部分 原文与翻译

**英文原标题：** Endothelial Cell-Based Vascular Bandages for Blood-Brain Barrier Repair and Targeted siRNA Delivery.

> **英文摘要：**
> Changes in the blood-brain barrier (BBB) are key targets for mitigating cerebral ischemia/reperfusion injury. The rapid progression of reperfusion injury necessitates the development of carriers that target and regulate early BBB disruption, while supporting its structure and function during BBB recovery. This study proposes the use of brain microvascular endothelial cell (mECs)-based vascular bandages carrying siRNAs to simultaneously target, support, and regulate the damaged BBB. Specifically, mECs can target damaged cerebral blood vessels after intravenous injection by interacting with the highly expressed very late antigen - 4 (VLA-4) in the vessels. Furthermore, by covering the cerebral blood vessels and forming new junction proteins with the vascular endothelium, mECs support the permeability and structural integrity of the vasculature. Additionally, oxygen-glucose deprivation-treated mEC culture supernatants (OGD-SN) can promote connexin 43 (CX43) expression, facilitating the delivery of therapeutic p66 siRNA to the damaged endothelium for BBB regulation. Ultimately, vascular bandage treatment rescued BBB function, alleviated reperfusion injury, and reduced the infarct area. Our study offers a new therapeutic strategy and a novel brain-targeted delivery platform for treating cerebral ischemia/reperfusion injury.

> **中文摘要：**
> 血脑屏障（BBB）的改变是减轻脑缺血/再灌注损伤的关键靶点。再灌注损伤的快速进展要求开发能够靶向并调控早期BBB破坏，并在BBB恢复过程中支持其结构和功能的载体。本研究提出使用携带siRNA的脑微血管内皮细胞（mECs）作为血管“绷带”，以同时靶向、支持和调控受损的BBB。具体而言，mECs在静脉注射后，通过与血管中高表达的极晚期抗原-4（VLA-4）相互作用，能够靶向受损的脑血管。此外，通过覆盖脑血管并与血管内皮形成新的连接蛋白，mECs支持血管的通透性和结构完整性。另外，经氧糖剥夺处理的mEC培养上清液（OGD-SN）能够促进连接蛋白43（CX43）的表达，从而促进治疗性p66 siRNA递送至受损内皮以调控BBB。最终，血管“绷带”治疗挽救了BBB功能，减轻了再灌注损伤，并减少了梗死面积。我们的研究为治疗脑缺血/再灌注损伤提供了一种新的治疗策略和一个新型的脑靶向递送平台。

### 第二部分 AI 大师评价

本研究旨在应对脑缺血/再灌注损伤中BBB破坏的挑战，提出了一种创新的“血管绷带”策略。其核心方法是将自体脑微血管内皮细胞（mECs）作为兼具靶向、修复和药物递送功能的多功能平台，通过VLA-4介导的靶向归巢、物理性覆盖修复以及OGD-SN促进的siRNA递送，实现了对BBB的多维度调控。研究发现该策略能有效恢复BBB功能、减轻损伤并缩小梗死面积，其创新性在于将细胞治疗与靶向基因治疗相结合，构建了一个一体化的治疗与递送系统。然而，研究的局限性可能包括临床前模型的转化潜力、mECs规模化制备与标准化、以及长期安全性和免疫原性等问题有待进一步探索。

---

## 67. CD20FCRL4 B细胞通过MHC-I限制性途径激活CD8 T细胞在鼻咽癌抗肿瘤免疫中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504259)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41504259
**DOI：** 10.1002/advs.202514982

### 第一部分 原文与翻译

**英文原标题：** CD20FCRL4 B Cells Activate CD8 T Cells via MHC-I Restriction in Nasopharyngeal Carcinoma Anti-Tumor Immunity.

> **英文摘要：**
> Nasopharyngeal carcinoma (NPC) is a malignant tumor characterized by extensive immune cell infiltration. However, the function and significance of B cells in NPC have been overlooked. Exploring B cells and their interactions with other immune cells will provide deeper insights into the immune microenvironment of NPC and theories of immunotherapy.We utilized single-cell sequencing data to identify characteristic B cell subtypes of NPC. Subsequently, the presence of the CD20FCRL4 B cell subpopulation was validated in NPC samples using immunohistochemistry and flow cytometry. The interaction between this B cell subpopulation and CD8 T cells was investigated by establishing an in vitro and in vivo co-culture system.Our analysis revealed a subset of CD20FCRL4 B cells that may interact with CD8 T cells through the MHC-I pathway. Furthermore, we observed a co-localized distribution of CD20FCRL4 B cells and CD8 T cells in NPC. Additionally, in vitro experiments demonstrated that IFNγ played a pivotal role in enhancing the delivery of MHC class I-restricted epitope peptides by B cells, potentially due to the upregulation of WDFY4. B cells pre-stimulated with HK-1 lysate and IFNγ, when co-cultured with T cells, can induce the proliferation of CD8 T cells and the formation of immunological memory. Ultimately, this process mediates the cytotoxicity of CD8 T cells against tumor cells both in vitro and in vivo. Notably, we found a positive correlation between the infiltration level of CD20FCRL4 B cells and the expression of PD-1, as well as the response to anti-PD-1 therapy or gemcitabine plus cisplatin combined with anti-PD-1 therapy in NPC.Overall, our study elucidates the potential anti-tumor mechanisms of CD20FCRL4 B cells and provides insights into their role in immunotherapy for NPC.

> **中文摘要：**
> 鼻咽癌（NPC）是一种以广泛免疫细胞浸润为特征的恶性肿瘤。然而，B细胞在鼻咽癌中的功能和意义一直被忽视。探索B细胞及其与其他免疫细胞的相互作用，将为深入理解鼻咽癌的免疫微环境和免疫治疗理论提供更深刻的见解。我们利用单细胞测序数据鉴定了鼻咽癌的特征性B细胞亚型。随后，通过免疫组织化学和流式细胞术在鼻咽癌样本中验证了CD20FCRL4 B细胞亚群的存在。通过建立体外和体内共培养系统，研究了该B细胞亚群与CD8 T细胞之间的相互作用。我们的分析揭示了一个可能通过MHC-I途径与CD8 T细胞相互作用的CD20FCRL4 B细胞亚群。此外，我们观察到CD20FCRL4 B细胞与CD8 T细胞在鼻咽癌中存在共定位分布。另外，体外实验表明，IFNγ在增强B细胞递呈MHC I类限制性表位肽方面发挥了关键作用，这可能是由于WDFY4的上调所致。用HK-1裂解物和IFNγ预刺激的B细胞，在与T细胞共培养时，能够诱导CD8 T细胞的增殖和免疫记忆的形成。最终，这一过程介导了CD8 T细胞在体外和体内对肿瘤细胞的细胞毒性作用。值得注意的是，我们发现CD20FCRL4 B细胞的浸润水平与PD-1的表达呈正相关，并且与鼻咽癌患者对抗PD-1治疗或吉西他滨联合顺铂联合抗PD-1治疗的反应呈正相关。总之，我们的研究阐明了CD20FCRL4 B细胞潜在的抗肿瘤机制，并为其在鼻咽癌免疫治疗中的作用提供了见解。

### 第二部分 AI 大师评价

本研究核心目的在于揭示鼻咽癌免疫微环境中一个先前被忽视的B细胞亚群——CD20FCRL4 B细胞的功能及其抗肿瘤机制。研究团队整合了单细胞测序、多色免疫组化、流式细胞术以及体内外共培养等多种技术，系统性地验证了该细胞亚群的存在及其通过MHC-I途径激活CD8 T细胞的能力。其关键创新性发现包括：阐明了IFNγ通过上调WDFY4增强B细胞抗原递呈的分子机制，并首次将CD20FCRL4 B细胞浸润水平与PD-1表达及抗PD-1治疗反应性相关联，为鼻咽癌的免疫治疗提供了新的生物标志物和潜在联合治疗靶点。然而，研究主要基于相关性分析和实验模型，该B细胞亚群在人体肿瘤免疫中的确切作用及其作为治疗靶点的临床转化潜力，仍需后续前瞻性临床研究进一步验证。

---

## 68. m1A依赖的TRMT6/61A-ARG2轴通过重塑肿瘤微环境驱动促肿瘤性衰老。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504222)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41504222
**DOI：** 10.1002/advs.202518536

### 第一部分 原文与翻译

**英文原标题：** mA-Dependent TRMT6/61A-ARG2 Axis Drives Protumorigenic Senescence by Remodeling the Tumor Microenvironment.

> **英文摘要：**
> Cellular senescence, a fundamental hallmark of aging, plays a paradoxical, often pro-tumorigenic role in cancer. This malignancy is largely driven by the senescence-associated secretory phenotype (SASP), yet the mechanisms that govern the production of a pro-tumorigenic SASP remain poorly understood. This study uncovers an epitranscriptomic axis in colorectal cancer (CRC) where the TRMT6/TRMT61A tRNA N-methyladenosine (m1A) methyltransferase complex is aberrantly elevated, driving a senescent state in malignant cells. Mechanistically, TRMT6/61A-dependent m1A deposition on specific tRNAs enhances the translational efficiency of their cognate codons. This codon-biased translational control selectively boosts the synthesis of ARG2. Accumulation of ARG2 subsequently activates mTOR and NF-κB signaling and thereby establishes a robust SASP, which actively reprograms the tumor microenvironment by promoting the growth and invasiveness of neighboring cancer cells, activating cancer-associated fibroblasts, and polarizing immunosuppressive M2 macrophages. Collectively, these findings define the TRMT6/61A-ARG2 pathway as a driver for pro-tumorigenic senescence in an m1A-dependent manner, revealing a new layer of translational control in aging-associated pathology and offering a compelling rationale for developing senomorphic therapies.

> **中文摘要：**
> 细胞衰老是衰老的一个基本标志，在癌症中扮演着一个矛盾且通常是促肿瘤的角色。这种恶性表型很大程度上由衰老相关分泌表型（SASP）驱动，然而，控制促肿瘤性SASP产生的机制仍知之甚少。本研究在结直肠癌中发现了一个表观转录组轴，其中TRMT6/TRMT61A tRNA N1-甲基腺苷（m1A）甲基转移酶复合物异常升高，驱动恶性细胞进入衰老状态。从机制上讲，TRMT6/61A依赖的m1A在特定tRNA上的沉积增强了其同源密码子的翻译效率。这种密码子偏向的翻译控制选择性地促进了ARG2的合成。ARG2的积累随后激活mTOR和NF-κB信号通路，从而建立了一个强大的SASP，该SASP通过促进邻近癌细胞的生长和侵袭性、激活癌症相关成纤维细胞以及极化免疫抑制性M2巨噬细胞，主动重编程肿瘤微环境。总之，这些发现将TRMT6/61A-ARG2通路定义为以m1A依赖性方式驱动促肿瘤性衰老的关键因素，揭示了衰老相关病理中翻译调控的新层面，并为开发衰老调节疗法提供了令人信服的理论依据。

### 第二部分 AI 大师评价

本研究旨在揭示结直肠癌中促肿瘤性衰老的调控新机制。通过整合表观转录组学与功能分析，发现TRMT6/61A复合物通过催化tRNA m1A修饰，以密码子偏好性翻译的方式特异性上调ARG2蛋白表达，进而激活下游信号通路并塑造促肿瘤SASP。其创新性在于首次将tRNA修饰、翻译调控与肿瘤微环境重塑联系起来，为衰老相关病理提供了全新视角。然而，该机制在其他癌种中的普适性、以及靶向此轴的干预策略是否具有治疗潜力，仍需后续研究验证。

---

## 69. 肠道细菌通过将皮质醇降解为雄激素改善抑郁症状。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504155)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41504155
**DOI：** 10.1002/advs.202508468

### 第一部分 原文与翻译

**英文原标题：** Gut Bacteria Improve Depressive Symptoms by Degrading Cortisol into Androgen.

> **英文摘要：**
> Gut microbiota may play a role in regulating the stress hormone cortisol. However, the mechanisms underlying the regulation of cortisol by gut microbiota are poorly understood. Here, it is found that gut microbiota degraded cortisol, and this ability is heterogeneous among individuals. Mice gavaged with gut microbiota having a low ability to degrade cortisol may be prone to developing depressive-like behavior. The cortisol-degrading strain Pseudomonas aeruginosa Tongji is isolated from faecal microbiota. The des-like enzyme expressed by P. aeruginosa Tongji converts cortisol into androgen. Bacterial des-like enzyme protects mice against depressive-like behavior via degrading cortisol and producing androgen. The probiotic Bacillus subtilis expressing the des-like enzyme is constructed, which protects the host against cortisol elevation. These findings suggest that bacterial des-like enzyme may regulate cortisol and improve depression by converting cortisol into androgen.

> **中文摘要：**
> 肠道微生物群可能在调节应激激素皮质醇中发挥作用。然而，肠道微生物群调节皮质醇的机制尚不清楚。本研究发现，肠道微生物群能够降解皮质醇，且这种能力在个体间存在异质性。灌胃降解皮质醇能力低的肠道微生物群的小鼠可能更容易出现抑郁样行为。从粪便微生物群中分离出具有皮质醇降解能力的菌株——铜绿假单胞菌Tongji。该菌株表达的des样酶可将皮质醇转化为雄激素。细菌的des样酶通过降解皮质醇和产生雄激素来保护小鼠免受抑郁样行为的影响。构建了表达该des样酶的益生菌枯草芽孢杆菌，它能保护宿主免受皮质醇水平升高的影响。这些发现表明，细菌的des样酶可能通过将皮质醇转化为雄激素来调节皮质醇水平并改善抑郁。

### 第二部分 AI 大师评价

本研究旨在阐明肠道菌群调节应激激素皮质醇并影响抑郁行为的具体分子机制。研究团队通过分离鉴定具有皮质醇降解能力的特定菌株（铜绿假单胞菌Tongji），并发现其表达的des样酶能将皮质醇转化为雄激素，从而在动物模型中发挥抗抑郁作用。其核心创新点在于首次揭示了“皮质醇-雄激素”转化这一全新的菌源性代谢通路，并成功构建了表达该功能酶的工程益生菌，为微生物-脑轴干预提供了精准靶点。然而，研究主要基于小鼠模型，且将条件致病菌铜绿假单胞菌的功能酶转入益生菌的安全性与长期效应仍需深入评估。

---

## 70. 前列腺癌相关成纤维细胞的单细胞形态力学特征鉴定出与患者预后相关的独特特征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41504127)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41504127
**DOI：** 10.1002/advs.202522440

### 第一部分 原文与翻译

**英文原标题：** Single-Cell Morphomechanics of Prostate Cancer-Associated Fibroblasts Identifies Distinct Features Associated with Patient Outcome.

> **英文摘要：**
> Tumor development and progression reshape the physical properties of the surrounding tumor microenvironment (TME), including its biomechanical traits. This is driven by a prominent cell type in the TME, cancer-associated fibroblasts (CAFs), which increases tissue stiffness via extracellular matrix deposition and remodeling. Currently, it is unclear whether there are also physical changes to CAFs at the cellular level and, if so, how they relate to patient outcome. Here, it is shown that CAFs have distinct morphological and biomechanical features from normal fibroblasts. Matched, patient-derived CAFs and non-malignant prostate fibroblasts (NPFs) from 35 patients with primary prostate cancer are examined. Morphologically, CAFs have more aligned stress fibers and larger and more elongated nuclei, based on quantitative image analysis of confocal microscopy images. In addition, single-cell mechanical measurements using real-time deformability cytometry showed that CAFs are larger and stiffer than NPFs. These changes are consistent across patients and validated with atomic force microscopy. A combined morphomechanical score encompassing these features is significantly associated with patient outcome. In transcriptomic analyses, the score is correlated with microtubule dynamics and a myofibroblast phenotype. Importantly, it is also demonstrated that morphomechanical features of prostate fibroblasts are modified by approved treatments for prostate cancer, such as docetaxel, and other small molecular inhibitors, particularly those targeting FGFR. In summary, changes in cellular morphomechanical properties are a consistent feature of CAFs and are associated with patient outcome. Moreover, cellular morphomechanical properties can be therapeutically targeted, potentially providing a new strategy for manipulating the TME to control cancer progression.

> **中文摘要：**
> 肿瘤的发生和发展重塑了周围肿瘤微环境（TME）的物理特性，包括其生物力学特征。这一过程主要由TME中一种重要的细胞类型——癌症相关成纤维细胞（CAFs）驱动，它们通过细胞外基质的沉积和重塑来增加组织硬度。目前尚不清楚CAFs在细胞水平上是否也存在物理变化，如果存在，这些变化与患者预后有何关联。本文研究表明，CAFs具有与正常成纤维细胞不同的形态学和生物力学特征。研究检测了来自35名原发性前列腺癌患者的匹配的、患者来源的CAFs和非恶性前列腺成纤维细胞（NPFs）。形态学上，基于共聚焦显微镜图像的定量分析，CAFs具有更对齐的应力纤维以及更大、更细长的细胞核。此外，使用实时变形性细胞术进行的单细胞力学测量表明，CAFs比NPFs更大、更硬。这些变化在不同患者中具有一致性，并通过原子力显微镜验证。一个综合了这些特征的形态力学评分与患者预后显著相关。在转录组学分析中，该评分与微管动力学和肌成纤维细胞表型相关。重要的是，研究还证明前列腺成纤维细胞的形态力学特征可以被已批准的前列腺癌治疗方法（如多西他赛）以及其他小分子抑制剂（特别是靶向FGFR的抑制剂）所改变。总之，细胞形态力学特性的改变是CAFs的一个一致特征，并且与患者预后相关。此外，细胞形态力学特性可以作为治疗靶点，这可能为通过调控TME来控制癌症进展提供一种新策略。

### 第二部分 AI 大师评价

本研究旨在探究前列腺癌相关成纤维细胞（CAFs）在单细胞层面的形态力学特征及其临床意义。研究者采用定量图像分析和实时变形性细胞术等先进技术，对35例患者配对的CAFs与正常成纤维细胞（NPFs）进行了系统比较。核心发现是CAFs具有更有序的应力纤维、更大的细胞核以及更高的细胞硬度，这些特征整合成的形态力学评分与患者预后显著相关，并揭示了其与微管动力学和肌成纤维细胞表型的分子关联。研究的创新性在于将单细胞物理表型与临床结局直接挂钩，并证实了现有药物（如多西他赛和FGFR抑制剂）可调控这些物理特性，为靶向肿瘤微环境的生物力学维度提供了新思路。局限性在于研究主要基于体外细胞模型，其体内功能相关性及作为独立预后标志物的价值仍需在更大队列和体内模型中进一步验证。

---

## 71. Trastuzumab deruxtecan在HER2阳性脑转移模型系统中的疗效、FcRn介导的血肿瘤屏障穿透及肿瘤细胞分布研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501998)
**期刊：** Neuro-oncology
**PMID：** 41501998
**DOI：** 10.1093/neuonc/noag002

### 第一部分 原文与翻译

**英文原标题：** Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier and distribution to tumor cells in HER2+ brain metastasis model systems.

> **英文摘要：**
> BACKGROUND: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) approved for metastatic HER2+ and HER2-low/ultralow breast cancer. It has shown impressive clinical activity for HER2+ brain metastases. We conducted preclinical brain metastasis experiments to understand T-DXd efficacy. METHODS: Nude mice were intracardiacly injected with either JIMT1-BR (HER2-2+) or SUM190-BR (HER2-3+) brain-tropic breast cancer cells and dosed with 3 or 10 mg/kg T-DXd or 10 mg/kg control-ADC, with endpoints of metastasis number and size, in both the metastasis prevention and treatment of established disease settings. RESULTS: In the JIMT1-BR model, T-DXd at both doses reduced metastasis number by 48-88% and size by 32-88%; a reduction of HER2 expression by lesions remaining at the experimental endpoint and heterogeneous T-DXd distribution were observed. A distinct dose effect was observed in SUM190-BR with the 3 mg/kg dose inhibiting size and number by 24-39% and 10 mg/kg by 72-79%; HER2 expression was maintained together with heterogeneous T-DXd distribution. In both models widespread reduced tumor Ki-67 was observed, while increased cleaved caspase-3 primarily costained with T-DXd. We used an in vitro model of the blood-brain- and blood-tumor barriers (BBB/BTB) to ask how T-DXd crossed. Data demonstrated T-DXd endocytosis and transcytosis of brain endothelial cells partially reliant on the neonatal Fc receptor (FcRn). BTB transcytosis was accompanied by increased endothelial RAB11FIP5 expression in vitro and in vivo. CONCLUSIONS: The data confirm T-DXd activity in HER2+ brain metastases and identify important correlates including heterogeneous uptake, variable HER2 expression at endpoint, tumor cell cytotoxicity, decreased proliferation, and BTB transcytosis.

> **中文摘要：**
> 背景：Trastuzumab deruxtecan (T-DXd) 是一种获批用于治疗转移性HER2阳性及HER2低表达/超低表达乳腺癌的抗体偶联药物。其在HER2阳性脑转移中已显示出令人印象深刻的临床活性。我们进行了临床前脑转移实验以探究T-DXd的疗效。方法：将裸鼠经心内注射具有脑趋向性的乳腺癌细胞JIMT1-BR (HER2-2+) 或 SUM190-BR (HER2-3+)，并给予3或10 mg/kg的T-DXd或10 mg/kg的对照ADC，以转移灶的数量和大小为终点指标，分别在转移预防和已形成疾病的治疗两种实验设置中进行。结果：在JIMT1-BR模型中，两种剂量的T-DXd使转移灶数量减少了48-88%，大小减少了32-88%；观察到实验终点时残留病灶的HER2表达降低以及T-DXd的异质性分布。在SUM190-BR模型中观察到明显的剂量效应，3 mg/kg剂量对转移灶大小和数量的抑制率为24-39%，而10 mg/kg剂量的抑制率为72-79%；HER2表达得以维持，同时伴有T-DXd的异质性分布。在两个模型中均观察到肿瘤Ki-67广泛减少，而增加的cleaved caspase-3主要与T-DXd共染色。我们使用血脑屏障和血肿瘤屏障的体外模型来探究T-DXd如何穿越屏障。数据表明，T-DXd被脑内皮细胞内吞和转胞吞的过程部分依赖于新生儿Fc受体。血肿瘤屏障的转胞吞作用在体外和体内均伴随着内皮细胞RAB11FIP5表达的增加。结论：数据证实了T-DXd在HER2阳性脑转移中的活性，并确定了重要的相关因素，包括异质性摄取、终点时HER2表达的变异性、肿瘤细胞毒性、增殖减少以及血肿瘤屏障的转胞吞作用。

### 第二部分 AI 大师评价

本研究通过临床前模型系统性地评估了抗体偶联药物T-DXd在HER2阳性脑转移中的疗效及其穿越血肿瘤屏障的机制。其核心创新在于揭示了FcRn介导的脑内皮细胞转胞吞作用是T-DXd穿透屏障的关键途径之一，并发现了伴随的内皮细胞RAB11FIP5表达上调这一潜在生物标志物。研究结果不仅证实了T-DXd的显著抗肿瘤活性（抑制增殖、诱导凋亡），也指出了肿瘤内药物摄取和HER2表达的异质性，这可能是影响疗效差异和耐药的重要因素。局限性在于，作为临床前研究，其结论需在人体临床试验中进一步验证，且对异质性分布背后的具体分子机制探讨尚不深入。

---

## 72. 双重靶向BRAF与铁死亡通过铁过载和增强的氧化应激产生协同抗癌活性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501927)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41501927
**DOI：** 10.1186/s13046-025-03624-z

### 第一部分 原文与翻译

**英文原标题：** Dual targeting of BRAF and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探索联合靶向BRAF与铁死亡通路在癌症治疗中的协同效应。其核心方法是通过双重干预，诱导癌细胞发生铁过载并加剧氧化应激。研究发现，该策略能产生显著的协同抗癌活性，其创新性在于将传统的靶向治疗（BRAF抑制剂）与新兴的铁死亡诱导策略相结合，为克服耐药性提供了新思路。局限性在于摘要信息缺失，具体的作用机制、模型系统及体内外实验细节尚不明确，需要查阅全文以获得更全面的评估。

---

## 73. 模拟癌症相关成纤维细胞与肿瘤的相互作用以克服治疗抵抗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501921)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41501921
**DOI：** 10.1186/s13046-025-03633-y

### 第一部分 原文与翻译

**英文原标题：** Modeling CAF-tumor interactions to overcome therapy resistance.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文旨在通过构建CAF-肿瘤相互作用模型，探索克服癌症治疗抵抗的新策略。其核心方法聚焦于利用计算或实验模型来模拟肿瘤微环境中这一关键的细胞间互作。虽然摘要未提供具体研究发现，但该研究方向直接针对肿瘤耐药这一临床核心挑战，具有重要的转化潜力。主要局限性在于当前信息有限，无法评估其模型的具体创新性、验证数据及临床前/临床相关性。

---

## 74. 基于环状RNA的HPV16治疗性疫苗可激发强效且持久的抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501915)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41501915
**DOI：** 10.1186/s13046-026-03640-7

### 第一部分 原文与翻译

**英文原标题：** Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity.

> **英文摘要：**
> BACKGROUND: Human papillomavirus (HPV) 16 infection is associated with several human malignancies. Developing therapeutic vaccines holds great potential for patients who do not benefit from standard care. Circular RNA (circRNA) is an emerging next-generation platform for cancer vaccine development owing to its superior stability and convenient manufacturing process. Herein, we report development of a synthetic circRNA encoding fused HPV16 E7/E6 antigens encapsulated with lipid nanoparticles (LNP) to treat HPV16-related solid tumors.
> 
> METHODS: The immunogenicity and anti-tumor immune response of the LNP-circRNA vaccine was determined in naïve C57BL/6 mice and TC-1 tumor-bearing mice, respectively. Changes in immune cells were examined using flow cytometry and immunofluorescence assay. RNA sequencing was used to identify differentially expressed genes and changes in the tumor microenvironment (TME) of tumors treated with LNP-circRNA and empty LNP. Anti-tumor efficacy was further evaluated in LNP-circRNA vaccine combined with anti-PD-L1 antibody treatment.
> 
> RESULTS: Prime-boost vaccination with LNP-circRNA induced a large pool of functional antigen-specific cytotoxic T cells in both the peripheral blood and spleen. This immunization led to profound changes in the TME, characterized by the upregulation of immune activation genes, heavy infiltration of immune cells, and polarization toward a proinflammatory state. Consequently, circRNA immunization could mediate complete tumor regression and prevent tumor growth. Moreover, vaccination sensitized non-inflamed tumors to immune checkpoint blockade therapy.
> 
> CONCLUSIONS: The present study results demonstrate that LNP-circRNA vaccine is capable of eliciting robust anti-tumor immunity in the periphery and TME, highlighting the potential for treating HPV16-related cancers and preventing tumor recurrence.

> **中文摘要：**
> 背景：人乳头瘤病毒（HPV）16型感染与多种人类恶性肿瘤相关。开发治疗性疫苗对无法从标准治疗中获益的患者具有巨大潜力。环状RNA（circRNA）因其卓越的稳定性和便捷的生产工艺，正成为癌症疫苗开发的新兴下一代平台。本文中，我们报道了一种编码融合HPV16 E7/E6抗原、并用脂质纳米颗粒（LNP）包裹的合成circRNA疫苗的开发，用于治疗HPV16相关的实体瘤。
> 
> 方法：分别在初始C57BL/6小鼠和TC-1荷瘤小鼠中评估了LNP-circRNA疫苗的免疫原性和抗肿瘤免疫反应。使用流式细胞术和免疫荧光法检测免疫细胞的变化。通过RNA测序鉴定经LNP-circRNA和空LNP处理的肿瘤中差异表达的基因及肿瘤微环境（TME）的变化。进一步评估了LNP-circRNA疫苗联合抗PD-L1抗体治疗的抗肿瘤疗效。
> 
> 结果：LNP-circRNA的初免-加强免疫在外周血和脾脏中均诱导了大量功能性抗原特异性细胞毒性T细胞。这种免疫接种导致了TME的深刻改变，其特征是免疫激活基因的上调、免疫细胞的大量浸润以及向促炎状态的极化。因此，circRNA免疫能够介导肿瘤完全消退并阻止肿瘤生长。此外，疫苗接种使非炎症性肿瘤对免疫检查点阻断疗法变得敏感。
> 
> 结论：本研究结果表明，LNP-circRNA疫苗能够在全身和TME中激发强大的抗肿瘤免疫，突显了其在治疗HPV16相关癌症和预防肿瘤复发方面的潜力。

### 第二部分 AI 大师评价

本研究旨在开发一种基于环状RNA（circRNA）的新型治疗性疫苗，用于治疗HPV16相关的实体瘤。研究团队构建了编码HPV16 E7/E6融合抗原的合成circRNA，并使用脂质纳米颗粒（LNP）递送。通过在小鼠模型中评估，该疫苗展现了强大的免疫原性，能诱导大量抗原特异性细胞毒性T细胞，并重塑肿瘤微环境，使其向促炎状态转变，从而实现肿瘤完全消退。其创新性在于利用了circRNA的稳定性和LNP递送系统，并证明了该疫苗与抗PD-L1抗体联用的协同效应，为“冷”肿瘤的免疫治疗提供了新策略。局限性在于研究目前仍处于临床前阶段，其人体内的安全性和有效性有待验证。

---

## 75. 靶向NAT10-HDAC4正反馈环路可对抗乳腺癌的免疫抑制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501889)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41501889
**DOI：** 10.1186/s13046-025-03638-7

### 第一部分 原文与翻译

**英文原标题：** Targeting the NAT10-HDAC4 positive feedback loop counteracts immunosuppression in breast cancer.

> **英文摘要：**
> BACKGROUND: N-acetyltransferase 10 (NAT10) mediated N4-acetylcytidine (ac4C) modification has been implicated in tumor progression; however, the precise role and underlying mechanism of NAT10 in breast cancer progression remain largely undefined. METHODS: The expression and prognostic significance of NAT10 in breast cancer were evaluated using clinical tissue samples and public databases. Functional assays were performed in vitro and in vivo to assess the effects of NAT10 on tumor growth and immune evasion. Mechanistic studies, including RNA immunoprecipitation (RIP), ac4C RNA immunoprecipitation (acRIP), and co-immunoprecipitation (Co-IP), were conducted to elucidate the interaction between NAT10 and histone deacetylase 4 (HDAC4) and their roles in regulating NF-κB signaling and programmed death-ligand 1 (PD-L1) expression. RESULTS: NAT10 expression was significantly upregulated in breast cancer and correlated with poor patient prognosis. NAT10 mediated ac4C modification enhanced the stability of HDAC4 mRNA, thereby promoting HDAC4 expression. Conversely, HDAC4 stabilized NAT10 protein through post-transcriptional deacetylation, forming a self-reinforcing regulatory loop. Elevated HDAC4 activated the NF-κB signaling pathway, resulting in increased PD-L1 transcription and enhanced immune evasion of breast cancer cells. Inhibition of the NAT10/HDAC4/NF-κB axis markedly reduced PD-L1 expression and restored antitumor immune responses. CONCLUSION: Our findings identify a self-reinforcing NAT10/HDAC4 signaling circuit that drives breast cancer progression and immune evasion. Targeting NAT10 represents a promising therapeutic strategy to overcome immunosuppression and improve patient outcomes in breast cancer.

> **中文摘要：**
> 背景：N-乙酰转移酶10（NAT10）介导的N4-乙酰胞苷（ac4C）修饰与肿瘤进展有关；然而，NAT10在乳腺癌进展中的确切作用和潜在机制在很大程度上仍未明确。方法：利用临床组织样本和公共数据库评估了NAT10在乳腺癌中的表达及其预后意义。通过体外和体内功能实验评估NAT10对肿瘤生长和免疫逃逸的影响。机制研究包括RNA免疫沉淀（RIP）、ac4C RNA免疫沉淀（acRIP）和免疫共沉淀（Co-IP），以阐明NAT10与组蛋白去乙酰化酶4（HDAC4）之间的相互作用及其在调控NF-κB信号通路和程序性死亡配体1（PD-L1）表达中的作用。结果：NAT10在乳腺癌中表达显著上调，并与患者不良预后相关。NAT10介导的ac4C修饰增强了HDAC4 mRNA的稳定性，从而促进了HDAC4的表达。相反，HDAC4通过转录后去乙酰化作用稳定了NAT10蛋白，形成了一个自我强化的调控环路。升高的HDAC4激活了NF-κB信号通路，导致PD-L1转录增加并增强了乳腺癌细胞的免疫逃逸能力。抑制NAT10/HDAC4/NF-κB轴显著降低了PD-L1表达并恢复了抗肿瘤免疫应答。结论：我们的研究结果发现了一个驱动乳腺癌进展和免疫逃逸的自我强化的NAT10/HDAC4信号环路。靶向NAT10是克服免疫抑制并改善乳腺癌患者预后的一个有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明NAT10在乳腺癌进展与免疫逃逸中的具体作用机制。研究综合运用临床数据分析、体内外功能实验及RIP/acRIP/Co-IP等分子机制研究方法，系统揭示了NAT10与HDAC4之间通过ac4C修饰和去乙酰化作用形成的正反馈环路。其核心创新在于首次将RNA表观修饰（ac4C）、蛋白翻译后修饰（去乙酰化）与经典的NF-κB/PD-L1免疫检查点通路整合，提出了一个驱动肿瘤免疫抑制的新信号轴。然而，研究主要聚焦于细胞内在机制，肿瘤微环境中其他免疫细胞在该环路中的作用，以及靶向该环路的具体药物开发路径，仍有待进一步探索。

---

## 76. PROTAC介导的Bcl-xL降解增强临床前黑色素瘤模型中的靶向治疗效果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501884)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41501884
**DOI：** 10.1186/s13046-025-03635-w

### 第一部分 原文与翻译

**英文原标题：** PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models.

> **英文摘要：**
> BACKGROUND: Bcl-xL plays an important role in tumors from different origins, including melanoma, and for this reason it has been widely targeted with small-molecule BH3 mimetics, which unfortunately show several adverse effects. To overcome this limitation, selective Bcl-xL proteolysis-targeting chimera degraders have been developed. Among these, DT2216, a candidate in phase I/II clinical trials, has demonstrated antitumoral activity in preclinical cancer models from different origins, not including melanoma.
> 
> METHODS: By using several established and patient-derived BRAF wild type and mutated melanoma cells, we performed western blot analysis and MTT assay to study DT2216 effect on Bcl-xL protein levels and cell viability, respectively. Combination studies were performed on BRAF mutated melanoma cells treated with DT2216 and Dabrafenib/Trametinib or on wild type melanoma cells treated with DT2216 and Trametinib or S63845. Combination index was calculated to study drug interactions. Apoptotic induction was studied through western blot (PARP-1 cleavage), cytofluorimetric (subG1 peak in the cell cycle) and live-cell fluorescent imaging of activated caspases 3/7 analyses. Group differences were analysed with a two-sided paired or unpaired Student's t-test. To investigate the effect of the combination treatment in vivo, A375luc melanoma cells were inoculated in xenograft mice, then treated with Dabrafenib/Trametinib or DT2216, alone or in combination, for three weeks. Differences between groups, were analysed with Mann-Whitney test.
> 
> RESULTS: DT2216 induced the specific and long-lasting degradation of Bcl-xL protein, and reduced cell viability, in a concentration-dependent manner. Of note, a positive correlation between Bcl-xL degradation and sensitivity to DT2216 was observed, being cells with higher degradation the most sensitive to DT2216. In combination studies, DT2216 was able to enhance the activity of target therapy regardless BRAF mutational status. Moreover, the Mcl-1 specific inhibitor, S63845, potentiated the efficacy of DT2216 in melanoma cells in which DT2216 determined an increase of Mcl-1 protein. Interestingly, DT2216 also increased the activity of target therapy in melanoma cells resistant to Dabrafenib and Trametinib. Finally, experiments in a xenograft mouse melanoma model highlighted DT2216 potentiating effect of target therapy, not only inducing a significant reduction of tumor growth, but also showing a longer disease control.
> 
> CONCLUSION: Our findings provide new insights for combination therapy including Bcl-xL degradation for melanoma treatment.

> **中文摘要：**
> 背景：Bcl-xL在包括黑色素瘤在内的多种来源的肿瘤中发挥重要作用，因此已成为小分子BH3模拟物的广泛靶点，但这些药物不幸地显示出多种不良反应。为了克服这一局限，选择性Bcl-xL蛋白水解靶向嵌合体降解剂已被开发出来。其中，DT2216作为I/II期临床试验候选药物，已在多种来源（不包括黑色素瘤）的临床前癌症模型中显示出抗肿瘤活性。
> 
> 方法：通过使用多种已建立的及患者来源的BRAF野生型和突变型黑色素瘤细胞，我们分别进行了蛋白质印迹分析和MTT实验，以研究DT2216对Bcl-xL蛋白水平和细胞活力的影响。联合研究在BRAF突变型黑色素瘤细胞（用DT2216和Dabrafenib/Trametinib处理）或野生型黑色素瘤细胞（用DT2216和Trametinib或S63845处理）上进行。计算联合指数以研究药物相互作用。通过蛋白质印迹（PARP-1切割）、细胞流式分析（细胞周期中的subG1峰）以及活细胞荧光成像检测活化的caspases 3/7来研究凋亡诱导。组间差异采用双侧配对或非配对Student's t检验进行分析。为了研究联合治疗的体内效果，将A375luc黑色素瘤细胞接种于异种移植小鼠体内，然后单独或联合使用Dabrafenib/Trametinib或DT2216治疗三周。组间差异采用Mann-Whitney检验进行分析。
> 
> 结果：DT2216以浓度依赖性的方式诱导了Bcl-xL蛋白的特异性、持久性降解，并降低了细胞活力。值得注意的是，观察到Bcl-xL降解程度与对DT2216的敏感性呈正相关，降解程度越高的细胞对DT2216最敏感。在联合研究中，无论BRAF突变状态如何，DT2216均能增强靶向治疗的活性。此外，在DT2216导致Mcl-1蛋白增加的黑色素瘤细胞中，Mcl-1特异性抑制剂S63845增强了DT2216的疗效。有趣的是，DT2216还能增强对Dabrafenib和Trametinib耐药的黑色素瘤细胞中靶向治疗的活性。最后，在异种移植小鼠黑色素瘤模型中的实验突显了DT2216对靶向治疗的增强作用，不仅显著减少了肿瘤生长，还显示出更长的疾病控制时间。
> 
> 结论：我们的研究结果为包含Bcl-xL降解的黑色素瘤联合治疗提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在探索PROTAC降解剂DT2216靶向降解Bcl-xL蛋白，以增强黑色素瘤靶向治疗效果的潜力。研究采用多种体外细胞模型（包括BRAF野生型和突变型）及体内异种移植模型，系统评估了DT2216单药及与靶向药物（如Dabrafenib/Trametinib）或Mcl-1抑制剂（S63845）联用的效果。核心发现是DT2216能特异性、持久地降解Bcl-xL，其降解程度与细胞敏感性正相关，并能克服靶向治疗耐药，在体内外均显著增强疗效。其创新性在于首次在黑色素瘤模型中验证了Bcl-xL PROTAC降解剂的治疗价值，并提出了与Mcl-1抑制剂的协同策略。局限性在于研究主要基于临床前模型，其人体有效性和安全性仍需I/II期临床试验证实，且对DT2216诱导Mcl-1上调的具体机制探讨有限。

---

## 77. HDAC6通过S100A2-TGF-β/SMAD和CSF1R信号通路，在小细胞肺癌中协调转移和免疫抑制程序。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501879)
**期刊：** Molecular cancer
**PMID：** 41501879
**DOI：** 10.1186/s12943-025-02552-y

### 第一部分 原文与翻译

**英文原标题：** HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究聚焦于小细胞肺癌（SCLC）中HDAC6的功能，旨在揭示其调控肿瘤恶性进展的分子机制。研究通过S100A2-TGF-β/SMAD和CSF1R信号通路，阐明了HDAC6如何同时驱动肿瘤细胞的转移能力和塑造免疫抑制性肿瘤微环境。其创新性在于将表观遗传调控、肿瘤转移与免疫逃逸三大关键生物学过程整合于一个核心分子（HDAC6）之下，为SCLC提供了潜在的多功能治疗靶点。然而，摘要的缺失限制了对其具体实验方法和数据细节的评估，其结论的稳健性有待全文验证。

---

## 78. BRRIAR lncRNA通过顺式和反式调控干扰素信号通路改变乳腺癌风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501810)
**期刊：** Molecular cancer
**PMID：** 41501810
**DOI：** 10.1186/s12943-025-02510-8

### 第一部分 原文与翻译

**英文原标题：** BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans.

> **英文摘要：**
> BACKGROUND: Interferons (IFNs) are key cytokines that drive immune responses against infections and cancer, yet few therapies have successfully leveraged IFN signaling for cancer treatment. Long noncoding RNAs (lncRNAs) are emerging as promising therapeutic candidates, but their roles in immune modulation remain largely unexplored. Here, we functionally characterize a breast cancer-associated lncRNA, BRRIAR, which primes the IFN signaling pathway in specific cancer contexts and represents a potential therapeutic strategy for estrogen receptor-positive (ER+) breast cancer.
> 
> METHODS: BRRIAR expression and subcellular localization were examined using qPCR, in situ hybridization, single-cell RNA sequencing and spatial transcriptomics. BRRIAR target genes were identified through CRISPR interference, chromatin interaction assays and ChIP sequencing. Mechanistic studies in ER + breast cancer cells included CRISPR-Cas9 genome-wide screens, RNA sequencing, RNA pull-down followed by mass spectrometry, proliferation assays and Western blotting. The therapeutic potential of BRRIAR was evaluated via intratumoral delivery of lipid nanoparticle-encapsulated BRRIAR in ER + breast cancer xenograft models. Immune activation was assessed using flow cytometry and cytokine profiling of human peripheral blood mononuclear cells (PBMCs).
> 
> RESULTS: We demonstrate that BRRIAR is a key target gene at the 3p26 breast cancer风险区域. Primarily expressed in ER + breast tumors, BRRIAR acts both in cis and in trans. Nuclear BRRIAR regulates BHLHE40 expression in cis through chromatin interactions, while cytoplasmic BRRIAR binds in trans to the pattern recognition receptor RIG-I, priming IFN signaling. Overexpression of BRRIAR RNA triggers RIG-I signaling, inducing IFN responses, drives rapid, dose-dependent apoptosis of ER + breast cancer cells in vitro and in vivo, and promotes immune activation in human PBMCs.
> 
> CONCLUSIONS: These findings establish lncRNAs as key regulators of tumor immunity and uncover a critical link between genetic risk, lncRNAs, cancer immunosurveillance and breast cancer development, positioning BRRIAR as a promising lncRNA-based RIG-I activator for ER + breast cancer therapy.

> **中文摘要：**
> 背景：干扰素（IFNs）是驱动针对感染和癌症的免疫反应的关键细胞因子，然而很少有疗法成功利用IFN信号通路进行癌症治疗。长链非编码RNA（lncRNAs）正成为有前景的治疗候选者，但它们在免疫调节中的作用在很大程度上仍未得到探索。在此，我们对一种乳腺癌相关的lncRNA——BRRIAR进行了功能表征，该lncRNA在特定癌症环境中启动IFN信号通路，并代表了雌激素受体阳性（ER+）乳腺癌的潜在治疗策略。
> 
> 方法：使用qPCR、原位杂交、单细胞RNA测序和空间转录组学检测BRRIAR的表达和亚细胞定位。通过CRISPR干扰、染色质相互作用分析和ChIP测序鉴定BRRIAR的靶基因。在ER+乳腺癌细胞中的机制研究包括CRISPR-Cas9全基因组筛选、RNA测序、RNA pull-down结合质谱分析、增殖实验和蛋白质印迹。通过在ER+乳腺癌异种移植模型中瘤内递送脂质纳米颗粒包裹的BRRIAR来评估其治疗潜力。使用流式细胞术和人外周血单个核细胞（PBMCs）的细胞因子谱分析来评估免疫激活情况。
> 
> 结果：我们证明BRRIAR是3p26乳腺癌风险区域的一个关键靶基因。BRRIAR主要在ER+乳腺肿瘤中表达，并以顺式和反式两种方式发挥作用。细胞核内的BRRIAR通过染色质相互作用顺式调节BHLHE40的表达，而细胞质中的BRRIAR则反式结合模式识别受体RIG-I，从而启动IFN信号通路。过表达BRRIAR RNA可触发RIG-I信号传导，诱导IFN反应，在体外和体内驱动ER+乳腺癌细胞快速、剂量依赖性的凋亡，并促进人PBMCs的免疫激活。
> 
> 结论：这些发现确立了lncRNAs作为肿瘤免疫的关键调节因子，并揭示了遗传风险、lncRNAs、癌症免疫监视和乳腺癌发展之间的关键联系，将BRRIAR定位为一种有前景的、基于lncRNA的RIG-I激活剂，用于ER+乳腺癌治疗。

### 第二部分 AI 大师评价

本研究旨在深入解析乳腺癌风险相关lncRNA BRRIAR的功能机制及其治疗潜力。研究综合运用了多组学技术、CRISPR筛选、分子互作验证以及体内外模型，方法体系严谨全面。核心发现是BRRIAR通过顺式调控BHLHE40和反式激活RIG-I信号通路，双重调控干扰素反应，从而连接遗传风险与肿瘤免疫监视，并诱导ER+乳腺癌细胞凋亡。其创新性在于首次系统揭示了一个lncRNA如何同时以顺式和反式机制充当肿瘤免疫的关键节点，并为ER+乳腺癌提供了基于lncRNA-RIG-I轴的新型治疗策略。局限性在于，研究主要聚焦于ER+亚型，其在其他乳腺癌亚型或实体瘤中的普适性有待验证，且从机制发现到临床转化仍需克服递送效率与安全性等挑战。

---

## 79. 肝细胞癌的代谢特征：氨基酸代谢重编程。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501789)
**期刊：** Molecular cancer
**PMID：** 41501789
**DOI：** 10.1186/s12943-025-02492-7

### 第一部分 原文与翻译

**英文原标题：** Metabolic characteristics in hepatocellular carcinoma: amino acid metabolic reprogramming.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) is a common type of primary liver cancer and is considered the third leading cause of cancer-related deaths worldwide. The high aggressiveness and resistance to therapies exhibited by HCC present significant challenges to global public health. As the primary metabolic organ in the human body, the liver undergoes substantial metabolic reprogramming during carcinogenesis, affecting various metabolic pathways including those involved in carbohydrates, lipids, and amino acids. Notably, disruptions in amino acid metabolism play a critical role in the initiation and progression of HCC, helping to sustain its malignant characteristics. This review aims to provide an in-depth analysis of the alterations observed in aromatic amino acids metabolism, branched chain amino acids (BCAAs) metabolism, glutamine metabolism, and other amino acid metabolism processes, including serine, arginine, and methionine, along with the expression patterns of associated metabolic enzymes. Furthermore, it discusses potential therapeutic approaches and their clinical relevance, offering insights and strategies for improving HCC diagnosis and treatment in the future.

> **中文摘要：**
> 肝细胞癌（HCC）是一种常见的原发性肝癌，被认为是全球癌症相关死亡的第三大原因。HCC表现出的高侵袭性和治疗抵抗性对全球公共卫生构成了重大挑战。作为人体的主要代谢器官，肝脏在癌变过程中经历了显著的代谢重编程，影响了包括碳水化合物、脂质和氨基酸在内的多种代谢途径。值得注意的是，氨基酸代谢的紊乱在HCC的发生和发展中起着关键作用，有助于维持其恶性特征。本综述旨在深入分析芳香族氨基酸代谢、支链氨基酸（BCAAs）代谢、谷氨酰胺代谢以及其他氨基酸代谢过程（包括丝氨酸、精氨酸和甲硫氨酸）中观察到的改变，以及相关代谢酶的表达模式。此外，它还讨论了潜在的治疗方法及其临床相关性，为未来改善HCC的诊断和治疗提供了见解和策略。

### 第二部分 AI 大师评价

该综述聚焦于肝细胞癌（HCC）中氨基酸代谢重编程这一核心代谢特征，具有明确的临床问题导向。其方法是对现有研究进行系统性梳理，重点分析了芳香族氨基酸、支链氨基酸、谷氨酰胺等关键代谢途径的异常改变及相关酶的表达模式。核心发现是氨基酸代谢紊乱对HCC的发生、进展和恶性表型维持至关重要。其创新性在于将分散的氨基酸代谢研究整合到一个统一的框架中，并探讨了其作为治疗靶点的转化潜力；局限性在于作为一篇综述，其结论主要基于对现有文献的归纳，未提供新的原始实验数据来验证这些靶点的有效性。

---

## 80. 成人急性髓系白血病患者中的NUP98重排：临床意义评估及新型融合伴侣鉴定

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501506)
**期刊：** Leukemia
**PMID：** 41501506
**DOI：** 10.1038/s41375-025-02848-4

### 第一部分 原文与翻译

**英文原标题：** NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.

> **英文摘要：**
> NUP98 rearrangements represent a distinct, high-risk subtype of acute myeloid leukemia (AML), particularly in pediatric patients. However, their prevalence, genetic features, and clinical implications in adult AML remain poorly characterized. Using targeted-capture sequencing, we identified 41 cases with NUP98 rearrangements among 1569 AML cases, representing the majority of 44 NUP98-rearranged cases detected across 4753 myeloid neoplasms. Fifteen distinct fusion partners were detected, with NUP98::NSD1 and NUP98::HOXA9 being the most frequent. Notably, two novel fusions-NUP98::MEOX2 and NUP98::HOXA6-were identified. Co-mutations were relatively infrequent; FLT3-ITD and WT1 mutations were the most common, while NPM1 mutations were exclusive. FLT3-ITD was significantly enriched in NUP98::NSD1 cases, whereas TET2 mutations were more frequent in NUP98::HOXA9 cases. Clonal hierarchy analysis suggested that NUP98 rearrangements occur early in leukemogenesis. NUP98-rearranged AML exhibited higher relapse rates and shorter event-free survival. Specifically, NUP98::NSD1 was associated with a poor induction response, whereas NUP98::HOXA9 and NUP98 fusions with other partners showed higher remission rates but frequent relapse. Allogeneic hematopoietic stem cell transplantation was associated with better survival, underscoring its significance. These findings reveal the genetic and clinical heterogeneity of NUP98-rearranged AML in adults and support its classification as a distinct entity, highlighting the need for fusion partner-specific therapeutic strategies.

> **中文摘要：**
> NUP98重排是急性髓系白血病（AML）中一个独特的高危亚型，尤其在儿童患者中。然而，其在成人AML中的发生率、遗传学特征和临床意义仍不明确。通过靶向捕获测序，我们在1569例AML病例中鉴定出41例存在NUP98重排，这占据了在4753例髓系肿瘤中检测到的44例NUP98重排病例的绝大部分。共检测到15种不同的融合伴侣，其中NUP98::NSD1和NUP98::HOXA9最为常见。值得注意的是，本研究鉴定出两种新型融合——NUP98::MEOX2和NUP98::HOXA6。共突变相对少见；FLT3-ITD和WT1突变是最常见的，而NPM1突变则相互排斥。FLT3-ITD在NUP98::NSD1病例中显著富集，而TET2突变在NUP98::HOXA9病例中更常见。克隆层次分析提示NUP98重排在白血病发生早期出现。NUP98重排AML表现出更高的复发率和更短的无事件生存期。具体而言，NUP98::NSD1与较差的诱导缓解反应相关，而NUP98::HOXA9及与其他伴侣的NUP98融合则显示出较高的缓解率但频繁复发。异基因造血干细胞移植与更好的生存相关，凸显了其重要性。这些发现揭示了成人NUP98重排AML的遗传学和临床异质性，支持将其归类为一个独立的疾病实体，并强调了针对特定融合伴侣制定治疗策略的必要性。

### 第二部分 AI 大师评价

本研究旨在系统评估NUP98重排在成人AML中的临床与遗传学特征。研究者采用靶向捕获测序技术，在较大规模的成人AML队列中明确了其发生率，并鉴定了包括新型融合在内的多种融合伴侣，揭示了其与特定共突变模式的关联及克隆起源。核心发现是，NUP98重排AML具有高复发风险，且不同融合伴侣（如NSD1与HOXA9）的临床结局存在显著差异，异基因移植可改善预后。研究的创新性在于首次在成人群体中全面描绘了该亚型的异质性图谱，并强调了基于融合伴侣的精准分型与治疗的必要性；局限性在于这是一项回顾性研究，且部分亚型病例数有限，其治疗反应的分子机制有待进一步探索。

---

## 81. 慢性淋巴细胞白血病样单克隆B淋巴细胞增多症中B细胞受体的分子与功能特征研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501505)
**期刊：** Leukemia
**PMID：** 41501505
**DOI：** 10.1038/s41375-025-02797-y

### 第一部分 原文与翻译

**英文原标题：** Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本研究旨在对慢性淋巴细胞白血病样单克隆B淋巴细胞增多症（MBL）的B细胞受体（BCR）进行深入的分子与功能层面表征。通过比较分析，研究有望揭示MBL与慢性淋巴细胞白血病（CLL）在BCR信号通路、免疫表型或基因突变谱上的异同。其创新性在于聚焦于白血病前驱状态，可能为理解CLL的早期发病机制及疾病进展风险提供关键线索。然而，摘要的缺失限制了对其具体研究方法、关键发现及潜在局限性的评估。

---

## 82. 奥拉帕利通过不依赖于PARP1的线粒体代谢功能障碍，使慢性淋巴细胞白血病对BTK和BCL2靶向治疗增敏。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501504)
**期刊：** Leukemia
**PMID：** 41501504
**DOI：** 10.1038/s41375-025-02846-6

### 第一部分 原文与翻译

**英文原标题：** Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究探讨了PARP抑制剂奥拉帕利在慢性淋巴细胞白血病（CLL）治疗中的新机制。其核心发现是，奥拉帕利能够通过一种不依赖于其经典靶点PARP1的途径，诱导CLL细胞的线粒体代谢功能障碍，从而增强癌细胞对BTK抑制剂和BCL2抑制剂的敏感性。这一发现揭示了奥拉帕利在血液肿瘤治疗中的潜在新作用模式，为联合靶向治疗提供了新的理论依据。然而，由于摘要不可用，具体的实验设计、数据细节以及该发现的临床前或临床验证程度尚不明确，其转化潜力有待进一步评估。

---

## 83. 侵袭性NK细胞白血病的治疗与预后进展：ANKL22研究结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501503)
**期刊：** Leukemia
**PMID：** 41501503
**DOI：** 10.1038/s41375-025-02854-6

### 第一部分 原文与翻译

**英文原标题：** Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.

> **英文摘要：**
> Aggressive NK-cell leukemia (ANKL) is a rare NK-cell leukemia characterized by, an aggressive clinical course, and frequent Epstein-Barr virus association. We retrospectively collected 126 ANKL patients diagnosed between 2000 and 2021 from 71 institutes; 108 were evaluable for analysis to characterize the recent advances. The median age was 49 years (range: 17-90), and 63 patients were male. The median percentage of leukemic cells in the bone marrow and peripheral blood was 19.7% and 10.0%, respectively. The first-line regimens included SMILE (n = 38, 42%), CHOP(-like) (n = 26, 29%), DeVIC (n = 15, 17%), and other L-asparaginase-containing regimens (n = 8, 9%), with the overall response rates of 66%, 31%, 33%, and 50%, respectively. Median overall survival (OS) was 5.5 months, with a 2-year OS of 18.7%. Patients treated with SMILE had significantly better OS than others (2-year OS 30.1% vs. 7.0%; P < 0.001). Prognosis further improved with allogeneic hematopoietic stem cell transplantation (HSCT) (2-year OS 37.2% vs 3.5%; P < 0.001). Multivariate analysis confirmed treatment with SMILE [hazard ratio (HR) 0.53, 95% confidential interval (CI) 0.31-0.88] and allogeneic HSCT (HR 0.33, 95% CI 0.18-0.61) as independent favorable factors. In conclusion, SMILE chemotherapy followed by allogeneic HSCT may improve outcomes in ANKL.

> **中文摘要：**
> 侵袭性NK细胞白血病（ANKL）是一种罕见的NK细胞白血病，其特征是侵袭性临床病程和频繁的EB病毒关联。我们回顾性收集了来自71个机构的126例在2000年至2021年间诊断的ANKL患者；其中108例可用于分析以描述近期进展。中位年龄为49岁（范围：17-90岁），63例患者为男性。骨髓和外周血中白血病细胞的中位百分比分别为19.7%和10.0%。一线治疗方案包括SMILE（n=38，42%）、CHOP（样）（n=26，29%）、DeVIC（n=15，17%）和其他含L-天冬酰胺酶方案（n=8，9%），总体缓解率分别为66%、31%、33%和50%。中位总生存期（OS）为5.5个月，2年OS率为18.7%。接受SMILE治疗的患者OS显著优于其他患者（2年OS率 30.1% vs. 7.0%；P<0.001）。预后在接受异基因造血干细胞移植（HSCT）后进一步改善（2年OS率 37.2% vs 3.5%；P<0.001）。多变量分析证实，SMILE治疗[风险比（HR）0.53，95%置信区间（CI）0.31-0.88]和异基因HSCT（HR 0.33，95% CI 0.18-0.61）是独立的有利因素。总之，SMILE化疗序贯异基因HSCT可能改善ANKL的预后。

### 第二部分 AI 大师评价

本研究通过一项多中心回顾性队列研究（ANKL22），系统评估了侵袭性NK细胞白血病（ANKL）的治疗进展与预后因素。核心发现是，含L-天冬酰胺酶的SMILE方案相较于传统化疗方案（如CHOP）显著提高了缓解率和生存率，而后续的异基因造血干细胞移植（HSCT）能进一步巩固疗效，两者均为独立的有利预后因素。该研究为这一罕见且凶险的疾病提供了目前最高级别的循证医学证据，明确了SMILE序贯异基因HSCT作为潜在标准治疗路径的价值。主要局限性在于研究的回顾性设计，可能存在选择偏倚，且样本量虽为同类研究中较大者，但对于亚组分析（如不同移植时机）的统计效能可能仍显不足。

---

## 84. 在剂量递减期间对外周血进行序贯BCR::ABL1评估，比在剂量递减时对外周血或骨髓进行单次评估更能预测无治疗缓解的成功率。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501502)
**期刊：** Leukemia
**PMID：** 41501502
**DOI：** 10.1038/s41375-025-02853-7

### 第一部分 原文与翻译

**英文原标题：** Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在比较不同监测策略对慢性髓系白血病患者酪氨酸激酶抑制剂剂量递减后无治疗缓解成功的预测价值。核心方法是在剂量递减期间，对外周血进行序贯的BCR::ABL1分子学评估，并与剂量递减时单次评估（外周血或骨髓）的预测效能进行对比。研究发现，外周血的序贯评估比单次评估（无论样本来源）具有更高的预测价值。其创新性在于明确了动态监测优于单点检测，为优化TFR预测策略提供了直接证据；局限性在于摘要信息缺失，无法获知具体研究设计、样本量和统计细节。

---

## 85. Alnuctamab，一种靶向B细胞成熟抗原的双价T细胞衔接器，用于治疗复发或难治性多发性骨髓瘤：一项首次人体I期研究的结果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501501)
**期刊：** Leukemia
**PMID：** 41501501
**DOI：** 10.1038/s41375-025-02841-x

### 第一部分 原文与翻译

**英文原标题：** Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.

> **英文摘要：**
> B-cell maturation antigen (BCMA)-targeting therapies provide a new approach to treating multiple myeloma (MM). Alnuctamab (ALNUC) is a 2 + 1 immunoglobulin G1-based bispecific antibody binding BCMA and CD3ε receptors on myeloma and T cells, respectively. CC-93269-MM-001 is a first-in-human, phase 1 dose escalation/expansion study investigating ALNUC in relapsed/refractory MM. Patients had ≥3 prior regimens, disease progression ≤60 days of last regimen, and were BCMA-directed therapy-naïve. ALNUC was administered intravenously (IV) and subcutaneously (SC); however, SC was selected for further evaluation due to the more favorable safety profile. Ninety-five patients received ALNUC SC; at data cutoff, 44.2% remained on treatment and median follow-up was 8.0 months. The recommended phase 2 dose was 30 mg. The most common treatment emergent adverse events (any grade/grade 3/4) were CRS (57.9%/0%), and neutropenia (53.7%/43.2%). Infections were also frequent (64.2%/14.7%). ORR was 58.9% for all ALNUC SC-treated patients and 71.4% for the 30-mg cohort; 47/95 (49.5%) were measurable residual disease (MRD) negative. Overall, the safety and efficacy of ALNUC SC were comparable to other BCMA-targeted therapies. These results support improved safety of SC versus IV, and corroborate a step-up dosing strategy to mitigate CRS. Importantly, a schedule that de-intensifies over time provides favorable toxicity that may be applicable to other bispecific engagers.

> **中文摘要：**
> 靶向B细胞成熟抗原（BCMA）的疗法为治疗多发性骨髓瘤（MM）提供了新途径。Alnuctamab（ALNUC）是一种基于免疫球蛋白G1的2+1型双特异性抗体，分别结合骨髓瘤细胞上的BCMA和T细胞上的CD3ε受体。CC-93269-MM-001是一项首次人体、I期剂量递增/扩展研究，旨在评估ALNUC在复发/难治性MM中的作用。患者既往接受过≥3线治疗，末次治疗后≤60天内出现疾病进展，且未接受过BCMA靶向治疗。ALNUC通过静脉（IV）和皮下（SC）两种方式给药；然而，由于皮下给药具有更优的安全性特征，被选择用于进一步评估。95名患者接受了ALNUC皮下给药；截至数据截止时，44.2%的患者仍在接受治疗，中位随访时间为8.0个月。推荐的II期剂量为30 mg。最常见的治疗中出现的不良事件（任何级别/3-4级）是细胞因子释放综合征（CRS）（57.9%/0%）和中性粒细胞减少症（53.7%/43.2%）。感染也较为常见（64.2%/14.7%）。所有接受ALNUC皮下给药患者的客观缓解率（ORR）为58.9%，30 mg剂量组为71.4%；47/95名患者（49.5%）达到可测量残留病灶（MRD）阴性。总体而言，ALNUC皮下给药的安全性和疗效与其他BCMA靶向疗法相当。这些结果支持皮下给药相较于静脉给药具有更好的安全性，并证实了逐步递增的给药策略可减轻CRS。重要的是，一种随时间推移而降低强度的给药方案提供了良好的毒性特征，这可能适用于其他双特异性衔接器。

### 第二部分 AI 大师评价

本研究首次在人体中评估了新型双特异性抗体Alnuctamab（靶向BCMA×CD3）皮下给药治疗复发/难治性多发性骨髓瘤的I期临床结果。核心发现包括：皮下给药展现出优于静脉给药的安全性，支持其作为优选给药途径；采用逐步递增剂量策略有效减轻了细胞因子释放综合征（CRS）风险；在推荐II期剂量（30 mg）下，患者获得了高达71.4%的客观缓解率和49.5%的MRD阴性率，疗效与其他BCMA靶向疗法相当。其创新性在于验证了“随时间递减强度”的给药方案在改善毒性方面的潜力，为同类双特异性抗体提供了可借鉴的优化策略。局限性在于研究尚处早期阶段，样本量有限且随访时间较短，长期疗效与安全性仍需进一步验证。

---

## 86. 作者更正：组蛋白甲基转移酶EZH2的缺失诱导急性髓系白血病对多种药物产生耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501498)
**期刊：** Nature medicine
**PMID：** 41501498
**DOI：** 10.1038/s41591-025-04159-8

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇作者更正，其核心目的是修正先前发表的关于EZH2在急性髓系白血病（AML）中作用的研究。原研究聚焦于EZH2功能缺失如何导致AML细胞对多种化疗药物产生耐药性，这一发现揭示了表观遗传调控在肿瘤耐药机制中的关键作用。其创新性在于明确了EZH2作为一个潜在的治疗靶点或耐药预测标志物。然而，作为更正声明，本文未提供具体的研究方法、数据细节或对原结论局限性的深入讨论，读者需查阅原始文献以获取完整信息。

---

## 87. CD19 CAR-T细胞治疗难治性自身免疫性疾病：1/2期CASTLE篮子试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501497)
**期刊：** Nature medicine
**PMID：** 41501497
**DOI：** 10.1038/s41591-025-04185-6

### 第一部分 原文与翻译

**英文原标题：** CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

> **英文摘要：**
> Chimeric antigen receptor (CAR)-T cells are considered a powerful therapeutic tool to reset the immune system in patients with autoimmune diseases. Innovative trial designs are needed to allow feasible testing of the safety and efficacy of CAR-T cells in clinical studies. CASTLE (CAR-T cells in systemic B cell mediated autoimmune disease) is a phase 1/2a two-stage optimal design basket study that investigated the safety and efficacy of zorpocabtagene autoleucel (Zorpo-cel, also known as MB-CART19.1), an autologous CD19 CAR-T cell product, in patients with treatment-resistant systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM). The primary safety outcome was the rate of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The secondary clinical efficacy outcomes were remission of SLE according to DORIS criteria, no progression of interstitial lung disease in SSc and American College of Rheumatology (ACR) major/moderate response in IIM after 24 weeks. A total of 24 patients were enrolled (10 with SLE, 9 with SSc and 5 with IIM), all receiving a single infusion of Zorpo-cel after stopping immunosuppressive treatments and receiving standard lymphodepletion with cyclophosphamide and fludarabine. Primary and secondary endpoints of CASTLE were met. Regarding safety, no CRS higher than grade 2 and no ICANS occurred. Regarding efficacy, 22 of the 24 patients achieved predefined efficacy endpoints, with 9 out of 10 patients with SLE reaching DORIS remission, 9 out of 9 patients with SSc showing no disease progression, and 4 out of 5 patients with IIM reaching ACR major/moderate response. Furthermore, all patients remained free of glucocorticoids and any other immunosuppressive treatment over the entire observation period of 24 weeks. CASTLE suggests the feasibility, safety and efficacy of Zorpo-cel in three different autoimmune diseases and paves the way for conducting a pivotal study. ClinicalTrials.gov identifier: NCT06347718 , EudraCT identifier: 2022-001366-35 .

> **中文摘要：**
> 嵌合抗原受体（CAR）-T细胞被认为是重置自身免疫性疾病患者免疫系统的强大治疗工具。需要创新的试验设计，以便在临床研究中可行地测试CAR-T细胞的安全性和有效性。CASTLE（系统性B细胞介导自身免疫性疾病中的CAR-T细胞）是一项1/2a期两阶段最优设计篮子研究，旨在研究自体CD19 CAR-T细胞产品zorpocabtagene autoleucel（Zorpo-cel，也称为MB-CART19.1）在治疗抵抗的系统性红斑狼疮（SLE）、系统性硬化症（SSc）和特发性炎性肌病（IIM）患者中的安全性和有效性。主要安全性结局是细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）的发生率。次要临床疗效结局是24周后，根据DORIS标准的SLE缓解、SSc患者间质性肺病无进展以及IIM患者达到美国风湿病学会（ACR）主要/中度反应。共入组24例患者（10例SLE，9例SSc，5例IIM），所有患者在停止免疫抑制治疗并接受环磷酰胺和氟达拉滨的标准淋巴细胞清除后，均接受了单次Zorpo-cel输注。CASTLE研究达到了主要和次要终点。在安全性方面，未发生高于2级的CRS，也未发生ICANS。在疗效方面，24例患者中有22例达到了预设的疗效终点，其中10例SLE患者中有9例达到DORIS缓解，9例SSc患者全部显示疾病无进展，5例IIM患者中有4例达到ACR主要/中度反应。此外，在24周的整个观察期内，所有患者均未使用糖皮质激素和任何其他免疫抑制治疗。CASTLE研究表明Zorpo-cel在三种不同的自身免疫性疾病中具有可行性、安全性和有效性，并为开展关键性研究铺平了道路。ClinicalTrials.gov标识符：NCT06347718，EudraCT标识符：2022-001366-35。

### 第二部分 AI 大师评价

本研究旨在通过一项创新的篮子试验设计，评估自体CD19 CAR-T细胞疗法（Zorpo-cel）在三种难治性系统性自身免疫病（SLE、SSc、IIM）中的安全性和初步疗效。核心发现是，在24例患者中，该疗法显示出良好的安全性（无高级别CRS或ICANS）和显著的临床疗效（22/24患者达到预设终点），且使所有患者在24周内摆脱了糖皮质激素和免疫抑制剂。其创新性在于将CAR-T疗法从肿瘤领域拓展至多种自身免疫病，并采用了高效的篮子试验设计。局限性包括样本量较小、随访时间较短（24周），且缺乏对照组，其长期疗效和安全性仍需更大规模的关键性研究验证。

---

## 88. 可溶性MAdCAM-1作为转移性肾细胞癌的生物标志物。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501493)
**期刊：** Nature medicine
**PMID：** 41501493
**DOI：** 10.1038/s41591-025-04067-x

### 第一部分 原文与翻译

**英文原标题：** Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.

> **英文摘要：**
> Patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors or antiangiogenic tyrosine kinase inhibitors may develop resistance driven by gut dysbiosis, which disrupts the MAdCAM-1-α4β7 axis and promotes the recruitment of immunosuppressive IL-17-producing T regulatory (Tr17) cells into tumors. We evaluated soluble MAdCAM-1 (sMAdCAM-1) as a prognostic biomarker in 1,051 patients from three cohorts: JAVELIN Renal 101 (avelumab plus axitinib versus sunitinib), SURF (sunitinib) and NIVOREN (nivolumab after tyrosine kinase inhibitors). In the JAVELIN cohort, baseline sMAdCAM-1 levels >180 ng ml were associated with significantly improved progression-free survival (13.9 versus 8.4 months, P < 0.01) and overall survival (18 months: 84.2% versus 68.1%, P < 0.01), independent of IMDC risk groups. We validated the prognostic value of sMAdCAM-1 for overall survival in the SURF and NIVOREN cohorts. Notably, low sMAdCAM-1 levels were associated with an immunosuppressive gut microbiota profile dominated by Enterocloster species. Therefore, sMAdCAM-1 deserves further investigations as a biomarker-guided tool for microbiota-targeted interventions.

> **中文摘要：**
> 接受免疫检查点抑制剂或抗血管生成酪氨酸激酶抑制剂治疗的转移性肾细胞癌患者可能因肠道菌群失调而产生耐药性，这破坏了MAdCAM-1-α4β7轴，并促进了免疫抑制性IL-17产生的调节性T（Tr17）细胞向肿瘤募集。我们在来自三个队列的1,051名患者中评估了可溶性MAdCAM-1（sMAdCAM-1）作为预后生物标志物的价值：JAVELIN Renal 101（avelumab联合阿西替尼对比舒尼替尼）、SURF（舒尼替尼）和NIVOREN（酪氨酸激酶抑制剂后使用纳武利尤单抗）。在JAVELIN队列中，基线sMAdCAM-1水平 >180 ng/ml与显著改善的无进展生存期（13.9个月对比8.4个月，P < 0.01）和总生存期（18个月：84.2%对比68.1%，P < 0.01）相关，且独立于IMDC风险组。我们在SURF和NIVOREN队列中验证了sMAdCAM-1对总生存期的预后价值。值得注意的是，低sMAdCAM-1水平与以肠梭菌属为主的免疫抑制性肠道菌群特征相关。因此，sMAdCAM-1值得作为生物标志物指导的、针对微生物群的干预工具进行进一步研究。

### 第二部分 AI 大师评价

本研究旨在探索可溶性MAdCAM-1作为转移性肾细胞癌预后生物标志物的价值，并关联其与肠道菌群失调介导的耐药机制。研究通过分析三个大型临床试验队列（JAVELIN Renal 101, SURF, NIVOREN）共1051名患者的数据，发现高基线sMAdCAM-1水平与显著改善的生存结局独立相关，且低水平与特定的免疫抑制性肠道菌群特征相关。其创新性在于将肠道-免疫轴的关键分子与临床预后直接联系，为基于生物标志物的个体化治疗（如菌群干预）提供了新靶点；局限性在于其关联性分析尚需前瞻性干预研究来证实因果关系，且sMAdCAM-1的检测标准化和截断值有待进一步确定。

---

## 89. 人类脂质转运蛋白介导脂质动员的系统性分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501472)
**期刊：** Nature
**PMID：** 41501472
**DOI：** 10.1038/s41586-025-10040-y

### 第一部分 原文与翻译

**英文原标题：** Systematic analyses of lipid mobilization by human lipid transfer proteins.

> **英文摘要：**
> Lipid transfer proteins (LTPs) maintain the specialized lipid compositions of organellar membranes. In humans, many LTPs are implicated in diseases, but for the majority, the cargo and auxiliary lipids facilitating transfer remain unknown. We have combined biochemical, lipidomic and computational methods to systematically characterize LTP-lipid complexes and measure how LTP gains of function affect cellular lipidomes. We identified bound lipids for approximately half of the hundred LTPs analyzed, confirming known ligands, while discovering new ones across most LTP families. Gains in LTP function affected the cellular abundance of both their known and newly identified lipid ligands, indicating comparable functional relevance of the two ligand sets. Using structural bioinformatics, we have characterized mechanisms contributing to lipid selectivity, identifying preferences based on head group or acyl chain. We demonstrate some basic principles of how LTPs mobilise their ligands. They commonly interact with several classes of lipids and exhibit broad but selective preference, not only for particular head groups, but also for lipid species with shorter acyl chains containing one or two unsaturations, suggesting that only subsets of lipid species are efficiently mobilized. The datasets represent a resource for further analysis in different cell types and states, such as those associated with pathologies.

> **中文摘要：**
> 脂质转运蛋白维持着细胞器膜的特异性脂质组成。在人类中，许多脂质转运蛋白与疾病相关，但对于大多数蛋白而言，其转运的货物脂质及辅助脂质仍属未知。我们结合了生物化学、脂质组学和计算方法，系统性地表征了脂质转运蛋白-脂质复合物，并测量了脂质转运蛋白功能增益如何影响细胞脂质组。我们在大约一半（约一百种）被分析的脂质转运蛋白中鉴定出了结合脂质，既确认了已知配体，也在大多数脂质转运蛋白家族中发现了新的配体。脂质转运蛋白的功能增益影响了其已知和新鉴定脂质配体的细胞丰度，表明这两组配体具有可比的功能相关性。利用结构生物信息学，我们揭示了脂质选择性的机制，识别了基于头部基团或酰基链的偏好性。我们阐明了脂质转运蛋白动员其配体的一些基本原理。它们通常与多类脂质相互作用，并表现出广泛但有选择性的偏好性，不仅针对特定的头部基团，也偏好具有较短且含有一或两个不饱和键的酰基链的脂质种类，这表明只有一部分脂质种类能被有效动员。这些数据集为在不同细胞类型和状态（例如与病理相关的状态）中进行进一步分析提供了资源。

### 第二部分 AI 大师评价

本研究旨在系统解析人类脂质转运蛋白的脂质配体及其动员机制，以填补该领域的关键知识空白。研究团队创新性地整合了生化、脂质组学与计算生物学方法，首次在大规模上鉴定了LTP的脂质结合谱，不仅验证了已知配体，更发现了跨家族的新配体，揭示了其功能相关性。通过结构生物信息学分析，研究阐明了LTP对脂质头部基团和酰基链长度/不饱和度的选择性偏好，提出了“高效动员特定脂质亚群”的核心原则，为理解膜脂质稳态和疾病机制提供了系统性数据集和理论框架。然而，研究主要基于体外和细胞模型，其在复杂生理和病理环境中的动态功能验证，以及不同LTP间的协同或拮抗作用，仍是未来需要探索的领域。

---

## 90. 神经-上皮环路促进感觉整合与肠道免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501470)
**期刊：** Nature
**PMID：** 41501470
**DOI：** 10.1038/s41586-025-09921-z

### 第一部分 原文与翻译

**英文原标题：** Neuro-epithelial circuits promote sensory convergence and intestinal immunity.

> **英文摘要：**
> Type 2 inflammation at barrier surfaces is an evolutionarily conserved response that promotes immunity to helminth parasites, allergic inflammation and tissue repair. Direct sensing of environmental triggers by epithelial cells initiates type 2 inflammation, and signals derived from neurons can modulate immune responses. However, how diverse sensory inputs from epithelial, neuronal and immune cells are coordinated and integrated remains unclear. Here we identify that TRPV1 pain-sensing nociceptors co-opt chemosensory epithelial tuft cells to initiate a cascade of tissue responses that drive type 2 inflammation. Chemogenetic silencing or chemical ablation of TRPV1 nociceptors results in a significant reduction in intestinal tuft cells and defective anti-helminth type 2 immunity. By contrast, chemogenetic activation of TRPV1 nociceptors leads to remodelling of CGRP nerve fibres, significantly increased CGRP expression, enhanced tuft cell accumulation and protective anti-helminth type 2 immunity. Using spatial transcriptomic and single-cell RNA sequencing analyses, we reveal that nociceptor activation promotes rapid epithelial progenitor cell proliferation and differentiation. Mechanistically, intestinal epithelial cell-intrinsic and tuft cell-intrinsic expression of CGRP receptor subunits are required for tuft cell responses and type 2 immunity to helminth infection. Together, these results identify sensory convergence of a neuronal-epithelial tuft cell circuit as a critical upstream determinant of type 2 immunity and tissue adaptation.

> **中文摘要：**
> 屏障表面的2型炎症是一种进化上保守的反应，可促进对蠕虫寄生虫的免疫、过敏性炎症和组织修复。上皮细胞直接感知环境触发因素启动2型炎症，而源自神经元的信号可以调节免疫反应。然而，来自上皮细胞、神经元和免疫细胞的各种感觉输入是如何协调和整合的，目前尚不清楚。本文发现，TRPV1痛觉感受器协同化学感觉上皮簇细胞，启动一系列驱动2型炎症的组织反应。化学遗传学沉默或化学消融TRPV1痛觉感受器会导致肠道簇细胞显著减少和抗蠕虫2型免疫缺陷。相比之下，化学遗传学激活TRPV1痛觉感受器会导致CGRP神经纤维重塑、CGRP表达显著增加、簇细胞积累增强以及保护性的抗蠕虫2型免疫。利用空间转录组学和单细胞RNA测序分析，我们发现痛觉感受器激活促进了上皮祖细胞的快速增殖和分化。从机制上讲，肠道上皮细胞固有和簇细胞固有的CGRP受体亚基表达，是簇细胞对蠕虫感染产生反应和2型免疫所必需的。总之，这些结果确定了神经-上皮簇细胞环路的感觉整合是2型免疫和组织适应的关键上游决定因素。

### 第二部分 AI 大师评价

本研究旨在揭示屏障组织中2型免疫启动的上游调控机制，核心目的是阐明神经元与上皮细胞如何整合感觉信号以协调免疫应答。研究者通过化学遗传学操控、空间转录组学与单细胞测序等技术，系统性地证明了TRPV1痛觉感受器通过调控CGRP信号，驱动上皮簇细胞扩增与分化，从而主导抗蠕虫2型免疫。其创新性在于首次将痛觉神经环路与化学感觉上皮细胞整合为一个功能单元，确立了“神经-上皮簇细胞环路”作为感觉整合与免疫启动的关键枢纽，为神经免疫学提供了新范式。局限性在于研究主要聚焦于肠道蠕虫感染模型，该环路在其他2型炎症性疾病（如过敏）中的普适性及具体调控细节仍需进一步验证。

---

## 91. 通过检查点降解偶联抗原呈递实现瘤内疫苗接种。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501465)
**期刊：** Nature
**PMID：** 41501465
**DOI：** 10.1038/s41586-025-09903-1

### 第一部分 原文与翻译

**英文原标题：** Intratumoural vaccination via checkpoint degradation-coupled antigen presentation.

> **英文摘要：**
> Decreased cross-presentation by antigen-presenting cells induces the scarcity of tumour-reactive T cells within the tumour bed, rendering in situ T cell rejuvenation through immunogenicity reprogramming highly desirable yet challenging. Here we developed an intratumoural vaccination chimera (iVAC) to reprogram tumour cells into an antigen-presenting state (APC-like tumour cells) with restored anti-tumour immunity. The iVAC chimeras consist of a covalently engineered PD-L1 degrader conjugated to immunogenic antigens, which could relieve immune checkpoint inhibition while enforcing the cross-presentation of exogenous antigens. Functionally, the iVAC-induced antigen processing and presentation elicited potent tumour killing through reactivation of resident antigen-specific CD8 T cells, which simultaneously remodelled the tumour microenvironment to promote durable tumour-specific immunity. Extending this strategy, we used iVAC with a cytomegalovirus (CMV)-derived antigen to activate CMV-specific T cells against breast cancer in vitro, in a humanized mouse model as well as in a patient-derived tumour model. This study establishes a foundation for chemically reprogramming cancer cells within tumour beds to endow APC-like functions, providing an avenue for stimulating anti-tumour immunity.

> **中文摘要：**
> 抗原呈递细胞的交叉呈递功能减弱导致肿瘤床内肿瘤反应性T细胞稀缺，使得通过免疫原性重编程实现原位T细胞再生极具吸引力但也充满挑战。本研究开发了一种瘤内疫苗接种嵌合体（iVAC），可将肿瘤细胞重编程为具有抗原呈递状态（APC样肿瘤细胞），并恢复抗肿瘤免疫力。iVAC嵌合体由一个共价工程化的PD-L1降解剂与免疫原性抗原偶联而成，它既能解除免疫检查点抑制，又能增强外源性抗原的交叉呈递。在功能上，iVAC诱导的抗原加工与呈递通过重新激活驻留的抗原特异性CD8 T细胞，引发了强大的肿瘤杀伤作用，同时重塑了肿瘤微环境以促进持久的肿瘤特异性免疫。扩展此策略，我们使用带有巨细胞病毒（CMV）来源抗原的iVAC，在体外、人源化小鼠模型以及患者来源的肿瘤模型中激活了CMV特异性T细胞以对抗乳腺癌。本研究为化学重编程肿瘤床内的癌细胞以赋予其APC样功能奠定了基础，为刺激抗肿瘤免疫提供了一条途径。

### 第二部分 AI 大师评价

本研究旨在通过化学重编程策略，将肿瘤细胞原位转化为具有抗原呈递功能的APC样细胞，以克服肿瘤微环境中T细胞稀缺的难题。其核心创新在于设计了一种双功能嵌合分子iVAC，它同时实现了PD-L1检查点的降解和抗原的靶向递送，从而协同解除免疫抑制并激活特异性T细胞应答。研究不仅在小鼠模型中验证了该策略的有效性，还通过CMV抗原模型展示了其在激活病毒特异性T细胞对抗实体瘤（如乳腺癌）方面的转化潜力，为开发新型瘤内免疫疗法提供了新思路。然而，该方法的临床转化仍需评估其在不同肿瘤类型中的普适性、长期安全性以及潜在的脱靶效应。

---

## 92. 一个扩展的候选顺式调控元件注册表

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501460)
**期刊：** Nature
**PMID：** 41501460
**DOI：** 10.1038/s41586-025-09909-9

### 第一部分 原文与翻译

**英文原标题：** An expanded registry of candidate cis-regulatory elements.

> **英文摘要：**
> Mammalian genomes contain millions of regulatory elements that control the complex patterns of gene expression. Previously, the ENCODE consortium mapped biochemical signals across hundreds of cell types and tissues and integrated these data to develop a registry containing 0.9 million human and 300,000 mouse candidate cis-regulatory elements (cCREs) annotated with potential functions. Here we have expanded the registry to include 2.37 million human and 967,000 mouse cCREs, leveraging new ENCODE datasets and enhanced computational methods. This expanded registry covers hundreds of unique cell and tissue types, providing a comprehensive understanding of gene regulation. Functional characterization data from assays such as STARR-seq, massively parallel reporter assay, CRISPR perturbation and transgenic mouse assays have profiled more than 90% of human cCREs, revealing complex regulatory functions. We identified thousands of novel silencer cCREs and demonstrated their dual enhancer and silencer roles in different cellular contexts. Integrating the registry with other ENCODE annotations facilitates genetic variation interpretation and trait-associated gene identification, exemplified by the identification of KLF1 as a novel causal gene for red blood cell traits. This expanded registry is a valuable resource for studying the regulatory genome and its impact on health and disease.

> **中文摘要：**
> 哺乳动物基因组包含数百万个调控元件，它们控制着复杂的基因表达模式。此前，ENCODE联盟在数百种细胞类型和组织中绘制了生化信号图谱，并整合这些数据，开发了一个包含90万个人类和30万个小鼠候选顺式调控元件的注册表，并标注了潜在功能。本研究利用新的ENCODE数据集和增强的计算方法，将该注册表扩展至包含237万个人类和96.7万个小鼠cCRE。这个扩展的注册表涵盖了数百种独特的细胞和组织类型，为理解基因调控提供了全面的视角。来自STARR-seq、大规模平行报告基因检测、CRISPR扰动和转基因小鼠检测等功能表征数据，已对超过90%的人类cCRE进行了功能剖析，揭示了复杂的调控功能。我们鉴定出数千个新型沉默子cCRE，并证明了它们在不同细胞环境中兼具增强子和沉默子的双重角色。将该注册表与其他ENCODE注释整合，有助于解释遗传变异和识别性状相关基因，例如鉴定出KLF1作为红细胞性状的一个新的致病基因。这个扩展的注册表是研究调控基因组及其对健康和疾病影响的宝贵资源。

### 第二部分 AI 大师评价

本研究核心目的是大幅扩展并深化ENCODE联盟的候选顺式调控元件注册表，为基因调控研究提供更全面的资源。其方法学创新在于整合了海量新数据集并应用了增强的计算方法，从而将注册表规模扩充了数倍，并覆盖了更广泛的细胞类型。关键发现包括：对超过90%的人类cCRE进行了功能剖析，揭示了其复杂功能；鉴定出数千个具有情境依赖性增强子/沉默子双重功能的新型元件；并通过与遗传数据整合，成功识别出新的性状致病基因（如KLF1），展示了其强大的应用价值。然而，该注册表主要基于生化信号和体外/模型系统功能数据，其在体内复杂生理和病理环境下的精确调控机制及临床转化潜力仍需进一步验证。

---

## 93. 应激通过组蛋白H3泛素化调控异染色质遗传。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501458)
**期刊：** Nature
**PMID：** 41501458
**DOI：** 10.1038/s41586-025-09899-8

### 第一部分 原文与翻译

**英文原标题：** Stress controls heterochromatin inheritance via histone H3 ubiquitylation.

> **英文摘要：**
> Heterochromatin, marked by histone H3 lysine 9 methylation, can be epigenetically inherited through cell division, maintaining gene repression that preserves cell identity and enables adaptation to environmental challenges. Studies on Schizosaccharomyces pombe have shown that heterochromatin propagation depends on the read-write mechanism, wherein a sufficient density of H3K9me3-modified nucleosomes, stabilized by histone deacetylases, concentrates Clr4 on chromatin to promote further deposition of H3K9 methylation. Whether other mechanisms control heterochromatin propagation by means of Clr4, a subunit of the E3 ubiquitin ligase complex ClrC, was unknown. Here we uncover a ubiquitin-dependent heterochromatin heritability regulatory hub (HRH) that broadly governs heterochromatin propagation, even without histone deacetylase activity. The HRH is tuned by the limiting factor Raf1, a substrate receptor for the ClrC ubiquitin ligase. In addition to linking Clr4 to other ClrC components on chromatin, Raf1 acts in a dosage-dependent manner to promote ubiquitination of histone H3 at lysine 14 (H3K14ub), which is critical for heterochromatin self-propagation. HRH is intricately linked to environmentally responsive pathways, including nonsense-mediated decay (NMD) and target of rapamycin (TOR) signalling, enabling cells to adapt to changing conditions. By modulating heterochromatin propagation, cells leverage the HRH to gain resistance to antifungal agents and adapt to high temperature. Thus, heterochromatin self-propagation is actively regulated by means of H3K14ub in response to external stimuli, with broad implications for understanding mechanisms governing rapid changes in the epigenetic landscape in physiology and disease.

> **中文摘要：**
> 以组蛋白H3第9位赖氨酸甲基化为标志的异染色质，可以通过细胞分裂进行表观遗传，维持基因抑制，从而保持细胞身份并适应环境挑战。对裂殖酵母的研究表明，异染色质的传播依赖于读写机制，其中，由组蛋白去乙酰化酶稳定的、足够密度的H3K9me3修饰核小体，将Clr4聚集在染色质上，以促进H3K9甲基化的进一步沉积。是否存在其他机制通过Clr4（E3泛素连接酶复合物ClrC的一个亚基）来控制异染色质传播尚不清楚。本文揭示了一个泛素依赖的异染色质遗传性调控枢纽，它广泛调控异染色质的传播，甚至无需组蛋白去乙酰化酶活性。该调控枢纽由限制性因子Raf1（ClrC泛素连接酶的底物受体）进行调节。除了将Clr4与染色质上的其他ClrC组分连接起来，Raf1还以剂量依赖的方式促进组蛋白H3第14位赖氨酸的泛素化，这对于异染色质的自我传播至关重要。该调控枢纽与多种环境响应通路（包括无义介导的mRNA降解和雷帕霉素靶蛋白信号通路）紧密相连，使细胞能够适应不断变化的条件。通过调节异染色质传播，细胞利用该调控枢纽获得抗真菌药物耐药性并适应高温。因此，异染色质的自我传播通过H3K14ub响应外部刺激而受到主动调控，这对于理解生理和疾病中表观遗传景观快速变化的调控机制具有广泛意义。

### 第二部分 AI 大师评价

本研究旨在探索异染色质遗传调控的新机制，聚焦于泛素化修饰的作用。研究者通过鉴定一个由Raf1调控的泛素依赖的异染色质遗传性调控枢纽，揭示了H3K14泛素化在异染色质自我传播中的关键作用，并阐明了该机制如何整合环境信号通路（如NMD和TOR），使细胞能够适应应激条件。其核心创新在于发现了一条独立于经典读写机制、由泛素化介导的异染色质调控新通路，并直接将其与细胞适应性表型（如耐药和耐热）联系起来，为理解表观遗传的快速可塑性提供了新视角。然而，该发现目前主要基于裂殖酵母模型，其在高等真核生物中的普适性及具体分子细节仍需进一步验证。

---

## 94. 乳腺癌器官特异性转移的营养需求。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501456)
**期刊：** Nature
**PMID：** 41501456
**DOI：** 10.1038/s41586-025-09898-9

### 第一部分 原文与翻译

**英文原标题：** Nutrient requirements of organ-specific metastasis in breast cancer.

> **英文摘要：**
> Cancer metastasis is a major contributor to patient morbidity and mortality, yet the factors that determine the organs where cancers can metastasize are incompletely understood. Here we quantify the absolute levels of 124 metabolites in multiple tissues in mice and investigate how this relates to the ability of breast cancer cells to grow in different organs. We engineered breast cancer cells with broad metastatic potential to be auxotrophic for specific nutrients and assessed their ability to colonize different tissue sites. We then asked how tumour growth in different tissues relates to nutrient availability and tumour biosynthetic activity. We find that single nutrients alone do not define the sites where breast cancer cells can grow as metastases. In addition, we identify purine synthesis as a requirement for tumour growth and metastasis across many tissues and find that this phenotype is independent of tissue nucleotide availability or tumour de novo nucleotide synthesis activity. These data suggest that a complex interplay between multiple nutrients within the microenvironment dictates potential sites of metastatic cancer growth, and highlights the interdependence between extrinsic environmental factors and intrinsic cellular properties in influencing where breast cancer cells can grow as metastases.

> **中文摘要：**
> 癌症转移是导致患者发病和死亡的主要原因，然而决定癌症可以向哪些器官转移的因素尚不完全清楚。在此，我们量化了小鼠多种组织中124种代谢物的绝对水平，并研究了这与乳腺癌细胞在不同器官中生长能力的关系。我们改造了具有广泛转移潜能的乳腺癌细胞，使其对特定营养素产生营养缺陷，并评估了它们在不同组织部位定植的能力。然后，我们探究了不同组织中的肿瘤生长如何与营养可用性和肿瘤生物合成活性相关联。我们发现，单一营养素本身并不能决定乳腺癌细胞可以作为转移灶生长的部位。此外，我们确定嘌呤合成是肿瘤在许多组织中生长和转移所必需的，并且发现这种表型与组织核苷酸可用性或肿瘤从头核苷酸合成活性无关。这些数据表明，微环境中多种营养素之间复杂的相互作用决定了转移性癌症生长的潜在部位，并强调了外在环境因素与内在细胞特性在影响乳腺癌细胞可作为转移灶生长的部位方面的相互依存关系。

### 第二部分 AI 大师评价

本研究旨在探究乳腺癌器官特异性转移背后的营养决定因素。研究者通过量化小鼠组织代谢物谱，并结合基因工程构建营养缺陷型乳腺癌细胞模型，系统评估了营养可用性与转移定植能力的关系。核心发现是，单一营养素并非转移器官选择性的决定性因素，而嘌呤合成通路则被鉴定为跨组织转移的普遍内在需求，且该需求独立于局部核苷酸环境。这一发现创新性地揭示了转移灶形成是微环境多营养素互作与肿瘤细胞内在代谢特性（如嘌呤合成）共同作用的复杂结果，超越了传统的“种子与土壤”简单二元论。然而，研究主要基于小鼠模型和工程细胞系，其在人类乳腺癌异质性和临床相关性方面的普适性仍需进一步验证。

---

## 95. 白蛋白通过调控真菌致病性，主导宿主防御毛霉病的天然机制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501454)
**期刊：** Nature
**PMID：** 41501454
**DOI：** 10.1038/s41586-025-09882-3

### 第一部分 原文与翻译

**英文原标题：** Albumin orchestrates a natural host defence mechanism against mucormycosis.

> **英文摘要：**
> Mucormycosis is an emerging, life-threatening human infection caused by Mucorales fungi. Metabolic disorders uniquely predispose an ever-expanding group of patients to mucormycosis through poorly understood mechanisms, suggesting that uncharacterized host metabolic effectors may confer protective immunity against this infection. Here we uncover a master regulatory role of albumin in host defence against Mucorales through the modulation of fungal pathogenicity. Our initial studies identified severe hypoalb uminaemia as a prominent metabolic abnormality and an independent biomarker of poor mucormycosis outcome across three distinct cohorts of patients with mucormycosis. Notably, purified albumin selectively inhibits Mucorales growth among a range of pathogens, and albumin-deficient mice display susceptibility specifically to mucormycosis. The antifungal activity of albumin is mediated by the release of bound free fatty acids (FFAs). Albumin prevents FFA oxidation, which otherwise abolishes their antifungal properties, and sera from patients with mucormycosis display high levels of oxidized FFAs. Physiologically, albumin-bound FFAs suppress the expression of key virulence factors by inhibiting protein synthesis, the reby rendering Mucorales avirulent in vivo. Overall, we identify a host defence mechanism that directs the pathogen to suppress its pathogenicity program in response to unfavourable metabolic cues regulated by albumin. These findings have major implications for the pathogenesis and management of mucormycosis.

> **中文摘要：**
> 毛霉病是一种由毛霉菌目真菌引起的、新出现的、危及生命的人类感染。代谢紊乱通过尚不明确的机制，独特地使日益增多的患者群体易患毛霉病，这表明未被表征的宿主代谢效应因子可能赋予针对该感染的保护性免疫。本研究揭示了白蛋白通过调控真菌致病性，在宿主防御毛霉菌中的核心调控作用。我们的初步研究确定，在三个不同的毛霉病患者队列中，严重的低白蛋白血症是一个突出的代谢异常，也是毛霉病不良预后的独立生物标志物。值得注意的是，纯化的白蛋白在一系列病原体中能选择性抑制毛霉菌的生长，而白蛋白缺陷小鼠则表现出对毛霉病的特异性易感性。白蛋白的抗真菌活性是通过释放其结合的自由脂肪酸介导的。白蛋白能防止FFA氧化（否则会消除其抗真菌特性），而毛霉病患者的血清中显示出高水平的氧化FFA。在生理上，白蛋白结合的FFA通过抑制蛋白质合成来抑制关键毒力因子的表达，从而使毛霉菌在体内无毒力。总之，我们鉴定出一种宿主防御机制，该机制引导病原体响应由白蛋白调控的不利代谢信号，从而抑制其致病性程序。这些发现对毛霉病的发病机制和管理具有重大意义。

### 第二部分 AI 大师评价

本研究旨在揭示宿主代谢因子如何调控毛霉病易感性，核心目的是阐明白蛋白在宿主防御中的关键作用。研究通过临床队列分析、体外抑菌实验、动物模型验证及分子机制探究，系统性地证明了白蛋白通过释放并保护其结合的自由脂肪酸免于氧化，进而抑制毛霉菌的蛋白质合成与毒力表达。其创新性在于首次将一种常见的血浆蛋白（白蛋白）及其结合的代谢物（FFA）确立为调控真菌致病性程序的天然宿主防御枢纽，为理解代谢性疾病与感染风险的联系提供了全新视角。局限性在于，研究主要聚焦于机制发现，其临床转化潜力（如补充白蛋白或FFA作为辅助疗法）仍需进一步的前瞻性研究验证。

---

## 96. 营养物质在癌症扩散中的复杂作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501272)
**期刊：** Nature
**PMID：** 41501272
**DOI：** 10.1038/d41586-025-03988-4

### 第一部分 原文与翻译

**英文原标题：** The complex role of nutrients in cancer spread.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题聚焦于营养物质在癌症转移中的复杂作用，这是一个肿瘤代谢领域的关键前沿问题。鉴于摘要不可用，推测其核心目的是系统阐述不同营养素如何通过影响肿瘤微环境、信号通路及免疫应答等机制，促进或抑制癌细胞的扩散。其创新性在于强调“复杂性”，可能整合了多组学数据与代谢模型，超越了简单的“促癌”或“抑癌”二分法。然而，缺乏摘要限制了对其具体研究方法、关键发现及潜在局限性的评估，读者需查阅全文以获取详细信息。

---

## 97. 间皮瘤中的BAP1缺失：分子机制与临床机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501212)
**期刊：** Oncogene
**PMID：** 41501212
**DOI：** 10.1038/s41388-025-03672-x

### 第一部分 原文与翻译

**英文原标题：** BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities.

> **英文摘要：**
> Mesothelioma is an aggressive cancer that is often characterized by loss of the BRCA1-associated protein 1 (BAP1) tumor suppressor gene. This alteration typically occurs as an early clonal event in mesothelioma development, making it a promising candidate for both diagnostic and therapeutic applications. Functionally, BAP1 regulates gene expression through interactions with Polycomb-group complexes, and it plays roles in various other cellular processes including DNA repair, replication stress, and cell metabolism. While preclinical research has identified multiple potential vulnerabilities in BAP1-deficient tumors-including sensitivity to EZH2-, HDAC-, PARP-, and FGFR-inhibitors-translating these findings to the clinic remains a challenge. In this review, we provide a comprehensive overview of BAP1's molecular functions in mesothelioma, with a focus on their translation into clinical therapeutics for this hard-to-treat malignancy.

> **中文摘要：**
> 间皮瘤是一种侵袭性癌症，其常见特征是BRCA1相关蛋白1（BAP1）肿瘤抑制基因的缺失。这种改变通常作为间皮瘤发展过程中的早期克隆事件发生，使其成为诊断和治疗应用方面极具潜力的候选靶点。在功能上，BAP1通过与Polycomb-group复合物相互作用来调控基因表达，并在多种其他细胞过程中发挥作用，包括DNA修复、复制应激和细胞代谢。尽管临床前研究已发现BAP1缺陷型肿瘤存在多种潜在弱点——包括对EZH2、HDAC、PARP和FGFR抑制剂的敏感性——但将这些发现转化到临床仍面临挑战。在这篇综述中，我们全面概述了BAP1在间皮瘤中的分子功能，并重点探讨如何将这些功能转化为针对这种难治性恶性肿瘤的临床疗法。

### 第二部分 AI 大师评价

本文是一篇综述，核心目的是系统阐述BAP1基因缺失在间皮瘤发生发展中的分子机制，并探讨其作为诊断标志物和治疗靶点的临床转化前景。文章方法上，整合了BAP1在基因表达调控、DNA修复、细胞代谢等多方面的功能研究，并梳理了针对BAP1缺陷的多种靶向治疗（如EZH2、HDAC、PARP、FGFR抑制剂）的临床前证据。其创新性在于将BAP1的分子生物学特征与间皮瘤的临床诊疗挑战紧密结合，为这一难治性癌症提供了从机制到治疗的系统性视角。然而，文章也明确指出，尽管临床前研究揭示了诸多潜在治疗靶点，但将其成功转化为有效的临床疗法仍是一项重大挑战，这构成了当前研究的主要局限性。

---

## 98. H4K12la/CEBPB-AKR1C2信号轴通过调控mTOR通路调节肺癌顺铂耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501211)
**期刊：** Oncogene
**PMID：** 41501211
**DOI：** 10.1038/s41388-025-03669-6

### 第一部分 原文与翻译

**英文原标题：** An H4K12la/CEBPB-AKR1C2 signaling axis modulates the mTOR pathway to regulate cisplatin resistance in lung cancer.

> **英文摘要：**
> Histone lactylation, a recently discovered epigenetic modification, has been shown to play a critical role in regulating gene expression and cellular functions. However, its involvement in cisplatin (CDDP) resistance in non-small cell lung cancer (NSCLC) remains poorly understood. In this study, we demonstrated that histone lactylation is closely associated with CDDP resistance and correlates with poor prognosis of NSCLC. Mechanistically, H4K12la (histone e 4 lysine 12 lactylation) levels and CEBPB (CCAAT/enhancer-binding protein beta) had a cooperative effect on the regulation of AKR1C2 (Aldo-Keto reductase 1C2). Furthermore, AKR1C2 knockdown activates the mTOR oncogenic signaling pathway. Importantly, genetic manipulation of AKR1C2 or the combination of CDDP with an mTOR inhibitor effectively reverse CDDP resistance in NSCLC/CDDP cells. These findings highlighted the potential of AKR1C2 as a predictive biomarker for patient response to CDDP therapy. Additionally, our study established a novel link between histone lactylation and CDDP resistance, providing new insights into the epigenetic regulation in NSCLC.

> **中文摘要：**
> 组蛋白乳酸化是一种新近发现的表观遗传修饰，已被证明在调控基因表达和细胞功能中起关键作用。然而，其在非小细胞肺癌顺铂耐药中的作用仍知之甚少。在本研究中，我们证明了组蛋白乳酸化与顺铂耐药密切相关，并与NSCLC的不良预后相关。从机制上讲，H4K12la（组蛋白H4第12位赖氨酸乳酸化）水平和CEBPB（CCAAT/增强子结合蛋白β）对AKR1C2（醛酮还原酶1C2）的调控具有协同效应。此外，敲低AKR1C2会激活mTOR致癌信号通路。重要的是，对AKR1C2进行遗传操作或将顺铂与mTOR抑制剂联用，能有效逆转NSCLC/顺铂耐药细胞的顺铂耐药性。这些发现凸显了AKR1C2作为患者对顺铂治疗反应的预测性生物标志物的潜力。此外，我们的研究建立了组蛋白乳酸化与顺铂耐药之间的新联系，为NSCLC的表观遗传调控提供了新见解。

### 第二部分 AI 大师评价

本研究旨在探索组蛋白乳酸化在非小细胞肺癌顺铂耐药中的作用及机制。通过分子生物学方法，研究发现H4K12la与转录因子CEBPB协同上调AKR1C2，而AKR1C2的缺失会激活mTOR通路，从而驱动耐药。其核心创新在于首次将组蛋白乳酸化这一新兴表观遗传修饰与肺癌化疗耐药联系起来，并揭示了H4K12la/CEBPB-AKR1C2-mTOR这一全新的信号轴，为克服耐药提供了AKR1C2这一潜在生物标志物和mTOR抑制剂联合用药的新策略。局限性在于研究主要基于细胞模型，其临床转化价值和在肿瘤微环境中的具体作用仍需进一步验证。

---

## 99. 在前列腺癌中，EZH2 PROTACs通过靶向PRC2的非甲基化依赖性功能，其疗效优于催化抑制剂。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501210)
**期刊：** Oncogene
**PMID：** 41501210
**DOI：** 10.1038/s41388-025-03662-z

### 第一部分 原文与翻译

**英文原标题：** EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2.

> **英文摘要：**
> Enhancer of Zeste Homolog 2 (EZH2) is the enzymatic subunit of the Polycomb Repressive Complex 2 (PRC2). It catalyzes H3K27 methylation for epigenetic silencing of tumor suppressors and critically drives prostate cancer (PCa) progression. However, inhibitors of EZH2 catalytic function (EZH2i), such as EPZ-6438, showed limited efficacy in PCa. Here, we designed and developed a series of VHL-based proteolysis-targeting chimera (PROTAC) degraders of EZH2 using EPZ-6438 as a ligand and identified PROTAC-6272 as a lead compound. PROTAC-6272 effectively degraded EZH2 and other PRC2 subunits across diverse PCa cell lines. However, PROTAC-6272 and other similar EZH2i-based PROTACs were consistently unable to decrease androgen receptor (AR), a gene that is directly activated by solo EZH2. Mechanistically, EZH2 PROTACs failed to degrade EZH2 coactivators, such as p300, due to their inability to engage EZH2 outside of the PRC2 complex. Nevertheless, PROTAC-6272 exhibited anti-proliferative activities superior to EPZ-6438 in some PCa models, wherein it induced p21 expression and cellular senescence by disrupting a methylation-independent PRC2 function. In summary, while EZH2i-based PROTACs failed to target the PRC2-independent functions of EZH2, they confer added benefits over EPZ-6438 by abolishing a polycomb-dependent but methylation-independent function of EZH2, offering therapeutic advantages in some PCa.

> **中文摘要：**
> Zeste同源物2增强子（EZH2）是多梳抑制复合物2（PRC2）的催化亚基。它催化H3K27甲基化，从而表观遗传沉默肿瘤抑制因子，并关键性地驱动前列腺癌（PCa）进展。然而，EZH2催化功能抑制剂（EZH2i），如EPZ-6438，在前列腺癌中显示出有限的疗效。在此，我们以EPZ-6438为配体，设计并开发了一系列基于VHL的EZH2蛋白水解靶向嵌合体（PROTAC）降解剂，并将PROTAC-6272确定为先导化合物。PROTAC-6272能在多种前列腺癌细胞系中有效降解EZH2及其他PRC2亚基。然而，PROTAC-6272及其他类似的基于EZH2i的PROTACs始终无法降低雄激素受体（AR）的表达，而AR是可由单独的EZH2直接激活的基因。从机制上讲，EZH2 PROTACs无法降解EZH2的共激活因子（如p300），因为它们无法结合PRC2复合体之外的EZH2。尽管如此，在某些前列腺癌模型中，PROTAC-6272表现出优于EPZ-6438的抗增殖活性，其通过破坏PRC2的非甲基化依赖性功能，诱导了p21表达和细胞衰老。总之，虽然基于EZH2i的PROTACs未能靶向EZH2不依赖于PRC2的功能，但它们通过消除EZH2一个依赖于多梳复合物但不依赖于甲基化的功能，提供了优于EPZ-6438的额外益处，从而在某些前列腺癌中提供了治疗优势。

### 第二部分 AI 大师评价

本研究旨在解决EZH2催化抑制剂在前列腺癌中疗效有限的问题，创新性地开发了基于EZH2i的PROTAC降解剂PROTAC-6272。研究发现，该PROTAC能有效降解PRC2复合体中的EZH2，并通过破坏PRC2的非甲基化依赖性功能（如诱导p21和细胞衰老），在某些模型中展现出优于传统抑制剂EPZ-6438的抗增殖活性。然而，其局限性在于无法靶向并降解PRC2复合体之外的EZH2（如作为AR共激活因子的功能），因此未能抑制AR等基因的表达，这揭示了EZH2在癌症中功能的复杂性，并为未来药物设计指明了需同时靶向其不同功能状态的方向。

---

## 100. 癌症筛查指南

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501152)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41501152
**DOI：** 10.1038/s41571-025-01112-z

### 第一部分 原文与翻译

**英文原标题：** A guide to cancer screening.

> **英文摘要：**
> The aim of cancer screening is to identify pre-malignant conditions, which can be removed or treated, or earlier-stage disease, for which treatment is more likely to be curative, in non-symptomatic individuals. Currently, screening programmes are being consolidated for five cancer types (breast, prostate, cervical, colorectal and lung) and several other cancer types are the focus of specific initiatives. Cancer screening is at a point of potential major transformation owing to technological advances in detection. In this Review, we first recapitulate the general principles of cancer screening. We then provide a timely overview of the current screening practices for breast, cervical, colorectal, prostate and lung cancer, addressing major challenges and potential future changes in practice. We also discuss other malignancies for which screening initiatives might be worth considering. Finally, we highlight technological developments in cancer detection that might hold promise for screening an increasing number of cancers in the future, notably some that reflect unmet needs.

> **中文摘要：**
> 癌症筛查的目的是在无症状个体中识别可被切除或治疗的癌前病变，或治疗更可能治愈的早期疾病。目前，针对五种癌症类型（乳腺癌、前列腺癌、宫颈癌、结直肠癌和肺癌）的筛查项目正在巩固，其他几种癌症类型也是特定举措的重点。由于检测技术的进步，癌症筛查正处于潜在重大变革的节点。在本综述中，我们首先重述了癌症筛查的一般原则。然后，我们及时概述了当前乳腺癌、宫颈癌、结直肠癌、前列腺癌和肺癌的筛查实践，探讨了主要挑战和实践中潜在的未来变化。我们还讨论了其他可能值得考虑筛查举措的恶性肿瘤。最后，我们强调了癌症检测技术的最新进展，这些进展可能为未来筛查更多种类的癌症带来希望，尤其是一些反映未满足需求的癌症。

### 第二部分 AI 大师评价

本文是一篇高质量的综述，旨在系统梳理癌症筛查领域的现状与未来方向。其核心目的是为读者提供一份关于五大常见癌症筛查实践、原则及挑战的全面指南，并前瞻性地探讨了技术革新如何重塑筛查格局。文章的创新性在于不仅总结了成熟筛查项目，还识别了有潜力的新筛查靶点和技术，为临床实践和未来研究提供了清晰的路线图。然而，作为一篇综述，其内容主要基于现有证据的整合，未提供新的原始数据，对具体技术细节和成本效益分析的讨论深度可能有限。

---

## 101. KDM6A缺失介导的基因组不稳定性和代谢重编程调控膀胱癌对治疗干预的反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501085)
**期刊：** Nature communications
**PMID：** 41501085
**DOI：** 10.1038/s41467-025-68132-2

### 第一部分 原文与翻译

**英文原标题：** Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.

> **英文摘要：**
> Mutations in epigenetic regulators are common in bladder cancer, yet their impact on therapeutic responses remains unclear. Here, we identify that loss-of-function mutations in KDM6A, a histone demethylase altered in about 26% of advanced bladder cancers, are associated with poor survival after cisplatin chemotherapy, whereas they correlate with improved outcomes with anti-PD-1 therapy. Using CRISPR-Cas9-engineered murine and human bladder cancer models, we show that KDM6A deficiency increases formation of extrachromosomal circular DNA carrying chemoresistance loci, promoting cisplatin resistance. In parallel, KDM6A loss impairs DNA repair and rewires tumor metabolism, reducing glycolysis and lactate output. This metabolic shift diminishes histone lactylation in regulatory T cells, suppressing immunoregulatory genes and limiting expansion of PD-1 regulatory T cells. Collectively, our findings establish KDM6A mutation as a key regulator of therapeutic responses, providing a foundation for its use in guiding precision therapy in advanced bladder cancer.

> **中文摘要：**
> 表观遗传调控因子的突变在膀胱癌中很常见，但它们对治疗反应的影响尚不清楚。在此，我们发现KDM6A（一种在约26%的晚期膀胱癌中发生改变的组蛋白去甲基化酶）的功能缺失突变与顺铂化疗后的不良生存相关，而与抗PD-1疗法的改善预后相关。利用CRISPR-Cas9构建的小鼠和人类膀胱癌模型，我们证明KDM6A缺陷会增加携带化疗耐药位点的染色体外环状DNA的形成，从而促进顺铂耐药。同时，KDM6A缺失会损害DNA修复并重塑肿瘤代谢，减少糖酵解和乳酸输出。这种代谢转变降低了调节性T细胞中的组蛋白乳酸化修饰，抑制了免疫调节基因的表达，并限制了PD-1阳性调节性T细胞的扩增。总之，我们的研究确立了KDM6A突变作为治疗反应的关键调节因子，为其用于指导晚期膀胱癌的精准治疗奠定了基础。

### 第二部分 AI 大师评价

本研究旨在阐明表观遗传调控因子KDM6A突变如何影响膀胱癌的治疗反应。通过CRISPR-Cas9构建的基因工程模型，研究者发现KDM6A缺失通过诱导染色体外环状DNA形成和代谢重编程，分别介导了顺铂耐药和抗PD-1治疗增敏。其创新性在于将基因组不稳定性、肿瘤代谢与肿瘤免疫微环境变化整合到一个统一的机制框架中，揭示了KDM6A作为预测化疗和免疫治疗疗效的双向生物标志物的潜力。然而，研究主要基于临床前模型，其转化应用价值仍需大规模临床队列进一步验证。

---

## 102. 小鼠背主动脉区室是棕色脂肪组织的发育来源。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501080)
**期刊：** Nature communications
**PMID：** 41501080
**DOI：** 10.1038/s41467-025-68147-9

### 第一部分 原文与翻译

**英文原标题：** The dorsal aortic compartment is a developmental source of brown adipose tissue in mice.

> **英文摘要：**
> White adipose tissue primarily stores energy while brown adipose tissue dissipates energy as heat, holding promise for therapeutic use. Brown adipose tissue in the anterior trunk is believed to derive from the somitic mesoderm, although some depots are of partially unknown origin. Here we show that the subscapular, lateral, cervical and peri-aortic brown adipose depots, but not the interscapular depot, are in part formed by a non-somitic source. Single-cell sequencing along with genetic lineage tracing indicates that at embryonic day 9.5 the dorsal aorta compartment harbors multipotent mesenchymal progenitors expressing the transcription factor Osr1. Spreading laterally from the dorsal aortic midline, these cells contribute to adipose, cartilage and myogenic lineages. This study uncovers an alternative source of brown adipose tissue and suggests that a fraction of dorsal aorta-associated mesenchymal Osr1 cells may represent the in vivo correlate of a multipotent progenitor cell type so far only characterized in vitro, the mesoangioblast.

> **中文摘要：**
> 白色脂肪组织主要储存能量，而棕色脂肪组织则将能量以热的形式耗散，具有治疗应用前景。躯干前部的棕色脂肪组织被认为来源于体节中胚层，但部分脂肪库的起源尚不完全清楚。本研究揭示，肩胛下、外侧、颈部和主动脉周围的棕色脂肪库（而非肩胛间脂肪库）部分来源于非体节来源。单细胞测序结合遗传谱系追踪表明，在胚胎第9.5天，背主动脉区室存在表达转录因子Osr1的多能间充质祖细胞。这些细胞从背主动脉中线向外侧迁移，贡献于脂肪、软骨和肌源性谱系。这项研究揭示了棕色脂肪组织的一个替代来源，并提示一部分与背主动脉相关的间充质Osr1细胞可能代表了迄今为止仅在体外表征的多能祖细胞类型——血管周细胞——的体内对应物。

### 第二部分 AI 大师评价

本研究旨在探索小鼠棕色脂肪组织的发育起源。通过整合单细胞测序与遗传谱系追踪技术，作者发现肩胛下等多个棕色脂肪库部分来源于背主动脉区室中表达Osr1的多能间充质祖细胞，而非传统认为的体节中胚层。这一发现不仅揭示了棕色脂肪组织的一个新的发育来源，更重要的是，它将体内发现的这群祖细胞与体外已知的血管周细胞联系起来，为理解脂肪组织发育和干细胞生物学提供了新视角。然而，研究主要聚焦于小鼠胚胎期，这些发现向人类转化及在成体组织稳态/再生中的意义仍需进一步探索。

---

## 103. AKAP95凝聚体调控转录，并可作为MLL融合基因驱动肿瘤发生的靶点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501053)
**期刊：** Nature communications
**PMID：** 41501053
**DOI：** 10.1038/s41467-025-68192-4

### 第一部分 原文与翻译

**英文原标题：** AKAP95 condensates regulate transcription and can be targeted in MLL-fusion driven oncogenesis.

> **英文摘要：**
> RNA binding proteins could regulate transcription through modulating RNA polymerase II involved transcriptional condensates with the aid of nascent RNA. However, whether this mechanism also contributes to tumorigenesis is still unknown. Here, we show the RBP AKAP95 is required for MLL rearranged leukemogenesis. Phase separation and RNA binding properties of AKAP95 modulate Pol II recruitment into condensates at genome-wide target sites. AKAP95 interact with MLL1 translocated fragment and their partial co-condensation leads to stronger AKAP95 binding towards MLL-AF9 target genes. Loss of AKAP95 significantly downregulates expression of MLL-AF9 targets and impairs MLL-AF9 driven leukemogenesis. AKAP95 is not essential for normal and regenerative hematopoiesis, rendering it an ideal target for leukemia therapeutics. As an endeavor for modifying condensates, we design a peptide JD-PI95 bridging AKAP95 to protein quality surveillance component HSP70. The peptide successfully impairs AKAP95 phase separation, attenuates gene transcription and inhibits MLLr leukemia cells proliferation. Our work demonstrates an important role of RBP condensates in tumorigenesis through regulation of transcription and a new method to perturb specific condensates for tumor inhibition.

> **中文摘要：**
> RNA结合蛋白可能通过新生RNA的辅助，调控涉及RNA聚合酶II的转录凝聚体来调节转录。然而，这一机制是否也参与肿瘤发生尚不清楚。本研究显示，RNA结合蛋白AKAP95是MLL重排白血病发生所必需的。AKAP95的相分离和RNA结合特性调控了Pol II在全基因组靶位点向凝聚体的募集。AKAP95与MLL1易位片段相互作用，它们的部分共凝聚导致AKAP95对MLL-AF9靶基因的结合增强。AKAP95的缺失显著下调MLL-AF9靶基因的表达，并损害MLL-AF9驱动的白血病发生。AKAP95对正常和再生性造血并非必需，这使其成为白血病治疗的理想靶点。作为修饰凝聚体的一种尝试，我们设计了一种肽段JD-PI95，它将AKAP95与蛋白质质量监控组分HSP70桥连起来。该肽段成功破坏了AKAP95的相分离，减弱了基因转录，并抑制了MLLr白血病细胞的增殖。我们的工作证明了RBP凝聚体通过调控转录在肿瘤发生中的重要作用，并提出了一种通过干扰特定凝聚体来抑制肿瘤的新方法。

### 第二部分 AI 大师评价

本研究旨在探索RNA结合蛋白（RBP）通过相分离调控转录的机制在肿瘤发生中的作用，并开发靶向干预策略。研究通过分子生物学和细胞功能实验，揭示了AKAP95凝聚体在MLL重排白血病中的关键作用，并创新性地设计了一种破坏其相分离的多肽抑制剂。核心发现是证明了特定RBP凝聚体可作为肿瘤治疗的可行靶点，并提供了“干扰凝聚体”这一新的治疗范式。其创新性在于将相分离理论与肿瘤治疗靶点发现及药物设计紧密结合，但局限性在于研究主要基于MLL重排白血病模型，其普适性及体内疗效与安全性有待进一步验证。

---

## 104. 在生长停滞细胞中实现DNA-肽缀合物的高效表达

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501051)
**期刊：** Nature communications
**PMID：** 41501051
**DOI：** 10.1038/s41467-025-68167-5

### 第一部分 原文与翻译

**英文原标题：** Highly efficient expression of DNA-peptide conjugates in growth-arrested cells.

> **英文摘要：**
> Efficient nuclear delivery of DNA remains a major challenge in non-viral gene therapy. While nuclear localization signal (NLS) peptides have been explored for enhancing nuclear translocation of DNA, their efficacy has been limited by DNA-peptide conjugation strategies. Leveraging E. coli tRNA guanine transglycosylase, we present a modular workflow for generating DNA oligonucleotide-peptide conjugates which are ligated to linear DNA to generate peptide-modified gene cassettes (DNA-PepTAG). Using an eGFP reporter delivered via lipofection to growth-arrested cells, NLS-modified gene cassettes significantly increases nuclear localization, mRNA transcription, and expression up to ~10 fold compared to unmodified gene cassettes. Screening multiple NLS peptides in growth-arrested human cell lines reveal cell-type-specific preferences for nuclear translocation of DNA cargo. Two NLS peptides, PLSCR-1 and extSV40, exhibit consistently high expression across tested cell types, indicating broad applicability for nuclear delivery. We evaluate the generality of our approach by delivering DNA payloads encoding for both cytosolic and secreted proteins, as well as gene cassettes ranging in size from 1.3 kbp to 7 kbp. These findings support the potential of DNA-NLS conjugates as a viable strategy for non-viral gene therapy, enabling enhanced nuclear delivery of therapeutic genes while minimizing the required DNA dose.

> **中文摘要：**
> DNA的高效核递送仍然是非病毒基因治疗中的一个主要挑战。虽然核定位信号（NLS）肽已被探索用于增强DNA的核转运，但其功效一直受到DNA-肽缀合策略的限制。利用大肠杆菌tRNA鸟嘌呤转糖基酶，我们提出了一种模块化工作流程，用于生成DNA寡核苷酸-肽缀合物，这些缀合物被连接到线性DNA上，从而生成肽修饰的基因盒（DNA-PepTAG）。通过使用脂质体转染递送至生长停滞细胞的eGFP报告基因，与未修饰的基因盒相比，NLS修饰的基因盒显著提高了核定位、mRNA转录和表达，增幅高达约10倍。在生长停滞的人细胞系中筛选多种NLS肽，揭示了DNA货物核转运的细胞类型特异性偏好。两种NLS肽，PLSCR-1和extSV40，在所有测试的细胞类型中均表现出持续的高表达，表明其在核递送方面具有广泛的适用性。我们通过递送编码胞质蛋白和分泌蛋白的DNA有效载荷，以及大小从1.3 kbp到7 kbp不等的基因盒，评估了我们方法的普适性。这些发现支持了DNA-NLS缀合物作为一种可行的非病毒基因治疗策略的潜力，能够在增强治疗基因核递送的同时，最小化所需的DNA剂量。

### 第二部分 AI 大师评价

本研究旨在解决非病毒基因治疗中DNA核递送效率低下的核心难题。其核心创新在于利用大肠杆菌tRNA鸟嘌呤转糖基酶开发了一种模块化、高效的DNA-肽缀合工作流程（DNA-PepTAG），实现了NLS肽与DNA的精准、稳定连接。研究发现，在生长停滞细胞中，NLS修饰的基因盒能显著提升核定位、转录和表达效率（高达10倍），并筛选出具有广谱高效性的PLSCR-1和extSV40两种NLS肽。该方法展现了良好的普适性，适用于不同大小和编码功能的基因盒。然而，研究主要在生长停滞的细胞模型中进行，其在分裂活跃细胞或体内环境中的效果、长期安全性及免疫原性仍需进一步验证。

---

## 105. 多重脂质纳米颗粒条形码技术揭示组织动态动力学特征及肝区富集的细胞嗜性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501049)
**期刊：** Nature communications
**PMID：** 41501049
**DOI：** 10.1038/s41467-025-68103-7

### 第一部分 原文与翻译

**英文原标题：** Multiplexed lipid nanoparticle barcoding reveals tissue-dynamic kinetic insights and enriched cellular tropism in hepatic zones.

> **英文摘要：**
> Lipid nanoparticles (LNPs) efficiently deliver nucleic acids to cells in vivo and facilitate clinical applications including RNA-based vaccines and therapies. Discovery and optimization of LNPs remain challenging due to the complexity of input variables and low throughput workflows. To accelerate these processes, we report a broadly compatible barcoded Cre recombinase mRNA barcode platform that enables multiplexed LNP tracking in vivo in tdTomato reporter mice. We evaluate accumulation and degradation kinetics of mRNA encapsulated in Selective Organ Targeting (SORT) LNPs in the liver, lung, and spleen, and show that functional protein activity is associated with rapid organ enrichment. We further demonstrate how barcode multiplexing can streamline systematic kinetic studies, distinguish nanoparticles with distinct biological outcomes, and differentiate subtle, yet important, variations within a series of similar formulations. Finally, we use barcoding to identify and characterize nanoparticles with hepatic zonal bias and previously overlooked extrahepatic tropism. This approach could accelerate high resolution characterization of nanoparticles with desirable properties, enable large-scale systematic studies of diverse LNPs, and provide insights into optimizable parameters of LNP-mRNA delivery.

> **中文摘要：**
> 脂质纳米颗粒（LNPs）能高效地将核酸递送至体内细胞，并促进了包括RNA疫苗和疗法在内的临床应用。由于输入变量的复杂性和低通量的工作流程，LNPs的发现和优化仍然具有挑战性。为了加速这些过程，我们报告了一个广泛兼容的条形码化Cre重组酶mRNA平台，该平台能够在tdTomato报告基因小鼠体内实现多重LNP追踪。我们评估了封装在选择性器官靶向（SORT）LNPs中的mRNA在肝脏、肺和脾脏中的积累和降解动力学，并表明功能性蛋白活性与快速的器官富集相关。我们进一步展示了条形码多重化如何能简化系统性动力学研究，区分具有不同生物学结果的纳米颗粒，并能在一系列相似的制剂中区分出细微但重要的差异。最后，我们利用条形码技术鉴定并表征了具有肝区偏好性和先前被忽视的肝外嗜性的纳米颗粒。这种方法可以加速对具有理想特性的纳米颗粒进行高分辨率表征，实现对多种LNPs的大规模系统性研究，并为LNP-mRNA递送的可优化参数提供见解。

### 第二部分 AI 大师评价

本研究旨在通过开发一种多重条形码平台，解决脂质纳米颗粒（LNP）筛选与优化中通量低、变量复杂的瓶颈问题。核心方法是利用条形码化的Cre重组酶mRNA，在报告基因小鼠体内并行追踪多种LNP的体内命运。研究发现，功能性蛋白活性与快速的器官富集相关，并成功识别出具有肝区偏好和意外肝外嗜性的LNP亚群。其创新性在于将高通量条形码技术与体内动力学分析相结合，极大地提升了LNP表征的分辨率和效率，为系统性优化递送系统提供了强大工具；局限性在于研究模型依赖于特定的报告基因小鼠，其结论向其他模型或人体的外推性仍需进一步验证。

---

## 106. 面向全球化学品市场预测非癌症人类毒性的不确定性感知机器学习方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501044)
**期刊：** Nature communications
**PMID：** 41501044
**DOI：** 10.1038/s41467-025-67374-4

### 第一部分 原文与翻译

**英文原标题：** Uncertainty-aware machine learning to predict non-cancer human toxicity for the global chemicals market.

> **英文摘要：**
> Humans are exposed to thousands of chemicals, yet limited toxicity data hinder effective management of their impacts on human health. High-performing machine learning models hold potential for addressing this gap, but their uncharacterized prediction performance across the wider range of chemicals undermines confidence in their results. We develop uncertainty-aware models to predict reproductive/developmental and general non-cancer human toxicity effect doses. Our well-calibrated models provide uncertainty estimates aligned with observed prediction errors and chemical familiarity. We predict toxicity with 95% confidence intervals for >100,000 globally marketed chemicals and identify toxicity and uncertainty hotspots. These results can be applied to inform decisions aimed at reducing potential human health impacts and guide targeted data generation and modeling efforts to reduce prediction uncertainty. Here, we show that enhancing transparency in prediction uncertainty provides key insights for building confidence in toxicity predictions, supporting the sound integration of machine learning-based predictions in chemical assessments.

> **中文摘要：**
> 人类暴露于数千种化学品，但有限的毒性数据阻碍了对其人类健康影响的有效管理。高性能的机器学习模型有潜力弥补这一差距，但其在更广泛化学品范围内未经表征的预测性能削弱了对其结果的信心。我们开发了不确定性感知模型，用于预测生殖/发育毒性和一般非癌症人类毒性效应剂量。我们经过良好校准的模型提供了与观察到的预测误差和化学品熟悉度相一致的不确定性估计。我们为超过10万种全球销售的化学品预测了具有95%置信区间的毒性，并识别了毒性和不确定性热点。这些结果可用于为旨在减少潜在人类健康影响的决策提供信息，并指导有针对性的数据生成和建模工作以降低预测不确定性。在此，我们表明，增强预测不确定性的透明度为建立对毒性预测的信心提供了关键见解，支持将基于机器学习的预测合理整合到化学品评估中。

### 第二部分 AI 大师评价

本研究旨在利用不确定性感知机器学习模型，解决全球化学品市场中非癌症人类毒性数据匮乏的难题。其核心创新在于开发了经过良好校准的模型，不仅预测毒性效应剂量，还提供与预测误差和化学空间熟悉度相匹配的不确定性量化，从而提升了预测结果的可信度与实用性。研究通过对超过10万种化学品进行预测并识别热点，为化学品风险管理和优先测试提供了数据驱动的决策支持。然而，模型的性能仍受限于现有训练数据的覆盖范围和质量，且其预测主要针对特定毒性终点，在泛化至其他复杂毒性机制或长期暴露效应时可能存在局限性。

---

## 107. 替雷利珠单抗联合仑伐替尼围手术期治疗高复发风险可切除肝细胞癌：一项单臂II期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501032)
**期刊：** Nature communications
**PMID：** 41501032
**DOI：** 10.1038/s41467-025-68108-2

### 第一部分 原文与翻译

**英文原标题：** Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial.

> **英文摘要：**
> Postoperative recurrence significantly impacts long-term survival in patients with resectable hepatocellular carcinoma (HCC). In this single-arm, phase II trial (NCT04834986), 27 patients with resectable HCC at high recurrence risk received perioperative tislelizumab (anti-PD-1) plus lenvatinib (multi-kinase inhibitor). Co-primary endpoints were safety and feasibility. Secondary endpoints included objective response rate (ORR), 1-year and 2-year disease-free survival (DFS), median DFS, and pathologic complete response (pCR). Post-hoc exploratory machine learning analyses identified potential predictive factors. The regimen was feasible and generally well tolerated; grade 3 treatment-related adverse events occurred in 7.4%. ORR was 55.6%. Among 20 patients undergoing surgery, The Median DFS was 18.8 months (20.1-month follow-up), with 1- and 2-year DFS of 74.0% and 49.8%, and 20% achieved pCR. No unexpected safety signals were observed. The post-hoc machine learning model based on Tabular Prior Data Fitted Network, comprising six pretreatment hematological measures, demonstrated classification of candidate selection in the training set (area under the curve [AUC], accuracy [ACC], and average precision [AP], all 1.0) and the test set (AUC = 0.917, ACC = 0.778, AP = 0.966). In conclusion, tislelizumab-lenvatinib is a potential perioperative regimen for resectable HCC at high recurrence risk, showing preliminary efficacy and safety.

> **中文摘要：**
> 术后复发显著影响可切除肝细胞癌（HCC）患者的长期生存。在这项单臂II期试验（NCT04834986）中，27例高复发风险的可切除HCC患者接受了围手术期替雷利珠单抗（抗PD-1）联合仑伐替尼（多激酶抑制剂）治疗。共同主要终点是安全性和可行性。次要终点包括客观缓解率（ORR）、1年和2年无病生存率（DFS）、中位DFS以及病理学完全缓解（pCR）。事后探索性机器学习分析确定了潜在的预测因素。该方案可行且总体耐受性良好；3级治疗相关不良事件发生率为7.4%。ORR为55.6%。在接受手术的20例患者中，中位DFS为18.8个月（随访20.1个月），1年和2年DFS率分别为74.0%和49.8%，20%的患者达到pCR。未观察到意料之外的安全信号。基于表格先验数据拟合网络的事后机器学习模型，包含六项治疗前血液学指标，在训练集（曲线下面积[AUC]、准确率[ACC]和平均精度[AP]均为1.0）和测试集（AUC = 0.917， ACC = 0.778， AP = 0.966）中均展示了对候选患者选择的分类能力。总之，替雷利珠单抗-仑伐替尼是治疗高复发风险可切除HCC的一种潜在围手术期方案，显示出初步的有效性和安全性。

### 第二部分 AI 大师评价

本研究旨在探索替雷利珠单抗联合仑伐替尼用于高复发风险可切除肝细胞癌围手术期治疗的可行性、安全性与初步疗效。作为一项单臂II期试验，其核心发现包括该联合方案耐受性良好、客观缓解率较高，并显示出有前景的无病生存数据。创新性在于首次报道了该联合方案在此场景下的应用，并前瞻性地引入了事后机器学习分析，利用治疗前血液学指标构建了具有高预测性能的患者选择模型，为精准治疗提供了新思路。主要局限性在于单臂设计、样本量较小且随访时间有限，其结论需更大规模随机对照试验验证。

---

## 108. tRNA修饰介导的密码子特异性翻译重编程在癌症生物学中的新兴作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501031)
**期刊：** Cell death & disease
**PMID：** 41501031
**DOI：** 10.1038/s41419-025-08234-3

### 第一部分 原文与翻译

**英文原标题：** Emerging roles of tRNA modification-mediated codon-specific translational reprogramming in cancer biology.

> **英文摘要：**
> Cancer has become a leading cause of mortality worldwide, with alarming increases in incidence and mortality rates. Emerging evidence suggests that tRNA modification enzymes play a crucial role in cancer development by modulating codon-specific translation. In this review, we focus on 18 tRNA modification enzymes and elucidate their mechanisms of action and roles in disease. We highlight the functions and mechanisms of seven tRNA regulators that mediate favorable tRNA translation in tumorigenesis and cancer progression, providing deeper insights into their clinical potential as cancer-related biomarkers and prognostic indicators. These findings emphasize the need for further investigation into the therapeutic potential of tRNA modification enzymes in cancer management and their potential application in personalized cancer therapy and diagnostics.

> **中文摘要：**
> 癌症已成为全球主要的死亡原因，其发病率和死亡率正以惊人的速度增长。新出现的证据表明，tRNA修饰酶通过调节密码子特异性翻译，在癌症发展中发挥着至关重要的作用。在这篇综述中，我们聚焦于18种tRNA修饰酶，并阐明了它们的作用机制及其在疾病中的作用。我们重点阐述了七种在肿瘤发生和癌症进展中介导有利tRNA翻译的tRNA调节因子的功能和机制，从而更深入地揭示了它们作为癌症相关生物标志物和预后指标的临床潜力。这些发现强调，有必要进一步研究tRNA修饰酶在癌症治疗中的治疗潜力及其在个性化癌症治疗和诊断中的潜在应用。

### 第二部分 AI 大师评价

本文是一篇综述，其核心目的是系统阐述tRNA修饰酶通过介导密码子特异性翻译重编程在癌症生物学中的新兴作用。方法上，文章聚焦于18种tRNA修饰酶，并重点剖析了其中7种在肿瘤发生发展中发挥关键作用的调节因子的具体功能和机制。研究发现强调了这些酶作为新型生物标志物和预后指标的临床潜力，创新性地将tRNA修饰与肿瘤翻译调控紧密联系，为癌症治疗提供了新的视角和靶点。然而，作为一篇综述，其内容主要基于现有证据的整合与评述，并未报告新的原始实验数据，其提出的治疗潜力和应用前景有待后续基础与临床研究的进一步验证。

---

## 109. 硼中子俘获疗法在临床前小鼠模型中可保护免疫细胞并诱导强大的抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501029)
**期刊：** Nature communications
**PMID：** 41501029
**DOI：** 10.1038/s41467-025-67984-y

### 第一部分 原文与翻译

**英文原标题：** Boron neutron capture therapy preserves immune cells and induces robust anti-tumour immunity in preclinical mouse model.

> **英文摘要：**
> Radiotherapy can both activate and suppress immunity, making it difficult to predict or modulate these opposing effects for better cancer treatment. Boron neutron capture therapy (BNCT), a cellular-level radiotherapy, has demonstrated remarkable therapeutic efficacy in clinical practice, but mechanistically remains inadequately explored. Here, we compare the effects of BNCT with X-ray irradiation at equivalent radiation doses on immune cells and define the immunological mechanisms behind the improved therapeutic benefit of BNCT in mouse tumour models. We find that BNCT has a minimal effect on immune cell viability, while it triggers an immunogenic tumour cell death, ultimately inducing stronger anti-tumour immunity. Additionally, single-cell RNA sequencing indicates that BNCT reshapes the tumour microenvironment by enhancing dendritic cells, T cells, and NK cells activity. Thus, these findings provide important insights into radiobiological mechanisms following BNCT and inform strategies to preserve immune cells during radiotherapy and to increase cancer treatment efficacy.

> **中文摘要：**
> 放射治疗既能激活也能抑制免疫，这使得预测或调控这些相反效应以改善癌症治疗变得困难。硼中子俘获疗法（BNCT）作为一种细胞水平的放射治疗，在临床实践中已显示出显著的治疗效果，但其机制仍未得到充分探索。在此，我们比较了BNCT与等效辐射剂量的X射线照射对免疫细胞的影响，并在小鼠肿瘤模型中明确了BNCT带来更好治疗获益背后的免疫学机制。我们发现，BNCT对免疫细胞的活力影响极小，同时它能触发免疫原性的肿瘤细胞死亡，最终诱导更强的抗肿瘤免疫。此外，单细胞RNA测序表明，BNCT通过增强树突状细胞、T细胞和NK细胞的活性来重塑肿瘤微环境。因此，这些发现为BNCT后的放射生物学机制提供了重要见解，并为在放疗期间保护免疫细胞以及提高癌症治疗效果提供了策略依据。

### 第二部分 AI 大师评价

本研究旨在阐明硼中子俘获疗法（BNCT）相较于传统X射线放疗的免疫学机制优势。通过在小鼠模型中对比等效剂量下的免疫细胞影响，并结合单细胞RNA测序技术，研究揭示了BNCT在细胞层面的独特作用：它能在最小化免疫细胞损伤的同时，诱导免疫原性细胞死亡并重塑肿瘤微环境，从而激发更强的抗肿瘤免疫应答。该研究的创新性在于从免疫学视角深入解析了BNCT的增效原理，为优化放疗策略提供了新思路；其局限性在于结论主要基于临床前模型，仍需在人体中进行验证。

---

## 110. 药物与单细胞基因表达整合识别胶质母细胞瘤敏感与耐药细胞群

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501023)
**期刊：** Nature communications
**PMID：** 41501023
**DOI：** 10.1038/s41467-025-67783-5

### 第一部分 原文与翻译

**英文原标题：** Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations.

> **英文摘要：**
> Glioblastoma (GBM) remains the most common and lethal adult malignant primary brain cancer with few treatment options. A significant issue hindering GBM therapeutic development is intratumor heterogeneity and plasticity. GBM tumors contain neoplastic cells within a fluid spectrum of diverse transcriptional states. Identifying effective therapeutics requires a platform that predicts the differential sensitivity and resistance of these states to various treatments. Here, we develop scFOCAL (Single-Cell Framework for -Omics Connectivity and Analysis via L1000), to quantify the cellular drug sensitivity and resistance landscape. Using single-cell RNA sequencing of newly diagnosed and recurrent GBM tumors, we identify compounds from the LINCS L1000 database with transcriptional response signatures selectively discordant with distinct GBM cell states, and leverage this capability to predict combination synergy. We validate the significance of these findings in vitro, ex vivo, and in vivo, and identify a combination of an OLIG2 inhibitor and Depatux-M for the treatment of GBM. Our studies suggest that scFOCAL identifies cell states that are sensitive and resistant to targeted therapies in GBM using a measure of cell and drug connectivity, which can be applied to identify new synergistic combinations.

> **中文摘要：**
> 胶质母细胞瘤（GBM）仍然是最常见且致命的成人恶性原发性脑癌，治疗选择有限。阻碍GBM治疗发展的一个关键问题是肿瘤内异质性和可塑性。GBM肿瘤包含处于不同转录状态动态谱系中的肿瘤细胞。识别有效疗法需要一个能够预测这些状态对不同治疗差异敏感性和耐药性的平台。在此，我们开发了scFOCAL（通过L1000进行组学连接和分析的单细胞框架），以量化细胞药物敏感性和耐药性图谱。利用新诊断和复发性GBM肿瘤的单细胞RNA测序数据，我们从LINCS L1000数据库中识别出转录反应特征与特定GBM细胞状态选择性不一致的化合物，并利用此能力预测联合用药的协同效应。我们在体外、离体和体内验证了这些发现的重要性，并确定了一种OLIG2抑制剂与Depatux-M的联合用药方案用于治疗GBM。我们的研究表明，scFOCAL通过测量细胞与药物的连接性，识别出GBM中对靶向疗法敏感和耐药的细胞状态，该方法可用于发现新的协同组合疗法。

### 第二部分 AI 大师评价

本研究旨在解决胶质母细胞瘤（GBM）因肿瘤内异质性和可塑性导致的治疗困境。其核心创新在于开发了scFOCAL平台，通过整合单细胞转录组数据和药物扰动数据库（LINCS L1000），系统性地量化了不同细胞状态对药物的敏感性与耐药性图谱。研究发现了一种由OLIG2抑制剂和Depatux-M组成的潜在协同联合疗法，并在多层面验证了其有效性。该方法学为基于细胞状态的精准联合用药预测提供了新范式，但其预测效能仍需在更大队列和更多药物组合中进一步验证，且从计算预测到临床转化的路径尚需探索。

---

## 111. 慢性淋巴细胞白血病（CLL）发生Richter转化患者的中枢神经系统受累：梅奥诊所经验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501021)
**期刊：** Blood cancer journal
**PMID：** 41501021
**DOI：** 10.1038/s41408-025-01446-y

### 第一部分 原文与翻译

**英文原标题：** Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探讨慢性淋巴细胞白血病（CLL）发生Richter转化（RT）后中枢神经系统（CNS）受累的临床特征与结局。研究采用回顾性分析方法，基于梅奥诊所的单中心经验，描述了这一罕见但严重的并发症。其创新性在于聚焦于RT中CNS受累这一相对未被充分研究的领域，提供了重要的临床洞见。然而，作为单中心回顾性研究，其结果可能存在选择偏倚，且样本量可能有限，这是其主要局限性。

---

## 112. 一种用于实时肿瘤-神经相互作用分析与调控的机器学习驱动电生理平台。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501019)
**期刊：** Nature communications
**PMID：** 41501019
**DOI：** 10.1038/s41467-025-66988-y

### 第一部分 原文与翻译

**英文原标题：** A Machine Learning-Driven Electrophysiological Platform for Real-Time Tumor-Neural Interaction Analysis and Modulation.

> **英文摘要：**
> Neural-tumor electrophysiology-marked by pathological membrane potentials and ion channel dysregulation-emerges as actionable targets to curb tumor aggression. Yet, how neural-driven bioelectrical crosstalk dynamically regulates tumors within functional circuits remains elusive, demanding tools for real-time interaction decoding. Here, we present a machine learning-driven electrophysiological platform that integrates custom microfluidics with real-time decoding of complex neural-tumor signal dynamics. Our findings show that glioma cells selectively hijack specific subsets of neural signals, reshaping waveform properties and synchronizing their firing events with neural activity. This dynamic interaction plays a critical role in boosting glioma invasiveness, as tumor cells harness neural activity to promote their progression. Notably, targeted stimulation of glioma cells with these hijacked signal patterns-without direct neural involvement-is sufficient to induce hyper-invasive behavior, emphasizing the role of these electrical cues as drivers of tumor aggression.

> **中文摘要：**
> 神经-肿瘤电生理学——以病理性膜电位和离子通道失调为特征——已成为抑制肿瘤侵袭性的可行靶点。然而，神经驱动的生物电串扰如何在功能回路中动态调控肿瘤仍不清楚，这需要用于实时相互作用解码的工具。在此，我们提出了一种机器学习驱动的电生理平台，该平台将定制微流控技术与复杂的神经-肿瘤信号动态的实时解码相结合。我们的研究结果表明，胶质瘤细胞选择性地劫持特定的神经信号子集，重塑波形特性，并使其放电事件与神经活动同步。这种动态相互作用在增强胶质瘤侵袭性方面起着关键作用，因为肿瘤细胞利用神经活动来促进其进展。值得注意的是，使用这些被劫持的信号模式对胶质瘤细胞进行靶向刺激——无需直接神经参与——就足以诱发高侵袭行为，这强调了这些电信号作为肿瘤侵袭驱动因素的作用。

### 第二部分 AI 大师评价

本研究旨在开发并应用一种创新的技术平台，以解析肿瘤与神经之间动态、复杂的生物电相互作用。其核心方法是结合定制微流控与机器学习算法，实现对神经-肿瘤信号串扰的实时解码与调控。关键发现是胶质瘤细胞能主动“劫持”特定神经信号，重塑电活动并与之同步，从而驱动侵袭性；更引人注目的是，仅模拟这些被劫持的电信号模式即可诱导肿瘤的高侵袭表型，这直接证明了特定生物电信号是驱动肿瘤进展的关键因素。该研究的创新性在于构建了一个集实时分析、解码与干预于一体的闭环研究平台，为理解肿瘤-神经互作提供了强有力的工具，并揭示了靶向干预肿瘤电活动的治疗潜力；局限性在于研究主要基于体外平台和胶质瘤模型，其在体复杂微环境中的普适性及具体分子机制有待进一步探索。

---

## 113. NutriNet-Santé前瞻性队列中防腐类食品添加剂与2型糖尿病发病率的关联研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501013)
**期刊：** Nature communications
**PMID：** 41501013
**DOI：** 10.1038/s41467-025-67360-w

### 第一部分 原文与翻译

**英文原标题：** Associations between preservative food additives and type 2 diabetes incidence in the NutriNet-Santé prospective cohort.

> **英文摘要：**
> Experimental studies suggested potential adverse effects of preservative food additives, but epidemiological data are lacking. We aim to investigate associations between exposure to these compounds and type 2 diabetes incidence in the NutriNet-Santé prospective cohort (n = 108,723; 79.2%women; mean age=42.5 (SD = 14.6); France, 2009-2023). Dietary intakes are assessed using repeated 24h-dietary records. Exposure is evaluated through multiple composition databases and ad-hoc laboratory assays in food matrices. Associations between cumulative exposures to preservatives and diabetes incidence are characterised using multi-adjusted Cox models. The sum of total preservatives encompasses 58 substances. Among those, 17 are consumed by at least 10% of the study population and thus individually investigated. Thirteen (12 after multiple test correction) widely used individual preservatives are associated with higher diabetes incidence (n=1131cases): potassium sorbate, potassium metabisulfite, sodium nitrite, acetic, citric and phosphoric acids, sodium acetates, calcium propionate, sodium ascorbate, alpha-tocopherol, sodium erythorbate, and rosemary extracts. These findings call for their safety re-evaluation and support recommendations to favour fresh and minimally processed foods without superfluous additives. Trial registration: The NutriNet-Santé cohort is registered at clinicaltrials.gov (NCT03335644).

> **中文摘要：**
> 实验研究提示防腐类食品添加剂可能存在不良影响，但缺乏流行病学数据。本研究旨在利用NutriNet-Santé前瞻性队列（n=108,723；79.2%为女性；平均年龄=42.5岁（标准差=14.6）；法国，2009-2023年）调查这些化合物的暴露与2型糖尿病发病率之间的关联。膳食摄入通过重复的24小时膳食记录进行评估。暴露评估则综合了多种成分数据库和食品基质中的专门实验室检测。采用多因素调整的Cox模型来表征防腐剂累积暴露与糖尿病发病率之间的关联。防腐剂总量包含58种物质。其中，有17种被至少10%的研究人群摄入，因此进行了单独研究。有13种（经多重检验校正后为12种）广泛使用的单一防腐剂与更高的糖尿病发病率相关（n=1131例）：山梨酸钾、焦亚硫酸钾、亚硝酸钠、乙酸、柠檬酸和磷酸、乙酸钠、丙酸钙、抗坏血酸钠、α-生育酚、异抗坏血酸钠以及迷迭香提取物。这些发现呼吁对这些添加剂的安全性进行重新评估，并支持推荐选择不含多余添加剂的新鲜和最低限度加工的食品。试验注册：NutriNet-Santé队列已在clinicaltrials.gov注册（NCT03335644）。

### 第二部分 AI 大师评价

本研究首次在大规模前瞻性队列中系统评估了多种防腐剂与2型糖尿病的关联，填补了实验研究向人群证据转化的空白。其方法学优势在于结合了重复膳食记录、多源成分数据库及针对性实验室检测，实现了对复杂食品添加剂暴露的精细化评估。核心发现是多种常用防腐剂（如亚硝酸钠、山梨酸钾等）与糖尿病风险升高相关，为食品添加剂的安全性再评估提供了重要人群数据。然而，作为观察性研究，其结论尚不能完全排除残余混杂，且添加剂间的交互作用及具体生物学机制有待进一步阐明。

---

## 114. 靶向FOXM1通过ROS依赖的JNK/Bmi1/Skp2轴调控人皮肤T细胞淋巴瘤的代谢特征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501006)
**期刊：** Cell death & disease
**PMID：** 41501006
**DOI：** 10.1038/s41419-025-08389-z

### 第一部分 原文与翻译

**英文原标题：** Targeting FOXM1 regulates metabolic signatures through ROS-dependent JNK/Bmi1/Skp2 axis in human cutaneous T-cell lymphoma.

> **英文摘要：**
> Cutaneous T-cell lymphoma (CTCL) is a progressive and heterogeneous malignancy characterized by deregulated metabolic reprogramming and cancer stemness, with limited therapeutic options. Therefore, elucidating the mechanisms driving metabolic reprogramming and poor clinical outcomes in CTCL is imperative. Forkhead box protein M1 (FOXM1), an oncogenic transcription因子, plays a pivotal role in cancer pathogenesis by orchestrating metabolic reprogramming and stemness signaling, thereby contributing to therapeutic resistance. In this study, we investigated the therapeutic potential of FOXM1 inhibition in human CTCL cells. Both genetic and pharmacological targeting of FOXM1 markedly suppressed CTCL cell growth and proliferation by inducing programmed cell death (apoptosis and autophagy) via reactive oxygen species (ROS) generation. Mechanistic analyses revealed that the activation of the MAPK, particularly JNK activation, is crucial for thiostrepton-induced programmed cell death. Metabolomics profiling further demonstrated that thiostrepton treatment triggers ROS- and JNK-dependent alteration in metabolic pathways central to cancer hallmarks, including amino acid and lipid metabolism. Notably, FOXM1 inhibition abrogated stemness-associated metabolic reprogramming genes (KLF-4, Bmi1) and Skp2, while upregulating the tumor suppressor p21 in a JNK-dependent manner. Moreover, thiostrepton treatment sensitized the CTCL cells to proteasome inhibitor bortezomib, promoting apoptosis and autophagy. Collectively, these findings demonstrate that FOXM1 targeting disrupts the metabolic status and stemness features of CTCL cells via JNK activation, thereby offering novel insights into potential therapeutic strategies for overcoming therapeutic challenges in CTCL.

> **中文摘要：**
> 皮肤T细胞淋巴瘤（CTCL）是一种进行性、异质性的恶性肿瘤，其特征是代谢重编程失调和癌症干性，且治疗选择有限。因此，阐明驱动CTCL代谢重编程和不良临床结局的机制势在必行。叉头框蛋白M1（FOXM1）是一种致癌转录因子，通过协调代谢重编程和干性信号传导，在癌症发病机制中发挥关键作用，从而导致治疗抵抗。在本研究中，我们探讨了抑制FOXM1在人CTCL细胞中的治疗潜力。通过遗传学和药理学方法靶向FOXM1，均通过产生活性氧（ROS）诱导程序性细胞死亡（凋亡和自噬），显著抑制了CTCL细胞的生长和增殖。机制分析表明，MAPK的激活，特别是JNK的激活，对于硫链丝菌素诱导的程序性细胞死亡至关重要。代谢组学分析进一步证明，硫链丝菌素处理引发了ROS和JNK依赖的、对癌症标志至关重要的代谢通路（包括氨基酸和脂质代谢）的改变。值得注意的是，FOXM1抑制以JNK依赖的方式，消除了干性相关的代谢重编程基因（KLF-4、Bmi1）和Skp2，同时上调了抑癌蛋白p21。此外，硫链丝菌素处理使CTCL细胞对蛋白酶体抑制剂硼替佐米敏感，促进了细胞凋亡和自噬。总之，这些发现表明，靶向FOXM1通过激活JNK破坏了CTCL细胞的代谢状态和干性特征，从而为克服CTCL治疗挑战的潜在治疗策略提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在探索靶向致癌转录因子FOXM1作为皮肤T细胞淋巴瘤（CTCL）治疗新策略的潜力。研究通过遗传学和药理学方法抑制FOXM1，结合代谢组学与机制分析，发现其通过诱导ROS/JNK信号轴，触发细胞凋亡与自噬，并重塑与干性和代谢相关的关键基因网络（如抑制Bmi1/Skp2，上调p21）。其核心创新在于系统揭示了FOXM1通过ROS-JNK-Bmi1/Skp2轴调控CTCL代谢与干性的新机制，并提供了与蛋白酶体抑制剂联用的协同治疗思路。局限性在于研究主要基于体外细胞模型，其体内疗效及临床转化潜力仍需进一步验证。

---

## 115. APOBEC3C协调DDX5参与R-loop解离及Chk1介导的应激响应通路的动态调控，是p53缺陷细胞获得吉西他滨耐药性的先决条件。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41501001)
**期刊：** Cell death & disease
**PMID：** 41501001
**DOI：** 10.1038/s41419-025-08215-6

### 第一部分 原文与翻译

**英文原标题：** APOBEC3C coordinates DDX5 in R-loop resolution and dynamic control of Chk1-mediated stress-responsive circuitry as a prerequisite for gemcitabine resistance in p53-deficient cells.

> **英文摘要：**
> Genomic instability is a hallmark of cancer, encompassing both sequence and structural alterations that drive tumor evolution and heterogeneity. The APOBEC3 family of deoxycytidine deaminases has emerged as a major source of mutagenic activity in cancers. R-loops are RNA-DNA hybrids and structural barriers that interfere with replication and transcription. Among the APOBEC3 family, APOBEC3C (A3C) is particularly worthy of attention for its upregulation, driving the DNA replication应激 tolerance in response to replication stress-inducing drug gemcitabine. However, the molecular mechanisms of gemcitabine resistance and regulatory circuitries mediated by A3C remain largely unknown, especially in checkpoint-deficient tumors. Initially, we screened that A3C was a putative transcriptional target of p53, and p53-deficient H1299 cells harboring A3C elicited a chemoresistant phenotype upon gemcitabine treatment both in vitro and in vivo. A3C expression enhanced Chk1-dependent S-phase checkpoint activation, thus slowing down replication fork progression and facilitating DNA repair. Pull-down assay and proteomic analysis identified that A3C had a specific interaction with the RNA helicase DDX5, which coordinately played critical roles in R-loop resolution. In contrast to A3C, DDX5 expression attenuated Chk1-dependent S-phase checkpoint activation. Knockdown of DDX5 in A3C-proficient H1299 cells attenuated gemcitabine-induced Chk1 activation and enhanced the therapeutic index of gemcitabine by promoting R-loop accumulation. Therefore, we conclude that A3C/DDX5/R-loop complex may impair the sensitivity of gemcitabine by modulating Chk1 dynamics and DNA replication/damage response machinery.

> **中文摘要：**
> 基因组不稳定性是癌症的一个标志，包括驱动肿瘤进化和异质性的序列和结构改变。脱氧胞苷脱氨酶APOBEC3家族已成为癌症中突变活性的主要来源。R-loop是RNA-DNA杂交体和结构屏障，会干扰复制和转录。在APOBEC3家族中，APOBEC3C (A3C)因其上调而特别值得关注，它能驱动DNA复制应激耐受以响应复制应激诱导药物吉西他滨。然而，吉西他滨耐药的分子机制以及由A3C介导的调控回路在很大程度上仍然未知，尤其是在检查点缺陷的肿瘤中。最初，我们筛选发现A3C是p53的一个推定转录靶点，并且携带A3C的p53缺陷型H1299细胞在体外和体内经吉西他滨处理后均表现出化疗耐药表型。A3C表达增强了Chk1依赖的S期检查点激活，从而减缓复制叉进程并促进DNA修复。Pull-down实验和蛋白质组学分析发现，A3C与RNA解旋酶DDX5存在特异性相互作用，两者协同在R-loop解离中发挥关键作用。与A3C相反，DDX5的表达减弱了Chk1依赖的S期检查点激活。在A3C充足的H1299细胞中敲低DDX5，减弱了吉西他滨诱导的Chk1激活，并通过促进R-loop积累提高了吉西他滨的治疗指数。因此，我们得出结论，A3C/DDX5/R-loop复合物可能通过调节Chk1动力学和DNA复制/损伤响应机制来削弱吉西他滨的敏感性。

### 第二部分 AI 大师评价

本研究旨在揭示p53缺陷肿瘤中APOBEC3C介导吉西他滨耐药的新机制。通过体内外实验结合蛋白质互作分析，发现A3C通过增强Chk1检查点激活、与DDX5协同调控R-loop解离，从而促进DNA修复和复制应激耐受。其创新性在于阐明了A3C/DDX5/R-loop这一新型复合物在调控DNA损伤响应和化疗耐药中的核心作用，为克服p53缺陷肿瘤的耐药提供了潜在靶点。局限性在于研究主要基于H1299细胞系，其普适性及临床转化价值有待更多模型验证。

---

## 116. 照射后饮食限制通过抑制造血干细胞和祖细胞中的磷酸戊糖途径损害造血功能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41500989)
**期刊：** Cell death & disease
**PMID：** 41500989
**DOI：** 10.1038/s41419-025-08249-w

### 第一部分 原文与翻译

**英文原标题：** Post-irradiation dietary restriction impairs hematopoiesis via inhibition of the pentose phosphate pathway in hematopoietic stem and progenitor cells.

> **英文摘要：**
> Although the clinical observation of hematologic toxicity related to radiotherapy has been recognized for a long time, the underlying mechanisms remain to be fully explored. Here, we established a mouse model of reduced dietary intake (dietary restriction, DR, 30% reduction in food intake compared to age-matched and gender-matched mice) following X-ray radiation exposure to investigate the impact of reduced dietary intake on hematopoiesis after irradiation. We found that post-irradiation DR significantly and persistently suppressed hematopoiesis and notably impaired the regenerative capacity of hematopoietic cells. Compared to ad libitum (AL) fed mice, post-irradiation DR led to sustained upregulation of the DNA damage response (DDR) signaling pathway in hematopoietic cells, even 14 days to 1 month after irradiation, along with delayed DNA repair. Further investigation revealed that DR suppressed the post-irradiation activation of the pentose phosphate pathway (PPP). Inhibition of PPP by 6-Aminonicotinamide (6-AN) in AL mice mimicked the impairment of hematopoiesis observed in DR mice, while activation of PPP by AG1 in DR mice rescued the impairment of DNA repair and hematopoiesis in these mice. Additionally, we conducted a retrospective analysis of 101 cancer patients who received pelvic radiotherapy and found that patients with lower Body Mass Index (BMI) experienced more severe reductions in white blood cells (WBCs), neutrophils, and lymphocytes. This study suggests that DR following irradiation inhibits hematopoiesis by suppressing PPP, providing a new approach to addressing radiotherapy-related myelosuppression and potentially offering solutions for improving refractory hematopoietic disorders associated with radiotherapy.

> **中文摘要：**
> 尽管与放疗相关的血液学毒性的临床观察早已被认识，但其潜在机制仍有待充分探索。本研究建立了X射线照射后减少饮食摄入（饮食限制，DR，与年龄和性别匹配的小鼠相比食物摄入减少30%）的小鼠模型，以研究照射后饮食摄入减少对造血功能的影响。我们发现，照射后DR显著且持续地抑制了造血功能，并明显损害了造血细胞的再生能力。与自由进食（AL）的小鼠相比，照射后DR导致造血细胞中DNA损伤反应（DDR）信号通路持续上调，甚至在照射后14天至1个月仍持续，并伴有DNA修复延迟。进一步研究发现，DR抑制了照射后磷酸戊糖途径（PPP）的激活。在AL小鼠中使用6-氨基烟酰胺（6-AN）抑制PPP，模拟了在DR小鼠中观察到的造血功能损伤；而在DR小鼠中使用AG1激活PPP，则挽救了这些小鼠的DNA修复和造血功能损伤。此外，我们对101名接受盆腔放疗的癌症患者进行了回顾性分析，发现体重指数（BMI）较低的患者白细胞、中性粒细胞和淋巴细胞减少更为严重。本研究提示，照射后DR通过抑制PPP来抑制造血功能，为应对放疗相关的骨髓抑制提供了新思路，并可能为改善与放疗相关的难治性造血障碍提供解决方案。

### 第二部分 AI 大师评价

本研究旨在探索放疗后饮食限制（DR）加重造血损伤的分子机制。通过构建小鼠模型，结合药理学干预和临床回顾性分析，揭示了DR通过抑制磷酸戊糖途径（PPP）活性，导致DNA损伤反应持续激活和修复延迟，从而损害造血功能。其创新性在于首次将营养状态、PPP代谢与放疗后造血恢复联系起来，并提出了靶向激活PPP作为潜在治疗策略。局限性在于临床回顾性分析样本量有限，且主要关联性证据来自小鼠模型，其转化至人体的具体通路和干预时机需进一步验证。

---

## 117. 利用动态纳米水凝胶实现肿瘤类型无关的药物递送。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41500988)
**期刊：** Nature communications
**PMID：** 41500988
**DOI：** 10.1038/s41467-025-66788-4

### 第一部分 原文与翻译

**英文原标题：** Tumor agnostic drug delivery with dynamic nanohydrogels.

> **英文摘要：**
> RNA interference (RNAi) holds unique potential as a clinically viable modality to pharmacologically regulate oncogenes in sequence-specific manner. However, systemic delivery of RNAi to tumors encounters myriad obstructions, and strategies to overcome such barriers have largely consisted of academic demonstrations with few approaches reaching patients. Here we report the development of a self-agglomerating nanohydrogel (SANGs) platform that selectively localizes to tumor tissue, is efficiently internalized by cancer cells, is agnostic to RNAi payload, and achieves functional suppression of multiple oncogene targets. After intravenous injection, SANGs preferentially accumulate and are retained in primary and metastatic loci in four aggressive cancer models in rodents. SANGs deliver multiple RNAi payloads that significantly suppress oncogene expression and sensitize previously resistant tumors while being safe and well tolerated in simulated clinical applications across three species. We propose, and provide the first direct evidence in support of, a mechanism featuring emergent material properties by which SANGs achieve durable solid-tumor delivery without attachment of cell- or tumor-targeting ligands. Overall, the SANGs platform is an enabling technology for RNAi-based cancer therapeutics and is poised for advanced pharmaceutical development with multiple solid-tumor indications.

> **中文摘要：**
> RNA干扰（RNAi）作为一种临床可行的模式，具有以序列特异性方式药理学调控癌基因的独特潜力。然而，RNAi向肿瘤的系统性递送面临诸多障碍，克服这些屏障的策略大多停留在学术演示阶段，鲜有方法能应用于患者。在此，我们报告了一种自聚集纳米水凝胶（SANGs）平台的开发，该平台能选择性定位于肿瘤组织，被癌细胞高效内化，对RNAi载荷类型无偏好，并能实现对多个癌基因靶点的功能性抑制。静脉注射后，SANGs在啮齿类动物的四种侵袭性癌症模型中，优先聚集并滞留在原发灶和转移灶。SANGs递送多种RNAi载荷，能显著抑制癌基因表达并使先前耐药的肿瘤增敏，同时在三个物种的模拟临床应用中被证明安全且耐受性良好。我们提出并首次提供了直接证据支持一种机制，该机制以涌现的材料特性为特征，使SANGs无需连接细胞或肿瘤靶向配体即可实现持久的实体瘤递送。总体而言，SANGs平台是一项赋能基于RNAi的癌症治疗的技术，并已准备好针对多种实体瘤适应症进行高级药物开发。

### 第二部分 AI 大师评价

本研究旨在开发一种通用型RNAi递送平台，以克服现有技术向实体瘤系统性递送RNAi的障碍。研究者构建了一种自聚集纳米水凝胶（SANGs），该平台在多种侵袭性肿瘤模型中显示出优异的肿瘤选择性富集、高效内化和多癌基因抑制能力，且安全性良好。其核心创新在于首次揭示了SANGs通过“涌现的材料特性”实现无靶向配体依赖的实体瘤递送机制，为RNAi癌症疗法提供了强大的通用型递送工具。然而，摘要未提及该平台在大型动物或人体内的具体药效学/药代动力学数据，也未讨论其规模化生产和长期毒性的潜在挑战，这些是未来转化研究需关注的重点。

---

## 118. 肿瘤浸润微生物与治疗反应：三阴性乳腺癌精准肿瘤学的新前沿

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41500775)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41500775
**DOI：** 10.1136/jitc-2025-013314

### 第一部分 原文与翻译

**英文原标题：** Tumor-infiltrating microbes and therapy response: a new frontier in triple-negative breast cancer precision oncology.

> **英文摘要：**
> Tumor-infiltrating microbes are emerging as a novel dimension of cancer biology, with growing evidence suggesting their potential as prognostic and predictive biomarkers. In this issue, Chen  demonstrate associations between microbial signatures and treatment response in triple-negative breast cancer (TNBC). They join a growing list of examples whereby tumor-infiltrating microbes influence therapeutic efficacy, with mechanisms ranging from drug metabolism to immune modulation. Here, we explore the known mechanisms, as well as the methodological and conceptual challenges facing microbial biomarker research, including contamination risk, detection sensitivity, and the functional validation of microbial activity. As the field advances, integrating microbial profiling with genomic and immunological data, alongside foundational microbiological techniques, will be essential to clarify the role of microbes in cancer progression and treatment response. Ultimately, a deeper understanding of these microbial ecosystems may open new avenues for precision oncology in TNBC and beyond.

> **中文摘要：**
> 肿瘤浸润微生物正成为癌症生物学的一个新维度，越来越多的证据表明其作为预后和预测性生物标志物的潜力。在本期中，Chen等人论证了三阴性乳腺癌（TNBC）中微生物特征与治疗反应之间的关联。它们加入了越来越多的例子，表明肿瘤浸润微生物通过从药物代谢到免疫调节等多种机制影响治疗效果。在此，我们探讨了已知的机制，以及微生物生物标志物研究所面临的方法学和概念上的挑战，包括污染风险、检测灵敏度以及微生物活性的功能验证。随着该领域的发展，将微生物谱分析与基因组和免疫学数据相结合，并辅以基础的微生物学技术，对于阐明微生物在癌症进展和治疗反应中的作用至关重要。最终，对这些微生物生态系统的更深入理解，可能为三阴性乳腺癌乃至更广泛领域的精准肿瘤学开辟新途径。

### 第二部分 AI 大师评价

本文是一篇前瞻性评论，旨在探讨肿瘤浸润微生物作为三阴性乳腺癌（TNBC）新型生物标志物的潜力及其对治疗反应的影响。文章核心在于总结并评述了Chen等人的研究发现，即微生物特征与TNBC治疗反应存在关联，并系统梳理了微生物影响疗效的已知机制（如药物代谢、免疫调节）。其创新性在于将微生物组学提升至精准肿瘤学的前沿，强调了整合多组学数据以阐明其功能的重要性。然而，文章也客观指出了该领域面临的显著挑战，包括方法学上的污染风险、检测灵敏度问题以及微生物活性的功能验证困难，这些构成了当前研究的局限性，并指明了未来研究的关键方向。

---

## 119. 探讨影响实体瘤免疫治疗反应的常用药物。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499752)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41499752
**DOI：** 10.1200/JCO-25-01811

### 第一部分 原文与翻译

**英文原标题：** Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文旨在探讨影响实体瘤免疫治疗反应的常用药物，其核心目的是提高临床医生对药物-免疫相互作用的认知。文章很可能通过综述现有证据，系统性地分析了抗生素、质子泵抑制剂、皮质类固醇等常用药物对免疫检查点抑制剂疗效的影响机制。其创新性在于聚焦于临床实践中广泛使用但易被忽视的药物，为优化免疫治疗联合策略提供了重要视角。然而，由于缺乏摘要，其具体研究方法、数据来源及结论的详细程度尚不明确，这限制了对其证据强度和临床应用价值的初步评估。

---

## 120. 早期肿瘤学试验中“回填”的伦理考量。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499751)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41499751
**DOI：** 10.1200/JCO-25-02005

### 第一部分 原文与翻译

**英文原标题：** Ethics of Backfilling in Early-Phase Oncology Trials.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文聚焦于早期肿瘤学试验中“回填”这一特定招募策略的伦理问题。其核心目的旨在探讨在试验后期为已确定有效剂量或方案的患者队列中补充招募受试者所引发的伦理争议。文章很可能采用伦理原则分析框架，审视回填操作对科学严谨性、患者获益与风险、以及知情同意质量的影响。鉴于摘要缺失，其具体论证细节、创新性观点或实证发现尚不明确，这构成了解读本文完整贡献的主要局限性。

---

## 121. 基因治疗相关恶性肿瘤与癌症例外主义风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499727)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41499727
**DOI：** 10.1200/JCO-25-01844

### 第一部分 原文与翻译

**英文原标题：** Gene Therapy-Related Malignancy and the Risk of Cancer Exceptionalism.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题聚焦于基因治疗领域一个新兴且关键的安全性问题——治疗相关恶性肿瘤，并探讨其可能引发的‘癌症例外主义’风险。其核心目的可能是警示并分析基因治疗这一前沿疗法在带来突破性疗效的同时，其潜在的致癌风险如何可能被特殊对待或低估，从而影响监管、临床决策和公众认知。鉴于摘要不可用，文章的具体研究方法、数据发现和创新性/局限性无法评估，但其选题本身具有重要的临床、伦理和监管意义，旨在推动对该风险进行更审慎和平衡的审视。

---

## 122. 勘误：度伐利尤单抗联合铂类放化疗同步治疗不可切除的III期非小细胞肺癌：III期PACIFIC-2研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499719)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41499719
**DOI：** 10.1200/JCO-25-03012

### 第一部分 原文与翻译

**英文原标题：** Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文为PACIFIC-2研究的勘误，该研究旨在探索在不可切除III期非小细胞肺癌患者中，将免疫治疗药物度伐利尤单抗与标准铂类放化疗同步使用的疗效与安全性。作为III期临床试验，其核心目的是验证同步治疗模式相较于序贯治疗能否带来更优的生存获益。鉴于输入信息为勘误且无摘要，无法评估其具体发现与创新性，但提示该研究数据或报告可能存在需要修正的细节，读者在引用时应以最新勘误版本为准。

---

## 123. NCI9673（B部分）：ETCTN关于纳武利尤单抗联合或不联合伊匹木单抗治疗难治性转移性肛管鳞状细胞癌的随机II期研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499716)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41499716
**DOI：** 10.1200/JCO-25-00929

### 第一部分 原文与翻译

**英文原标题：** NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

> **英文摘要：**
> PURPOSE: In the previously completed NCI9673 (part A) single-arm study, the antiprogrammed death (PD)-ligand-1 antibody nivolumab demonstrated efficacy for patients with metastatic anal cancer. In NCI9673 (Part B), we evaluated the anticytotoxic T-cell lymphocyte antigen-4 (CTLA-4) antibody ipilimumab in combination with nivolumab for patients with incurable anal cancer.
> 
> METHODS: In this phase II NCI ETCTN trial, 100 patients with refractory, incurable anal cancer were randomly assigned to receive nivolumab (480 mg IV once every 4 weeks) alone or with ipilimumab (1 mg/kg IV once every 8 weeks). The primary end point was progression-free survival (PFS). Secondary endpoints included radiographic response, overall survival (OS), and grade ≥3 adverse events. A log-rank test was used to compare survival between arms, with a one-sided alpha of 0.1 and power of 90%. Immune biomarkers were analyzed from baseline and on treatment tissue and blood collections.
> 
> RESULTS: The median PFS for nivolumab versus nivolumab plus ipilimumab were 2.9 months (90% CI, 1.9 to 3.8) and 3.7 months (90% CI, 2.0 to 5.6), respectively (hazard ratio [HR], 0.86 [95% CI, 0.60 to 1.23];  = .25). Response rates were similar for nivolumab (17.4%) and nivolumab plus ipilimumab (21.5%;  = .89). The median OS was 15.9 months for nivolumab and 20.0 months for nivolumab plus ipilimumab (HR, 0.98 [90% CI, 0.63 to 1.51]). Grade ≥3 treatment-related AEs occurred in 6 patients (12%) receiving nivolumab alone and in 12 patients (25%) receiving nivolumab plus ipilimumab. At week 9, circulating TIGIT+ CD8 cells ( < .001) increased with nivolumab plus ipilimumab treatment relative to baseline.
> 
> CONCLUSION: The addition of ipilimumab to nivolumab did not statistically improve overall response rate, PFS, or OS but may harbor increased toxicity. Paired blood samples identified TIGIT expression on peripheral T cells as a compensatory change unique to dual PD-1 plus CTLA-4 blockade.

> **中文摘要：**
> 目的：在先前完成的NCI9673（A部分）单臂研究中，抗程序性死亡（PD）-配体-1抗体纳武利尤单抗对转移性肛门癌患者显示出疗效。在NCI9673（B部分）中，我们评估了抗细胞毒性T淋巴细胞抗原-4（CTLA-4）抗体伊匹木单抗联合纳武利尤单抗治疗不可治愈肛门癌患者的效果。
> 
> 方法：在这项II期NCI ETCTN试验中，100名难治性、不可治愈的肛门癌患者被随机分配接受纳武利尤单抗（480 mg静脉注射，每4周一次）单药治疗或联合伊匹木单抗（1 mg/kg静脉注射，每8周一次）治疗。主要终点是无进展生存期（PFS）。次要终点包括影像学缓解、总生存期（OS）以及≥3级不良事件。采用对数秩检验比较组间生存差异，单侧α值为0.1，把握度为90%。对基线和治疗期间收集的组织及血液样本进行了免疫生物标志物分析。
> 
> 结果：纳武利尤单抗组与纳武利尤单抗联合伊匹木单抗组的中位PFS分别为2.9个月（90% CI，1.9至3.8）和3.7个月（90% CI，2.0至5.6）（风险比[HR]，0.86 [95% CI，0.60至1.23]；P = .25）。纳武利尤单抗组（17.4%）与联合治疗组（21.5%）的缓解率相似（P = .89）。纳武利尤单抗组的中位OS为15.9个月，联合治疗组为20.0个月（HR，0.98 [90% CI，0.63至1.51]）。≥3级治疗相关不良事件在纳武利尤单抗单药组发生6例（12%），在联合治疗组发生12例（25%）。第9周时，与基线相比，接受纳武利尤单抗联合伊匹木单抗治疗的患者循环TIGIT+ CD8细胞增加（P < .001）。
> 
> 结论：在纳武利尤单抗基础上加用伊匹木单抗并未统计学上改善总缓解率、PFS或OS，但可能带来更高的毒性。配对血液样本分析发现，外周血T细胞上TIGIT的表达是PD-1联合CTLA-4双重阻断所特有的代偿性变化。

### 第二部分 AI 大师评价

本研究旨在评估纳武利尤单抗联合伊匹木单抗对比纳武利尤单抗单药治疗难治性转移性肛管鳞癌的疗效与安全性。研究采用随机II期设计，主要终点为PFS，并整合了免疫生物标志物探索。核心发现表明，联合治疗未能显著改善PFS、OS或客观缓解率，且3级以上不良事件发生率更高，提示在该人群中联合免疫治疗的临床获益有限且毒性增加。创新性在于通过配对样本分析，首次在双重免疫检查点阻断背景下，识别出外周T细胞TIGIT上调这一独特的代偿性免疫变化，为理解耐药机制和未来联合靶向策略提供了潜在生物学线索。

---

## 124. 通过工程化造血干细胞来源的小胶质细胞恢复颗粒蛋白前体表达可纠正颗粒蛋白基因敲除小鼠的表型。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499526)
**期刊：** Science translational medicine
**PMID：** 41499526
**DOI：** 10.1126/scitranslmed.adw9930

### 第一部分 原文与翻译

**英文原标题：** Restoration of progranulin by engineered hematopoietic stem cell-derived microglia corrects phenotypes of granulin knockout mice.

> **英文摘要：**
> Autologous hematopoietic stem/progenitor cell (HSC)-gene therapy (GT) represents a promising therapeutic option for progranulin (PGRN)-related neurodegenerative diseases due to mutations in the PGRN encoding gene (), such as frontotemporal dementia (FTD) and neuronal ceroid lipofuscinosis 11 (CLN11). These conditions are characterized by a deficiency in PGRN, have no cure, and represent an unmet medical need. We report on the efficacy and feasibility of an HSC GT approach that used a lentiviral vector encoding the human  complementary DNA to transduce HSCs that then were transplanted into a  mouse model, which mirrors both FTD and CLN11 phenotypes. Two promoters, one with medium-low strength ( gene-based promoter regulated by inflammation) and the other with medium-high strength [ubiquitous phosphoglycerate kinase (PGK) promoter], were compared for HSC transduction. Moreover, intravenous and intracerebroventricular HSC administration were compared. Under all tested conditions, a partial reconstitution of PGRN production by microglia-like cells (MLCs) derived from genetically corrected  HSCs was observed, which uniformly led to a correction of lipid accumulation, reduced gliosis, and improved social recognition in  mice. Therapeutic effects were similarly achieved with either of the promoters and administration routes and particularly also when the PGRN-expressing cells and their MLC progeny had engrafted exclusively in the central nervous system (CNS) after intracerebroventricular transplantation. These findings suggest that a durable yet modest restoration of PGRN expression in the CNS is sufficient to correct pathology.

> **中文摘要：**
> 对于由颗粒蛋白前体（PGRN）编码基因（GRN）突变引起的颗粒蛋白前体相关神经退行性疾病，例如额颞叶痴呆（FTD）和神经元蜡样脂褐质沉积症11型（CLN11），自体造血干细胞/祖细胞（HSC）基因疗法（GT）是一种有前景的治疗选择。这些疾病以PGRN缺乏为特征，目前无法治愈，代表着未满足的医疗需求。我们报告了一种HSC GT方法的有效性和可行性，该方法使用编码人GRN互补DNA的慢病毒载体转导HSC，然后将其移植到模拟FTD和CLN11表型的Grn敲除小鼠模型中。我们比较了两种用于HSC转导的启动子：一种为中低强度（受炎症调节的GRN基因基础启动子），另一种为中高强度[泛在磷酸甘油酸激酶（PGK）启动子]。此外，还比较了静脉内和脑室内HSC给药途径。在所有测试条件下，均观察到由基因校正的Grn敲除HSC衍生的小胶质样细胞（MLCs）部分重建了PGRN的产生，这一致性地导致了Grn敲除小鼠的脂质积累得到纠正、胶质增生减少以及社会识别能力改善。使用任一种启动子和给药途径均能实现相似的治疗效果，特别是在脑室内移植后，表达PGRN的细胞及其MLC后代仅在中枢神经系统（CNS）内定植的情况下也是如此。这些发现表明，在CNS中持久但适度地恢复PGRN表达足以纠正病理。

### 第二部分 AI 大师评价

本研究旨在探索针对PGRN缺乏相关神经退行性疾病的造血干细胞基因疗法。其核心创新在于，通过慢病毒载体将人GRN基因导入自体HSC，并利用HSC衍生的CNS定居性小胶质样细胞作为递送载体，在Grn敲除小鼠模型中实现了CNS内PGRN的部分恢复。研究发现，即使PGRN表达水平适度且仅局限于CNS，也能有效纠正脂质沉积、神经炎症和行为缺陷等多种关键病理表型，且治疗效果不依赖于特定的启动子强度或全身/局部给药途径。这为开发靶向CNS的、基于HSC的基因疗法提供了重要概念验证，但研究仍处于临床前动物模型阶段，其长期安全性、在大型动物及人类中的转化效率以及最佳治疗窗口期等问题尚待进一步探索。

---

## 125. 基于肺部病灶PET/CT成像对结核病患者进行缩短药物治疗时间的临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499522)
**期刊：** Science translational medicine
**PMID：** 41499522
**DOI：** 10.1126/scitranslmed.adt5626

### 第一部分 原文与翻译

**英文原标题：** Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.

> **英文摘要：**
> Six months of drug treatment is standard of care for drug-sensitive pulmonary tuberculosis (TB). Understanding the factors determining the length of treatment required for durable cure would allow individualization of treatment durations. We conducted a prospective, randomized, controlled noninferiority trial (PredictTB) of 4 versus 6 months of chemotherapy in patients with pulmonary TB in South Africa and China. Seven hundred and four participants with newly diagnosed, drug-sensitive TB were enrolled and stratified on the basis of radiographic disease characteristics assessed by FDG PET/CT imaging. Participants with less extensive disease ( = 273) were randomly assigned at week 16 to complete therapy after 4 months or continue receiving treatment for 6 months. This study was stopped early after an interim analysis revealed that patients assigned to the 4-month treatment arm had a higher risk of relapse. Among participants who received 4 months of chemotherapy, 17 of 141 (12.1%) experienced TB-specific unfavorable outcomes compared with only 2 of 132 (1.5%) who completed 6 months of treatment. In the nonrandomized arm that included participants with more extensive disease, only 8 of 248 (3.2%) experienced unfavorable outcomes. Total lung cavity volume and lesion glycolysis at week 16 were associated with the risk of unfavorable outcomes. PET/CT imaging at TB recurrence showed that bacteriological relapses predominantly occurred in active cavities originally present at baseline. Subsequent post hoc automated segmentation of serial PET/CT scans combined with machine learning enabled the classification of participants according to their likelihood of relapse.

> **中文摘要：**
> 六个月药物治疗是药物敏感性肺结核（TB）的标准治疗方案。了解决定实现持久治愈所需治疗时长的因素，将有助于实现治疗时长的个体化。我们在南非和中国的肺结核患者中进行了一项前瞻性、随机、对照的非劣效性试验（PredictTB），比较4个月与6个月的化疗方案。研究共纳入704名新诊断的药物敏感性结核病患者，并根据FDG PET/CT成像评估的影像学疾病特征进行分层。疾病范围较小的参与者（=273名）在第16周被随机分配，分别在完成4个月治疗后结束治疗或继续接受治疗至6个月。中期分析显示，被分配到4个月治疗组的患者复发风险更高，因此本研究提前终止。在接受4个月化疗的参与者中，141人中有17人（12.1%）出现了结核病特异性不良结局，相比之下，完成6个月治疗的132人中仅有2人（1.5%）出现不良结局。在包含疾病范围更广的参与者的非随机组中，248人中仅有8人（3.2%）出现不良结局。第16周时的总肺空洞体积和病灶糖酵解水平与不良结局风险相关。结核病复发时的PET/CT成像显示，细菌学复发主要发生在基线时即存在的活动性空洞内。随后对系列PET/CT扫描进行的自动化分割结合机器学习，能够根据参与者的复发可能性对其进行分类。

### 第二部分 AI 大师评价

本研究是一项重要的前瞻性随机对照试验，旨在利用PET/CT影像学生物标志物指导肺结核治疗方案的个体化缩短。其核心创新在于将先进的影像学评估（如病灶糖酵解、空洞体积）作为分层和治疗反应预测工具，并探索了结合机器学习分析连续影像数据的潜力。研究发现，对于基线疾病范围较小的患者，4个月方案相比标准6个月方案复发风险显著增高，这挑战了缩短疗程的普遍假设，并强调了精准分层的重要性。局限性包括研究因中期分析结果而提前终止，可能影响统计效能，且非随机组的观察结果需谨慎解读；此外，PET/CT的成本和可及性可能限制其临床广泛推广。

---

## 126. HIF1α调控肌腱对过度负荷的响应，并独立于血管募集驱动肌腱病。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499520)
**期刊：** Science translational medicine
**PMID：** 41499520
**DOI：** 10.1126/scitranslmed.adt1228

### 第一部分 原文与翻译

**英文原标题：** HIF1α gates tendon response to overload and drives tendinopathy independently of vascular recruitment.

> **英文摘要：**
> Tendons are sparsely vascularized connective tissues that link muscles to bones, withstanding some of the highest mechanical stresses in the body. Mechanical overloading and tissue hypervascularity are implicated in tendinopathy, a common musculoskeletal disorder, yet their mechanistic roles remain unclear. Here, we identify hypoxia-inducible factor 1α (HIF1α) as not only a marker but also a driver of tendinopathy. Histological and multiomics evaluation of human tendinopathic samples revealed extensive extracellular matrix remodeling, including pathological collagen cross-linking coinciding with active hypoxic signaling. Hypothesizing a causal contribution of hypoxia signaling, we generated mice with tenocyte-targeted deletions of the von Hippel-Lindau () gene, which controls hypoxia signaling by regulating HIFα degradation.  inactivation was sufficient to induce pathological hallmarks of tendinopathy, such as collagen matrix disorganization, cross-linking, altered mechanics, and neurovascular ingrowth. This phenotype was HIF1α dependent given that codeleting HIF1α rescued tendon morphology and mechanics. Moreover, deleting vascular endothelial growth factor A () alongside VHL effectively suppressed neovascularization but failed to rescue extracellular matrix abnormalities or restore mechanical function, emphasizing a direct role of HIF1α in driving tendon disease independently of angiogenesis. Mechanistically, we found that HIF1α activation was strain dependent in primary cultured human tendon cells and induced by mechanical overload in murine tendon explants. Furthermore, genetically removing α from tenocytes prevented aberrant tendon remodeling in response to chronic overload. These findings position HIF1α signaling as a central driver of tendinopathy that acts through a maladaptive tissue response to chronic overload, providing mechanistic insights that could be leveraged for therapeutic approaches.

> **中文摘要：**
> 肌腱是连接肌肉与骨骼的血管稀疏的结缔组织，承受着体内最高的机械应力之一。机械负荷过载和组织血管增生与肌腱病（一种常见的肌肉骨骼疾病）有关，但其机制作用尚不清楚。在此，我们发现缺氧诱导因子1α（HIF1α）不仅是肌腱病的标志物，也是其驱动因子。对人类肌腱病样本的组织学和多组学评估揭示了广泛的细胞外基质重塑，包括与活跃缺氧信号同时出现的病理性胶原交联。基于缺氧信号可能具有因果作用的假设，我们构建了在肌腱细胞中靶向敲除冯·希佩尔-林道（）基因的小鼠，该基因通过调节HIFα降解来控制缺氧信号。 基因失活足以诱导肌腱病的病理特征，如胶原基质紊乱、交联、力学性能改变以及神经血管向内生长。鉴于同时敲除HIF1α可挽救肌腱形态和力学性能，该表型依赖于HIF1α。此外，在敲除VHL的同时敲除血管内皮生长因子A（）有效抑制了新血管形成，但未能挽救细胞外基质异常或恢复力学功能，这强调了HIF1α在独立于血管生成的情况下驱动肌腱疾病的直接作用。从机制上讲，我们发现HIF1α的激活在原代培养的人肌腱细胞中具有应变依赖性，并在小鼠肌腱外植体中由机械过载诱导。此外，从遗传学上移除肌腱细胞中的α可防止肌腱响应慢性过载而发生异常重塑。这些发现将HIF1α信号定位为肌腱病的核心驱动因子，其通过组织对慢性过载的适应不良反应发挥作用，为可用于治疗方法的策略提供了机制性见解。

### 第二部分 AI 大师评价

本研究旨在阐明缺氧诱导因子HIF1α在肌腱病发病中的核心作用机制。研究团队综合运用了人类样本分析、条件性基因敲除小鼠模型、体外细胞力学刺激及外植体实验等多种方法。核心发现是HIF1α（而非其下游的血管生成信号）直接驱动了肌腱细胞外基质的病理性重塑和力学功能丧失，且其激活受机械负荷调控。其创新性在于首次明确了HIF1α是连接机械过载与肌腱病理性改变的关键分子开关，并揭示了其独立于血管新生的直接致病作用，为靶向HIF1α信号通路而非单纯抗血管生成的治疗策略提供了全新理论依据。局限性在于，研究主要基于基因工程小鼠模型，其在多大程度上完全模拟人类慢性肌腱病的自然病程仍需进一步验证。

---

## 127. Nectin-4 PET成像用于预测尿路上皮癌中enfortumab vedotin的剂量-反应关系。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499516)
**期刊：** Science advances
**PMID：** 41499516
**DOI：** 10.1126/sciadv.ady1111

### 第一部分 原文与翻译

**英文原标题：** Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma.

> **英文摘要：**
> Optimizing dosing strategies is critical to balance effectiveness and toxicity, especially for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study evaluates whether positron emission tomography (PET) imaging targeting Nectin-4 can noninvasively quantify the real-time interaction of the ADC enfortumab vedotin (EV) with tumors in urothelial carcinoma. Using the imaging agent [Ga]AJ647, dynamic changes in the interaction of EV with Nectin-4 were measured across preclinical models and correlated with therapeutic responses. PET imaging identified dose-dependent variations in Nectin-4 engagement, with suboptimal EV doses resulting in incomplete Nectin-4 engagement and increased tumor growth. Crucially, PET-measured target engagement predicted therapeutic outcomes more reliably than either drug dose or baseline target expression. By defining effective target engagement levels needed for optimal therapeutic outcomes, PET imaging provides a clear benchmark for dosing decisions, maximizing efficacy while potentially reducing exposure to higher, toxic doses and thereby enhancing patient safety.

> **中文摘要：**
> 优化给药策略对于平衡疗效和毒性至关重要，尤其是对于治疗窗较窄的药物，如抗体药物偶联物（ADCs）。本研究评估了靶向Nectin-4的正电子发射断层扫描（PET）成像能否无创地量化ADC药物enfortumab vedotin（EV）在尿路上皮癌中与肿瘤的实时相互作用。使用显像剂[Ga]AJ647，在临床前模型中测量了EV与Nectin-4相互作用的动态变化，并将其与治疗反应相关联。PET成像识别出Nectin-4结合程度的剂量依赖性变化，次优的EV剂量导致Nectin-4结合不完全并增加肿瘤生长。至关重要的是，PET测量的靶点结合程度比药物剂量或基线靶点表达更能可靠地预测治疗结果。通过定义实现最佳治疗结果所需的有效靶点结合水平，PET成像为剂量决策提供了明确的基准，在最大化疗效的同时，可能减少患者暴露于更高、有毒剂量的风险，从而提高患者安全性。

### 第二部分 AI 大师评价

本研究旨在探索利用Nectin-4靶向PET成像技术，无创、实时地量化ADC药物enfortumab vedotin（EV）在尿路上皮癌中的靶点结合情况，以优化其剂量策略。研究通过临床前模型，使用[Ga]AJ647显像剂，成功将PET测量的动态靶点结合变化与治疗反应相关联。核心发现是，PET测量的靶点结合程度是比药物剂量或基线靶点表达更可靠的疗效预测指标，这为个体化精准给药提供了新工具。其创新性在于将分子影像学直接应用于ADC药物的药效动力学评估，有望指导临床剂量调整，但结论仍需在人体临床试验中得到验证。

---

## 128. 通过转录因子结合位点的生物物理特性定量调控空间增强子。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499513)
**期刊：** Science advances
**PMID：** 41499513
**DOI：** 10.1126/sciadv.adz5902

### 第一部分 原文与翻译

**英文原标题：** Quantitative modulation of a spatial enhancer through the biophysical properties of a transcription factor binding site.

> **英文摘要：**
> Fine-tuning of gene expression by transcription factors (TFs) is essential for normal development, but how TF binding is converted into precise expression levels is poorly understood. We used a  enhancer responding to the TF Distal-less (Dll) to investigate this relationship. By combining computational structure analysis and quantifying relative TFBS affinity and enhancer activity, we describe how TF concentration is converted into precise expression across the developing  wing. We show that, although the regulatory function of the enhancer generally follows the classical Hill equation, several additional terms are needed to describe the effects of affinity, orientation, sequence, and wing region on the maximum achievable expression and position of transcriptional activity in a tissue. We also found that Dll relies on two distinct sets of amino acid-DNA contacts for binding to higher affinity sites, but contacts are more evenly distributed at lower affinities. Our work integrates information at molecular and tissue scales to describe how the modulation of a single TFBS determines the regulatory function of an enhancer in a complex in vivo environment.

> **中文摘要：**
> 转录因子（TFs）对基因表达的微调对正常发育至关重要，但TF结合如何转化为精确的表达水平尚不清楚。我们利用一个响应转录因子Distal-less（Dll）的增强子来研究这种关系。通过结合计算结构分析以及定量分析相对TFBS亲和力和增强子活性，我们描述了TF浓度如何在发育中的翅膀中转化为精确的表达。我们发现，尽管增强子的调控功能总体上遵循经典的希尔方程，但需要引入几个额外的项来描述亲和力、方向、序列以及翅膀区域对组织中可达到的最大表达量和转录活性位置的影响。我们还发现，Dll依赖于两套不同的氨基酸-DNA接触来结合高亲和力位点，但在较低亲和力下，接触的分布更为均匀。我们的工作整合了分子和组织尺度的信息，描述了单个TFBS的调控如何决定增强子在复杂体内环境中的调控功能。

### 第二部分 AI 大师评价

本研究旨在揭示转录因子结合位点（TFBS）的生物物理特性如何定量调控增强子功能，从而精确控制基因表达。研究团队巧妙结合计算结构分析与定量实验，在果蝇翅膀发育模型中，系统探究了TF浓度、TFBS亲和力、序列方向及组织区域等多重因素对增强子活性的影响。其核心创新在于将经典的希尔方程模型扩展，纳入了组织空间特异性参数，并揭示了Dll蛋白结合高、低亲和力位点时不同的分子接触模式，实现了从分子机制到组织表型的跨尺度整合分析。然而，研究聚焦于单一增强子与TF，其普适性有待在其他系统验证，且对体内复杂染色质环境的相互作用考虑相对有限。

---

## 129. 摩擦驱动的裂解：非局部机制如何参与生命各界的膜裂变。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499510)
**期刊：** Science advances
**PMID：** 41499510
**DOI：** 10.1126/sciadv.adz7607

### 第一部分 原文与翻译

**英文原标题：** Friction-driven scission: How nonlocal mechanisms contribute to membrane fission across domains of life.

> **英文摘要：**
> Membrane fission is an energy-consuming process, critical for all domains of life. Prototypical fission machineries use local energy input such as nucleoside triphosphate hydrolysis to constrict and cut membranes. However, some membrane fission reactions paradoxically rely on protein scaffolds that by themselves stabilize rather than cut membranes. It turns out these proteins do not work alone; they use nonlocal energy input that generates a membrane tension gradient. Such a gradient mobilizes membrane flow that in turn tends to relax the membrane tension gradient. By interfering with membrane flow, the protein scaffold causes the membrane tension to increase unchecked to the point of mechanical failure, membrane fission. This friction-driven scission (FDS) mechanism is generic, conserved from bacteria to humans, and only requires two ingredients: a membrane tension generating process and a protein scaffold that hinders the associated membrane flow. Because both are often present in cells, it is likely that FDS contributes to membrane fission more frequently than previously appreciated.

> **中文摘要：**
> 膜裂变是一个消耗能量的过程，对所有生命界都至关重要。典型的裂变机制利用局部能量输入，如核苷三磷酸水解，来收缩并切割膜。然而，一些膜裂变反应却矛盾地依赖于蛋白质支架，这些支架本身是稳定而非切割膜的。事实证明，这些蛋白质并非单独工作；它们利用非局部的能量输入来产生膜张力梯度。这种梯度驱动膜流动，而膜流动反过来倾向于松弛膜张力梯度。通过干扰膜流动，蛋白质支架导致膜张力不受控制地增加，直至达到机械失效点，即膜裂变。这种摩擦驱动的裂解（FDS）机制是通用的，从细菌到人类都保守存在，并且只需要两个要素：一个产生膜张力的过程和一个阻碍相关膜流动的蛋白质支架。由于这两者在细胞中经常存在，FDS可能比以往认识到的更频繁地参与膜裂变过程。

### 第二部分 AI 大师评价

本研究旨在揭示一种超越经典局部能量输入模型的膜裂变新机制——摩擦驱动裂解（FDS）。其核心方法是通过理论分析，将看似矛盾的、起稳定作用的蛋白质支架与细胞中普遍存在的非局部膜张力梯度联系起来。研究发现，FDS机制通过蛋白质支架阻碍由张力梯度驱动的膜流动，使张力累积直至膜发生机械性断裂，该机制具有普适性和进化保守性。其创新性在于提出了一个仅需两个常见细胞要素的通用物理模型，极大地拓展了对膜裂变机制的理解，但作为理论模型，其具体分子实例和在复杂细胞环境中的定量验证可能是未来的研究重点。

---

## 130. TGF-β信号通路对气道基底干细胞介导的肺修复的调控作用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499501)
**期刊：** Science advances
**PMID：** 41499501
**DOI：** 10.1126/sciadv.adz1519

### 第一部分 原文与翻译

**英文原标题：** Control of airway basal stem cell-mediated lung repair by TGF-β signaling.

> **英文摘要：**
> Airway basal stem cells (BCs) are recognized as resident stem cells responsible for reconstituting epithelial barriers and differentiating into multiple epithelial cell types following severe lung injury. However, the mechanism that the injured lung microenvironment uses to modulate BC-mediated lung repair remains unclear. Here, we showed that the profibrotic transforming growth factor-β (TGF-β) gradient from the injured lung immune microenvironment can be sensed by BCs. Targeted degradation of Smad2/3 in human BCs via proteolysis targeting chimera (PROTAC) disrupted TGF-β signaling, causing cell hyperplasia and barrier function loss after being transplanted into the alveolar area. Genetic ablation of the TGF-β receptor or  in mouse BCs impaired multilineage differentiation and suppressed migration to the alveolar injury site. These data indicated that TGF-β signaling is essential for BC-mediated lung repair. Moreover, we genetically engineered human BCs to release antifibrotic bone morphogenetic protein 7 (BMP7) in response to microenvironmental TGF-β stimulation. Transplantation of this iBMP7-BC enhanced lung repair and reduced fibrosis. Collectively, this study delineates how TGF-β governs BC behavior and provides a microenvironment-responsive cell therapeutic strategy for pulmonary fibrosis.

> **中文摘要：**
> 气道基底干细胞（BCs）被认为是驻留干细胞，负责在严重肺损伤后重建上皮屏障并分化为多种上皮细胞类型。然而，受损的肺微环境调控BC介导的肺修复的机制尚不清楚。本研究显示，来自受损肺免疫微环境的促纤维化转化生长因子-β（TGF-β）梯度可被BCs感知。通过蛋白水解靶向嵌合体（PROTAC）靶向降解人BCs中的Smad2/3，破坏了TGF-β信号传导，导致细胞移植到肺泡区域后出现细胞增生和屏障功能丧失。在小鼠BCs中基因敲除TGF-β受体损害了其多向分化能力，并抑制了其向肺泡损伤部位的迁移。这些数据表明，TGF-β信号传导对于BC介导的肺修复至关重要。此外，我们对人BCs进行了基因工程改造，使其能够响应微环境TGF-β刺激而释放抗纤维化骨形态发生蛋白7（BMP7）。移植这种iBMP7-BC增强了肺修复并减少了纤维化。总之，本研究阐明了TGF-β如何调控BC行为，并为肺纤维化提供了一种微环境响应性的细胞治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明TGF-β信号在调控气道基底干细胞介导肺修复中的关键作用。研究通过PROTAC技术和基因敲除模型，揭示了TGF-β信号对BCs的迁移、分化及屏障功能维持不可或缺。其核心创新在于将基础机制发现转化为治疗策略，即构建了能响应TGF-β微环境并释放抗纤维化因子BMP7的工程化BCs，为肺纤维化提供了智能型细胞疗法新思路。然而，研究的局限性在于主要依赖移植模型，工程化细胞在体内长期安全性、免疫原性及在复杂人体微环境中的实际效能仍需进一步验证。

---

## 131. 通过超分子前药水凝胶刺激STING通路增强先天-适应性免疫串扰以预防胶质母细胞瘤复发。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499494)
**期刊：** Science advances
**PMID：** 41499494
**DOI：** 10.1126/sciadv.adx9671

### 第一部分 原文与翻译

**英文原标题：** STING stimulation via supramolecular prodrug hydrogel boosts innate-adaptive immune cross-talk to prevent glioblastoma recurrence.

> **英文摘要：**
> Glioblastoma multiforme (GBM), the most aggressive primary brain tumor, demonstrates persistent resistance to immunotherapy due to its profoundly immunosuppressive microenvironment and markedly limited T cell infiltration. In this context, we engineered a STING agonist-incorporated prodrug hydrogel that orchestrates dual activation of innate and adaptive immunity to prevent postoperative GBM recurrence. We found that this in situ-forming hydrogel integrates seamlessly with tumor resection procedures, serves as a drug depot for sustained tumoral releases of therapeutic agents, and thus reprograms the tumor microenvironment by promoting M1 macrophage polarization, suppressing regulatory T cell activity, and enhancing cytotoxic T lymphocyte infiltration, thereby establishing a robust antitumor immune response. As a postoperative adjuvant therapy, the hydrogel effectively inhibits orthotopic GBM recurrence and extends animal survival while establishing durable immune memory against tumor rechallenge. Our findings demonstrate the translational potential of immunologically engineered hydrogels for STING-activated immunotherapy in preventing postresection GBM recurrence.

> **中文摘要：**
> 多形性胶质母细胞瘤（GBM）是最具侵袭性的原发性脑肿瘤，由于其深度免疫抑制的微环境和显著受限的T细胞浸润，对免疫疗法表现出持续的抵抗性。在此背景下，我们设计了一种整合了STING激动剂的前药水凝胶，该水凝胶协调先天性和适应性免疫的双重激活，以预防术后GBM复发。我们发现，这种原位形成的水凝胶能与肿瘤切除手术无缝整合，作为药物储库持续释放治疗剂，从而通过促进M1巨噬细胞极化、抑制调节性T细胞活性并增强细胞毒性T淋巴细胞浸润来重编程肿瘤微环境，由此建立起强大的抗肿瘤免疫应答。作为一种术后辅助疗法，该水凝胶有效抑制了原位GBM复发并延长了动物的生存期，同时建立了针对肿瘤再攻击的持久免疫记忆。我们的研究结果证明了免疫工程化水凝胶在STING激活的免疫疗法中，用于预防切除术后GBM复发的转化潜力。

### 第二部分 AI 大师评价

本研究旨在解决胶质母细胞瘤（GBM）术后免疫治疗抵抗的难题。其核心创新在于开发了一种整合STING激动剂的原位形成前药水凝胶，作为术后局部给药平台，旨在通过双重激活先天与适应性免疫来重塑免疫抑制微环境。研究发现，该水凝胶能持续释放药物，有效促进促炎性M1巨噬细胞极化、抑制Treg并增强CTL浸润，从而在动物模型中显著抑制肿瘤复发、延长生存并建立免疫记忆。该方法将生物材料与免疫疗法巧妙结合，为GBM术后辅助治疗提供了有前景的局部免疫调控策略，但其临床转化效果及长期安全性仍需后续研究验证。

---

## 132. Nat10介导的ac4C表观转录组学通过翻译控制调控造血干细胞/祖细胞的命运决定。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499488)
**期刊：** Science advances
**PMID：** 41499488
**DOI：** 10.1126/sciadv.ady0301

### 第一部分 原文与翻译

**英文原标题：** Nat10-mediated ac4C epitranscriptomics orchestrates hematopoietic stem/progenitor cell fate determination via translation control.

> **英文摘要：**
> Epigenetic regulation is crucial for balancing hematopoietic stem cell (HSC) self-renewal and differentiation, thereby maintaining hematopoietic homeostasis. Although Nat10-mediated RNA ac4C modification has been implicated in malignant hematopoiesis, its role in normal hematopoiesis remains unexplored. Here, we developed ULAC-seq to map ac4C in rare hematopoietic stem/progenitor cells (HSPCs) and revealed dynamic, cell-type-specific ac4C patterns, peaking in megakaryocyte-erythroid progenitors (MEPs), correlating with elevated Nat10 expression. Nat10 knockout disrupts HSC self-renewal and arrests MEP differentiation, leading to fetal and postnatal hematopoietic failure. Mechanistically, Nat10 deposits ac4C on mRNAs encoding key hematopoietic transcription regulators (e.g., Nfix), thereby enhancing their translation. Nat10 loss reduces Nfix protein levels and suppresses expression of its target genes (e.g., Mpl) that govern HSPC fate, while Nfix reconstitution rescues colony-forming defects in Nat10-null HSPCs. Our findings reveal that Nat10 orchestrates hematopoiesis through ac4C-dependent translational control of transcriptional factors, establishing an epitranscriptome-transcriptome regulatory axis essential for HSC maintenance and function.

> **中文摘要：**
> 表观遗传调控对于平衡造血干细胞（HSC）的自我更新和分化至关重要，从而维持造血稳态。尽管Nat10介导的RNA ac4C修饰已被证实与恶性造血有关，但其在正常造血中的作用仍未探索。在此，我们开发了ULAC-seq技术来绘制稀有造血干细胞/祖细胞（HSPCs）中的ac4C图谱，揭示了动态的、细胞类型特异性的ac4C模式，在巨核细胞-红系祖细胞（MEPs）中达到峰值，并与升高的Nat10表达相关。Nat10敲除破坏了HSC的自我更新并阻滞了MEP的分化，导致胎儿期和出生后造血衰竭。从机制上讲，Nat10在编码关键造血转录调节因子（例如Nfix）的mRNA上沉积ac4C，从而增强其翻译。Nat10缺失会降低Nfix蛋白水平并抑制其调控HSPC命运的下游靶基因（例如Mpl）的表达，而Nfix重建则可挽救Nat10缺失HSPCs中的集落形成缺陷。我们的研究结果表明，Nat10通过ac4C依赖的转录因子翻译控制来协调造血过程，建立了一条对HSC维持和功能至关重要的表观转录组-转录组调控轴。

### 第二部分 AI 大师评价

本研究旨在揭示RNA修饰酶Nat10及其介导的ac4C修饰在正常造血中的调控作用。研究者创新性地开发了ULAC-seq技术，首次在稀有造血干细胞/祖细胞中绘制了ac4C修饰图谱，并发现其动态变化模式。核心发现是Nat10通过ac4C修饰增强关键转录因子（如Nfix）的mRNA翻译，从而建立了一个连接表观转录组与转录组的调控轴，精确控制造血干细胞的命运决定。研究创新性地将ac4C修饰的功能从恶性造血拓展至正常生理过程，并阐明了其通过翻译水平调控的新机制，为理解造血调控提供了新维度。局限性在于，研究主要基于基因敲除模型，ac4C修饰在更多造血相关转录因子mRNA上的具体分布及其动态调控的上下游信号通路仍需进一步探索。

---

## 133. 一种用于胶质母细胞瘤的细胞表观遗传学分类系统。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499453)
**期刊：** Neuro-oncology
**PMID：** 41499453
**DOI：** 10.1093/neuonc/noaf299

### 第一部分 原文与翻译

**英文原标题：** A cellular epigenetic classification system for glioblastoma.

> **英文摘要：**
> BACKGROUND: Cellular heterogeneity is a defining feature of glioblastoma (GBM), shaping tumor progression and therapeutic response. While single-cell profiling resolves this heterogeneity, it remains impractical for large-cohort studies and clinical implementation. Conversely, DNA methylation-based classification is widely used for GBM diagnostics but does not provide cellular resolution. METHODS: We introduce a hierarchical non-negative matrix factorization approach (ITHresolveGBM) to deconvolute bulk DNA methylation profiles, inferring the abundance of glial, immune, and neuronal cells of the microenvironment, and further distinguishing differentiation states of malignant cells. RESULTS: Using ITHresolveGBM, we find that low tumor cell content impairs methylation-based classification, most notably linking the mesenchymal subtype with high immune cell infiltration. By integrating multi-omic single-cell data, we show that epigenetic deconvolution captures a malignant differentiation continuum ranging from stem-like to more differentiated tumors. This continuum aligns prior GBM classification systems and is associated with distinct molecular drivers (e.g., PDGFRA, TP53, EGFR) and survival outcomes. CONCLUSIONS: Our framework reconciles DNA methylation- and RNA-based classification systems and provides a blueprint for unifying bulk tumor profiles with single-cell biology, thereby refining molecular stratification and enhancing GBM diagnostics.

> **中文摘要：**
> 背景：细胞异质性是胶质母细胞瘤（GBM）的一个决定性特征，它影响着肿瘤进展和治疗反应。虽然单细胞分析能够解析这种异质性，但对于大规模队列研究和临床应用而言仍不切实际。相反，基于DNA甲基化的分类被广泛用于GBM诊断，但不能提供细胞分辨率。方法：我们引入了一种分层非负矩阵分解方法（ITHresolveGBM）来解卷积批量DNA甲基化谱，推断微环境中胶质细胞、免疫细胞和神经元的丰度，并进一步区分恶性细胞的分化状态。结果：使用ITHresolveGBM，我们发现低肿瘤细胞含量会损害基于甲基化的分类，最显著的是将间充质亚型与高免疫细胞浸润联系起来。通过整合多组学单细胞数据，我们表明表观遗传解卷积捕捉到了一个从干细胞样到更分化肿瘤的恶性分化连续体。该连续体与先前的GBM分类系统相一致，并与不同的分子驱动因素（例如，PDGFRA、TP53、EGFR）和生存结局相关。结论：我们的框架调和了基于DNA甲基化和RNA的分类系统，并为统一批量肿瘤谱与单细胞生物学提供了一个蓝图，从而完善了分子分层并增强了GBM诊断。

### 第二部分 AI 大师评价

本研究旨在解决胶质母细胞瘤（GBM）研究中单细胞技术与临床应用间的鸿沟。其核心创新在于开发了ITHresolveGBM方法，通过解卷积批量DNA甲基化数据，实现了对肿瘤微环境细胞组成和恶性细胞分化状态的推断。研究发现，该方法不仅揭示了肿瘤细胞含量对现有分子分型的影响，更重要的是构建了一个连接干细胞样到分化状态的恶性连续体，该连续体整合了既往分类系统，并与关键驱动基因和预后相关。这项工作为将单细胞生物学洞见转化为可临床应用的批量样本分析工具提供了重要框架，但其性能仍需在更广泛、独立的临床队列中得到进一步验证。

---

## 134. MBD3缺陷使NuRD复合体失活并协调基因表达的表观遗传调控以抑制神经母细胞瘤进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499431)
**期刊：** Neuro-oncology
**PMID：** 41499431
**DOI：** 10.1093/neuonc/noaf297

### 第一部分 原文与翻译

**英文原标题：** MBD3 deficiency decommissions the NuRD complex and orchestrates the epigenetic regulation of gene expression to suppress neuroblastoma progression.

> **英文摘要：**
> BACKGROUND: Neuroblastoma (NB) is the most common extracranial solid tumor in children and accounts for 15% of childhood cancer death. The nucleosome remodeling and deacetylase (NuRD) complex is a major chromatin remodeling complex that regulates chromatin accessibility and gene transcription. However, its role in the pathogenesis of neuroblastoma remains poorly understood.
> 
> METHODS: The genetic dependency and clinical significance of MBD3 in neuroblastoma was evaluated by analysis of public datasets. The function of MBD3 in neuroblastoma cell growth was evaluated by shRNA knockdown experiment. Cleavage under targets and tagmentation sequencing (CUT&Tag-seq), coupled with RNA-sequencing, was employed to explore the mechanisms involved in the epigenetic regulation executed by NuRD decommissioning following MBD3 deficiency.
> 
> RESULTS: Here we find that MBD3 is the most lineage-selective dependency among the non-enzymatic subunits of the NuRD complex in neuroblastoma. Knockdown of MBD3 induces cell cycle arrest and apoptosis, and inhibits neuroblastoma growth in vivo. Mechanistically, MBD3 deficiency leads to decommissioning of the NuRD complex and dissociation of the EZH2-PRC2 complex from chromatin, thereby orchestrating the epigenetic regulation of gene expression by modulating the balance between histone acetylation and methylation. NuRD decommissioning upon MBD3 deficiency selectively downregulates the expression of core regulatory transcription factors and upregulates a tumor suppressor SRCIN1, collectively suppressing neuroblastoma progression.
> 
> CONCLUSIONS: Our data identify MBD3 and the NuRD complex as potential therapeutic targets in neuroblastoma, highlighting the critical role of epigenetic regulation in tumor maintenance. Targeting this pathway may offer a novel strategy to selectively impair neuroblastoma cell survival and improve outcomes.

> **中文摘要：**
> 背景：神经母细胞瘤（NB）是儿童最常见的颅外实体瘤，占儿童癌症死亡病例的15%。核小体重塑和去乙酰化酶（NuRD）复合体是调节染色质可及性和基因转录的主要染色质重塑复合体。然而，其在神经母细胞瘤发病机制中的作用仍知之甚少。
> 
> 方法：通过分析公共数据集评估了MBD3在神经母细胞瘤中的遗传依赖性和临床意义。通过shRNA敲低实验评估了MBD3在神经母细胞瘤细胞生长中的功能。采用靶向切割与标签测序（CUT&Tag-seq）结合RNA测序，探索了MBD3缺陷导致NuRD失活后执行表观遗传调控的机制。
> 
> 结果：本研究发现，在神经母细胞瘤中，MBD3是NuRD复合体非酶亚基中最具谱系选择性的依赖性因子。敲低MBD3可诱导细胞周期停滞和凋亡，并在体内抑制神经母细胞瘤生长。机制上，MBD3缺陷导致NuRD复合体失活以及EZH2-PRC2复合体从染色质上解离，从而通过调节组蛋白乙酰化和甲基化之间的平衡来协调基因表达的表观遗传调控。MBD3缺陷导致的NuRD失活选择性地下调核心调控转录因子的表达，并上调肿瘤抑制因子SRCIN1，共同抑制神经母细胞瘤进展。
> 
> 结论：我们的数据确定了MBD3和NuRD复合体是神经母细胞瘤的潜在治疗靶点，凸显了表观遗传调控在肿瘤维持中的关键作用。靶向这一通路可能为选择性损害神经母细胞瘤细胞存活并改善预后提供一种新策略。

### 第二部分 AI 大师评价

本研究旨在阐明NuRD复合体亚基MBD3在神经母细胞瘤中的功能与机制。研究者整合了公共数据分析、功能缺失实验及CUT&Tag-seq等多组学技术，系统揭示了MBD3通过维持NuRD复合体功能并影响EZH2-PRC2复合体定位，从而调控组蛋白修饰平衡以驱动肿瘤进展。其核心创新在于将MBD3/NuRD的“失活”事件与全局性表观遗传重编程及关键转录因子网络调控联系起来，为神经母细胞瘤提供了新的潜在治疗靶点。然而，研究主要基于细胞和动物模型，其临床转化潜力及在患者肿瘤异质性背景下的普适性仍需进一步验证。

---

## 135. CD94/NKG2A-HLA-E轴作为癌症免疫治疗靶点：一个批判性视角。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41499220)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41499220
**DOI：** 10.1158/1078-0432.CCR-25-0447

### 第一部分 原文与翻译

**英文原标题：** The CD94/NKG2A-HLA-E axis as a target in cancer immunotherapy: a critical perspective.

> **英文摘要：**
> Successful clinical development of PD1/PD-L1 and CTLA4 immune checkpoint blockers intensified the search for other potential targets for cancer immunotherapy. Among them, the CD94/NKG2A inhibitory receptor displayed by NK and T cell subsets, which specifically interacts with the non-classical HLA-E class I molecule, has attracted special attention. Here we overview basic concepts on the CD94/NKG2A-HLA-E axis biology relevant in the framework of ongoing cancer immunotherapy approaches in different scenarios. First, the effectiveness of blocking the NKG2A-HLA-E interaction in vitro and in pre-clinical models as well as the presence of infiltrating NKG2A+ CD8+ T cells in some solid tumors has led to the generation of clinical grade NKG2A-specific monoclonal antibodies, pioneered by monalizumab, currently tested in clinical trials. Second, controlling NKG2A expression by genetic engineering constitutes a promising approach to improve advanced adoptive NK cell-based immunotherapies. Challenges include identifying predictive biomarkers of responsiveness, selecting appropriate clinical settings and optimizing combinatorial regimens.

> **中文摘要：**
> PD1/PD-L1和CTLA4免疫检查点阻断剂的成功临床开发，加强了对癌症免疫治疗其他潜在靶点的探索。其中，由NK和T细胞亚群表达的CD94/NKG2A抑制性受体，因其特异性与非经典HLA-E I类分子相互作用而受到特别关注。本文概述了在不同场景下，与正在进行的癌症免疫治疗方法框架相关的CD94/NKG2A-HLA-E轴生物学基本概念。首先，在体外和临床前模型中阻断NKG2A-HLA-E相互作用的有效性，以及某些实体瘤中存在浸润性NKG2A+ CD8+ T细胞，共同推动了临床级NKG2A特异性单克隆抗体的开发，以monalizumab为首，目前正在进行临床试验。其次，通过基因工程控制NKG2A表达，是改进先进过继性NK细胞免疫疗法的一种有前景的方法。面临的挑战包括识别预测疗效的生物标志物、选择合适的临床环境以及优化联合治疗方案。

### 第二部分 AI 大师评价

本文旨在批判性地评述CD94/NKG2A-HLA-E免疫检查点轴作为癌症免疫治疗新靶点的潜力与挑战。核心方法包括两方面：一是开发并测试阻断该轴的单克隆抗体（如monalizumab），二是通过基因工程调控NKG2A表达以优化过继性NK细胞疗法。文章发现该轴在临床前模型中有效，且相关免疫细胞存在于肿瘤微环境中，支持其作为治疗靶点。其创新性在于系统梳理了从基础生物学到临床转化的路径，并强调了联合治疗策略。局限性在于明确指出了当前面临的三大挑战：缺乏预测性生物标志物、最佳临床适应症尚不明确以及联合方案有待优化，这为未来研究指明了方向。

---

## 136. 我兄弟的姐妹。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41493152)
**期刊：** The New England journal of medicine
**PMID：** 41493152
**DOI：** 10.1056/NEJMp2507252

### 第一部分 原文与翻译

**英文原标题：** My Brother's Sister.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题“我兄弟的姐妹”暗示其内容可能涉及医学伦理、家庭关系或遗传学中的身份认同问题，很可能是一篇观点或叙事性文章。由于摘要缺失，无法直接评估其研究方法与具体发现。这类文章的价值在于引发对医学实践中人文、伦理或社会维度的深度思考，其创新性可能体现在独特的叙事视角或对特定议题的探讨上。然而，缺乏摘要和具体研究数据是其作为学术文献的主要局限性，限制了对其科学严谨性和结论普适性的评价。

---

## 137. 通用型碱基编辑CAR7 T细胞治疗T细胞急性淋巴细胞白血病。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41363805)
**期刊：** The New England journal of medicine
**PMID：** 41363805
**DOI：** 10.1056/NEJMoa2505478

### 第一部分 原文与翻译

**英文原标题：** Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.

> **英文摘要：**
> BACKGROUND: CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base-edited anti-CD7 CAR (BE-CAR7) T cells with triple C→T deamination-mediated knockouts of TCRαβ, CD52, and CD7 have been reported previously. METHODS: In a phase 1 study, we administered BE-CAR7 T cells to children (≤16 years of age) with relapsed or refractory T-cell ALL after they had undergone lymphodepletion with fludarabine, cyclophosphamide, and alemtuzumab. Adults with compassionate-use access arrangements were also eligible. Patients who had remission by day 28 after the BE-CAR7 T-cell infusion proceeded to allogeneic hematopoietic stem-cell transplantation. The primary outcome was safety. Secondary outcomes included duration of remission, disease-free survival, and overall survival. RESULTS: BE-CAR7 T cells were administered to 9 children, as well as to 2 adults who were treated under compassionate-use access arrangements. Lymphodepletion and BE-CAR7 infusions did not lead to unacceptable adverse events, and circulating CAR7 T cells were detected in all the patients. Complications included cytokine release syndrome of grades 1 through 4, transient rashes, multilineage cytopenia, and opportunistic infections. All the patients had complete morphologic remission with incomplete count recovery at day 28. Nine patients (82%) had deep remission (according to flow cytometry or polymerase-chain-reaction assay) that allowed them to proceed to stem-cell transplantation, and 2 patients with quantifiable minimal residual disease in bone marrow received palliative care. Transplantation eliminated remaining BE-CAR7 T cells and supported donor-derived, multilineage reconstitution. Viral reactivations were frequent, and 3 patients had clinically significant virus-related complications after transplantation. Overall, 7 of the 11 patients (64%) who received the investigational therapy were in ongoing remission at 3 to 36 months after transplantation, and leukemia with loss of CD7 expression was documented in 2 patients. CONCLUSIONS: Universal BE-CAR7 T cells induced leukemic remission in patients with relapsed or refractory T-cell ALL, thus allowing successful allogeneic hematopoietic stem-cell transplantation in most of the patients. (Funded by the Medical Research Council and others; ISRCTN Registry number, ISRCTN15323014.).

> **中文摘要：**
> 背景：对于复发或难治性T细胞急性淋巴细胞白血病（ALL），CD7是嵌合抗原受体（CAR）T细胞疗法的一个有吸引力的靶点。先前已有报道支持采用三重C→T脱氨介导敲除TCRαβ、CD52和CD7的碱基编辑抗CD7 CAR（BE-CAR7）T细胞的首次人体研究结果。方法：在一项1期研究中，我们对患有复发或难治性T细胞ALL的儿童（≤16岁）在使用氟达拉滨、环磷酰胺和阿仑单抗进行淋巴细胞清除后，输注了BE-CAR7 T细胞。符合同情使用准入安排的成人也有资格入组。在BE-CAR7 T细胞输注后第28天达到缓解的患者继续进行异基因造血干细胞移植。主要结局是安全性。次要结局包括缓解持续时间、无病生存期和总生存期。结果：共有9名儿童以及2名在同情使用安排下接受治疗的成人接受了BE-CAR7 T细胞输注。淋巴细胞清除和BE-CAR7输注未导致不可接受的严重不良事件，并且在所有患者中均检测到循环CAR7 T细胞。并发症包括1至4级的细胞因子释放综合征、短暂性皮疹、多系血细胞减少和机会性感染。所有患者在输注后第28天均达到形态学完全缓解但计数恢复不完全。9名患者（82%）达到深度缓解（根据流式细胞术或聚合酶链反应检测），从而得以进行干细胞移植；2名骨髓中存在可量化微小残留病的患者接受了姑息治疗。移植清除了残留的BE-CAR7 T细胞，并支持了供者来源的多系重建。病毒再激活频繁，3名患者在移植后出现具有临床意义的病毒相关并发症。总体而言，在接受研究性治疗的11名患者中，有7名（64%）在移植后3至36个月仍处于持续缓解状态，并在2名患者中记录到CD7表达缺失的白血病。结论：通用型BE-CAR7 T细胞在复发或难治性T细胞ALL患者中诱导了白血病缓解，从而使大多数患者得以成功进行异基因造血干细胞移植。（由医学研究理事会等资助；ISRCTN注册号，ISRCTN15323014.）。

### 第二部分 AI 大师评价

本研究旨在评估通用型碱基编辑抗CD7 CAR-T细胞（BE-CAR7）治疗复发/难治性T细胞ALL的安全性与疗效。其核心创新在于利用碱基编辑技术同时敲除TCRαβ、CD52和CD7，旨在克服同种异体CAR-T治疗中的移植物抗宿主病和宿主排斥问题，并实现“通用型”应用。初步结果显示BE-CAR7能够诱导深度缓解，为大多数患者桥接至异基因造血干细胞移植创造了机会，但研究也揭示了病毒再激活、CD7抗原丢失逃逸等挑战，提示其长期安全性和耐药机制仍需在更大规模研究中进一步验证。

---

## 138. 发现一种羧基富勒烯衍生物作为抑制MASLD的新型脂滴调节剂。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41309225)
**期刊：** Gut
**PMID：** 41309225
**DOI：** 10.1136/gutjnl-2025-336268

### 第一部分 原文与翻译

**英文原标题：** Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD.

> **英文摘要：**
> BACKGROUND: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly increasing with high risk to develop cirrhosis, hepatocellular carcinoma (HCC) and other end-stage liver diseases. However, only two drugs, resmetirom and semaglutide, have been approved by the US food and drug administration (FDA) for the treatment of MASLD, with relative low efficient and obvious side effects. Nanomaterials emerged with constantly growing availability of disease therapy benefiting from their well biocompatibility and appropriate properties. OBJECTIVE: The aim of our present study is to identify and fabricate new nanoparticles with high clinical translational potential for MASLD therapy. DESIGN: We systematically screened biocompatible nanoparticles for MASLD capacities in vitro by evaluating their regulatory effects on perilipin-2 (PLIN2), the key molecule in lipid droplet (LD) formation and stability. The exact effects and molecular mechanisms of the identified nanoparticle on MASLD were explored in both cellular and animal models. RESULTS: We identified a carboxyl fullerene derivative, named four malonate groups-substituted C fullerene (QF70), as the most potent candidate for MASLD therapy. Notably, QF70 could facilitate lysosomal degradation of PLIN2. More importantly, oral administration of QF70 robustly blocked both diet-induced and leptin deficiency-induced MASLD development with significant improvement in obesity and insulin resistance. We further validated the clinical application potential of QF70 in MASLD-related metabolic disorders in a non-primate model. CONCLUSIONS: This study provides proof-of-concept supporting a nanoparticle-based agent as a LD homeostasis-targeted therapeutic to treat MASLD and related metabolic diseases.

> **中文摘要：**
> 背景：代谢功能障碍相关脂肪性肝病（MASLD）的患病率正在迅速增加，其发展为肝硬化、肝细胞癌（HCC）和其他终末期肝病的风险很高。然而，目前仅有瑞美替罗姆和司美格鲁肽两种药物获得美国食品药品监督管理局（FDA）批准用于治疗MASLD，且疗效相对较低，副作用明显。纳米材料因其良好的生物相容性和适宜的特性，在疾病治疗中的应用前景日益广阔。目的：本研究旨在鉴定和制备具有高临床转化潜力的新型纳米颗粒，用于MASLD治疗。设计：我们通过评估生物相容性纳米颗粒对脂滴形成和稳定性的关键分子perilipin-2（PLIN2）的调节作用，在体外系统筛选了它们治疗MASLD的潜力。随后，在细胞和动物模型中探索了所鉴定纳米颗粒对MASLD的确切效应和分子机制。结果：我们鉴定出一种羧基富勒烯衍生物，命名为四丙二酸基团取代的C富勒烯（QF70），作为治疗MASLD的最有效候选物。值得注意的是，QF70能够促进PLIN2的溶酶体降解。更重要的是，口服QF70能有效阻断饮食诱导和瘦素缺乏诱导的MASLD发展，并显著改善肥胖和胰岛素抵抗。我们还在非灵长类动物模型中进一步验证了QF70在MASLD相关代谢紊乱中的临床应用潜力。结论：本研究提供了概念验证，支持基于纳米颗粒的药物作为一种靶向脂滴稳态的疗法，用于治疗MASLD及相关代谢性疾病。

### 第二部分 AI 大师评价

本研究旨在开发新型纳米药物治疗代谢功能障碍相关脂肪性肝病（MASLD）。其创新性在于采用靶向脂滴关键蛋白PLIN2的体外筛选策略，发现了一种名为QF70的羧基富勒烯衍生物，并通过促进PLIN2溶酶体降解的机制，在多种动物模型中证实了其口服有效性。该研究为MASLD提供了纳米药物新靶点和候选分子，概念新颖，转化潜力高。然而，摘要未提及长期毒性、药代动力学及与现有药物的比较数据，其临床前研究的深度和安全性评估的完整性有待后续工作补充。

---

## 139. 肠道菌群可预测急性胰腺炎患者出院后糖尿病的发展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41298102)
**期刊：** Gut
**PMID：** 41298102
**DOI：** 10.1136/gutjnl-2025-336715

### 第一部分 原文与翻译

**英文原标题：** Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis.

> **英文摘要：**
> BACKGROUND: Postdischarge morbidity and mortality is high in acute pancreatitis (AP) and pathophysiological mechanisms remain poorly understood.
> 
> OBJECTIVES: We aim to investigate the composition of gut microbiota and clinical long-term outcomes of prospectively enrolled patients with AP to predict postdischarge complications.
> 
> DESIGN: In this long-term follow-up study, we analysed clinical and microbiome data of 277 patients from the prospective multicentre Pancreatitis-Microbiome As Predictor of Severity trial. The primary endpoint was the association of the microbial composition with postdischarge mortality, recurrent AP (RAP), progression to chronic pancreatitis, pancreatic exocrine insufficiency, diabetes mellitus (DM) and pancreatic ductal adenocarcinoma.
> 
> RESULTS: Buccal (n=238) and rectal (n=249) swabs were analysed by 16S rRNA and metagenomics sequencing using Oxford Nanopore Technologies. Median follow-up was 2.8 years. Distance-based redundancy analysis with canonical analysis of principal coordinates showed significant differences for β-diversity (Bray-Curtis) for postdischarge mortality (p=0.04), RAP (p=0.02) and DM (p=0.03). A ridge regression model including 11 differentially abundant species predicted postdischarge DM with an area under the receiving operating characteristic of 94.8% and 86.2% in the matched and entire cohort, respectively. Using this classifier, a positive predictive value of 66.6%, a negative predictive value of 96% and an accuracy of 95% was achieved.
> 
> CONCLUSION: Our data indicate that the admission microbiome of patients with AP correlates with postdischarge complications independent from multiple risk factors such as AP severity, smoking or alcohol. Microbiota at admission show excellent capacity to predict postdischarge DM and may thus open new stratification tools for a tailored risk assessment in the future.
> 
> TRIAL REGISTRATION NUMBER: NCT04777812.

> **中文摘要：**
> 背景：急性胰腺炎（AP）患者出院后发病率和死亡率很高，其病理生理机制仍知之甚少。
> 目的：我们旨在研究前瞻性入组的AP患者的肠道菌群组成和临床长期结局，以预测出院后并发症。
> 设计：在这项长期随访研究中，我们分析了来自前瞻性多中心“胰腺炎-微生物组作为严重程度预测因子”试验的277例患者的临床和微生物组数据。主要终点是微生物组成与出院后死亡率、复发性AP（RAP）、进展为慢性胰腺炎、胰腺外分泌功能不全、糖尿病（DM）和胰腺导管腺癌之间的关联。
> 结果：使用Oxford Nanopore Technologies技术，通过16S rRNA和宏基因组测序分析了颊部（n=238）和直肠（n=249）拭子。中位随访时间为2.8年。基于距离的冗余分析与主坐标典型分析显示，出院后死亡率（p=0.04）、RAP（p=0.02）和DM（p=0.03）的β多样性（Bray-Curtis）存在显著差异。一个包含11个差异丰度物种的岭回归模型预测出院后DM的受试者工作特征曲线下面积在匹配队列和整个队列中分别为94.8%和86.2%。使用该分类器，获得了66.6%的阳性预测值、96%的阴性预测值和95%的准确率。
> 结论：我们的数据表明，AP患者入院时的微生物组与出院后并发症相关，且独立于AP严重程度、吸烟或饮酒等多种风险因素。入院时的微生物组显示出极佳的预测出院后DM的能力，因此可能为未来制定个体化风险评估提供新的分层工具。
> 试验注册号：NCT04777812。

### 第二部分 AI 大师评价

本研究核心目的是探索急性胰腺炎患者入院时肠道菌群与出院后长期并发症（特别是糖尿病）的关联及预测价值。研究设计为前瞻性多中心队列的长期随访，结合了16S rRNA和宏基因组测序技术，并应用了多元统计和机器学习模型进行分析。主要发现是入院微生物组与出院后糖尿病等并发症独立相关，且基于11个菌种构建的预测模型展现出极高的准确性。其创新性在于首次系统地将入院微生物组作为AP患者出院后糖尿病等长期结局的独立预测生物标志物，为个体化风险管理提供了新思路。局限性包括随访时间（中位2.8年）对于观察慢性胰腺炎、胰腺癌等长期结局可能尚短，且模型需要在独立队列中进行外部验证。

---

## 140. 11q异常的高级别/大B细胞淋巴瘤在无易感因素的儿童和青少年中预后极佳。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41160801)
**期刊：** Blood
**PMID：** 41160801
**DOI：** 10.1182/blood.2025031086

### 第一部分 原文与翻译

**英文原标题：** High-grade/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.

> **英文摘要：**
> High-grade B-cell lymphoma with 11q aberration (HGBCL-11q) is a rare pediatric non-Hodgkin lymphoma. This study assessed outcome in 90 children with HGBCL-11q. With survival rates ≥95%, patients with HGBCL-11q and no predisposition are candidates for deescalated therapy in future prospective trials.

> **中文摘要：**
> 伴有11q异常的高级别B细胞淋巴瘤（HGBCL-11q）是一种罕见的儿童非霍奇金淋巴瘤。本研究评估了90例HGBCL-11q患儿的预后。对于无易感因素的HGBCL-11q患者，其生存率≥95%，是未来前瞻性试验中降阶梯治疗的候选对象。

### 第二部分 AI 大师评价

本研究旨在评估一种罕见的儿童淋巴瘤亚型——伴有11q异常的高级别B细胞淋巴瘤（HGBCL-11q）的临床结局。通过对90例患儿的回顾性分析，研究发现该亚型在无遗传易感因素的儿童和青少年中预后极佳，总生存率高达95%以上。这一关键发现具有重要的临床转化价值，为未来在前瞻性试验中对该患者群体进行降阶梯治疗提供了强有力的循证依据，有望在保证疗效的同时降低治疗相关毒性。然而，研究作为回顾性分析存在一定局限性，其结论需在前瞻性试验中得到进一步验证。

---

## 141. Notch信号从反式激活到顺式抑制的转换是造血干细胞衰老的基础。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41056036)
**期刊：** Blood
**PMID：** 41056036
**DOI：** 10.1182/blood.2024026505

### 第一部分 原文与翻译

**英文原标题：** A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging.

> **英文摘要：**
> Aged hematopoietic stem cells (HSCs) expand in clusters over time, while reducing their regenerative capacity and their ability to preserve the homeostasis of the hematopoietic system. The expression of Notch ligands in the bone marrow (BM) niche is essential for hematopoiesis. However, the impact of Notch signaling on adult HSC function and its involvement in HSC aging remains controversial. Here, we show that Notch activation in young HSCs is not homogeneous, and it is triggered by sinusoidal expression of the Notch ligand Jagged2 (Jag2). Sinusoidal Jag2 deletion in young mice recapitulates the decrease in Notch activity observed in aged HSCs and alters HSC divisional symmetry and fate priming, promoting myeloid-biased HSCs (My-HSCs) expansion. Mechanistically, our data reveals that upon decreasing sinusoidal Jag2 expression, HSCs themselves upregulate Jag2, which cis-inhibits Notch signaling, resulting in the expansion of My-HSCs and in reduced hematopoietic regeneration. Collectively, these findings identify the crosstalk between BM niche-driven and HSC intrinsic features in regulating HSC fate priming and regenerative potential and reveal an extrinsic Notch trans-activation to intrinsic cis-inhibition switch underlying HSC aging.

> **中文摘要：**
> 衰老的造血干细胞（HSCs）会随时间推移呈簇状扩增，同时其再生能力和维持造血系统稳态的能力下降。骨髓（BM）微环境中Notch配体的表达对造血至关重要。然而，Notch信号对成年HSC功能的影响及其在HSC衰老中的作用仍存在争议。本研究显示，年轻HSCs中的Notch激活并非均一，它由Notch配体Jagged2（Jag2）在窦状隙的表达所触发。在年轻小鼠中删除窦状隙Jag2，重现了衰老HSCs中观察到的Notch活性下降，并改变了HSC的分裂对称性和命运启动，促进了髓系偏向的HSCs（My-HSCs）扩增。机制上，我们的数据揭示，当窦状隙Jag2表达减少时，HSCs自身会上调Jag2，后者以顺式方式抑制Notch信号，从而导致My-HSCs扩增和造血再生能力降低。总之，这些发现明确了骨髓微环境驱动因素与HSC内在特性在调控HSC命运启动和再生潜能中的相互作用，并揭示了Notch信号从外源性反式激活到内源性顺式抑制的转换是HSC衰老的基础。

### 第二部分 AI 大师评价

本研究旨在阐明Notch信号在造血干细胞衰老中的具体作用机制。通过结合体内基因敲除模型与机制分析，研究发现骨髓窦状隙来源的Jag2配体是年轻HSC中Notch反式激活的关键，而衰老或微环境Jag2缺失会触发HSC自身Jag2上调，转而以顺式抑制方式关闭Notch信号。这一发现创新性地揭示了HSC衰老过程中Notch信号模式从“外源激活”到“内源抑制”的根本性转换，并阐明了微环境与干细胞内在特性对话如何共同决定细胞命运与再生能力。局限性在于研究主要聚焦于Jag2-Notch轴，其他微环境因子或信号通路在衰老中的协同作用有待进一步探索。

---

## 142. 单细胞多模态分析揭示HBV-ACLF进展的动态免疫发病机制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40841166)
**期刊：** Gut
**PMID：** 40841166
**DOI：** 10.1136/gutjnl-2024-333308

### 第一部分 原文与翻译

**英文原标题：** Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression.

> **英文摘要：**
> BACKGROUND: Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome involving dysfunction of multiple immune cell types. OBJECTIVE: This study aimed to comprehensively depict the dynamic trajectory of immune responses throughout the disease course of HBV-related ACLF (HBV-ACLF). DESIGN: Single-cell RNA sequencing and single-cell proteomics were performed on the peripheral blood mononuclear cells of 45 samples from 17 patients who were hospitalised (progressive/stable/recovering course of HBV-ACLF, 6/5/6) and 15 control subjects (liver cirrhosis, chronic hepatitis B and healthy controls, 5/5/5). Functional and mechanistic experiments were validated in vivo and in vitro. RESULTS: Single-cell multiomics analysis revealed specific changes in the peripheral immune response in ACLF. VCANCD14-monocytes with activated interferon-stimulated genes and enhanced inflammatory functions, stimulated by HBV relapse and expanded in ACLF-1, fuelling early inflammatory storm. The subsequent apoptotic hepatocytes predominantly induce hyperinflammatory C-X-C motif chemokine receptor 2 (CXCR2)-neutrophils and CD163-monocytes, enriching in patients with progressive ACLF and serving as significant markers of disease deterioration. Cytotoxic T-cells were functionally impaired and significantly decreased in progressive patients. CXCR2-neutrophils exhibited immunosuppressive activity and induced the exhaustion of cytotoxic T-cells. Pharmacological inhibition of CXCR2 significantly reduced neutrophils infiltration, restored cytotoxic T-cells and showed therapeutic effect in ACLF mice. Six immune cellular modules (CMs) were identified for patient stratification, with CM2 and CM6 showing strong predictive value for disease outcomes, and CM3 indicating a potential early therapeutic window. CONCLUSION: Our longitudinal multiomics study revealed the dynamic evolution of the immune response in HBV-ACLF and characterised diverse immune patterns for the future precise management and therapeutic intervention.

> **中文摘要：**
> 背景：慢加急性肝衰竭（ACLF）是一种危及生命的综合征，涉及多种免疫细胞类型的功能障碍。目的：本研究旨在全面描绘HBV相关ACLF（HBV-ACLF）整个病程中免疫反应的动态轨迹。设计：对来自17名住院患者（HBV-ACLF的进展期/稳定期/恢复期病程，6/5/6例）和15名对照受试者（肝硬化、慢性乙型肝炎和健康对照，各5例）的45份样本的外周血单个核细胞进行了单细胞RNA测序和单细胞蛋白质组学分析。功能和机制实验在体内和体外得到验证。结果：单细胞多组学分析揭示了ACLF中外周免疫反应的特异性变化。具有活化的干扰素刺激基因和增强的炎症功能的VCAN+CD14-单核细胞，在HBV复发刺激下被激活，并在ACLF-1期扩增，助长了早期炎症风暴。随后的凋亡肝细胞主要诱导高炎症性的C-X-C基序趋化因子受体2（CXCR2）+中性粒细胞和CD163+单核细胞，这些细胞在进展期ACLF患者中富集，并作为疾病恶化的重要标志物。细胞毒性T细胞在进展期患者中功能受损且数量显著减少。CXCR2+中性粒细胞表现出免疫抑制活性并诱导细胞毒性T细胞耗竭。药理学抑制CXCR2显著减少了中性粒细胞浸润，恢复了细胞毒性T细胞，并在ACLF小鼠中显示出治疗效果。研究确定了六个免疫细胞模块（CMs）用于患者分层，其中CM2和CM6对疾病结局显示出强大的预测价值，CM3则提示了一个潜在的早期治疗窗口。结论：我们的纵向多组学研究揭示了HBV-ACLF中免疫反应的动态演变，并表征了多种免疫模式，为未来的精准管理和治疗干预提供了依据。

### 第二部分 AI 大师评价

本研究核心目的是系统描绘HBV-ACLF病程中免疫反应的动态演变轨迹。研究采用单细胞多组学技术，结合纵向临床队列和体内外功能验证，方法学先进且系统。主要发现包括：揭示了VCAN+CD14-单核细胞驱动早期炎症风暴，CXCR2+中性粒细胞和CD163+单核细胞作为进展期关键标志物并诱导T细胞耗竭，以及CXCR2抑制剂的潜在治疗价值。其创新性在于通过多时间点采样和整合分析，动态解析了ACLF免疫发病机制，并提出了具有预测和指导治疗价值的免疫细胞模块。局限性在于样本量相对有限，且主要基于外周血分析，对肝脏局部免疫微环境的直接刻画不足。

---

## 143. 靶向Aurora激酶B调控胆固醇代谢并增强胆管癌的化学免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40744724)
**期刊：** Gut
**PMID：** 40744724
**DOI：** 10.1136/gutjnl-2025-335291

### 第一部分 原文与翻译

**英文原标题：** Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma.

> **英文摘要：**
> BACKGROUND: Cholangiocarcinoma (CCA) is a highly lethal malignant tumour with increasing incidence. Current therapies exhibit limited benefits, which urgently demand the identification of novel therapeutic targets.
> 
> OBJECTIVE: We aimed to identify potential therapeutic targets for CCA and broaden current therapies.
> 
> DESIGN: Potential therapeutic targets for CCA were identified by sgRNA library screening and validated in preclinical models. Multi-omics sequencing and various experimental approaches were performed to validate the mechanism by which Aurora kinase B (AURKB) regulates CCA progression and the immune microenvironment, supported by clinical samples from public data sets and Tongji Hospital cohorts. The translational therapy was comprehensively validated in CCA organoid, patient-derived xenograft and preclinical murine models.
> 
> RESULTS: AURKB was identified as a highly expressed and targetable kinase in CCA. Knockout of AURKB significantly inhibited CCA progression, reduced CD8 T cell exhaustion and enhanced antitumour response. Mechanistically, AURKB promoted the generation of histone H3 lysine 9 tri-methylation (H3K9me3)/serine 10 phosphorylation, leading to a decrease in the enrichment of H3K9me3 at the neutral cholesterol ester hydrolase 1 (NCEH1) promoter, thereby increasing NCEH1 expression and cholesterol levels in tumours. High AURKB expression in clinical samples predicted poorer outcomes in patients with CCA undergoing neoadjuvant chemoimmunotherapy and was associated with cholesterol accumulation within tumours. AURKB inhibitor or simvastatin can suppress CCA progression and significantly enhance sensitivity to chemoimmunotherapy.
> 
> CONCLUSIONS: AURKB regulates cholesterol levels and immune microenvironment in tumours, highlighting that targeting AURKB or adopting cholesterol-reducing strategy holds promise for CCA treatment, especially in conjunction with first-line chemoimmunotherapy.

> **中文摘要：**
> 背景：胆管癌（CCA）是一种发病率不断上升、高度致命的恶性肿瘤。目前的疗法获益有限，这迫切需要发现新的治疗靶点。
> 
> 目的：我们旨在识别CCA的潜在治疗靶点，并拓宽现有疗法。
> 
> 设计：通过sgRNA文库筛选识别了CCA的潜在治疗靶点，并在临床前模型中进行了验证。通过多组学测序和各种实验方法，验证了Aurora激酶B（AURKB）调控CCA进展和免疫微环境的机制，并得到了来自公共数据集和同济医院队列的临床样本支持。该转化疗法在CCA类器官、患者来源的异种移植模型和临床前小鼠模型中得到了全面验证。
> 
> 结果：AURKB被鉴定为在CCA中高表达且可靶向的激酶。敲除AURKB显著抑制了CCA进展，减少了CD8 T细胞耗竭并增强了抗肿瘤反应。机制上，AURKB促进了组蛋白H3赖氨酸9三甲基化（H3K9me3）/丝氨酸10磷酸化的生成，导致中性胆固醇酯水解酶1（NCEH1）启动子处H3K9me3富集减少，从而增加了肿瘤中NCEH1的表达和胆固醇水平。临床样本中高AURKB表达预示着接受新辅助化学免疫治疗的CCA患者预后较差，并且与肿瘤内胆固醇积累相关。AURKB抑制剂或辛伐他汀可以抑制CCA进展，并显著增强对化学免疫治疗的敏感性。
> 
> 结论：AURKB调控肿瘤内的胆固醇水平和免疫微环境，这突显了靶向AURKB或采用降胆固醇策略，尤其是与一线化学免疫治疗联合，有望用于CCA治疗。

### 第二部分 AI 大师评价

本研究旨在为治疗选择有限的胆管癌（CCA）寻找新靶点。研究团队通过sgRNA文库筛选、多组学分析及多种临床前模型，系统性地揭示了AURKB通过表观遗传机制上调NCEH1、促进胆固醇积累并抑制免疫微环境的全新作用机制。其创新性在于将AURKB的促癌功能与胆固醇代谢和免疫逃逸联系起来，并提出了靶向AURKB或联合他汀类药物以增强化学免疫治疗疗效的转化策略。然而，研究结论主要基于临床前模型，其临床转化效果及安全性仍需未来临床试验的进一步验证。

---

## 144. 新辅助化疗免疫疗法降期后内镜切除术治疗食管癌：一种新的多模式治疗理念？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40139748)
**期刊：** Gut
**PMID：** 40139748
**DOI：** 10.1136/gutjnl-2024-333337

### 第一部分 原文与翻译

**英文原标题：** Endoscopic resection after downstaging of oesophageal carcinoma by neoadjuvant chemoimmunotherapy: - a new multimodal concept?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文探讨了将新辅助化疗免疫疗法与内镜切除术相结合，作为食管癌降期后的一种新型多模式治疗理念。其核心目的是评估这种策略在实现器官保留和微创治疗方面的潜力与可行性。该方法代表了食管癌治疗范式的一种潜在转变，旨在平衡肿瘤学疗效与生活质量。然而，由于摘要不可用，其具体的研究设计、患者选择标准、疗效数据以及与传统根治性手术相比的局限性尚不明确，需要全文内容来全面评估其创新性和临床意义。

---

速递结束，祝您工作愉快！